学术周报 · IF≥10 或专科旗舰刊
心血管科领域文献阅读汇编
2026年第45周 (2026-11-06) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Stroke | 28 | IF 11.1 |
| Hypertension research : official journal of the Japanese Society of Hypertension | 23 | IF 0.0 |
| European heart journal | 10 | IF 45.3 |
| Pharmacological research | 10 | IF 12.2 |
| Hypertension (Dallas, Tex. : 1979) | 10 | IF 0.0 |
| Circulation | 9 | IF 41.3 |
| Redox biology | 8 | IF 16.2 |
| JAMA cardiology | 6 | IF 15.2 |
| MedComm | 5 | IF 14.1 |
| Diabetologia | 5 | IF 10.4 |
1高血压 (41篇)
临床研究 (28篇)
Potassium-enriched table salt lowers blood pressure (BP) and reduces cardiovascular mortality. Whether these beneficial effects stem from reduced Na+ intake, increased K+ intake, or both is unknown. We tested the hypothesis that oral potassium chloride (KCl) supplementation lowers body Na+ content and BP in patients with essential hypertension (EH) or hyperaldosteronism, independent of salt intake. Between February 2024 and February 2025, we conducted a single-arm, prospective, longitudinal study with nonrandomized oral KCl intervention in 40 participants with hypertension. All received personalized (blood K+-adjusted) KCl supplementation (SPAN-K tablets, potassium chloride 600 mg; Aspen Pharmacare Australia Pty, Ltd) for 6 to 9 weeks. After the intervention, participants completed a routine diagnostic workup and were classified with EH or hyperaldosteronism. Primary end point: baseline muscle Na+ surplus in hyperaldosteronism. Secondary end point: interventional muscle Na+ mobilization and BP reduction. Seventeen participants were diagnosed with EH, and 23 with hyperaldosteronism. At baseline, patients with hyperaldosteronism showed higher muscle Na+ content (24.67±2.93 versus 22.48±3.37 mmol/L tissue volume, P=0.023; primary end point). Oral KCl increased 24-hour urine K+ excretion without altering 24-hour urine Na+. KCl supplementation successfully eliminated the muscle Na+ surplus in the hyperaldosteronism group (-1.90 mmol/L tissue volume [95% CI, -3.20 to -0.60]; P=0.005; secondary end point), lowered blood Na+/K+ ratios in both groups (EH, -5.34 [95% CI, -7.69 to -2.99]; P=4.6×10-5; hyperaldosteronism, -7.02 [95% CI, -9.04 to -5.01]; P=2.1×10-8), and reduced systolic BP (EH, -8.33 mm Hg [95% CI, -14.55 to -2.12]; P=0.010; hyperaldosteronism, -7.35 mm Hg [95% CI, -12.69 to -2.01]; P=0.008). To account for early study termination, a conservative significance threshold of α=0.025 was implemented, which all end points crossed. Oral KCl supplementation mobilizes intracellular Na+ stores, corrects pathological Na+/K+ distribution, and lowers BP across hypertension phenotypes. This safe, targeted approach warrants consideration as a scalable public health strategy for cardiovascular disease prevention. URL: https://www.clinicaltrials.gov; Unique identifier: NCT06569589.
中文摘要:富钾食盐可降低血压并减少心血管死亡。这些有益效应源于钠摄入减少、钾摄入增加还是两者共同作用尚不清楚。我们检验了以下假说:口服氯化钾补充可降低原发性高血压或高醛固酮症患者的体内钠含量和血压,且不依赖于食盐摄入。2024年2月至2025年2月,我们开展了一项单臂、前瞻性、纵向研究,对40名高血压参与者进行非随机口服氯化钾干预。所有参与者接受个体化(按血钾调整)氯化钾补充(SPAN-K片,氯化钾600 mg;Aspen Pharmacare Australia Pty, Ltd)6至9周。干预后,参与者完成常规诊断检查,并被分类为原发性高血压或高醛固酮症。主要终点:高醛固酮症患者的基线肌肉钠盈余。次要终点:干预后肌肉钠动员和血压降低。17名参与者被诊断为原发性高血压,23名为高醛固酮症。基线时,高醛固酮症患者肌肉钠含量更高(24.67±2.93 对 22.48±3.37 mmol/L组织体积,P=0.023;主要终点)。口服氯化钾增加24小时尿钾排泄,未改变24小时尿钠。氯化钾补充成功消除了高醛固酮症组的肌肉钠盈余(-1.90 mmol/L组织体积[95% CI,-3.20至-0.60];P=0.005;次要终点),降低了两组的血钠/钾比值(原发性高血压,-5.34[95% CI,-7.69至-2.99];P=4.6×10-5;高醛固酮症,-7.02[95% CI,-9.04至-5.01];P=2.1×10-8),并降低了收缩压(原发性高血压,-8.33 mm Hg[95% CI,-14.55至-2.12];P=0.010;高醛固酮症,-7.35 mm Hg[95% CI,-12.69至-2.01];P=0.008)。为考虑研究提前终止,采用了α=0.025的保守显著性阈值,所有终点均跨过该阈值。口服氯化钾补充可动员细胞内钠储存,纠正病理性钠/钾分布,并在不同高血压表型中降低血压。这种安全、靶向的方法值得考虑作为心血管疾病预防的可扩展公共卫生策略。URL: https://www.clinicaltrials.gov;唯一标识符:NCT06569589。
Hypertension is a silent killer, with over half of affected adults unaware of their condition1,2. This lack of awareness is a major concern, as early intervention is critical for preventing major adverse cardiovascular events3,4. Here we show that applying artificial intelligence (AI) to multimodal waveforms (photoplethysmography and accelerometry) recorded using a widely available consumer smartwatch (AI-PPG-ACC-HTN), without any cuff calibration, can detect hypertension with accuracy levels comparable to traditional cuffed blood pressure (BP) devices in the existing clinical framework. We validated AI-PPG-ACC-HTN in a prospective, multicenter study of 196 diverse participants free from known cardiovascular disease and antihypertensive medication against gold-standard 24-hour ambulatory BP monitoring. Over seven days of real-world monitoring, AI-PPG-ACC-HTN detected hypertension with a sensitivity of 65.8% (95% CI, 54.0%-76.3%), specificity of 90.0% (95% CI, 83.2%-94.7%), and positive predictive value (PPV) of 80.6% (95% CI, 68.6%-89.6%). In comparison, initial office BP screening achieved a sensitivity of 55.3% (95% CI, 43.4%-66.7%), specificity of 90.0% (95% CI, 83.2%-94.7%) and PPV of 77.8% (95% CI, 64.4%-88.0%). These results highlight an opportunity for consumer smartwatches to facilitate population-level opportunistic hypertension screening by prompting at-risk individuals toward clinical assessment and confirmatory diagnosis using established cuff-based methodologies, offering an accessible tool to address this major public health challenge.
中文摘要:高血压是无声杀手,超过半数 affected adults 不知道自己患病。这种认知缺失是重要问题,因为早期干预对预防主要不良心血管事件至关重要。研究显示,将人工智能(AI)应用于广泛可得的消费级智能手表记录的多模态波形(光电容积脉搏波与加速度计信号)(AI-PPG-ACC-HTN),无需袖带校准,即可在现有临床框架内以与传统袖带血压设备相当的准确度检测高血压。我们在前瞻性、多中心研究中验证 AI-PPG-ACC-HTN,研究纳入196名无已知心血管疾病且未服用降压药、背景多样的参与者,以金标准24小时动态血压监测为参照。在七天真实世界监测中,AI-PPG-ACC-HTN 检测高血压的敏感度为65.8%(95% CI,54.0%-76.3%),特异度为90.0%(95% CI,83.2%-94.7%),阳性预测值为80.6%(95% CI,68.6%-89.6%)。相比之下,初次诊室血压筛查的敏感度为55.3%(95% CI,43.4%-66.7%),特异度为90.0%(95% CI,83.2%-94.7%),阳性预测值为77.8%(95% CI,64.4%-88.0%)。这些结果提示,消费级智能手表有机会通过促使高危个体接受临床评估并使用既有袖带方法进行确诊,促进人群层面的机会性高血压筛查,为应对这一重大公共卫生挑战提供可及工具。
We aimed to assess whether home blood pressure (BP) self-recorded through a personal health record (PHR) application in a real-world setting was associated with cardiovascular disease (CVD) events among individuals not receiving antihypertensive treatment. Using an insurer-based database that links annual health checkup records and home BP self-recorded in the "kencom" PHR application, 6654 participants (mean age: 51.8 ± 9.1 years, males: 68.0%) not receiving antihypertensive treatment were selected. Morning home BP was calculated as the average of morning values over the first 28 days. Office BP was derived from annual health checkup data. The primary outcome was total CVD identified from hospitalization claims. Cox models were used to assess hazard ratios (HRs). The average of home systolic/diastolic BP was 124.5 ± 13.7/80.9 ± 10.9 mmHg, and 80.6% entered their home BP manually. The correlation between home and office BP was r = 0.56 for systolic and r = 0.61 for diastolic BP. During a mean follow-up of 2.79 ± 1.76 years (18,592 person-years), 447 total CVD events occurred. The HRs for total CVD per 1-SD higher in BP were 1.31 for home systolic, 1.12 for office systolic, 1.32 for home diastolic, and 1.21 for office diastolic BP. Results were consistent for stroke and heart failure. When home and office BP were entered simultaneously into the same model, only home systolic/ diastolic BP was independently associated with total CVD risk. Morning home BP self-recorded by users in a PHR application under real-world conditions was more strongly associated with CVD than office BP, supporting the potential value of PHR-based home BP.
中文摘要:评估在真实世界环境中通过个人健康记录(PHR)应用自我记录的家庭血压是否与非降压治疗人群的心血管疾病(CVD)事件相关。利用基于保险机构的数据库,将年度健康体检记录与「kencom」PHR应用中自我记录的家庭血压关联,选取6654名未接受降压治疗的参与者(平均年龄51.8±9.1岁,男性68.0%)。晨间家庭血压取前28天晨间值的平均值。诊室血压来自年度健康体检数据。主要结局为从住院理赔中识别的总CVD。采用Cox模型评估风险比(HR)。家庭收缩压/舒张压平均为124.5±13.7/80.9±10.9 mmHg,80.6%为手动录入家庭血压。家庭血压与诊室血压的相关性为收缩压r=0.56、舒张压r=0.61。平均随访2.79±1.76年(18,592人年)期间发生447例总CVD事件。血压每升高1个标准差对应的总CVD HR为家庭收缩压1.31、诊室收缩压1.12、家庭舒张压1.32、诊室舒张压1.21。脑卒中和心力衰竭结果一致。将家庭血压与诊室血压同时纳入同一模型时,仅家庭收缩压/舒张压与总CVD风险独立相关。真实世界条件下用户在PHR应用中自我记录的晨间家庭血压与CVD的关联强于诊室血压,支持基于PHR的家庭血压的潜在价值。
Current guidelines support bariatric surgery (BS) as an effective treatment mainly for patients with severe obesity and poorly controlled hypertension. However, evidence in non-severely obese Asian populations remains limited. This multicenter prospective cohort study included 248 Chinese patients with obesity and hypertension who underwent BS between 2010 and 2019 and were followed for up to 10 years. An exploratory mechanistic substudy (n = 14) evaluated 24-h ambulatory blood pressure (BP), various biomarkers, and urinary electrolytes before and after BS. Compared with baseline, adjusted mean systolic blood pressure (SBP) was lower by 16.4, 14.8, 15.1, 18.0, and 15.2 mmHg, while diastolic blood pressure (DBP) decreased by 11.4, 9.1, 9.9, 10.5, and 11.4 mmHg at 3 months, 6 months, and 1, 5, 10 years postoperatively. During postoperative Days 1 to 7 (POD1-7), mean SBP and DBP dropped by 8.6 and 10.4 mmHg, and the proportion achieving BP < 140/90 mmHg increased to 62.9% and remained at 70.8% even 10 years later. The substudy has observed that early BP reduction was accompanied by increased electrolytes and water excretion, as well as a transient suppression of renin-angiotensin-aldosterone system (RAAS)-related biomarkers, providing a direction for future in-depth exploration. These findings suggest that BS in Chinese patients was followed by rapid BP reductions, with lower BP observed among the smaller subsets assessed longer term, including those without severe obesity. Trial Registration: NCT07183137.
中文摘要:当前指南支持减重手术(BS)作为主要针对重度肥胖且血压控制不佳患者的有效治疗。但非重度肥胖亚洲人群中的证据仍有限。这项多中心前瞻性队列研究纳入248例2010至2019年间接受BS的中国肥胖合并高血压患者,随访至10年。一个探索性机制亚研究(n=14)评估BS前后24小时动态血压、多种生物标志物和尿电解质。与基线相比,术后3个月、6个月、1年、5年、10年调整后平均收缩压分别降低16.4、14.8、15.1、18.0和15.2 mmHg,舒张压分别降低11.4、9.1、9.9、10.5和11.4 mmHg。术后第1至7天(POD1-7),平均收缩压和舒张压下降8.6和10.4 mmHg,血压<140/90 mmHg的比例增至62.9%,并在10年后仍保持70.8%。亚研究观察到早期血压下降伴随电解质和水排泄增加,以及肾素-血管紧张素-醛固酮系统(RAAS)相关生物标志物的一过性抑制,为未来深入探索提供方向。这些发现提示中国患者接受BS后血压快速下降,在随访更久的小部分受试者(包括非重度肥胖者)中观察到更低血压。试验注册:NCT07183137。
Obesity and hypertension frequently coexist, and weight-reduction is recommended as a core strategy for blood pressure (BP) management in adults with overweight or obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and emerging multi-hormone receptor modulators (MHRMs) induce substantial weight loss alongside modest BP reductions. However, the extent to which weight-loss is associated with BP lowering across these therapies remains unclear. We conducted a systematic review and meta-analysis of phase 3 randomized controlled trials evaluating GLP-1RAs and MHRMs in adults with overweight or obesity (PROSPERO: CRD420251146441). We searched Ovid MEDLINE, Ovid Embase, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials from 1946 to December 2025. Risk of bias was assessed using the revised Cochrane Risk of Bias tool. Placebo-adjusted changes in body weight and BP at each trial's primary endpoint were pooled using random-effects meta-analysis with inverse-variance weighting. Meta-regression assessed the association between weight loss and BP reduction. Thirty-seven trials including 50,171 participants were analysed. Thirty-six trials had low risk of bias across all domains. Across all trials, 50% of participants were females, 16% had type 2 diabetes and 57% had hypertension. Median treatment duration was 68 weeks. Mean placebo-adjusted weight loss was -10.1% (95% CI -11.3 to -9.0) accompanied by a -4.9 mmHg (95% CI -5.5 to -4.3) reduction in systolic BP. Between-trial meta-regression showed that 76% of the variance in systolic BP reduction was explained by differences in weight loss (R2 = 0.76; P < 0.01), corresponding to a reduction of 0.37 mmHg (95% CI 0.28 to 0.45) per 1% change in body weight. Across phase 3 trials of GLP-1RAs and MHRMs, greater weight loss was strongly associated with larger reductions in BP, supporting pharmacological weight-loss therapies as an adjunct strategy for BP management in obesity. None.
中文摘要:肥胖与高血压常同时存在,超重或肥胖成人中减重被推荐为血压管理的核心策略。胰高血糖素样肽-1受体激动剂(GLP-1RAs)和新型多激素受体调节剂(MHRMs)可带来显著体重下降,同时伴有一定程度的血压降低。但这些治疗中体重下降与血压降低的关联程度仍不清楚。我们针对在超重或肥胖成人中评估GLP-1RAs和MHRMs的3期随机对照试验进行了系统综述和荟萃分析(PROSPERO:CRD420251146441)。检索了Ovid MEDLINE、Ovid Embase、Cochrane系统综述数据库和Cochrane对照试验中心注册库,时间范围为1946年至2025年12月。采用修订版Cochrane偏倚风险工具评估偏倚风险。各试验主要终点时体重和血压的安慰剂校正变化采用逆方差加权的随机效应荟萃分析合并。采用荟萃回归评估体重下降与血压降低之间的关联。共分析37项试验、50171名参与者。36项试验在所有领域偏倚风险低。全部试验中,50%参与者为女性,16%患有2型糖尿病,57%患有高血压。中位治疗持续时间为68周。平均安慰剂校正体重下降为-10.1%(95% CI -11.3至-9.0),同时收缩压降低-4.9 mmHg(95% CI -5.5至-4.3)。试验间荟萃回归显示,收缩压降低变异的76%可由体重下降差异解释(R²=0.76;P<0.01),相当于体重每变化1%对应收缩压降低0.37 mmHg(95% CI 0.28至0.45)。在GLP-1RAs和MHRMs的3期试验中,体重下降幅度越大与血压降低幅度越大呈强关联,支持药物性减重治疗作为肥胖人群血压管理的辅助策略。无。
Hypertension and frailty frequently coexist in older adults. However, relationships between their trajectories are unclear. This study aims to examine whether frailty progressed differently between individuals with and without hypertension before and after diagnosis. Data were drawn from 3 nationally representative cohorts across 14 countries, including 21 418 participants (mean baseline age 63.2±10.2 years) followed for 16 to 18 years. Individuals with hypertension at baseline were excluded. Hypertension was defined by self-reported physician diagnosis and antihypertensive medication use by self-report of taking any medication. Diagnosis timing was based on the first survey wave at which hypertension was reported. Coarsened exact matching matched participants who developed hypertension with those who did not. Piecewise linear mixed models estimated frailty trajectories before and after diagnosis. Among 10 709 participants who developed hypertension (median diagnosis age 70 years), frailty index rescaled to a 0 to 100 scale (0-100) increased by 0.63 points/y (95% CI, 0.57-0.70) before diagnosis and 1.09 points/y (95% CI, 0.97-1.21) after diagnosis. During the 8 years preceding diagnosis, participants who developed hypertension experienced greater increases in frailty index rescaled to a 0 to 100 scale than matched controls without hypertension (difference, 2.69 [95% CI, 2.43-2.95]). The corresponding difference during the 8 years after diagnosis was 1.51 (95% CI, 1.01-2.01). Among individuals with hypertension, antihypertensive medication use was associated with a nonsignificant reduction in frailty progression after diagnosis. Findings remained robust after excluding participants with cardiovascular conditions. Participants with hypertension experienced faster frailty progression before and after diagnosis. Studies using objective blood pressure measurement are needed to confirm this association.
中文摘要:高血压与衰弱在老年人中常共存。两者轨迹之间的关系尚不明确。本研究旨在考察高血压患者与无高血压者在诊断前后衰弱进展是否存在差异。数据来自14个国家3个全国代表性队列,纳入21 418名参与者(基线平均年龄63.2±10.2岁),随访16至18年。基线时患高血压者被排除。高血压由自我报告的医生诊断和自报服用任何降压药物定义。诊断时间依据首次报告高血压的调查波次确定。采用粗化精确匹配将发生高血压的参与者与未发生者匹配。分段线性混合模型估计诊断前后的衰弱轨迹。在10 709名发生高血压的参与者中(诊断中位年龄70岁),衰弱指数按0至100重新标度后,诊断前每年增加0.63分(95% CI,0.57-0.70),诊断后每年增加1.09分(95% CI,0.97-1.21)。诊断前8年间,发生高血压的参与者衰弱指数(0至100标度)增幅大于匹配的无高血压对照(差值2.69,95% CI,2.43-2.95)。诊断后8年的相应差值为1.51(95% CI,1.01-2.01)。在高血压个体中,使用降压药物与诊断后衰弱进展的非显著减缓相关。排除患有心血管疾病者后结果仍稳健。高血压参与者在诊断前后均表现出更快的衰弱进展。需采用客观血压测量的研究确认这一关联。
Fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) may not fully capture the heterogeneity underlying dysglycemia or its associations with cardiometabolic risk factors (CMRFs). We cross-sectionally investigated whether continuous glucose monitoring (CGM) measures and glycemic profiles could reveal 10-year cardiovascular disease (CVD) risk and individual CMRFs among individuals without diabetes. We included 1,356 participants without prevalent diabetes or CVD from the Framingham Heart Study, who wore a blinded Dexcom G6 Pro CGM for up to 10 days. CGM glycemic profiles were characterized using 1) binary classification of glycemic burden and variability and 2) unsupervised clustering of CGM measures. We performed multivariable-adjusted linear and logistic regression models to examine associations of CGM measures and profiles with 10-year CVD risk estimates (PREVENT equations) and individual CMRFs. Participants' mean was age 59.3 years; 55.8% were women, and 92.6% were non-Hispanic White. CGM measures were positively associated with 10-year CVD risk estimates and CMRFs. For example, 1 SD higher % time >140 mg/dL (15.4%) was associated with 2% higher 10-year CVD risk estimates and 21-26% higher odds of hypertension and dyslipidemia, even after adjusting for FPG. Glycemic profiles representing higher CGM dysglycemia revealed discordance with traditionally defined glycemic status (FPG and HbA1c). Although 48.1-84.2% of individuals with traditionally defined prediabetes were included in CGM profiles representing higher dysglycemia, such profiles were associated with 6-7% higher 10-year CVD risk estimates, in addition to worse CMRFs. Glycemic measures reflective of continuous glucose dynamics may provide additional insights into cardiometabolic risk beyond traditional measures.
中文摘要:空腹血糖和HbA1c可能无法充分反映血糖异常的异质性及其与心脏代谢危险因素(CMRFs)的关联。我们在无糖尿病人群中横断面研究连续血糖监测(CGM)指标和血糖谱是否能揭示10年心血管病风险和个体CMRFs。纳入Framingham心脏研究1356名无糖尿病和心血管病参与者,佩戴盲法Dexcom G6 Pro CGM最多10天。CGM血糖谱通过血糖负荷与变异性的二分类以及CGM指标的无监督聚类刻画。采用多变量校正线性和logistic回归模型分析CGM指标和血糖谱与10年心血管病风险估计值(PREVENT方程)及个体CMRFs的关联。参与者平均年龄59.3岁;55.8%为女性,92.6%为非西班牙裔白人。CGM指标与10年心血管病风险估计值和CMRFs正相关。例如,血糖>140 mg/dL时间百分比每增加1个标准差(15.4%),10年心血管病风险估计值高2%,高血压和血脂异常的比值比高21–26%,即使校正空腹血糖后仍如此。代表更高CGM血糖异常的血糖谱与传统定义的血糖状态(空腹血糖和HbA1c)不一致。传统定义糖尿病前期的个体中48.1–84.2%被纳入代表更高血糖异常的CGM谱,这些谱与10年心血管病风险估计值高6–7%相关,并伴有更差的CMRFs。反映连续血糖动态的血糖指标可能为传统指标之外的心脏代谢风险提供额外信息。
In 2025, the Endocrine Society (ES) updated the guidelines for primary aldosteronism (PA), introducing more inclusive diagnostic criteria: plasma renin activity (PRA) ≤1 ng/mL per hour, plasma aldosterone concentration (PAC) ≥7.5 ng/dL by liquid chromatography-tandem mass spectrometry, and aldosterone-to-renin ratio >15. We compared PA positivity by comparing these updated criteria against broader permissive criteria (PRA <1 ng/mL per hour, PAC >5 ng/dL, without an aldosterone-to-renin ratio requirement). We retrospectively analyzed deidentified adults with PRA and PAC measurements between January and August 2025. Patients were categorized by ES versus permissive criteria. Biochemical and clinical characteristics were compared. Of 60 449 patients, 13.0% (n=7883) met ES screening criteria for PA versus 26.2% (n=15 872) by permissive criteria. Among the 8006 (13.2%) permissive-positive/ES-negative patients, 6325 did not meet ES criteria due to PAC 5 to 7.5 ng/dL, despite 55.2% having a PRA <0.5 ng/mL per hour. An additional 1681 patients were excluded by ES criteria because the aldosterone-to-renin ratio was ≤15, despite a median PAC of 9.00 (8-10) ng/dL. Among permissive-positive/ES-negative patients, PRA ≤ 0.25 ng/mL per hour was associated with higher odds of atrial fibrillation (odds ratio, 2.38; P=0.004), hypertension (odds ratio, 1.27; P=0.0002) and hypokalemia (K<3.5; odds ratio, 1.66; P=0.0012). Current ES thresholds potentially exclude PA cases with a biochemical phenotype consistent with milder or earlier renin-independent aldosterone production. If validated in cohorts with comprehensive clinical data, the biochemical definition of PA may need to expand to include a greater proportion of individuals with renin-independent aldosterone production.
中文摘要:2025年,内分泌学会更新了原发性醛固酮增多症的指南,引入更宽泛的诊断标准:血浆肾素活性≤1 ng/mL每小时,液相色谱-串联质谱法测定血浆醛固酮浓度≥7.5 ng/dL,醛固酮与肾素比值>15。我们将这些更新标准与更宽松的标准(PRA<1 ng/mL每小时、PAC>5 ng/dL,不要求醛固酮与肾素比值)进行比较,以评估PA阳性情况。回顾性分析2025年1月至8月间有PRA和PAC测量的去标识成人。患者按ES标准与宽松标准分组,比较生化和临床特征。60 449例患者中,13.0%(n=7883)符合ES筛查标准,而宽松标准为26.2%(n=15872)。在8006例(13.2%)宽松阳性/ES阴性患者中,6325例因PAC为5至7.5 ng/dL而未达ES标准,尽管其中55.2%的患者PRA<0.5 ng/mL每小时。另有1681例因醛固酮与肾素比值≤15被ES标准排除,尽管中位PAC为9.00(8-10)ng/dL。在宽松阳性/ES阴性患者中,PRA≤0.25 ng/mL每小时与心房颤动(比值比2.38;P=0.004)、高血压(比值比1.27;P=0.0002)和低钾血症(K<3.5;比值比1.66;P=0.0012)的更高几率相关。当前ES阈值可能排除生化表型符合较轻或更早期非肾素依赖性醛固酮生成的PA病例。若在具有完整临床数据的队列中得到验证,PA的生化定义可能需要扩大,以纳入更大比例的非肾素依赖性醛固酮生成个体。
Several clinical trials have shown that intensive systolic blood pressure (SBP) lowering confers cardiovascular benefits. However, whether baseline metabolic syndrome (MetS) severity modifies these benefits and risks remains unclear. This post hoc analysis of the STEP trial included 8231 participants with complete MetS severity data. Baseline MetS severity was quantified using an age-, sex-, and ethnicity-specific MetS scoring model and analyzed as tertiles and continuously. The primary outcome was a composite of stroke, acute coronary syndrome, acute decompensated heart failure, coronary revascularization, atrial fibrillation, and cardiovascular death. Cox models and restricted cubic spline analyses were used to assess treatment-effect heterogeneity. During a median follow-up of 3.32 years, intensive SBP lowering reduced the risk of the primary outcome compared with standard treatment. The absolute incidence of the primary outcome and major adverse cardiac events was highest in the highest MetS tertile. Across MetS tertiles, event rates were lower in the intensive-treatment group, with the largest reduction in the middle tertile for the primary outcome (Q2: HR, 0.66; 95% CI, 0.44-0.99). No significant treatment-by-MetS interaction was observed in tertile-based or spline analyses. For safety outcomes, no significant treatment-by-MetS tertile interaction was observed, although hypotension was numerically more frequent with intensive treatment among participants in the highest MetS tertile. These findings suggest that baseline MetS severity identifies patients with higher absolute cardiovascular risk but does not significantly modify the relative efficacy of intensive SBP lowering. Careful monitoring for treatment-related hypotension may be warranted, particularly among patients with higher metabolic burden.
中文摘要:多项临床试验显示,强化收缩压(SBP)降低可带来心血管获益。基线代谢综合征(MetS)严重程度是否改变这些获益与风险仍不清楚。这项STEP试验的事后分析纳入8231名具有完整MetS严重程度数据的参与者。基线MetS严重程度采用按年龄、性别和族裔特异的MetS评分模型量化,并按三分位和连续变量分析。主要结局为卒中、急性冠脉综合征、急性失代偿性心力衰竭、冠脉血运重建、心房颤动和心血管死亡的复合终点。采用Cox模型和限制性立方样条分析评估治疗效应异质性。中位随访3.32年期间,与标准治疗相比,强化SBP降低减少了主要结局风险。主要结局和主要不良心脏事件的绝对发生率在MetS最高三分位组最高。各MetS三分位组中,强化治疗组事件率较低,主要结局降幅在中三分位组最大(Q2:HR,0.66;95% CI,0.44-0.99)。三分位或样条分析均未观察到显著的MetS与治疗交互作用。安全性结局方面,未观察到MetS三分位与治疗的显著交互作用,尽管在MetS最高三分位组中低血压在强化治疗下数值上更常见。这些发现提示,基线MetS严重程度可识别绝对心血管风险更高的患者,但未显著改变强化SBP降低的相对疗效。对治疗相关低血压进行仔细监测可能有必要,尤其在代谢负担较高的患者中。
We investigated the association between blood pressure (BP) and the risk of cardiovascular disease (CVD) in individuals with non-proteinuric chronic kidney disease (CKD) without diabetes. Using a large-scale nationwide administrative claims and health checkup database in Japan, we identified 287,238 non-diabetic adults with an estimated glomerular filtration rate <60 mL/min/1.73 m2 and negative/trace proteinuria. We examined the association between BP and CVD events by modeling BP both as a continuous variable and as a categorical variable according to the 2017 ACC/AHA guideline classification. The primary outcome was a composite of myocardial infarction, stroke, heart failure, and atrial fibrillation. Multivariable Cox regression analyses showed that higher systolic BP (SBP) was associated with increased CVD risk (hazard ratio [HR] 1.05 per 10 mmHg; 95% CI 1.04-1.05). Compared with normal BP, the HRs were 1.03 (95% CI 1.00-1.07) for elevated BP, 1.08 (1.05-1.11) for stage 1 hypertension, and 1.20 (1.17-1.24) for stage 2 hypertension. Restricted cubic spline analysis showed an increase in CVD risk at SBP levels above ~130 mmHg. However, among individuals receiving antihypertensive medication, a U-shaped association was observed, with an increased risk also evident at SBP levels below ~130 mmHg. In individuals with non-proteinuric CKD without diabetes, higher SBP was positively associated with increased cardiovascular risk. However, a U-shaped association observed among individuals receiving antihypertensive treatment suggests that the relationship between BP and cardiovascular risk may be complex in this population, highlighting the potential importance of individualized clinical assessment.
中文摘要:在无糖尿病的非蛋白尿性慢性肾脏病成人中,考察血压与心血管疾病风险之间的关联。利用日本大规模全国行政理赔与健康体检数据库,识别出287,238名估算肾小球滤过率低于60 mL/min/1.73 m²且尿蛋白阴性或痕量的非糖尿病成人。将血压分别按连续变量和依据2017 ACC/AHA指南分类的类别变量建模,分析血压与心血管疾病事件的关联。主要结局为心肌梗死、卒中、心力衰竭和心房颤动的复合终点。多变量Cox回归分析显示,较高的收缩压与心血管疾病风险升高相关(每10 mmHg的风险比1.05;95% CI 1.04-1.05)。与正常血压相比,血压升高、1期高血压和2期高血压的风险比分别为1.03(95% CI 1.00-1.07)、1.08(1.05-1.11)和1.20(1.17-1.24)。限制性立方样条分析显示,收缩压高于约130 mmHg时心血管疾病风险上升。在接受降压药治疗的人群中观察到U型关联,收缩压低于约130 mmHg时风险也升高。在无糖尿病的非蛋白尿性慢性肾脏病个体中,较高的收缩压与心血管风险升高呈正相关。接受降压治疗人群中观察到的U型关联提示,该人群血压与心血管风险的关系可能较复杂,个体化临床评估可能具有潜在重要性。
Hypertension is a major cardiovascular risk factor with an incompletely understood cause. We aimed to unravel its proteomic landscape and investigate potential molecular mechanisms underlying its risk related to modifiable exposures. Leveraging protein quantitative trait loci from 3 biobank-scale studies (deCODE, Fenland, and UKB-PPP [UK Biobank Pharma Proteomics Project]) based on distinct proteomic platforms (SomaScan or Olink), we performed proteome-wide Mendelian randomization to identify and cross-platform validate proteins causally associated with hypertension and blood pressure (BP). Bayesian colocalization was applied to detect shared causal variants underpinning the identified associations. A broad range of modifiable risk factors were systematically assessed for their causal associations with hypertension/BP, followed by mediation analyses exploring potential proteomic pathways linking risk factors to hypertension/BP. The discovery Mendelian randomization analyses (deCODE) identified 190 significant causal associations between 118 proteins and hypertension/BP, which were overall consistent in the cross-platform replication analyses (Fenland and UKB-PPP). Fifty-four protein-hypertension/BP pairs were further supported by genetic colocalization. Triangulation of evidence from Mendelian randomization and colocalization prioritized 28 proteins as key causal signatures. Among these, 10 proteins (particularly ALDH2 [mitochondrial aldehyde dehydrogenase] and ULK3 [serine/threonine-protein kinase]) were found to mediate the associations of 8 genetically predicted modifiable risk factors with hypertension/BP, with ALDH2 emerging as a central hub across multiple causal pathways. This study systematically characterized the causal proteomic landscape of hypertension and highlighted proteins implicated in its modifiable risk. These findings provide novel insights into the molecular cause of hypertension and identify promising candidates for further therapeutic investigation.
中文摘要:高血压是主要的心血管危险因素,其病因尚未完全明确。研究旨在揭示高血压的蛋白质组景观,并探讨可改变暴露相关风险背后的潜在分子机制。利用3项生物样本库规模研究deCODE、Fenland和UKB-PPP的蛋白质数量性状位点,这些研究基于SomaScan或Olink等不同蛋白质组平台,开展全蛋白质组孟德尔随机化,以识别并与血压和高血压存在因果关联的蛋白质,并进行跨平台验证。应用贝叶斯共定位检测支持上述关联的共享因果变异。系统评估广泛可改变危险因素与高血压或血压的因果关联,随后通过中介分析探索连接危险因素与高血压或血压的潜在蛋白质通路。发现阶段的孟德尔随机化分析deCODE识别出118种蛋白质与高血压或血压之间存在190个显著因果关联,这些关联在跨平台复制分析Fenland和UKB-PPP中总体一致。54个蛋白质与高血压或血压配对进一步获得遗传共定位支持。综合孟德尔随机化和共定位证据,优先确定28种蛋白质为关键因果特征。其中10种蛋白质,尤其是ALDH2线粒体乙醛脱氢酶和ULK3丝氨酸/苏氨酸蛋白激酶,介导8种遗传预测的可改变危险因素与高血压或血压之间的关联,ALDH2成为多个因果通路的中心节点。该研究系统刻画了高血压的因果蛋白质组景观,突出了与可改变风险相关的蛋白质。这些发现为高血压的分子病因提供了新见解,并识别出有前景的进一步治疗研究候选。
The effects of intensive systolic blood pressure (SBP) control on cardiovascular (CV) and kidney outcomes across different Kidney Disease Improving Global Outcomes (KDIGO) risk categories remain unclear. We performed a secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) and the SPRINT-eligible Action to Control Cardiovascular Risk in Diabetes Blood Pressure (ACCORD-BP) trial. Participants were categorized into low, moderate, and high/very-high KDIGO risk groups. The primary outcomes were composite adverse CV events (defined as nonfatal myocardial infarction (MI), nonfatal stroke, fatal or hospitalized heart failure (HF), and CV mortality) and composite adverse kidney events (defined as a sustained decline in eGFR of ≥ 40% and end-stage kidney disease (ESKD)). We found that intensive BP control reduced the risk of composite CV events (HR 0.68; 95% CI 0.59-0.78), with attenuated benefits in higher KDIGO risk categories (P for interaction = 0.055). This interaction was mainly driven by nonfatal MI and fatal or hospitalized HF (both P for interaction < 0.05). Intensive BP control increased the risk of composite kidney events (HR 1.88; 95% CI 1.52-2.33), mainly in low- and moderate-risk groups rather than in high/very-high risk groups (P for interaction = 0.04). Similar patterns were observed for sustained eGFR decline (P for interaction = 0.03), but not for ESKD (HR 1.05; 95% CI 0.74-1.48; P for interaction = 0.71). The KDIGO risk classification modified the effects of intensive BP control. Balancing CV benefits against potential kidney impacts in patients with different KDIGO risks during intensive BP treatment is recommended. Trial Registration: ClinicalTrials.gov Identifiers: NCT01206062 (SPRINT) and NCT00000620 (ACCORD).
中文摘要:强化收缩压控制对不同KDIGO风险分层下心血管和肾脏结局的影响仍不明确。对SPRINT试验和符合SPRINT条件的ACCORD-BP试验进行二次分析。参与者按KDIGO风险分为低、中、高/极高风险组。主要结局为复合不良心血管事件(非致死性心肌梗死、非致死性卒中、致死性或住院心力衰竭及心血管死亡)和复合不良肾脏事件(eGFR持续下降≥40%和终末期肾病)。强化血压控制降低复合心血管事件风险(HR 0.68;95% CI 0.59-0.78),在较高KDIGO风险类别中获益减弱(交互P=0.055)。该交互主要由非致死性心肌梗死和致死性或住院心力衰竭驱动(交互P均<0.05)。强化血压控制增加复合肾脏事件风险(HR 1.88;95% CI 1.52-2.33),主要见于低和中风险组而非高/极高风险组(交互P=0.04)。eGFR持续下降呈相似模式(交互P=0.03),终末期肾病未见此模式(HR 1.05;95% CI 0.74-1.48;交互P=0.71)。KDIGO风险分类改变了强化血压控制的效果。建议在强化血压治疗中权衡不同KDIGO风险患者的心血管获益与潜在肾脏影响。试验注册:ClinicalTrials.gov标识NCT01206062(SPRINT)和NCT00000620(ACCORD)。
Evidence guiding treatment selection for patients already receiving long-term antihypertensive therapy remains uncertain, particularly in older adults. We compared long-term outcomes associated with continued use of angiotensin receptor blockers (ARBs) versus calcium channel blockers (CCBs) among older adults receiving sustained antihypertensive therapy. Using linked administrative claims and health examination data from Japan, we conducted a retrospective cohort study of individuals aged ≥65 years who had continuously received either ARBs or CCBs for at least 12 months, with this time point defined as the landmark for follow-up. Discrete-time proportional hazards models with inverse probability of treatment and censoring weights were used to account for confounding and informative censoring. A total of 59,558 individuals (20,028 ARB users and 39,530 CCB users) were included, with a median follow-up of 4.75 years. Sustained ARB use was associated with a lower risk of heart failure hospitalization (hazard ratio [HR] 0.817, 95% confidence interval [CI] 0.758-0.882) and end-stage renal disease (HR 0.162, 95% CI 0.089-0.295). Risks of myocardial infarction and major adverse cardiovascular events were similar between groups, and stroke risk did not differ meaningfully. Blood pressure levels were comparable throughout follow-up. Among older adults receiving long-term antihypertensive therapy, continued use of ARBs was associated with lower risks of heart failure hospitalization and ESRD/dialysis compared with CCBs, despite similar blood pressure control. These findings may inform treatment selection in patients already established on antihypertensive therapy.
中文摘要:对于已经接受长期降压治疗的患者,尤其是老年人,治疗选择的循证依据仍不明确。本研究比较持续使用血管紧张素受体阻滞剂(ARB)与钙通道阻滞剂(CCB)的老年人在长期降压治疗中的结局。利用日本关联的行政索赔与健康体检数据,开展回顾性队列研究,纳入年龄≥65岁且连续接受ARB或CCB至少12个月的个体,并将该时间点定义为随访界标。采用离散时间比例风险模型,并结合治疗和删失的逆概率加权,以控制混杂和有信息删失。共纳入59,558人(ARB使用者20,028人,CCB使用者39,530人),中位随访4.75年。持续使用ARB与较低的心力衰竭住院风险(HR 0.817,95%CI 0.758-0.882)和终末期肾病风险(HR 0.162,95%CI 0.089-0.295)相关。心肌梗死和主要不良心血管事件风险在两组间相近,卒中风险无实质性差异。随访期间血压水平相当。在接受长期降压治疗的老年人中,与CCB相比,持续使用ARB与较低的心力衰竭住院和终末期肾病/透析风险相关,尽管血压控制相似。这些结果可为已建立降压治疗患者的治疗选择提供参考。
Poor subjective sleep quality and moderate-to-severe depressive symptoms have both been associated with hypertension, but the extent to which depressive symptoms account for the sleep quality-hypertension association remains uncertain, particularly in community-based populations. This cross-sectional study analyzed data from 210,925 adults in the 2018 Korea Community Health Survey. Sleep quality was assessed with the Pittsburgh Sleep Quality Index and categorized as good or poor, while depressive symptoms were measured with the Patient Health Questionnaire-9 and dichotomized at a score of 10 to indicate moderate-to-severe depressive symptoms. Hypertension was defined as a self-reported physician diagnosis. Logistic regression models estimated associations between sleep quality, depressive symptoms, and hypertension, and counterfactual mediation analysis decomposed the association between poor sleep quality and hypertension into direct and indirect components, adjusting for sociodemographic, behavioral, and clinical factors. Poor sleep quality was associated with higher odds of hypertension (total effect odds ratio [OR], 1.119; 95% confidence interval [CI], 1.091-1.146). The natural direct effect remained significant after accounting for depressive symptoms (OR 1.106, 95% CI 1.078-1.133), whereas the natural indirect effect was statistically significant but small (OR 1.012, 95% CI 1.007-1.016), corresponding to a mediation proportion of 10.8% and 14.6% among non-employed participants. These findings suggest that poor subjective sleep quality was associated with hypertension and that moderate-to-severe depressive symptoms statistically accounted for only a modest proportion of the observed association. Because of the cross-sectional design, these findings should be interpreted as exploratory and hypothesis-generating rather than as evidence of temporal or causal relationships.
中文摘要:主观睡眠质量差与中重度抑郁症状均与高血压相关,但抑郁症状能在多大程度上解释睡眠质量与高血压之间的关联仍不确定,在社区人群中尤其如此。本横断面研究分析2018年韩国社区健康调查中210925名成人的数据。睡眠质量用匹兹堡睡眠质量指数评估并分为良好或差,抑郁症状用患者健康问卷-9测量,以10分为界二分,表示中重度抑郁症状。高血压定义为自我报告的医生诊断。Logistic回归模型估计睡眠质量、抑郁症状与高血压之间的关联,反事实中介分析将睡眠质量差与高血压的关联分解为直接和间接成分,并调整社会人口学、行为和临床因素。睡眠质量差与高血压比值比更高相关(总效应比值比[OR] 1.119;95%置信区间[CI] 1.091-1.146)。在考虑抑郁症状后,自然直接效应仍显著(OR 1.106,95% CI 1.078-1.133),自然间接效应有统计学意义但较小(OR 1.012,95% CI 1.007-1.016),对应中介比例为10.8%,在非就业参与者中为14.6%。这些发现提示,主观睡眠质量差与高血压相关,中重度抑郁症状在统计学上仅解释观察关联中的较小比例。由于横断面设计,这些发现应解释为探索性和产生假设,而非时间或因果关系的证据。
Hyperuricemia commonly coexists with hypertension and is associated with increased renal and cardiovascular risk, yet few antihypertensive agents lower serum uric acid. This study compared the urate-lowering effects of sacubitril/valsartan versus valsartan in adults with primary hypertension and asymptomatic hyperuricemia. This single-center, prospective, randomized, open-label clinical trial enrolled adults with mild-to-moderate primary hypertension and fasting serum uric acid ≥ 420 μmol/L from September 2021 to December 2024, with 12 weeks of follow-up. Participants were randomized 1:1 to sacubitril/valsartan 200 mg once daily or valsartan 160 mg once daily. A standardized stepwise add-on protocol with amlodipine was used to achieve blood pressure control. The primary outcome was the change in fasting serum uric acid from baseline to week 12. In the primary intention-to-treat analysis using multiple imputation, treatment-effect estimates were pooled across imputed datasets using Rubin's rules. In the fully adjusted model, sacubitril/valsartan was associated with a greater reduction in serum uric acid at week 12 than valsartan (β = 30.13 μmol/L; 95% CI, 4.33-55.92; P = 0.022). Similar findings were observed in the per-protocol analysis. Blood pressure control at week 12 was comparable between treatment groups, although more participants assigned to valsartan required escalation to amlodipine 10 mg than those assigned to sacubitril/valsartan (17/75 [22.67%] vs. 4/75 [5.33%]; P = 0.008). In adults with primary hypertension and asymptomatic hyperuricemia, sacubitril/valsartan was associated with greater serum uric acid reduction than valsartan over 12 weeks while achieving comparable blood pressure control. These findings suggest that sacubitril/valsartan may have a favorable uric acid profile among hypertensive patients with asymptomatic hyperuricemia. Trial Registration Chinese Clinical Trial Registry: ChiCTR2100050320 ( https://www.chictr.org.cn ). Date of Registration: September 1, 2021.
中文摘要:高尿酸血症常与高血压并存,并与肾脏和心血管风险增加相关,但能降低血清尿酸的降压药较少。本研究在原发性高血压合并无症状高尿酸血症成人中比较沙库巴曲/缬沙坦与缬沙坦的降尿酸作用。这项单中心、前瞻性、随机、开放标签临床试验于2021年9月至2024年12月纳入轻至中度原发性高血压且空腹血清尿酸≥420 μmol/L的成人,随访12周。参与者按1:1随机接受沙库巴曲/缬沙坦200 mg每日一次或缬沙坦160 mg每日一次。采用标准化阶梯加用氨氯地平方案以实现血压控制。主要结局为基线至第12周空腹血清尿酸变化。在主意向性治疗分析中采用多重插补,治疗效应估计通过Rubin规则在插补数据集间合并。在完全校正模型中,沙库巴曲/缬沙坦在第12周血清尿酸降低幅度大于缬沙坦(β=30.13 μmol/L;95% CI,4.33-55.92;P=0.022)。符合方案分析观察到相似结果。第12周血压控制两组相当,但分配至缬沙坦者需要上调至氨氯地平10 mg的人数多于沙库巴曲/缬沙坦组(17/75 [22.67%] 对比 4/75 [5.33%];P=0.008)。在原发性高血压合并无症状高尿酸血症成人中,沙库巴曲/缬沙坦在12周内血清尿酸降低幅度大于缬沙坦,同时血压控制相当。这些结果提示沙库巴曲/缬沙坦在合并无症状高尿酸血症的高血压患者中可能具有有利的尿酸谱。试验注册:中国临床试验注册中心 ChiCTR2100050320(https://www.chictr.org.cn)。注册日期:2021年9月1日。
Very heterogeneous data have been published concerning prevalence and clinical management of Hypertensive Emergencies (HE) and Uncontrolled Hypertension (UH). The aim of our study was to characterize HE and UH patients evaluating: (i) Blood Pressure (BP) management in Emergency Department (ED), the pharmacological treatment and its adherence to guidelines recommendation; (ii) variables associated with the presence of organ damage; and (iii), as an exploratory analysis, the impact of BP on in-hospital mortality. We performed a multicentre (Niguarda Hospital - Milan and Pio XI Hospital - Desio) retrospective study evaluating patients admitted to ED with BP values ≥ 180/120 mmHg during 2017 and 2019. 1838 patients were admitted to the ED with a BP ≥ 180/120 mmHg (0.95% of total admissions) of whom 37.7% were HE and the remaining (62.3%) were UH. The reduction in Systolic and Diastolic BP (SBP/DBP respectively) was similar in HE (40.6/16.9 ± 26.3/17.7 mmHg) and UH (39.3/15.5 ± 22.4/16.0 mmHg). The most used drugs were intravenous furosemide, nitroglycerin, clonidine and labetalol for HE. Age, smoking, heart failure, previous acute coronary syndrome, chronic kidney disease and diabetes mellitus present a positive association HEs while female sex and chronic anti-hypertensive therapies with 2 or more drugs results as protective variables. Finally, regarding the exploratory analysis, BP at ED admission and its management didn't present significant association with in-hospital mortality. In conclusions, our study demonstrated that adherence to guidelines in the management of HE/UH could be further improved.
中文摘要:关于高血压急症(HE)和未控制高血压(UH)的患病率与临床管理,已发表的数据差异很大。研究目的是描述HE和UH患者特征,评估急诊科血压管理、药物治疗及其与指南推荐的一致性;分析与靶器官损害相关的变量;并作为探索性分析,观察血压对院内死亡率的影响。研究为多中心回顾性研究,纳入米兰Niguarda医院和Desio Pio XI医院2017年与2019年急诊就诊且血压≥180/120 mmHg的患者。共有1838例患者因血压≥180/120 mmHg就诊于急诊科,占全部就诊的0.95%,其中37.7%为HE,其余62.3%为UH。HE与UH的收缩压和舒张压下降幅度相似,HE为40.6/16.9±26.3/17.7 mmHg,UH为39.3/15.5±22.4/16.0 mmHg。HE最常用的药物为静脉呋塞米、硝酸甘油、可乐定和拉贝洛尔。年龄、吸烟、心力衰竭、既往急性冠脉综合征、慢性肾脏病和糖尿病与HE呈正相关,女性以及使用两种或以上降压药进行慢性抗高血压治疗为保护性变量。探索性分析中,急诊入院时血压及其管理未显示与院内死亡率有显著关联。结论认为,HE/UH管理中对指南的依从性仍有进一步提升空间。
Co-occurring obesity and hypertension is associated with high cardiovascular risk, whereas the prognostic significance of underweight in the presence of hypertension remains uncertain. We examined whether the association between body mass index category and 10-year risk of major adverse cardiovascular events differed across blood pressure categories. Using the Japan Medical Claims Database from 2005 to 2023, we analyzed 6,262,298 adults without prior cardiovascular disease, chronic renal failure, dialysis, or antihypertensive medication use at baseline. Blood pressure was classified as normal (<120 and <80 mmHg), high-normal (120-129 and <80 mmHg), elevated (130-139 and/or 80-89 mmHg), stage 1 hypertension (140-159 and/or 90-99 mmHg), or stage 2/3 hypertension (≥160 and/or ≥100 mmHg). Body mass index was classified as underweight (<18.5 kg/m²), normal weight (18.5-24.9), overweight (25.0-29.9), or obesity (≥30.0). The primary outcome was major adverse cardiovascular events within 10 years. Multivariable Cox proportional hazards models estimated hazard ratios for combined blood pressure and body mass index categories, using normal blood pressure with normal weight as the reference. During a median follow-up of 1,183 days, 34,034 participants experienced major adverse cardiovascular events. Underweight showed a marked blood pressure-dependent increase in risk, with the hazard ratio rising from 1.14 (95% confidence interval, 1.07-1.22) in normal blood pressure to 5.01 (4.23-5.93) in stage 2/3 hypertension. The interaction between blood pressure category and body mass index category was significant. These findings suggest that higher blood pressure may amplify the adverse prognostic significance of underweight.
中文摘要:肥胖与高血压并存与心血管风险升高相关,但低体重在高血压状态下的预后意义仍不明确。研究分析体重指数分类与10年主要不良心血管事件风险之间的关联是否随血压分类不同而变化。利用日本医疗索赔数据库2005至2023年数据,纳入6,262,298名基线无既往心血管病、慢性肾功能衰竭、透析或降压药使用的成年人。血压分为正常(<120且<80 mmHg)、正常高值(120-129且<80 mmHg)、升高(130-139和/或80-89 mmHg)、1期高血压(140-159和/或90-99 mmHg)、2/3期高血压(≥160和/或≥100 mmHg)。体重指数分为低体重(<18.5 kg/m²)、正常体重(18.5-24.9)、超重(25.0-29.9)、肥胖(≥30.0)。主要结局为10年内主要不良心血管事件。多变量Cox比例风险模型估计血压与体重指数联合分类的风险比,以血压正常且体重正常为参照。中位随访1,183天,34,034名参与者发生主要不良心血管事件。低体重的风险随血压升高呈明显增加,风险比从血压正常时的1.14(95%置信区间1.07-1.22)升至2/3期高血压时的5.01(4.23-5.93)。血压分类与体重指数分类的交互作用显著。这些发现提示,较高的血压可能放大低体重的不良预后意义。
Simultaneous pancreas-kidney transplantation (SPKTx) and kidney transplantation alone (KTx) are common treatment modalities for individuals with type 1 diabetes with end-stage kidney disease. This study compared metabolic and macrovascular disease outcomes between SPKTx and KTx in recipients with type 1 diabetes. We conducted a systematic search of the Embase, MEDLINE and Scopus databases (last searched 23 February 2025). We included retrospective and case-control studies, owing to a lack of randomised controlled trials in English, with adult patients. We excluded studies reporting on a return to dialysis post transplant, islet-kidney transplantation or separate pancreas-kidney transplants. Bias and study quality were assessed via the Newcastle-Ottawa scale for cohort studies. Demographic and outcome data were synthesised as both categorical and continuous data, with pooled means and summary statistics computed where applicable. Meta-analysis was performed on post-transplant outcomes in studies evaluating total cholesterol (TC), triglyceride (TG) level, HDL, LDL, blood pressure, HbA1c and renal function. Macrovascular outcomes included the frequency of new or adverse events associated with coronary artery disease (CAD), cerebrovascular disease (CeVD) and peripheral vascular disease (PVD). A total of 15 studies (n=564 SPKTx, 419 KTx) were included. Meta-analysis demonstrated lower post-transplant TC (mean difference -0.41 mmol/l [95% CI -0.60, -0.22], p<0.01, I2=37%), TG level (mean difference -0.76 mmol/l [95% CI -1.02, -0.49], p<0.01, I2=86%), LDL (mean difference -0.28 mmol/l [95% CI -0.42, -0.14], p<0.01, I2=15%), HbA1c (mean difference -28.79 mmol/mol [95% CI -35.75, -21.82], p<0.01, I2=98%; mean difference -2.61% [95% CI -3.05, -2.16], p<0.01) and creatinine levels (mean difference -21.54 μmol/l [95% CI -39.23, -3.85], p=0.02, I2=90%) following SPKTx compared with KTx. Mean antihypertensive agent use per participant decreased post SPKTx (1.0 vs 2.5 pre transplant; p<0.01), but was not significantly different from post-KTx groups. HbA1c increased following KTx (69 mmol/mol [8.5%]) compared with pre KTx (53 mmol/mol [7.0%], p<0.01). Progression of CAD, CeVD and PVD occurred across both groups post transplant. PVD showed more than a twofold increase in amputations and revascularisations post transplant. No difference was observed in the post-transplant frequency of CAD, CeVD or PVD between SPKTx and KTx. Evidence from this study was limited by a lack of subgroup data for analysis, a lack of randomised studies and a paucity of reported lifestyle factors influencing outcomes. SPKTx demonstrates a superior metabolic profile post transplant to that in KTx in recipients with type 1 diabetes. However, this does not translate into differences in the risk of CAD or PVD post transplant, with PVD accounting for the greatest burden of macrovascular disease. This protocol has been registered a priori on PROSPERO (CRD42024622408).
中文摘要:同期胰肾联合移植(SPKTx)和单纯肾移植(KTx)是合并终末期肾病的1型糖尿病患者常用治疗方式。本研究比较SPKTx与KTx受者代谢及大血管疾病结局。我们系统检索Embase、MEDLINE和Scopus数据库(末次检索2025年2月23日)。由于缺乏英文随机对照试验,纳入成人患者的回顾性和病例对照研究。排除移植后恢复透析、胰岛-肾移植或分期胰肾移植的研究。采用纽卡斯尔-渥太华量表评估队列研究偏倚和研究质量。人口学和结局数据按分类及连续变量汇总,适当时计算合并均值和汇总统计量。对评估总胆固醇(TC)、甘油三酯(TG)、HDL、LDL、血压、HbA1c和肾功能的研究进行移植后结局荟萃分析。大血管结局包括冠状动脉疾病(CAD)、脑血管疾病(CeVD)和外周血管疾病(PVD)相关新发或不良事件的发生频率。共纳入15项研究(SPKTx n=564,KTx n=419)。荟萃分析显示,与KTx相比,SPKTx后TC更低(均数差 -0.41 mmol/l [95% CI -0.60, -0.22],p<0.01,I2=37%)、TG水平更低(均数差 -0.76 mmol/l [95% CI -1.02, -0.49],p<0.01,I2=86%)、LDL更低(均数差 -0.28 mmol/l [95% CI -0.42, -0.14],p<0.01,I2=15%)、HbA1c更低(均数差 -28.79 mmol/mol [95% CI -35.75, -21.82],p<0.01,I2=98%;均数差 -2.61% [95% CI -3.05, -2.16],p<0.01)及肌酐水平更低(均数差 -21.54 μmol/l [95% CI -39.23, -3.85],p=0.02,I2=90%)。SPKTx后每名受者平均降压药使用减少(移植前2.5 vs 移植后1.0;p<0.01),但与KTx后组无显著差异。KTx后HbA1c较KTx前升高(69 mmol/mol [8.5%] vs 53 mmol/mol [7.0%],p<0.01)。两组移植后均出现CAD、CeVD和PVD进展。PVD表现为移植后截肢和血运重建增加超过两倍。SPKTx与KTx移植后CAD、CeVD或PVD发生频率无差异。本研究证据受限于缺乏可用于分析的亚组数据、缺乏随机研究以及影响结局的生活方式因素报告较少。SPKTx在1型糖尿病受者中显示出优于KTx的移植后代谢特征。然而,这并未转化为移植后CAD或PVD风险的差异,PVD构成最大的大血管疾病负担。该方案已在PROSPERO前瞻性注册(CRD42024622408)。
Circadian blood pressure (BP) values may be different from clinic BP values. Thus, antihypertensive therapy guided solely by clinic BP might not prove appropriate. Moreover, ambulatory BP parameters are superior to clinic BP in predicting outcomes, indicating they should receive more attention as therapeutic targets. Among all relevant 24-h BP parameters, in both untreated and treated patients, two clinically unpredictable windows with proven prognostic relevance deserve attention: the period after awakening and the nighttime one. Some patients exhibit higher BP after awakening, which is associated with increased risk. In untreated patients, underdosed therapy could be started. In treated ones, most likely the drug taken the previous morning could not provide adequate duration of action. In this context, a medication with delayed onset of action and peak effect after several hours added in the evening could be of benefit to blunt morning BP rise. Others show high nighttime BP, which is associated with increased risk. In untreated patients, this can lead to prescribe underdosed therapy. In treated patients, most likely antihypertensive therapy in the morning does not cover the 24-h period. In this context, a drug with rapid onset of action and peak effect after few hours added in the evening could reduce high nighttime BP. Globally, evening therapy must be tailored to nighttime BP pattern to achieve the desired effect in the early morning or during the night. Future studies in which antihypertensive therapy is tailored to circadian BP profile, a more physiological definition of chronotherapy, should be scheduled.
中文摘要:昼夜血压值可能不同于诊室血压值,仅依据诊室血压指导降压治疗未必合适。动态血压参数在预测结局方面优于诊室血压,提示应更重视其作为治疗目标。在所有相关的24小时血压参数中,无论未治疗还是已治疗患者,两个临床难以预测但已证实具有预后意义的时间窗值得关注:觉醒后时段和夜间时段。部分患者觉醒后血压较高,与风险增加相关。未治疗患者可开始剂量不足的治疗。已治疗患者最可能是前一日早晨服用的药物作用持续时间不足。在此情况下,晚间加用起效延迟、数小时后达峰的药物可能有助于削弱晨峰血压。另一些患者夜间血压高,也与风险增加相关。未治疗患者可因此给予剂量不足的治疗。已治疗患者最可能是早晨降压治疗未覆盖24小时。在此情况下,晚间加用起效快、数小时内达峰的药物可降低夜间高血压。总体而言,晚间治疗必须根据夜间血压模式调整,以在清晨或夜间达到预期效果。未来应安排将降压治疗按昼夜血压谱调整的研究,这是对时间治疗学更生理化的定义。
Intensive blood pressure treatment reduces cardiovascular events, but the optimal achieved home systolic blood pressure (SBP) level for older patients with hypertension remains uncertain. This secondary analysis was based on data from the Strategy of Blood Pressure Intervention in Older Hypertensive Patients trial. Morning and evening home blood pressure measurements obtained between 3 and 12 months after enrollment were used to calculate the achieved home SBP. Participants were then categorized into four achieved home SBP groups: <125 mmHg, 125-130 mmHg, 130-135 mmHg, and ≥135 mmHg. The primary outcome was a composite of cardiovascular events. Among 7681 participants included in this analysis, 261 primary events occurred during the median follow-up of 3.43 years. Compared with home SBP ≥ 135 mmHg, the absolute risk reduction for the primary composite outcome was 1.70% in the <125 mmHg group, 1.36% in the 125-130 mmHg group. In multivariable analyses, home SBP < 125 mmHg and 125-130 mmHg were associated with lower risks of the primary composite outcome, with adjusted HRs of 0.62 (95% CI, 0.42-0.90) and 0.66 (95% CI, 0.47-0.94), respectively. Similar protective associations were observed for stroke (adjusted HR, 0.36; 95% CI, 0.19-0.66). Lower home SBP categories were not associated with a statistically significant increase in the primary safety outcome. These findings suggest that achieving home SBP below 130 mmHg, and further approaching 125 mmHg in selected patients with a high risk of stroke and good treatment tolerance, may provide additional cardiovascular benefit beyond the conventional threshold.
中文摘要:强化降压可减少心血管事件,但老年高血压患者最佳的家庭收缩压达标水平仍不确定。本分析基于老年高血压患者血压干预策略试验数据的二次分析。入组后3至12个月获得的晨间和晚间家庭血压测量用于计算家庭收缩压达标值。参与者按家庭收缩压达标水平分为四组:<125 mmHg、125-130 mmHg、130-135 mmHg和≥135 mmHg。主要结局为心血管事件复合终点。纳入分析的7681名参与者中,在中位随访3.43年期间发生261例主要事件。与家庭收缩压≥135 mmHg相比,<125 mmHg组主要复合结局的绝对风险降低为1.70%,125-130 mmHg组为1.36%。多变量分析中,家庭收缩压<125 mmHg和125-130 mmHg与主要复合结局风险较低相关,校正HR分别为0.62(95% CI,0.42-0.90)和0.66(95% CI,0.47-0.94)。卒中方面观察到相似的保护关联(校正HR,0.36;95% CI,0.19-0.66)。较低家庭收缩压类别与主要安全性结局的统计学显著增加无关。这些结果表明,将家庭收缩压控制在130 mmHg以下,并在卒中风险高且治疗耐受良好的部分患者中进一步接近125 mmHg,可能带来超过常规阈值的额外心血管获益。
High-altitude erythrocytosis (HAE) may have vascular implications, but its association with arterial stiffness in long-term high-altitude residents remains unclear. We conducted a cross-sectional study of adults from Chengdu and high-altitude areas of Sichuan Province between January 2024 and February 2026. After excluding participants with ankle-brachial index <0.90 or atrial fibrillation, 3346 participants were included (2271 low-altitude and 1075 high-altitude residents). Arterial stiffness was assessed by brachial-ankle pulse wave velocity (baPWV); the primary outcome was mean baPWV, and the clinical outcome was mean baPWV ≥1800 cm/s. High-altitude residents had higher mean baPWV than low-altitude residents (1576.1 ± 403.1 vs 1474.4 ± 309.4 cm/s), with a higher prevalence of mean baPWV ≥1800 cm/s (23.8% vs 14.8%). Among high-altitude residents, 114 had HAE and 961 did not. Participants with HAE had higher mean baPWV (1969.4 ± 563.0 vs 1529.5 ± 352.0 cm/s). After adjustment for age, sex, body mass index, systolic blood pressure, heart rate, smoking, alcohol drinking, diabetes, lipid parameters and estimated glomerular filtration rate, HAE remained associated with higher mean baPWV (β, 297.5 cm/s; 95% CI, 219.6-375.5; P < 0.001) and higher odds of mean baPWV ≥1800 cm/s (OR, 3.30; 95% CI, 1.98-5.48; P < 0.001). Hemoglobin-category, continuous hemoglobin, and restricted cubic spline analyses supported a positive, nonlinear hemoglobin-baPWV association. HAE was associated with greater baPWV burden among long-term high-altitude residents, but causality cannot be inferred.
中文摘要:高原红细胞增多症(HAE)可能对血管产生影响,但其与长期高原居民动脉僵硬度的关联仍不明确。我们于2024年1月至2026年2月在成都及四川省高海拔地区开展了一项成人横断面研究。排除踝臂指数<0.90或心房颤动的参与者后,共纳入3346人(低海拔居民2271人,高海拔居民1075人)。动脉僵硬度采用臂踝脉搏波传导速度(baPWV)评估;主要结局为平均baPWV,临床结局为平均baPWV≥1800 cm/s。高海拔居民平均baPWV高于低海拔居民(1576.1±403.1 vs 1474.4±309.4 cm/s),平均baPWV≥1800 cm/s的比例更高(23.8% vs 14.8%)。高海拔居民中,114例有HAE,961例无HAE。HAE者平均baPWV更高(1969.4±563.0 vs 1529.5±352.0 cm/s)。调整年龄、性别、体重指数、收缩压、心率、吸烟、饮酒、糖尿病、血脂参数和估算肾小球滤过率后,HAE仍与较高平均baPWV相关(β,297.5 cm/s;95% CI,219.6-375.5;P<0.001),并与平均baPWV≥1800 cm/s的较高比值比相关(OR,3.30;95% CI,1.98-5.48;P<0.001)。血红蛋白分类、连续血红蛋白和限制性立方样条分析支持血红蛋白与baPWV呈正向非线性关联。HAE与长期高原居民更高的baPWV负担相关,但不能推断因果关系。
Primary aldosteronism is the most common secondary endocrine form of hypertension. Specific treatment directly against aldosterone excess improves control of (and may cure) hypertension and reduces long-term cardiovascular and renal morbidity in patients with primary aldosteronism. Optimal treatment is guided by the results of adrenal venous sampling, with unilateral adrenalectomy being the preferred management for those with lateralizing forms and medical treatment with a mineralocorticoid antagonist for those with bilateral forms. Seated saline suppression testing, being highly specific for primary aldosteronism, provides a means of confirming the diagnosis and, being highly sensitive for lateralizing primary aldosteronism, allows selection of patients most likely to benefit from adrenal venous sampling and spares those with a negative seated saline suppression testing from having to undergo this invasive and expensive procedure. Recent studies, however, have reported poor performance of the seated saline suppression testing, probably in part due to deviation from published procedural methodology, including inappropriate patient selection, failure to render patients' potassium replete by the time of the test, or failure to commence the saline infusion on time. This has prompted the development of a clear and comprehensive standard operating protocol for seated saline suppression testing so that high-quality test results can be more readily attained and usefully applied both for interpreting research studies and for clinical decision-making.
中文摘要:原发性醛固酮增多症是高血压最常见的继发性内分泌病因。针对醛固酮过多的特异性治疗可改善高血压控制,甚至可能治愈高血压,并降低患者长期心血管与肾脏疾病负担。最佳治疗由肾上腺静脉采血结果指导:单侧病变者首选单侧肾上腺切除术,双侧病变者采用盐皮质激素受体拮抗剂药物治疗。坐位盐水抑制试验对原发性醛固酮增多症具有高特异性,可用于确诊;对单侧型原发性醛固酮增多症具有高敏感性,有助于筛选最可能从肾上腺静脉采血获益的患者,并使试验阴性的患者免于接受这种有创且昂贵的检查。近期研究报道坐位盐水抑制试验表现不佳,部分原因可能是偏离已发表的操作方法,包括患者选择不当、试验时未使患者钾水平恢复正常,或未按时开始盐水输注。这促使制定清晰、全面的坐位盐水抑制试验标准操作方案,以便更容易获得高质量试验结果,并有效用于解释研究和临床决策。
Physical exercise and antihypertensive medications are routinely co-prescribed for treating hypertension. Contemporary international guidelines separately establish the expected effects of pharmacological and exercise interventions. However, meta-analytical evidence assessing the additional effect of exercise on antihypertensive medication is lacking. We conducted a systematic review and meta-analysis of randomised controlled trials evaluating the effects of exercise interventions in adults receiving stable antihypertensive medication. The outcomes included blood pressure parameters, body composition, lipid profiles, glycaemic markers, and cardiorespiratory fitness. Mean differences (MDs) with 95% CIs were pooled using random-effects models, and the risk of bias of the studies was assessed using the RoB2 tool. This systematic review with meta-analysis was registered in PROSPERO (CRD420261277175). Forty-eight studies (2085 participants across 57 publications) fulfilled the inclusion criteria. Compared with usual care on a background of stable medication, exercise reduced office SBP (MD -7.9 mmHg; 95% CI -10.3 to -5.6; I² = 78%) and office DBP (-4.4; -5.8 to -3.1; I² = 64%). The magnitude of these reductions is comparable to that expected from adding a further antihypertensive agent, although the certainty of evidence was low and the prediction intervals were wide. Beyond these effects, significant improvements were observed across multiple outcomes, including office mean blood pressure (MAP), 24 h ambulatory DBP, daytime DBP, nighttime ambulatory blood pressure, body weight, BMI, HDL-c, triglycerides, fasting glucose, and cardiorespiratory fitness. In contrast, no significant between-group differences were observed for changes in 24 h ambulatory SBP, daytime SBP, 24 h MAP, daytime MAP, body fat percentage, waist circumference, total cholesterol, LDL-c, and HbA1c levels. Evidence quality ranged from low to very low for ambulatory SBP, whereas it was moderate for diastolic and nocturnal measurements. No exercise modality (aerobic, resistance, combined, high-intensity interval, or isometric training) was significantly superior to another for any outcome. Adding structured exercise to stable antihypertensive therapy was associated with further reductions in office blood pressure and several ambulatory blood-pressure indices, and with improvements in cardiovascular risk factors; however, given the heterogeneity and risk of bias, the certainty was low to moderate for most estimates, and trials testing exercise-guided medication adjustment are warranted.
中文摘要:体力运动与降压药物常被同时处方用于治疗高血压。国际指南分别给出药物和运动干预的预期效应,但评估运动在降压药物治疗基础上额外作用的荟萃分析证据不足。我们系统检索并荟萃分析随机对照试验,纳入正在接受稳定降压药物治疗的成人,评价运动干预的效果。结局包括血压参数、体成分、血脂谱、血糖标志物和心肺适能。采用随机效应模型合并均数差(MD)及95%CI,并用RoB2工具评估偏倚风险。该系统评价与荟萃分析注册于PROSPERO(CRD420261277175)。48项研究(57篇文献,2085名参与者)符合纳入标准。在稳定用药背景下,与常规照护相比,运动降低诊室收缩压(MD -7.9 mmHg;95%CI -10.3至-5.6;I²=78%)和诊室舒张压(-4.4;-5.8至-3.1;I²=64%)。这些降幅与再加用一种降压药的预期效应相当,但证据确定性低,预测区间宽。诊室平均血压、24小时动态舒张压、日间舒张压、夜间动态血压、体重、BMI、HDL-c、甘油三酯、空腹血糖和心肺适能也有显著改善。24小时动态收缩压、日间收缩压、24小时平均血压、日间平均血压、体脂百分比、腰围、总胆固醇、LDL-c和HbA1c变化未见显著组间差异。动态收缩压的证据质量低至极低,舒张压和夜间测量的证据质量为中等。有氧、抗阻、联合、高强度间歇或等长训练在任何结局上均未显示显著优于其他模式。在稳定降压治疗基础上加入结构化运动与诊室血压及部分动态血压指标进一步下降相关,并与心血管危险因素改善相关;鉴于异质性和偏倚风险,多数估计的确定性为低至中等,仍需开展以运动指导药物调整的试验。
Home blood pressure monitoring (HBPM) is recommended for the management of hypertension; however, patients' understanding of hypertension and HBPM remains insufficient. This multicenter cross-sectional study assessed knowledge of hypertension and HBPM among 1920 patients receiving pharmacological treatment across 12 states in India and identified factors associated with relatively higher knowledge. Knowledge was evaluated across four domains: understanding of clinic and home blood pressure (BP) thresholds, awareness of causes of hypertension, recognition of risks associated with uncontrolled BP, and awareness of the benefits of HBPM. The median knowledge score was 1 (range 0-7), indicating generally low knowledge. Knowledge varied across domains, with particularly poor understanding of BP thresholds and limited awareness of HBPM benefits, while awareness of causes and complications was relatively higher but still insufficient. Relatively higher knowledge (≥75th percentile) was observed in 38.0% of participants and was more common among participants with prior HBPM experience than among those without prior HBPM experience (46.9% vs. 29.9%, p < 0.001). Higher education, type of healthcare facility, and prior HBPM experience were associated with relatively higher knowledge. These findings suggest that knowledge of hypertension among patients in India is limited and domain-specific, with critical gaps in areas essential for interpreting and utilizing BP measurements. Improving hypertension management may require not only promoting HBPM but also strengthening patient education. Clinical trial registration status: Registered at Clinical Trials Registry-India (CTRI) under CTRI/2023/02/049486 on 06 February 2023.
中文摘要:家庭血压监测(HBPM)被推荐用于高血压管理,但患者对高血压及HBPM的理解仍不充分。这项多中心横断面研究评估了印度12个邦1920例接受药物治疗的患者对高血压和HBPM的认知情况,并识别与认知水平相对较高相关的因素。认知评估涵盖四个方面:对诊室与家庭血压阈值的理解、对高血压病因的了解、对血压控制不良相关风险的认识,以及对HBPM益处的知晓。认知得分中位数为1分(范围0—7分),总体认知水平偏低。各领域认知存在差异,对血压阈值的理解尤为不足,对HBPM益处的知晓有限;对病因和并发症的知晓相对较高,但仍不充分。38.0%的参与者认知相对较高(≥第75百分位),有HBPM既往经验者中更为常见(46.9%对29.9%,p<0.001)。较高教育程度、医疗机构类型及既往HBPM经验与相对较高的认知相关。结果提示,印度患者对高血压的认知有限且呈领域特异性,在解读和利用血压测量所必需的关键方面存在明显缺口。改善高血压管理可能不仅需要推广HBPM,还需加强患者教育。临床试验注册情况:2023年2月6日在印度临床试验注册中心(CTRI)注册,注册号CTRI/2023/02/049486。
Accurate ambulatory blood pressure monitoring (ABPM) is essential for cardiovascular risk assessment and hypertension management, but conventional cuff-based ABPM causes discomfort and sleep disturbance, potentially affecting measurement reliability. The European Society of Hypertension (ESH) established evaluation criteria for cuffless blood pressure devices, with the awake/asleep test as the primary evaluation test for automated wearable devices. This study evaluated whether Alysis-001, a software-based cuffless blood pressure estimation algorithm using sensor data from a wrist-worn device, meets ESH awake/asleep test criteria in hypertensive patients under two data extraction strategies: (1) arm-stabilized periods only ( ≥ 10 s static); (2) including low-intensity activity (high-intensity excluded). We prospectively enrolled 92 hypertensive outpatients receiving antihypertensive treatment who simultaneously wore Alysis Wear and underwent conventional 24-h ABPM; 78 completed the study. Under both strategies, Alysis-001 demonstrated excellent agreement with reference ABPM across all measurement periods, with intraclass correlation coefficients exceeding 0.70 for systolic and diastolic blood pressure. Alysis-001 successfully met all ESH awake/asleep test criteria under both strategies: mean difference between awake-asleep blood pressure changes ≤5 mmHg, standard deviation ≤8 mmHg, and correlation coefficients ≥0.70 for both systolic and diastolic blood pressure. Alysis-001 also demonstrated high sensitivity, specificity, and accuracy in identifying non-dippers under both strategies. To our knowledge, this represents the first evaluation of a Device Type 3 cuffless blood pressure algorithm (automated, wearable, demographic-calibrated, not at heart level) meeting ESH awake/asleep test criteria, suggesting Alysis-001's potential as a clinically viable alternative for ambulatory blood pressure monitoring in hypertensive patients.
中文摘要:准确的动态血压监测(ABPM)对心血管风险评估和高血压管理至关重要,但传统袖带式ABPM会引起不适和睡眠干扰,可能影响测量可靠性。欧洲高血压学会(ESH)为无袖带血压设备建立了评价标准,其中清醒/睡眠测试是自动可穿戴设备的主要评价测试。本研究评估Alysis-001这一基于软件的無袖带血压估计算法(使用腕戴设备的传感器数据)在高血压患者中是否满足ESH清醒/睡眠测试标准,并比较两种数据提取策略:(1)仅手臂稳定期(≥10秒静止);(2)纳入低强度活动(排除高强度活动)。研究前瞻性纳入92例接受降压治疗的高血压门诊患者,同时佩戴Alysis Wear并接受传统24小时ABPM,78例完成研究。两种策略下,Alysis-001在所有测量时段均与参考ABPM显示出良好一致性,收缩压和舒张压的组内相关系数均超过0.70。Alysis-001在两种策略下均成功满足ESH清醒/睡眠测试的全部标准:清醒-睡眠血压变化的平均差≤5 mmHg,标准差≤8 mmHg,收缩压和舒张压的相关系数均≥0.70。两种策略下,Alysis-001识别非杓型血压者的敏感性、特异性和准确性也较高。据我们所知,这是首次评估一种Device Type 3无袖带血压算法(自动、可穿戴、按人口学特征校准、非心脏水平)满足ESH清醒/睡眠测试标准,提示Alysis-001可能成为高血压患者动态血压监测的临床可行替代方案。
Since the first Baveno Consensus Conference in 1990, successive conferences held every 5 years have transformed the field of cirrhosis and portal hypertension, evolving from a focus on variceal bleeding to a pathophysiology-based framework centred on risk stratification, clinically significant portal hypertension (CSPH), and the prevention of decompensation. Building on this progress, the Baveno Cooperation, in collaboration with the Vascular Liver Disease Interest Group (VALDIG), convened an expert faculty to review the evidence published since Baveno VII and update clinical guidance for patients with advanced chronic liver disease (ACLD), portal hypertension, and vascular liver diseases. The Baveno VIII Consensus Conference, held in March 2026 in Baveno, Italy, was based on a structured consensus process across nine panels addressing key domains of ACLD, portal hypertension, and vascular liver diseases. Statements and recommendations were developed through iterative review of the evidence and voting among faculty, with strong consensus defined as >80% faculty agreement. A total of 272 statements and recommendations achieved strong consensus. Key areas included non-invasive risk stratification in compensated ACLD (cACLD), modifiers of steatotic liver disease, prevention of first and further decompensation, management of portal hypertensive bleeding and further decompensation, cirrhosis recompensation, and vascular liver diseases, including Budd-Chiari syndrome, portosinusoidal vascular disorder (PSVD) or non-cirrhotic portal fibrosis (NCPF), and portal vein thrombosis (PVT). The central role of CSPH and the expanding use of non-invasive tests were reaffirmed, and several diagnostic and prognostic cut-offs were revised. New to Baveno VIII is the inclusion of selected guidance for paediatric patients. Recommendations from previous conferences that were not specifically revised in Baveno VIII, such as those on hepatic venous pressure gradient (HVPG) measurement, remain valid. Finally, a research agenda identifying 153 priority topics is proposed.
中文摘要:自1990年首次Baveno共识会议以来,每5年召开一次的后续会议改变了肝硬化和门静脉高压领域,重点从静脉曲张出血转向以病理生理为基础、围绕风险分层、临床显著门静脉高压(CSPH)和预防失代偿的框架。在此基础上,Baveno协作组与血管性肝病兴趣组(VALDIG)召集专家组,回顾Baveno VII以来发表的证据,并更新针对晚期慢性肝病(ACLD)、门静脉高压和血管性肝病患者的临床指导。Baveno VIII共识会议于2026年3月在意大利Baveno举行,采用结构化共识流程,设九个专家组,覆盖ACLD、门静脉高压和血管性肝病的关键领域。声明和建议通过反复审查证据和专家投票形成,强共识定义为超过80%的专家同意。共有272条声明和建议达成强共识。关键领域包括代偿期ACLD(cACLD)的无创风险分层、脂肪性肝病的修饰因素、首次及进一步失代偿的预防、门静脉高压性出血和进一步失代偿的处理、肝硬化再代偿,以及血管性肝病,包括Budd-Chiari综合征、门窦血管性疾病(PSVD)或非肝硬化门静脉纤维化(NCPF)和门静脉血栓(PVT)。会议重申CSPH的核心作用和越来越多使用无创检测,并修订了若干诊断和预后截断值。Baveno VIII新增了对儿科患者的选定指导。既往会议中未在Baveno VIII专门修订的建议仍然有效,例如肝静脉压力梯度(HVPG)测量相关建议。最后,提出了包含153个优先主题的研究议程。
Angiotensinogen (AGT) is the precursor of angiotensin peptides and a key determinant of renin-angiotensin-aldosterone system activity. ART101 is an investigational N-acetylgalactosamine-conjugated small interfering RNA (GalNAc-siRNA) designed to durably suppress hepatic AGT synthesis. To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of the AGT-targeting GalNAc-siRNA in healthy volunteers and to provide an initial exploratory assessment of blood pressure effects in patients with hypertension. This phase I study was conducted from January 2025 to April 2026 with 24-week follow-up. Part A was a double-blind, placebo-controlled, single ascending-dose trial; part B was an open-label, single-dose study. The study took place at Beijing Friendship Hospital, Capital Medical University, Beijing, China. Part A enrolled 40 healthy adults randomized 6:2 to receive the GalNAc-siRNA (25-600 mg) or placebo; 39 completed the study. Part B enrolled 8 patients with hypertension receiving the GalNAc-siRNA, 600 mg; all completed the study. A single subcutaneous injection of the AGT-targeting GalNAc-siRNA (25, 75, 150, 300, or 600 mg) or placebo in part A; a single open-label subcutaneous injection of GalNAc-siRNA, 600 mg, in part B. The primary outcome was safety and tolerability; secondary outcomes included pharmacokinetics, pharmacodynamics, exploratory blood pressure assessments, and renin-angiotensin-aldosterone system biomarkers. Among 40 healthy volunteers (27 [67.5%] male; mean [SD] age, 40.4 [7.8] years) and 8 patients (6 [75.0%] male; mean [SD] age, 47.3 [10.3] years) with hypertension, the AGT-targeting GalNAc-siRNA was well tolerated. In part A, treatment-emergent adverse events (TEAEs) occurred in 23 of 30 active-treatment participants (76.7%) vs 7 of 10 placebo recipients (70.0%); in part B, 6 of 8 patients (75.0%) had TEAEs. No serious adverse events, injection site reactions, or hyperkalemia were observed; all TEAEs were mild to moderate. Plasma exposure (maximum plasma concentration [Cmax] and area under the plasma concentration-time curve [AUC]) increased with dose over the wide dose range from 25 mg to 600 mg. Mean maximum serum AGT reductions of 93% (at 600 mg) in healthy volunteers and 90% (at 600 mg) in patients with hypertension were observed. At 24 weeks after a single 600-mg dose, the placebo-corrected 24-hour ambulatory systolic blood pressure decreased by 12.9 mm Hg in healthy participants. In this phase I study, no serious treatment-related safety signals were identified. Sustained, dose-dependent AGT reductions and exploratory blood pressure lowering were observed. These findings support further investigation of the AGT-targeting GalNAc-siRNA as a potential long-acting therapeutic for hypertension. China Drug Clinical Registry Identifiers: CTR20250041 (part A) and CTR20253973 (part B).
中文摘要:血管紧张素原(AGT)是血管紧张素肽的前体,也是肾素-血管紧张素-醛固酮系统活性的关键决定因素。ART101是一种在研的N-乙酰半乳糖胺(GalNAc)偶联小干扰RNA(siRNA),设计用于持久抑制肝脏AGT合成。研究旨在评估靶向AGT的GalNAc-siRNA单次递增剂量在健康志愿者中的安全性、耐受性、药代动力学和药效学,并对高血压患者的血压影响作初步探索性评估。这项I期研究于2025年1月至2026年4月开展,随访24周。A部分为双盲、安慰剂对照、单次递增剂量试验;B部分为开放标签、单次给药研究。研究在首都医科大学附属北京友谊医院进行。A部分纳入40名健康成人,按6:2随机接受GalNAc-siRNA(25-600 mg)或安慰剂;39人完成研究。B部分纳入8名高血压患者,接受GalNAc-siRNA 600 mg;全部完成研究。A部分给予单次皮下注射靶向AGT的GalNAc-siRNA(25、75、150、300或600 mg)或安慰剂;B部分给予单次开放标签皮下注射GalNAc-siRNA 600 mg。主要结局为安全性和耐受性;次要结局包括药代动力学、药效学、探索性血压评估和肾素-血管紧张素-醛固酮系统生物标志物。在40名健康志愿者(27名[67.5%]男性;平均[SD]年龄40.4[7.8]岁)和8名高血压患者(6名[75.0%]男性;平均[SD]年龄47.3[10.3]岁)中,靶向AGT的GalNAc-siRNA耐受性良好。A部分中,30名活性治疗参与者有23名(76.7%)发生治疗中出现的不良事件(TEAE),10名安慰剂接受者中有7名(70.0%);B部分8名患者中有6名(75.0%)发生TEAE。未观察到严重不良事件、注射部位反应或高钾血症;所有TEAE均为轻至中度。血浆暴露(最大血药浓度[Cmax]和血浆浓度-时间曲线下面积[AUC])在25 mg至600 mg的宽剂量范围内随剂量增加而升高。健康志愿者中血清AGT平均最大降幅为93%(600 mg时),高血压患者中为90%(600 mg时)。单次600 mg给药后24周,健康参与者的安慰剂校正24小时动态收缩压降低12.9 mmHg。在这项I期研究中,未发现严重的治疗相关安全性信号。观察到持续、剂量依赖性的AGT降低和探索性血压下降。这些结果支持将靶向AGT的GalNAc-siRNA作为潜在长效高血压治疗进一步研究。中国药物临床试验登记与信息公示平台注册号:CTR20250041(A部分)和CTR20253973(B部分)。
Hypertension affects over 1.3 billion people worldwide and is the leading modifiable cause of cardiovascular morbidity and mortality. Approximately one-third of individuals with hypertension exhibit a low-renin phenotype, a clinically heterogeneous subgroup in whom the underlying etiology remains uncharacterized in most cases. Among its mechanistic contributors, non-classical apparent mineralocorticoid excess (NC-AME), defined by partial insufficiency of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), represents a prevalent and underrecognized cause of cortisol-mediated mineralocorticoid receptor overactivation that has, to date, lacked a formal clinical definition, standardized diagnostic criteria, or evidence-based therapeutic framework. This Scientific Statement addresses that gap. The panel formally defines NC-AME as a syndrome of partial 11β-HSD2 insufficiency occurring in the absence of biallelic HSD11B2 variants, biochemically characterized by an elevated cortisol-to-cortisone (F/E) ratio and low cortisone concentration, and typically associated with low plasma renin, normal-to-low aldosterone, and elevated blood pressure. The Statement consolidates evidence across three mechanistic domains, genetic and epigenetic dysregulation of HSD11B2, endogenous and exogenous enzyme inhibition, and patient-specific alterations (i.e. age, sex, renal function), and proposes both a structured, an LC-MS/MS-based diagnostic algorithm, and a resource-adapted diagnostic approach. Mineralocorticoid receptor antagonists are endorsed as mechanism-directed first-line therapy, with blood pressure and renin normalization as co-primary treatment targets. Acquired and reversible causes are classified separately to guide clinical management. A research agenda is advanced to drive threshold standardization, multicenter validation, and integration of NC-AME into hypertension guidelines across endocrinology, cardiology, and nephrology.
中文摘要:高血压影响全球超过13亿人,是心血管疾病发病和死亡最主要的可干预原因。约三分之一高血压患者表现为低肾素表型,这一临床异质性亚组中多数病例的病因仍未明确。在相关机制中,非经典型表观盐皮质激素过多(NC-AME)由11β-羟类固醇脱氢酶2型(11β-HSD2)部分不足所定义,是皮质醇介导的盐皮质激素受体过度激活的常见但被低估的原因;此前缺乏正式临床定义、标准化诊断标准和循证治疗框架。本科学声明填补这一空白。专家组将NC-AME正式定义为不存在HSD11B2双等位基因变异时发生的部分性11β-HSD2不足综合征,其生化特征为皮质醇与可的松比值(F/E)升高和可的松浓度降低,通常伴血浆肾素降低、醛固酮正常至偏低和血压升高。声明整合了三个机制领域的证据:HSD11B2的遗传与表观遗传调控异常、内源性和外源性酶抑制、患者个体差异(即年龄、性别、肾功能),并提出基于LC-MS/MS的结构化诊断流程以及适应资源条件的诊断路径。盐皮质激素受体拮抗剂被推荐为机制导向的一线治疗,血压和肾素正常化作为共同主要治疗目标。获得性和可逆性病因单独分类以指导临床管理。声明提出研究议程,以推动阈值标准化、多中心验证,并将NC-AME纳入内分泌学、心脏病学和肾脏病学的高血压指南。
基础研究 (13篇)
Hypertension is a major driver of neurovascular dysfunction and cognitive decline, yet the molecular mechanisms linking elevated arterial pressure to impaired cerebral blood flow remain poorly defined. Piezo1, a mechanosensitive cation channel enriched in the brain endothelium, is a candidate mediator of cerebral blood flow deficits during hypertension. Using 2 distinct mouse models of hypertension-BPH/2J mice (genetically hypertensive strain) and angiotensin II-infused C57BL/6J mice-we assessed brain endothelial Piezo1 activity using patch-clamp electrophysiology. Endothelial-specific Piezo1 deletion models were used to evaluate the role of the channel in hypertension-associated cerebrovascular impairment. Cerebral blood flow responses were measured in vivo by laser speckle contrast imaging, and super-resolution nanoscopy was used to quantify Piezo1 nanoscale organization. Behavioral testing was used to assess cognition. Genetic manipulation of endothelial Piezo1 had minimal impact on baseline blood pressure. However, cerebral endothelial Piezo1 activity was markedly elevated in different hypertension models. Deletion of endothelial Piezo1 protected against hypertension-induced cerebrovascular deficits, including impaired vasomotion, reduced functional hyperemia, and blunted CO2-evoked hyperemia. Super-resolution imaging revealed that hypertension increased Piezo1 clustering, consistent with electrophysiological findings of enhanced channel coupling and open probability. Mechanistically, Piezo1 hyperactivity was PKC (protein kinase C)-dependent, and the PKC-Piezo1 spatial association was enhanced during hypertension. Importantly, PKC inhibition normalized brain endothelial Piezo1 activity, restored cerebral blood flow responses, and rescued cognitive performance. Hypertension increased the gain of Piezo1 function in brain endothelial cells, promoting dysfunctional neurovascular signaling and cognitive impairment. Targeting Piezo1 or PKC signaling selectively restored cerebrovascular regulation. This work identifies a mechanosensitive pathway that could be leveraged to protect the hypertensive brain.
中文摘要:高血压是神经血管功能障碍和认知下降的重要驱动因素,但动脉压升高导致脑血流受损的分子机制仍不明确。Piezo1是一种富集于脑内皮细胞的机械敏感阳离子通道,是高血压期间脑血流缺陷的候选介导者。研究采用两种高血压小鼠模型——BPH/2J小鼠(遗传性高血压品系)和血管紧张素II输注的C57BL/6J小鼠——用膜片钳电生理评估脑内皮Piezo1活性。利用内皮特异性Piezo1缺失模型评估该通道在高血压相关脑血管损伤中的作用。通过激光散斑对比成像在体内测量脑血流反应,并用超分辨纳米显微镜量化Piezo1的纳米尺度组织。行为学测试用于评估认知。内皮Piezo1的遗传操作对基线血压影响很小。然而,不同高血压模型中脑内皮Piezo1活性明显升高。缺失内皮Piezo1可防止高血压诱导的脑血管缺陷,包括血管运动受损、功能性充血降低和CO2诱发的充血减弱。超分辨成像显示高血压增加Piezo1成簇,这与电生理发现的通道耦联增强和开放概率升高一致。机制上,Piezo1过度活跃依赖PKC(蛋白激酶C),高血压时PKC与Piezo1的空间关联增强。抑制PKC使脑内皮Piezo1活性正常化,恢复脑血流反应并改善认知表现。高血压增加脑内皮细胞中Piezo1功能的增益,促进神经血管信号功能障碍和认知损害。选择性靶向Piezo1或PKC信号可恢复脑血管调节。这项工作识别出一条可用于保护高血压脑的机械敏感通路。
Preeclampsia (PE) is a severe pregnancy disorder characterized by hypertension and multi-organ dysfunction. Impaired trophoblast function and defective spiral artery remodeling are considered the central pathological features of PE, leading to placental ischemia/hypoxia and a subsequent inflammatory cascade. Increasing evidence has demonstrated that pyroptosis contributes to placental dysfunction and the establishment of a pro-inflammatory microenvironment in PE; however, the mechanisms remain largely unclear. O-linked β-N-acetylglucosamine (O-GlcNAc) modification is a reversible post-translational modification (PTM) that plays critical roles in maintaining cellular homeostasis and regulating multiple forms of programmed cell death (PCD), yet its role in pyroptosis during PE has not been elucidated. In the present study, we found that O-GlcNAcylation was markedly reduced in placental tissues from patients with PE and negatively correlated with pyroptosis. In both an LPS-induced PE-like mouse model and trophoblast cells, enhancement of O-GlcNAcylation significantly suppressed pyroptosis and ameliorated PE-like phenotypes. IP-MS identified UBAP2L as a critical O-GlcNAcylated protein. Mechanistically, T446, an O-GlcNAcylation site of UBAP2L, contributed to maintaining its protein stability by preventing ubiquitin-mediated proteasomal degradation and promoted its interaction with DDX21, thereby promoting stress granule assembly. This process suppressed inflammasome activation and pyroptosis, improved trophoblast function, and ameliorated PE-like phenotypes. Collectively, our findings define an O-GlcNAcylation-UBAP2L-DDX21-stress granule-pyroptosis axis in PE and nominate O-GlcNAc signaling as a therapeutic target.
中文摘要:子痫前期(PE)是一种以高血压和多器官功能障碍为特征的严重妊娠疾病。滋养细胞功能受损与螺旋动脉重塑缺陷被认为是PE的核心病理特征,可导致胎盘缺血/缺氧及随后的炎症级联反应。越来越多证据显示,细胞焦亡参与PE中胎盘功能障碍和促炎微环境的建立,但其机制仍很不清楚。O-连接β-N-乙酰葡糖胺(O-GlcNAc)修饰是一种可逆的翻译后修饰(PTM),在维持细胞稳态和调控多种程序性细胞死亡(PCD)中发挥关键作用,但其在PE细胞焦亡中的作用尚未阐明。PE患者胎盘组织中O-GlcNAc修饰明显降低,且与细胞焦亡呈负相关。在LPS诱导的PE样小鼠模型和滋养细胞中,增强O-GlcNAc修饰可显著抑制细胞焦亡并改善PE样表型。IP-MS鉴定出UBAP2L是关键O-GlcNAc修饰蛋白。机制上,UBAP2L的O-GlcNAc修饰位点T446通过阻止泛素介导的蛋白酶体降解来维持其蛋白稳定性,并促进其与DDX21相互作用,从而促进应激颗粒组装。该过程抑制炎性体激活和细胞焦亡,改善滋养细胞功能,并缓解PE样表型。这些结果共同定义了PE中的O-GlcNAc修饰-UBAP2L-DDX21-应激颗粒-细胞焦亡轴,并提示O-GlcNAc信号可作为治疗靶点。
Nocturnal hypertension is a strong predictor of cardio-cerebrovascular disease, yet its underlying mechanisms remain largely unknown. In this study, we identified CD36 as a key regulator of blood pressure (BP) rhythms and as a gatekeeper of nocturnal hypertension. Its deficiency disrupts circadian BP rhythms. We continuously monitored 48-hour BP using telemetry in CD36 global knockout mice and renal proximal tubule-specific CD36 knockout mice. We also collected serum samples and ambulatory BP monitoring data from patients with nocturnal hypertension to assess the relationship between CD36 expression and nocturnal hypertension. A comprehensive screening of various factors affecting BP and circadian rhythms was conducted to explore the molecular mechanisms. Our telemetry data revealed significantly elevated BP during the daytime (inactive period) in both CD36 global knockout and renal proximal tubule-specific knockout mice compared with their control counterparts. Furthermore, levels of platelet CD36 were negatively correlated with the severity of nocturnal hypertension in humans. Mechanistically, CD36 modulates BP rhythms through the AMPK (AMP-activated protein kinase)/HDAC5 (histone deacetylase 5)/PER1 pathway: its deficiency activates phosphorylated AMPK, leading to the dissociation of the HDAC5-PER1 complex, enhancing PER1 nuclear accumulation, and desynchronizing the oscillations of intrarenal renin-angiotensin-aldosterone system genes and clock-controlled genes, ultimately disrupting BP rhythm. Our findings highlight CD36 as a critical integrator that links renal clocks to BP homeostasis, establishing it as a potential predictor and therapeutic target for nocturnal hypertension.
中文摘要:夜间高血压是心脑血管病的强预测因素,其机制在很大程度上仍不清楚。本研究将CD36鉴定为血压节律的关键调控因子和夜间高血压的闸门。CD36缺失会破坏血压昼夜节律。我们通过遥测连续监测CD36全身敲除小鼠和肾近端小管特异性CD36敲除小鼠的48小时血压。同时收集夜间高血压患者血清样本和动态血压监测数据,评估CD36表达与夜间高血压的关系。对影响血压和昼夜节律的多种因素进行系统筛查,以探索分子机制。遥测数据显示,与相应对照小鼠相比,CD36全身敲除小鼠和肾近端小管特异性敲除小鼠在白天(非活动期)血压显著升高。人群中血小板CD36水平与夜间高血压严重程度呈负相关。机制上,CD36通过AMPK/HDAC5/PER1通路调节血压节律:CD36缺失激活磷酸化AMPK,促使HDAC5-PER1复合物解离,增强PER1核内蓄积,使肾内肾素-血管紧张素-醛固酮系统基因与钟控基因的振荡失同步,最终破坏血压节律。研究结果提示CD36是连接肾脏生物钟与血压稳态的关键整合因子,可作为夜间高血压的潜在预测指标和治疗靶点。
Hypertension is a pervasive global health challenge, impacting more than 1 billion individuals worldwide. Despite strides in therapeutic strategies, a significant proportion of patients remain resistant to the currently available therapies. Although conventional treatments predominantly focus on cardiac, renal, and cerebral targets, emerging research underscores the pivotal role of the gut and its microbiota. Yet, the precise mechanisms governing interactions between the gut microbiota and the host blood pressure remain unclear. We combined fecal microbiota transplantation between normotensive and hypertensive rats, an intersectional genetic strategy in a serotonin receptor 3a (5HT3a) receptor Cre rat line to activate, ablate, and restore serotonin-sensing colonic vagal neurons, in vivo calcium imaging and radiotelemetric blood pressure recordings, and measurements of intestinal serotonin (5-hydroxytryptamine [5-HT]) and 5HT3a receptor signaling in rats and in colonic biopsies from normotensive and hypertensive human subjects (N=5 per group; 36 to 75 years of age). A marked decrease in both intestinal 5-HT and vagal 5HT3a receptor signaling was observed in hypertensive rats and humans, and in rats subjected to fecal microbiota transplantation from hypertensive rats. Leveraging the intersectional genetic strategy in a Cre rat line, we demonstrate that intestinal 5HT3a receptor vagal signaling is a crucial link between the gut microbiota and blood pressure homeostasis and that recovery of 5-HT signaling in colon-innervating vagal neurons can alleviate hypertension. Here, we describe a neural host-microbiota interaction that is mediated by intestinal serotonin (5-HT) signaling via the vagal 5HT3a, which is crucial for maintenance of blood pressure homeostasis. This finding enhances our comprehension of hypertensive pathophysiology and unveils a promising new therapeutic target for combating resistant hypertension associated with gut dysbiosis.
中文摘要:高血压是全球普遍存在的健康挑战,影响超过10亿人。治疗策略虽有进展,仍有相当比例患者对现有治疗抵抗。传统治疗主要针对心脏、肾脏和脑,新近研究强调肠道及其微生物群的关键作用,但肠道微生物群与宿主血压相互作用的精确机制仍不清楚。研究联合使用正常血压与高血压大鼠之间的粪菌移植、5-羟色胺受体3a(5HT3a)受体Cre大鼠品系中的交叉遗传策略以激活、消融和恢复感知5-羟色胺的结肠迷走神经元、在体钙成像与遥测血压记录,并测定大鼠及正常血压和高血压受试者结肠活检中的肠道5-羟色胺(5-HT)与5HT3a受体信号(每组N=5;36至75岁)。高血压大鼠和高血压人群以及接受高血压大鼠粪菌移植的大鼠中,肠道5-HT与迷走5HT3a受体信号均明显下降。利用Cre大鼠品系的交叉遗传策略,研究证明肠道5HT3a受体迷走信号是肠道微生物群与血压稳态之间的关键联系,恢复支配结肠的迷走神经元中的5-HT信号可减轻高血压。这里描述了一种由肠道5-羟色胺(5-HT)经迷走5HT3a介导的神经性宿主-微生物群相互作用,该作用对维持血压稳态至关重要。该发现加深了对高血压病理生理学的理解,并揭示了一个有前景的新治疗靶点,用于对抗与肠道菌群失调相关的难治性高血压。
Although antihypertensive drugs mitigate hypertensive vascular injury, their vascular benefits are not fully explained by blood pressure reduction alone. Many cardiovascular drugs reshape the gut microbiota, which in turn influences their vascular pharmacology. We therefore investigated whether gut microbiota remodeling contributes to nifedipine-mediated vascular protection in high-salt hypertensive rats and a pilot patient cohort. Combining 16S rRNA sequencing, untargeted metabolomics, fecal microbiota transplantation, microbiota depletion, supplementation, and selective receptor antagonism, we found that nifedipine ameliorated gut dysbiosis. Transplantation of nifedipine-modulated microbiota improved intestinal barrier integrity and reduced vascular inflammation, oxidative stress, collagen deposition, and vascular smooth muscle cell (VSMC) phenotypic switching, while only marginally lowering blood pressure. Conversely, microbiota depletion markedly attenuated these vascular benefits despite preserving nifedipine-induced blood pressure lowering. These vascular benefits were associated with nifedipine-restored Bifidobacterium animalis subsp. lactis 420 (B420) and increased inosine availability. Supplementation with either recapitulated major vascular protective effects of nifedipine without statistically significant changes in blood pressure. In hypertensive patients, nifedipine treatment was associated with higher intestinal B420 abundance and inosine levels. In vitro, inosine modulated macrophages in an Adora2b- and Rap1-dependent manner, with accompanying changes in cAMP and KLF4, ameliorating VSMC dysfunction via paracrine signaling. In vivo, systemic Adora2b antagonism attenuated the vascular protective effects of both inosine and B420. Together, our findings support a gut microbiota-dependent component of nifedipine-mediated vascular protection that extends beyond blood pressure lowering, involving B420, increased inosine availability, and Adora2b signaling. We also nominate B420 and inosine as candidate adjuncts to calcium channel blocker therapy.
中文摘要:降压药物虽可减轻高血压性血管损伤,但其血管获益不能仅由血压下降充分解释。许多心血管药物可重塑肠道菌群,进而影响其血管药理学作用。因此,我们在高盐高血压大鼠和一个小型患者队列中研究肠道菌群重塑是否参与硝苯地平介导的血管保护。结合16S rRNA测序、非靶向代谢组学、粪菌移植、菌群清除、补充干预和选择性受体拮抗,我们发现硝苯地平改善了肠道菌群失调。移植经硝苯地平调节的菌群可改善肠道屏障完整性,并减少血管炎症、氧化应激、胶原沉积和血管平滑肌细胞(VSMC)表型转换,而血压仅轻度下降。相反,菌群清除明显削弱了这些血管获益,尽管仍保留硝苯地平诱导的降压作用。这些血管获益与硝苯地平恢复动物双歧杆菌乳亚种420(B420)及增加肌苷可利用性相关。补充B420或肌苷均可重现硝苯地平的主要血管保护作用,而血压无统计学显著变化。在高血压患者中,硝苯地平治疗与更高的肠道B420丰度和肌苷水平相关。体外,肌苷以Adora2b和Rap1依赖的方式调节巨噬细胞,并伴随cAMP和KLF4变化,通过旁分泌信号改善VSMC功能障碍。体内,全身性Adora2b拮抗削弱了肌苷和B420的血管保护作用。这些发现支持硝苯地平介导的血管保护存在独立于降压之外的肠道菌群依赖成分,涉及B420、肌苷可利用性增加和Adora2b信号。并提示B420和肌苷可作为钙通道阻滞剂治疗的候选辅助手段。
Hypertension leads to concomitant injuries in the kidney and vasculature, yet the molecular mechanisms underlying this coordinated pathology remain incompletely understood. Here, we identify activation of the CYP4A/20-HETE/GPR75 axis as being associated with coordinated renal and vascular injury in hypertension. In hypertension, this pathway was concurrently activated in the liver, kidney, and vasculature and was associated with renal fibrosis, endothelial dysfunction, and oxidative stress. Pharmacological inhibition of CYP4A attenuated these pathological changes, supporting a functional contribution of this axis to hypertensive organ injury. Genetic and pharmacological evidence further demonstrated that FGF21 acts as an endogenous negative regulator of CYP4A/20-HETE signaling. Mechanistically, FGF21 restored expression of the nuclear receptor NR1D1, which was suppressed under hypertensive conditions, and this effect was associated with reduced CYP4A expression independently of ERK1/2 signaling. The functional relevance of the FGF21-NR1D1 axis was supported by the observation that NR1D1 antagonism largely abolished the protective effects of FGF21. Thus, these findings elucidate a mechanistic axis linking FGF21-NR1D1 signaling to the CYP4A/20-HETE/GPR75 pathway and suggest that modulation of this pathway may represent a potential therapeutic strategy for hypertensive renal and vascular injury.
中文摘要:高血压可引起肾脏与血管的同步损伤,这一协同病理过程的分子机制尚未完全阐明。研究识别出CYP4A/20-HETE/GPR75轴的激活与高血压时肾脏和血管的协同损伤相关。高血压状态下,该通路在肝脏、肾脏和血管中同时激活,并与肾纤维化、内皮功能障碍和氧化应激相关。药理学抑制CYP4A可减轻这些病理改变,支持该轴对高血压器官损伤的功能性贡献。遗传学和药理学证据进一步表明,FGF21是CYP4A/20-HETE信号的内源性负性调节因子。机制上,FGF21恢复了高血压状态下受抑制的核受体NR1D1表达,这一效应与CYP4A表达降低相关,且不依赖ERK1/2信号。NR1D1拮抗在很大程度上消除FGF21的保护作用,支持FGF21-NR1D1轴的功能相关性。这些结果阐明了连接FGF21-NR1D1信号与CYP4A/20-HETE/GPR75通路的机制轴,并提示调节该通路可能成为高血压肾血管损伤的潜在治疗策略。
Pulmonary hypertension (PH) is characterized by progressive pulmonary vascular remodeling, primarily driven by the hyperproliferation of pulmonary artery smooth muscle cells (PASMCs) and their resistance to apoptosis. Metabolic reprogramming, particularly enhanced glycolysis, has been proposed to be involved in PASMCs activation. However, the implicated mechanisms remain incompletely understood. Here, using in-vitro cultured PASMCs and in-vivo PH models, we showed that malate-aspartate shuttle (MAS), a critical system connecting glycolysis to oxidative phosphorylation, was significantly inhibited in PASMCs during PH progression. The contribution of MAS-mediated NADH shuttling to energy supply markedly decreased, while fatty acid oxidation capacity and mitochondrial oxidative phosphorylation were activated as compensatory mechanisms to meet energy demands. Notably, Slc25a11, a key component of the MAS, were significantly decreased by hypoxia, whose silencing lead to evidenced PASMC activation and further recapitulated the major pathological phenotype of PH. Conversely, restoring MAS activity via Slc25a11 overexpression suppressed PASMC hyperproliferation, thereby preventing hypoxia-induced PH progression. Mechanistically, the downregulation of Slc25a11 and subsequent MAS inactivation redirected glucose-derived carbon flux towards the pentose phosphate pathway, generating NADPH to support the antioxidative system and protect PASMCs from oxidative stress. Furthermore, Slc25a11 deficiency hindered the mitochondrial-cytoplasm transfer of α-ketoglutarate (α-KG), resulting in cytoplasmic and nuclear α-KG deficiency. Insufficient nuclear α-KG reduced the activity of the histone demethylase KDM5, increasing H3K4 tri-methylation and activating transcription of proliferation-related genes. Therapeutically, α-KG supplementation restored nuclear α-KG levels, normalized histone demethylation, and ameliorated PASMC hyperproliferation in both in vitro and in vivo PH models. Collectively, this study identified MAS as a critical mediator linking metabolic changes to PASMC phenotype alterations through the modulation of glucose-derived carbon flux and epigenetic modifications. Restoration of MAS activity or α-KG supplementation may provide a potential therapeutic strategy for clinical intervention in patients with PH.
中文摘要:肺动脉高压(PH)以进行性肺血管重塑为特征,主要由肺动脉平滑肌细胞(PASMCs)过度增殖及凋亡抵抗驱动。代谢重编程,尤其是糖酵解增强,被认为参与PASMCs活化,但相关机制仍未完全明确。本研究利用体外培养的PASMCs和体内PH模型发现,连接糖酵解与氧化磷酸化的关键系统苹果酸-天冬氨酸穿梭(MAS)在PH进展中的PASMCs内显著受抑。MAS介导的NADH穿梭对能量供应的贡献明显下降,而脂肪酸氧化能力和线粒体氧化磷酸化被激活,作为满足能量需求的补偿机制。缺氧显著降低MAS关键组分Slc25a11,沉默该基因导致PASMCs活化,并进一步重现PH的主要病理表型。相反,通过过表达Slc25a11恢复MAS活性可抑制PASMCs过度增殖,从而阻止缺氧诱导的PH进展。机制上,Slc25a11下调及随后的MAS失活使葡萄糖来源的碳通量转向磷酸戊糖途径,生成NADPH以支持抗氧化系统并保护PASMCs免受氧化应激。Slc25a11缺陷还阻碍α-酮戊二酸(α-KG)从线粒体向胞质转移,造成胞质和核内α-KG不足。核内α-KG不足降低组蛋白去甲基化酶KDM5活性,增加H3K4三甲基化并激活增殖相关基因转录。治疗上,补充α-KG可恢复核内α-KG水平,使组蛋白去甲基化正常化,并在体外和体内PH模型中改善PASMCs过度增殖。总体而言,本研究将MAS确定为通过调节葡萄糖来源碳通量和表观遗传修饰,把代谢变化与PASMCs表型改变联系起来的关键介质。恢复MAS活性或补充α-KG可能为PH患者的临床干预提供潜在治疗策略。
Hypertension remains a leading modifiable risk factor for cardiovascular morbidity and mortality worldwide. Beyond conventional pharmacotherapy, growing interest has focused on bioactive natural compounds with vascular-protective properties. Coumarins, a diverse class of plant-derived benzopyrones, have emerged as potential modulators of blood pressure through their effects on endothelial function, oxidative stress, inflammation, and vascular remodeling. This review aimed to critically synthesize current evidence on the role of coumarins in hypertension management, integrating mechanistic insights, preclinical findings, pharmacokinetic considerations, and available clinical data. A structured analysis of experimental and clinical literature was conducted, emphasizing vascular signaling pathways implicated in hypertension. Data from in vitro studies, animal models of elevated blood pressure, observational cohorts, and randomized interventions were evaluated, with particular attention to nitric oxide bioavailability, reactive oxygen species modulation, inflammatory cytokine regulation, smooth muscle cell proliferation, and autonomic control mechanisms. Preclinical studies consistently demonstrate that several coumarin derivatives enhance endothelial-dependent vasodilation, restore nitric oxide signaling, reduce oxidative stress via NADPH oxidase inhibition, attenuate pro-inflammatory cytokine expression, and limit vascular smooth muscle cell proliferation. In hypertensive animal models, these effects translate into improved baroreflex sensitivity and reduced blood pressure. Observational studies and limited clinical trials suggest an inverse association between dietary coumarin intake and blood pressure levels; however, randomized evidence remains scarce and occasionally inconclusive. Coumarins exhibit multifaceted vascular-protective properties that support their potential as adjunctive agents in hypertension management. While mechanistic and preclinical data are compelling, robust, well-designed clinical trials are required to clarify efficacy, safety, optimal dosing, and patient stratification strategies before definitive therapeutic recommendations can be made.
中文摘要:高血压仍是全球心血管疾病发病和死亡的主要可改变危险因素。在常规药物治疗之外,对具有血管保护作用的生物活性天然化合物的兴趣不断增加。香豆素是一类多样的植物来源苯并吡喃酮,可通过影响内皮功能、氧化应激、炎症和血管重塑,成为血压的潜在调节剂。本综述旨在批判性整合香豆素在高血压管理中作用的现有证据,纳入机制见解、临床前发现、药代动力学考虑和可获得的临床数据。对实验和临床文献进行了结构化分析,重点关注与高血压相关的血管信号通路。评估了体外研究、血压升高动物模型、观察性队列和随机干预的数据,尤其关注一氧化氮生物利用度、活性氧调节、炎性细胞因子调控、平滑肌细胞增殖和自主神经控制机制。临床前研究一致显示,若干香豆素衍生物增强内皮依赖性血管舒张,恢复一氧化氮信号,通过抑制NADPH氧化酶减少氧化应激,减弱促炎细胞因子表达,并限制血管平滑肌细胞增殖。在高血压动物模型中,这些效应转化为压力反射敏感性改善和血压降低。观察性研究和有限的临床试验提示,膳食香豆素摄入与血压水平呈负相关;随机证据仍然稀少,且有时无定论。香豆素表现出多方面的血管保护特性,支持其作为高血压管理辅助药物的潜力。机制和临床前数据具有说服力,但在作出明确治疗建议之前,仍需稳健、设计良好的临床试验来阐明疗效、安全性、最佳剂量和患者分层策略。
Obesity is associated with increased salt sensitivity and hypertension, but the mechanisms underlying altered renal sodium handling remain unclear. The Na-Cl cotransporter (NCC) is a key regulator of sodium reabsorption in the distal convoluted tubule and is dynamically regulated in response to changes in electrolyte balance. This study investigated whether diet-induced obesity (DIO) alters NCC responsiveness to salt loading in vivo and explored the underlying mechanisms using an ex vivo kidney slice model. Male C57BL/6 J mice were fed either a control or a high-fat (HF) diet for 22 weeks, followed by 2 weeks of NaCl loading. HF-fed mice developed obesity, hyperglycemia, hyperinsulinemia, and elevated systolic blood pressure. Although NaCl loading increased urinary sodium excretion and decreased serum aldosterone in both control and obese mice, the increase in urinary sodium excretion was attenuated in obese mice, suggesting enhanced renal sodium reabsorption. In addition, NaCl loading reduced NCC phosphorylation in control mice, whereas this response was attenuated in DIO mice, with no change in total NCC expression. Notably, STE20/SPS1-related proline-alanine-rich protein kinase (SPAK) phosphorylation was not significantly different among groups. In ex vivo kidney slice experiments, high-concentration insulin attenuated the high-potassium-induced suppression of NCC phosphorylation, whereas high glucose had no effect. These findings suggest that DIO impairs the normal suppression of NCC activity in response to salt loading without affecting basal NCC expression. Ex vivo findings suggest that insulin may modulate NCC responsiveness, although whether this mechanism contributes to NCC regulation in vivo remains uncertain. Impaired NCC responsiveness may promote renal sodium retention and could represent one potential mechanism linking obesity to altered sodium handling and blood pressure regulation.
中文摘要:肥胖与盐敏感性和高血压相关,但肾脏钠处理改变的机制仍不清楚。Na-Cl共转运体(NCC)是远曲小管钠重吸收的关键调节因子,并随电解质平衡变化而动态调节。本研究在体内观察饮食诱导肥胖(DIO)是否改变NCC对钠负荷的反应,并利用离体肾切片模型探讨相关机制。雄性C57BL/6 J小鼠分别接受对照饮食或高脂饮食22周,随后进行2周NaCl负荷。高脂喂养小鼠出现肥胖、高血糖、高胰岛素血症和收缩压升高。NaCl负荷使对照组和肥胖组小鼠尿钠排泄增加、血清醛固酮降低,但肥胖小鼠尿钠排泄的增加减弱,提示肾脏钠重吸收增强。NaCl负荷降低对照组小鼠NCC磷酸化,而DIO小鼠该反应减弱,总NCC表达无变化。STE20/SPS1相关富含脯氨酸-丙氨酸蛋白激酶(SPAK)磷酸化在各组间无显著差异。离体肾切片实验中,高浓度胰岛素减弱高钾诱导的NCC磷酸化抑制,高糖则无影响。这些结果提示DIO损害钠负荷对NCC活性的正常抑制,而不影响基础NCC表达。离体结果提示胰岛素可能调节NCC反应性,但该机制是否参与体内NCC调控仍不确定。NCC反应性受损可能促进肾脏钠潴留,并可能是连接肥胖与钠处理改变及血压调节异常的潜在机制之一。
G protein-coupled receptor 75 (GPR75) has recently attracted considerable attention as a novel regulator of metabolic, immune, and vascular processes. Current evidence suggests that two structurally distinct molecules have been proposed as candidate endogenous ligands for GPR75: 20-hydroxyeicosatetraenoic acid (20-HETE), a cytochrome P450-derived lipid metabolite, and C-C motif chemokine ligand 5 (CCL5; RANTES), a chemokine involved in immune regulation. Among these ligands, 20-HETE functions as a potent agonist of GPR75, leading to activation of Gαq/11-dependent signaling pathways and β-arrestin recruitment. In contrast, although CCL5 has also been reported to interact with GPR75, its role as a direct receptor agonist remains controversial and may be highly context-dependent. Notably, GPR75 is broadly expressed in tissues involved in the regulation of energy homeostasis, including the hypothalamus, adipose tissue, liver, pancreas, and vascular system. Population genetic studies have demonstrated that loss-of-function variants in GPR75 are associated with a reduced risk of obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and hypertension. Evidence from animal models further supports a role for GPR75 in the regulation of feeding behavior, insulin sensitivity, lipid metabolism, vascular tone, and inflammatory responses. This review provides a comprehensive overview of the structural characteristics, ligand recognition mechanisms, signaling properties, and tissue distribution of GPR75 and discusses its functions in both the central nervous system and peripheral metabolic tissues. Elucidating how GPR75 integrates, differentiates, and transduces signals derived from these distinct ligands may provide new opportunities for therapeutic intervention in obesity, diabetes, MASLD, and their associated complications.
中文摘要:G蛋白偶联受体75(GPR75)近年来作为代谢、免疫和血管过程的新型调控因子受到较多关注。现有证据提示,两种结构不同的分子被提出为GPR75的候选内源性配体:20-羟二十碳四烯酸(20-HETE),一种细胞色素P450衍生的脂质代谢物;以及C-C基序趋化因子配体5(CCL5;RANTES),一种参与免疫调节的趋化因子。在这些配体中,20-HETE作为GPR75的有效激动剂,激活Gαq/11依赖的信号通路并招募β-抑制蛋白。与之相对,尽管CCL5也被报道可与GPR75相互作用,但其作为直接受体激动剂的作用仍存争议,且可能高度依赖具体情境。GPR75在参与能量稳态调控的组织中广泛表达,包括下丘脑、脂肪组织、肝脏、胰腺和血管系统。群体遗传学研究显示,GPR75功能缺失变异与肥胖、2型糖尿病、代谢功能障碍相关脂肪性肝病(MASLD)和高血压风险降低相关。动物模型证据进一步支持GPR75参与摄食行为、胰岛素敏感性、脂质代谢、血管张力和炎症反应的调控。本综述系统概述GPR75的结构特征、配体识别机制、信号特性及组织分布,并讨论其在中枢神经系统和外周代谢组织中的功能。阐明GPR75如何整合、区分并转导来自这些不同配体的信号,可能为肥胖、糖尿病、MASLD及其相关并发症的治疗干预提供新机会。
The cardiac hormone ANP (atrial natriuretic peptide) maintains intravascular volume homeostasis through coordinated endothelial and renal effects. Since in vitro studies suggested that this circuit involves the inhibition of adrenal aldosterone release, here we investigated whether ANP indeed mediates endocrine heart-to-adrenal communication in vivo. Mouse models with zona glomerulosa (ZG)-restricted deletion of the ANP receptor, GC-A (guanylyl cyclase-A), or the downstream cyclic GMP-stimulated PDE (phosphodiesterase) 2A were established through Cre/LoxP technology. Immunoblots and immunohistochemistry demonstrated high expression of GC-A and PDE2A in ZG cells. Cell-specific deletion of GC-A led to mildly expanded ZG, with more aldosterone synthase-expressing cells and elevated plasma aldosterone. While in control mice a high-salt diet reduced ZG thickness and aldosterone production, in their ZG GC-A knockout littermates these responses were blunted, provoking hypervolemic hypertension. Notably, ZG PDE2A knockout mice did not exhibit such alterations. In cultured human adrenal cells, ANP counteracted the stimulatory effects of Angiotensin II on aldosterone synthase expression and cell proliferation pathways through activation of cGMP-dependent protein kinase I. Notably, in human aldosterone-producing adrenal adenomas, the expression of GC-A was markedly lower than in healthy adrenal cortical tissue, suggesting reduced ANP/GC-A signaling in the tumor cells. ANP-mediated heart-adrenal communication moderates ZG cell growth and aldosterone release and participates in the inhibitory effects of dietary salt/volume load. Conversely, impaired ANP/cGMP signaling leads to excessive ZG cell growth and aldosterone production. Reinforcing this pathway with novel antibody- or peptide-based therapies may benefit patients with hyperaldosteronism and resistant hypertension.
中文摘要:心脏激素ANP通过协调内皮与肾脏效应维持血管内容量稳态。体外研究提示该环路涉及抑制肾上腺醛固酮释放,因此本研究探讨ANP是否在体内介导心脏到肾上腺的内分泌通讯。通过Cre/LoxP技术建立球状带限制性敲除ANP受体GC-A或其下游cGMP刺激的磷酸二酯酶2A的小鼠模型。免疫印迹和免疫组化显示GC-A与PDE2A在球状带细胞中高表达。细胞特异性敲除GC-A导致球状带轻度扩大,醛固酮合酶表达细胞增多,血浆醛固酮升高。对照小鼠高盐饮食可降低球状带厚度和醛固酮生成,而球状带GC-A敲除同窝小鼠中这些反应减弱,并引起高容量性高血压。球状带PDE2A敲除小鼠未出现这类改变。在培养的人肾上腺细胞中,ANP通过激活cGMP依赖性蛋白激酶I拮抗血管紧张素II对醛固酮合酶表达和细胞增殖通路的刺激作用。在人醛固酮生成性肾上腺腺瘤中,GC-A表达明显低于健康肾上腺皮质组织,提示肿瘤细胞中ANP/GC-A信号减弱。ANP介导的心脏-肾上腺通讯调节球状带细胞生长和醛固酮释放,并参与膳食盐/容量负荷的抑制作用。相反,ANP/cGMP信号受损会导致球状带细胞过度生长和醛固酮生成过多。用新型抗体或肽类疗法强化该通路可能使醛固酮增多症和难治性高血压患者获益。
The pathogenic mechanism underlying diseases caused by mitochondrial DNA (mtDNA) mutation, including hypertension, persists as an unresolved global challenge. Although mutation-induced mitochondrial defects have been well characterized, how these mito-perturbations are converted into critical intermediary signaling cascades and contribute to diseases remain unknown. Here, using human induced pluripotent stem cell (hiPSC)-derived vascular organoids (VOs) and vascular cells, the hypertensive mt. tRNAIle4263A > G mutation was identified to induce vascular senescence, apoptosis and vascular-specific dysfunction through mitochondria-endoplasmic reticulum (ER) interaction. For the first time, this study mapped the transcriptional reprogramming landscape of human VOs carrying this mutation. Through systematic screening and functional validation, ER stress was screened out, together with downstream mitochondria-associated ER membranes-mitochondrial Ca2+ overload resulting in vascular abnormality. Pathological reactive oxygen species (ROS) elevation, driven by tRNAIle destabilization and bioenergetic failure, acts as the primary instigator of maladaptive ER stress activation in this cascade. Pharmacological targeting of this axis-using mito-Tempol (a mitochondria-targeted ROS scavenger), Tauro Ursodeoxycholic Acid (an ER stress inhibitor), or RU265 (a highly-selective mitochondrial calcium uniporter inhibitor)-rescues vascular abnormality. This study highlights mt. tRNAIle4263A > G mutation orchestrates vascular pathology through ROS induced activation of inter-organelle communication, resolving a long-standing knowledge gap between mtDNA mutations and diseases and establishing therapeutic nexuses for mtDNA mutation-related cardiovascular diseases.
中文摘要:线粒体DNA(mtDNA)突变所致疾病(包括高血压)的致病机制仍是未解决的全球性难题。突变引起的线粒体缺陷已被较好描述,但这些线粒体扰动如何转化为关键中间信号级联并促成疾病仍不清楚。利用人诱导多能干细胞(hiPSC)来源的血管类器官(VOs)和血管细胞,发现高血压相关mt. tRNAIle4263A>G突变通过线粒体-内质网相互作用诱导血管衰老、凋亡和血管特异性功能障碍。研究首次绘制了携带该突变的人VOs转录重编程图谱。通过系统筛选和功能验证,筛选出内质网应激,以及下游线粒体相关内质网膜-线粒体Ca2+超载导致血管异常。tRNAIle不稳定和生物能量失败驱动的病理性活性氧(ROS)升高,是该级联中适应不良性内质网应激激活的主要启动因素。使用线粒体靶向ROS清除剂mito-Tempol、内质网应激抑制剂牛磺熊去氧胆酸或高选择性线粒体钙单向转运体抑制剂RU265药理学靶向该轴,可挽救血管异常。研究强调mt. tRNAIle4263A>G突变通过ROS诱导的细胞器间通讯激活 orchestrate 血管病理,填补了mtDNA突变与疾病之间长期存在的知识空白,并为mtDNA突变相关心血管疾病建立了治疗连接。
Essential hypertension, characterized by vascular dysfunction, remains a leading modifiable cause of death globally. Perivascular adipose tissue (PVAT), which normally reduces vasoconstriction, becomes contractile in hypertension due to increased reactive oxygen species (ROS). Brown PVAT has emerged as a protective regulator of vascular tone. Follistatin, an activin antagonist, induces adipose tissue browning via AMPK (AMP-activated protein kinase). We recently reported improved blood pressure and vascular function by follistatin in the spontaneously hypertensive rat (SHR) model of essential hypertension. Here, we investigate whether follistatin reduces ROS and induces browning in SHR PVAT to restore PVAT-mediated vascular function. SHRs were treated with vehicle, follistatin, or hydralazine for 8 weeks. Mesenteric white and thoracic brown PVAT from SHR and normotensive Wistar-Kyoto mice were used, with wire myography used to assess vascular function. PVAT nitric oxide, ROS, and browning markers were assessed via immunohistochemistry. PVAT was treated ex vivo to assess mechanisms of browning. Unbiased proteomic analysis of PVAT was performed using liquid chromatography-mass spectrometry. SHR PVAT dysfunction, manifesting as a procontractile effect, was inhibited by follistatin through reducing ROS, enhancing NO bioavailability, and promoting browning. These effects were mediated by activin neutralization and AMPK phosphorylation. Hydralazine-induced blood pressure reduction did not replicate follistatin effects, suggesting vascular benefits of follistatin are mediated by direct PVAT modulation. Proteomic analysis revealed a shift in proteome towards a normal state, upregulating processes associated with adipose browning. Follistatin restores PVAT-mediated vascular relaxation via ROS reduction, activin neutralization, and AMPK-dependent browning, positioning the potential for PVAT as a therapeutic target for vascular dysfunction in essential hypertension.
中文摘要:原发性高血压以血管功能障碍为特征,仍是全球主要的可干预死因。血管周围脂肪组织(PVAT)正常情况下可减弱血管收缩,在高血压中因活性氧(ROS)增加而转为促收缩。棕色PVAT已成为血管张力的保护性调节因素。卵泡抑素是一种激活素拮抗剂,经AMPK诱导脂肪组织棕色化。我们近期报道,卵泡抑素可改善原发性高血压的自发性高血压大鼠(SHR)模型的血压和血管功能。本研究探讨卵泡抑素是否减少SHR的PVAT中ROS并诱导棕色化,从而恢复PVAT介导的血管功能。SHR接受溶媒、卵泡抑素或肼屈嗪治疗8周。使用SHR与正常血压Wistar-Kyoto小鼠的肠系膜白色PVAT和胸部棕色PVAT,采用线肌张力描记评估血管功能。通过免疫组化评估PVAT一氧化氮、ROS及棕色化标志物。对PVAT进行离体处理以评估棕色化机制。采用液相色谱-质谱对PVAT进行非靶向蛋白质组分析。SHR的PVAT功能障碍表现为促收缩效应,卵泡抑素通过减少ROS、提高NO生物利用度及促进棕色化而抑制该效应。这些作用由激活素中和与AMPK磷酸化介导。肼屈嗪降低血压未复制卵泡抑素效应,提示卵泡抑素的血管获益由直接调节PVAT介导。蛋白质组分析显示蛋白质组向正常状态转变,上调与脂肪棕色化相关的过程。卵泡抑素通过减少ROS、中和激活素及AMPK依赖性棕色化恢复PVAT介导的血管舒张,使PVAT成为原发性高血压血管功能障碍的潜在治疗靶点。
2脑卒中/脑血管病 (31篇)
临床研究 (24篇)
Identifying the intensity and frequency of physical activity associated with early independent walking in nonambulatory patients with subacute stroke may inform daily physical activity promotion during hospitalization, which was the aim of the present study. This multicenter prospective cohort study was conducted at 11 facilities. Baseline was defined as admission to a subacute rehabilitation ward, with subacute referring to the phase after completion of acute stroke treatment. Patients with subacute stroke and a Functional Ambulation Category of 1 to 2 at admission were included. Physical activity was measured using an accelerometer for 1 week at baseline. The outcome was achievement of independent walking at 1 month from baseline (Functional Ambulation Category ≥4). To examine the intensity of physical activity associated with the outcome, modified Poisson regression was used to evaluate time spent in low -intensity physical activity (LPA; low-LPA, 1.6-1.9 metabolic equivalents [METs]), high-LPA (2.0-2.9 METs), and moderate-to-vigorous intensity physical activity (≥3.0 METs). Furthermore, to assess frequency associated with activity intensity, bouts of physical activity at or above the intensity level (≥1.6, ≥2.0, or ≥3.0 METs) were calculated as short-bouts (≥5 to <10 minutes) and long-bouts (≥10 minutes), and their associations with the outcome were examined. Of 389 participants (mean age, 68.1 years; 45.0% female), 113 achieved independent walking during follow-up. Time spent in high-LPA was associated with independent walking when expressed per 5 min/d (risk ratio, 1.067 [95% CI, 1.010-1.131]), whereas low-LPA and moderate-to-vigorous intensity physical activity were not. The number of short-bouts at ≥2.0 METs was associated with independent walking (risk ratio, 1.208 [95% CI, 1.060-1.375]), whereas long-bouts were not relevant. Accumulation of high-LPA and short-bouts at ≥2.0 METs was associated with early independent walking. These findings may help characterize activity intensity and bout frequency associated with walking independence in nonambulatory patients with subacute stroke during inpatient rehabilitation. URL: https://www.umin.ac.jp/ctr; Unique identifier: UMIN000058526.
中文摘要:识别与亚急性卒中不能步行患者早期独立步行相关的身体活动强度和频率,可为住院期间的日常身体活动促进提供依据,本研究即以此为目标。这项多中心前瞻性队列研究在11家机构开展。基线定义为入住亚急性康复病房,亚急性指急性卒中治疗完成后的阶段。纳入入院时功能步行分类为1至2级的亚急性卒中患者。基线时使用加速度计测量身体活动1周。结局为基线后1个月达到独立步行(功能步行分类≥4级)。为考察与结局相关的身体活动强度,采用改良Poisson回归评估低强度身体活动(LPA;低LPA,1.6-1.9代谢当量[METs])、高LPA(2.0-2.9 METs)和中高强度身体活动(≥3.0 METs)的时间。进一步评估与活动强度相关的频率,将至少达到该强度水平(≥1.6、≥2.0或≥3.0 METs)的身体活动片段计算为短片段(≥5至<10分钟)和长片段(≥10分钟),并检验其与结局的关联。389名参与者(平均年龄68.1岁;女性45.0%)中,113名在随访期间达到独立步行。高LPA时间与独立步行相关,按每5分钟/天表示(风险比1.067[95% CI,1.010-1.131]),低LPA和中高强度身体活动则无此关联。≥2.0 METs的短片段数量与独立步行相关(风险比1.208[95% CI,1.060-1.375]),长片段无相关性。高LPA和≥2.0 METs短片段的累积与早期独立步行相关。这些发现有助于描述亚急性卒中不能步行患者住院康复期间与步行独立相关的活动强度和片段频率。URL: https://www.umin.ac.jp/ctr; Unique identifier: UMIN000058526。
Stroke recovery is highly heterogeneous, and predictive neurophysiological markers of motor outcome are still needed. Although transcranial magnetic stimulation-derived motor evoked potentials (MEPs) are widely used to assess corticospinal integrity, their trial-to-trial variability remains poorly explored and has largely been interpreted as noise rather than a source of clinically relevant information. In this prospective longitudinal observational study, we investigated MEP peak-to-peak amplitude and amplitude variability in 77 patients with subacute stroke assessed at baseline (T0, early subacute phase) and after a 2-month high-intensity daily rehabilitation program (T1), alongside 10 age- and sex-matched healthy controls. MEPs were recorded from both hemispheres at rest. Clinical outcomes were evaluated using the Fugl-Meyer Upper Extremity scale and a Motor Recovery Index. Seventy-seven patients with subacute stroke (mean age, 68.5±12.7 years; 41.6% women) and 10 age- and sex-matched healthy controls (mean age, 73.9±4.3 years; 40.0% women) were included. At T0, MEP amplitude was lower in the affected than in the unaffected hemisphere (0.16±0.02 versus 0.38±0.01 mV; P=5.42×10-10), as was MEP variance (0.013±0.002 versus 0.038±0.003 mV2; P=8.43×10-12). Regarding T1, MEP amplitude increased over time in the affected hemisphere (0.21±0.02 mV; P=0.01), whereas MEP variance remained unchanged (P=0.55). Importantly, baseline MEP amplitude was strongly associated with motor status at follow-up (Fugl-Meyer Upper Extremity scale at T1; P=9.52×10-9), but not with the degree of recovery. In contrast, baseline MEP variability was significantly associated with both motor outcome (Fugl-Meyer Upper Extremity scale at T1; P=2.76×10-7) and the Motor Recovery Index (P=0.009), indicating a specific link with recovery potential. These findings reveal a dissociation between MEP amplitude and variability, suggesting that they capture complementary aspects of corticospinal function. Although amplitude reflects the current functional state of motor pathways, variability appears to index network flexibility and adaptive capacity. MEP variability may, therefore, represent a novel neurophysiological biomarker for predicting motor recovery and guiding personalized rehabilitation strategies after stroke.
中文摘要:脑卒中恢复高度异质,仍需可用于预测运动结局的神经生理标志物。经颅磁刺激衍生的运动诱发电位广泛用于评估皮质脊髓束完整性,但其逐次试验间变异性研究不足,多被视为噪声而非具有临床意义的信息来源。这项前瞻性纵向观察研究纳入77例亚急性期脑卒中患者,在基线(T0,亚急性早期)及2个月高强度每日康复训练后(T1)评估运动诱发电位峰峰值振幅与振幅变异性,并纳入10名年龄和性别匹配的健康对照。静息状态下记录双侧半球运动诱发电位。临床结局采用Fugl-Meyer上肢量表和运动恢复指数评估。共纳入77例亚急性期脑卒中患者(平均年龄68.5±12.7岁;女性41.6%)和10名年龄和性别匹配的健康对照(平均年龄73.9±4.3岁;女性40.0%)。T0时,患侧半球运动诱发电位振幅低于健侧(0.16±0.02 mV对0.38±0.01 mV;P=5.42×10⁻¹⁰),运动诱发电位方差亦低于健侧(0.013±0.002 mV²对0.038±0.003 mV²;P=8.43×10⁻¹²)。至T1,患侧半球运动诱发电位振幅随时间增加(0.21±0.02 mV;P=0.01),而运动诱发电位方差未变化(P=0.55)。基线运动诱发电位振幅与随访时运动状态强相关(T1时Fugl-Meyer上肢量表;P=9.52×10⁻⁹),但与恢复程度无关。相反,基线运动诱发电位变异性与运动结局(T1时Fugl-Meyer上肢量表;P=2.76×10⁻⁷)及运动恢复指数(P=0.009)均显著相关,提示其与恢复潜力存在特定联系。这些发现揭示运动诱发电位振幅与变异性之间的分离,提示二者捕捉皮质脊髓功能的互补方面。振幅反映运动通路的当前功能状态,变异性似乎反映网络灵活性和适应能力。运动诱发电位变异性可能成为预测运动恢复并指导脑卒中后个体化康复策略的新型神经生理生物标志物。
Vascular geometry may impede catheter navigation during mechanical thrombectomy. We evaluated whether cervical curvature predicts recanalization success. This is a retrospective single-center cohort of 160 anterior large vessel occlusion patients treated with mechanical thrombectomy at a comprehensive stroke center (Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO) from May 2019 to February 2021. Cervical curvature was computed using 3-dimensional vessel centerlines derived from preprocedural computed tomography angiography. Primary outcomes were successful recanalization (final modified Thrombolysis in Cerebral Infarction score ≥2b) and intracranial access time (puncture→first pass). Associations were evaluated with multivariable linear or logistic regression, adjusting for age, National Institutes of Health Stroke Scale, first-line device, and access route. Random Forest and Gradient Boosting models with Gini Importance and Shapley Additive Explanation explained feature importance. Mean age was 67±15 years; median National Institutes of Health Stroke Scale 16; mean total curvature was 9.80±2.85. Median intracranial access time was 24 minutes (interquartile range, 17-32), with no correlation to cervical curvature (ρ=0.054; adjusted β=0.20 min/unit [95% CI, -0.75, 1.15]; P=0.676). Successful recanalization occurred in 86% and varied across curvature tertiles (low 91%, mid 93%, high 75%; P=0.017). Per-unit curvature increase was associated with recanalization failure (adjusted odds ratio, 1.21 [95% CI, 1.02-1.43]; P=0.028). Receiver operating characteristic-derived curvature threshold (>11.54) identified a high-risk group (adjusted odds ratio, 5.10 [95% CI, 1.88-13.84]; P=0.001). Machine learning confirmed cervical curvature as the dominant predictor, with a Shapley Additive Explanation peak effect at 11.65. Cervical curvature independently predicts mechanical thrombectomy recanalization failure, with a threshold effect near 11.6 units. Preprocedural curvature assessment derived from routine computed tomography angiography may improve risk stratification and inform mechanical thrombectomy strategy.
中文摘要:血管几何形态可能妨碍机械取栓时的导管导航。本研究评估颈部血管曲度能否预测再通成功。这是一项单中心回顾性队列研究,纳入2019年5月至2021年2月在综合卒中中心(密苏里州圣路易斯Barnes-Jewish医院/华盛顿大学医学院)接受机械取栓的160例前循环大血管闭塞患者。颈部血管曲度基于术前计算机断层扫描血管造影得出的三维血管中心线计算。主要结局为成功再通(最终改良脑梗死溶栓分级≥2b)和颅内到达时间(穿刺至首次通过)。采用多变量线性或逻辑回归评估相关性,并校正年龄、美国国立卫生研究院卒中量表评分、一线器械和入路。随机森林和梯度提升模型结合基尼重要性与Shapley加性解释说明特征重要性。平均年龄67±15岁;美国国立卫生研究院卒中量表评分中位数16;平均总曲度9.80±2.85。颅内到达时间中位数24分钟(四分位距17-32),与颈部血管曲度无相关性(ρ=0.054;校正β=0.20分钟/单位[95% CI,-0.75,1.15];P=0.676)。成功再通率为86%,在不同曲度三分位组间有差异(低91%,中93%,高75%;P=0.017)。曲度每增加1个单位与再通失败相关(校正比值比1.21[95% CI,1.02-1.43];P=0.028)。受试者工作特征曲线得出的曲度阈值(>11.54)识别出高风险组(校正比值比5.10[95% CI,1.88-13.84];P=0.001)。机器学习确认颈部血管曲度是主要预测因素,Shapley加性解释峰值效应位于11.65。颈部血管曲度可独立预测机械取栓再通失败,阈值效应接近11.6个单位。基于常规计算机断层扫描血管造影的术前曲度评估可能改善风险分层并为机械取栓策略提供依据。
Several phase III clinical trials testing cytoprotective approaches have recently been completed, and many of these studies report a clinical benefit. Reviewing the outcomes of these trials in light of their specific designs reveals intriguing results. Trials designed with shorter treatment time windows (≤24 hours) and featuring high rates of recanalization therapies predominantly show neutral outcomes, that is, no therapeutic benefit. Studies using later time points (>24 hours to 14 days) and often enrolling patients in whom recanalization is not or only infrequently established show clear treatment effects. These results challenge our current understanding of cytoprotective approaches, which are believed to primarily target the penumbra as the key to therapeutic success. The reasons for this are unclear. They may include other, potentially unknown mechanisms of action that improve clinical outcome even when applied within longer time windows rather than exerting acute cytoprotection. Here, we discuss such potential mechanisms, to what extent they could explain the results of recent cytoprotection trials, and review consequences for future translational and clinical research.
中文摘要:近期完成了多项检验细胞保护方法的III期临床试验,其中不少研究报告了临床获益。结合这些试验的具体设计审视其结果,可以看到耐人寻味的发现。采用较短治疗时间窗(≤24小时)且再通治疗比例较高的试验大多显示中性结果,即没有治疗获益。采用较晚时间点(>24小时至14天)、且常纳入未实现再通或再通不常实现患者的试验,则显示出明确的治疗效应。这些结果挑战了当前对细胞保护方法的认识,即认为主要靶向半暗带是治疗成功的关键。其原因尚不清楚。可能涉及其他潜在未知的作用机制,在较长时间窗内应用时改善临床结局,而非发挥急性细胞保护作用。这里讨论这些潜在机制、它们能在多大程度上解释近期细胞保护试验的结果,并回顾其对未来转化研究和临床研究的影响。
Moyamoya disease (MMD) is a progressive cerebrovascular disease linked to immune dysregulation, yet T-cell metabolic reprogramming and regulatory T-cell (Treg) function remain poorly understood. Here, we integrated multi-omics approaches, including mass cytometry, single-cell RNA sequencing, bulk RNA sequencing, metabolomics, and flow cytometry to characterize T-cell metabolic alterations and Treg dysfunction in MMD, uncovering a key metabolic-immune axis. Compared with healthy controls, MMD patients showed chronic immune activation and broad suppression of amino acid, glycolytic, and fatty acid metabolic pathways. Although Tregs were aberrantly expanded, they displayed metabolic inflexibility, together with impaired intercellular communication. Single-cell transcriptomics indicated Treg-to-Th17 conversion, while flow cytometry confirmed increased IL-17A+ cells within the CD4+FOXP3+ compartment. Besides, these dysfunctional Tregs correlated with advanced Suzuki stages, ischemic stroke, and posterior cerebral artery involvement. Bulk transcriptomic and serum metabolomic analyses further confirmed coordinated immune activation and metabolic suppression at the gene, protein, pathway, and metabolite levels. These findings define a metabolic-immune axis in MMD in which metabolically constrained, functionally unstable Tregs may contribute to neuroinflammation and vascular remodeling, suggesting that restoring Treg metabolic fitness could represent a therapeutic strategy.
中文摘要:烟雾病(MMD)是一种与免疫失调相关的进行性脑血管病,但T细胞代谢重编程和调节性T细胞(Treg)功能仍认识不足。该研究整合质谱流式细胞术、单细胞RNA测序、bulk RNA测序、代谢组学和流式细胞术等多组学方法,刻画MMD中T细胞代谢改变与Treg功能障碍,揭示一条关键代谢-免疫轴。与健康对照相比,MMD患者表现为慢性免疫激活以及氨基酸、糖酵解和脂肪酸代谢通路的广泛抑制。Treg虽异常扩增,却呈现代谢不灵活,并伴有细胞间通讯受损。单细胞转录组提示Treg向Th17转化,流式细胞术证实CD4+FOXP3+细胞群中IL-17A+细胞增多。这些功能失调的Treg与较高Suzuki分期、缺血性卒中及大脑后动脉受累相关。Bulk转录组和血清代谢组分析进一步在基因、蛋白、通路和代谢物水平证实免疫激活与代谢抑制的协同变化。这些发现定义了MMD中的代谢-免疫轴,其中代谢受限、功能不稳定的Treg可能参与神经炎症和血管重塑,提示恢复Treg代谢适应性或可作为治疗策略。
Health literacy is a critical component of high-quality stroke care. Across the continuum from prevention through recovery, health literacy is strongly associated with functional outcomes and stroke-related morbidity. Despite its importance, it is often overlooked, leaving patients and caregivers overwhelmed by communication demands that exceed their capacity. These mismatches are especially pronounced among individuals with stroke-related cognitive or language impairments, limited English proficiency, socioeconomic disadvantage, or limited digital literacy. This scientific statement synthesizes current evidence on the role of health literacy and communication within stroke systems of care and identifies nurse-led opportunities to advance equity and patient-centered outcomes while recognizing this as a shared interprofessional responsibility. Nurse-led interventions, including teach-back-based education, dyadic psychoeducational programs, and tailored digital support, have demonstrated improvements in stroke knowledge, self-efficacy, quality of life, and caregiver preparedness. However, the literature is marked by methodological heterogeneity. Many studies are underpowered and infrequently use validated health literacy or communication measures. Future directions include standardized assessment of health literacy; literacy-sensitive, nurse-led, and interprofessional care models; workforce training in plain-language and culturally responsive communication; and organizational health literacy principles. Emerging technologies, including telehealth and artificial intelligence, offer promise for improving communication and personalization but require rigorous evaluation to minimize bias and ensure equity and usability.
中文摘要:健康素养是高质量卒中照护的关键组成部分。从预防到康复的连续过程中,健康素养与功能结局和卒中相关疾病负担密切相关。健康素养的重要性明确,却常被忽视,使患者和照护者面对超出其能力的沟通要求。这种不匹配在存在卒中相关认知或语言障碍、英语能力有限、社会经济弱势或数字素养有限的人群中尤为突出。本科学声明综合健康素养与沟通在卒中照护系统中作用的现有证据,识别护士主导、可促进公平和以患者为中心结局的机会,同时将其视为跨专业共同责任。护士主导的干预包括基于回授法的教育、二元心理教育项目和量身定制的数字支持,已显示可改善卒中知识、自我效能、生活质量和照护者准备度。文献存在方法学异质性。许多研究检验效能不足,且较少使用经过验证的健康素养或沟通测量工具。未来方向包括健康素养的标准化评估;具有素养敏感性、由护士主导并体现跨专业协作的照护模式;面向工作人员开展简明语言和文化响应性沟通培训;以及组织层面的健康素养原则。远程医疗和人工智能等新兴技术有望改善沟通和个体化,但需要严格评估以减少偏倚并确保公平和可用性。
Subjective social status (SSS) represents self-perceived social position and may affect poststroke recovery. Despite impacting various medical outcomes, SSS remains understudied in stroke. We hypothesized that higher SSS is associated with better stroke recovery at 3- and 12-months poststroke. In this prospective cohort study, patients were enrolled between October 2016 and February 2020. We examined associations between 3-month SSS score and clinician-reported, performance, and patient-reported outcomes at 3- and 12-month study visits. Ordinal multivariable regression analysis evaluated 3-month SSS score as a predictor of 12-month modified Rankin Scale score. The 494 participants had a median age of 63.5 years; 200 (41%) were women, and median (interquartile range) acute National Institutes of Health Stroke Scale score was 4 (2-8). Scores on SSS showed no meaningful associations with performance outcomes and some associations with clinician-reported outcomes (eg, 3-month modified Rankin Scale: ρ, -0.12 [95% CI, -0.21 to -0.03], false discovery rate-adjusted P=0.017; 12-month modified Rankin Scale: ρ12mo, -0.18 [95% CI, -0.27 to -0.09], false discovery rate-adjusted P=0.001). Conversely, higher SSS showed strong, consistent correlations with patient-reported outcomes, including with less psychological distress and higher Stroke Impact Scale-Activities of Daily Living (ρ3mo, 0.18 [95% CI, 0.09-0.26]; ρ12mo, 0.17 [95% CI, 0.07-0.26]; all false discovery rate-adjusted P<0.05). Item-level analyses of Stroke Impact Scale-Activities of Daily Living revealed that SSS remained most strongly and consistently linked to complex Stroke Impact Scale-Activities of Daily Living motor tasks over time. In ordinal multivariable regression adjusted for age, sex, stroke subtype, initial severity, and the selected objective socioeconomic status proxies (eg, educational attainment, employment, and marital status), 3-month SSS score significantly predicted 12-month modified Rankin Scale score (β, 0.14 [95% CI, 0.02-0.26]; P=0.014). In patients with predominantly mild stroke, 3-month SSS score may serve as a significant social determinant of health that is associated with long-term functional recovery, a relationship closely linked with psychological distress. SSS scores at 3 months poststroke may identify vulnerable patients, enabling development, validation, and targeted application of interventions that optimize stroke recovery.
中文摘要:主观社会地位(SSS)反映自我感知的社会位置,可能影响卒中后恢复。尽管SSS影响多种医疗结局,但在卒中领域研究仍不足。我们假设较高的SSS与卒中后3个月和12个月更好的恢复相关。在这项前瞻性队列研究中,患者于2016年10月至2020年2月入组。我们检验了3个月SSS评分与3个月和12个月研究访视时临床医生报告、操作表现及患者报告结局之间的关联。有序多变量回归分析评估3个月SSS评分对12个月改良Rankin量表评分的预测作用。494名参与者中位年龄63.5岁;200名(41%)为女性,急性美国国立卫生研究院卒中量表评分中位数(四分位距)为4(2-8)。SSS评分与操作表现结局无有意义关联,与部分临床医生报告结局存在一定关联(例如,3个月改良Rankin量表:ρ,-0.12[95% CI,-0.21至-0.03],错误发现率校正P=0.017;12个月改良Rankin量表:ρ12mo,-0.18[95% CI,-0.27至-0.09],错误发现率校正P=0.001)。相反,较高的SSS与患者报告结局呈强而一致的关联,包括更轻的心理困扰和更高的卒中影响量表-日常生活活动能力(ρ3mo,0.18[95% CI,0.09-0.26];ρ12mo,0.17[95% CI,0.07-0.26];所有错误发现率校正P<0.05)。卒中影响量表-日常生活活动能力的条目水平分析显示,SSS随时间推移仍与复杂的卒中影响量表-日常生活活动能力运动任务关联最强且最一致。在调整年龄、性别、卒中亚型、初始严重程度及选定客观社会经济地位替代指标(如教育程度、就业状况和婚姻状况)的有序多变量回归中,3个月SSS评分显著预测12个月改良Rankin量表评分(β,0.14[95% CI,0.02-0.26];P=0.014)。在以轻型卒中为主的患者中,3个月SSS评分可能作为重要的健康社会决定因素与长期功能恢复相关,这一关系与心理困扰密切相关。卒中后3个月的SSS评分可能识别脆弱患者,从而帮助开发、验证并针对性应用优化卒中恢复的干预措施。
Contrast-associated acute kidney injury (CA-AKI) after endovascular thrombectomy (EVT) worsens outcomes in acute ischemic stroke, but threshold-based definitions do not capture prognostic information from subthreshold changes. We tested whether early creatinine change within 48 hours of EVT conveys graded prognostic information beyond dichotomous CA-AKI. We performed a secondary analysis of the CAN-REST registry (Contrast-Associated Nephropathy After Endovascular Stroke Treatment), a retrospective multicenter observational cohort study of 6638 EVT-treated adults with acute ischemic stroke enrolled at 73 centers in 16 countries between January 1 and December 31, 2023. Early creatinine change was quantified as the natural logarithm ratio of 48-hour creatinine to baseline creatinine (ln[48-hour/baseline creatinine]), with CA-AKI defined per Kidney Disease: Improving Global Outcomes criteria (≥0.3 mg/dL or ≥1.5× baseline rise within 48 hours). Multivariable logistic regression adjusted for prespecified baseline and periprocedural covariates examined associations with 90-day modified Rankin Scale shift and in-hospital mortality; linear versus restricted cubic spline specification was selected by likelihood ratio testing, and contrasts were estimated at ±10%, ±25%, and ±50%. Greater creatinine worsening within 48 hours of EVT was independently associated with an unfavorable 90-day modified Rankin Scale shift (adjusted common odds ratio per 1-unit log-ratio increase, 1.48 [95% CI, 1.07-2.04]; linear) and in-hospital mortality (nonlinear dose-response, of larger magnitude). A 10% increase in creatinine at 48 hours-well below Kidney Disease: Improving Global Outcomes threshold-was associated with worse functional outcome (adjusted common odds ratio, 1.04 [95% CI, 1.01-1.07]) and death (adjusted odds ratio, 1.22 [95% CI, 1.13-1.32]); a 10% decrease in creatinine at 48 hours was associated with lower odds of both outcomes (adjusted common odds ratio, 0.96 [95% CI, 0.93-0.99]; adjusted odds ratio, 0.74 [95% CI, 0.65-0.86]). The functional-outcome association concentrated at upper modified Rankin Scale cut-points (severe disability, death); effect modification by baseline renal function was not significant. Early creatinine change after EVT conveys graded, outcome-specific prognostic information extending below formal CA-AKI thresholds, with a dose-response detectable at changes as modest as ±10%, complementing binary CA-AKI as a framework for post-EVT renal risk assessment. URL: https://www.clinicaltrials.gov; Unique identifier: NCT06596603.
中文摘要:血管内取栓(EVT)后对比剂相关急性肾损伤(CA-AKI)会恶化急性缺血性卒中的结局,但基于阈值的定义无法捕捉亚阈值变化的预后信息。我们检验EVT后48小时内早期肌酐变化是否在二分类CA-AKI之外提供分级预后信息。对CAN-REST注册研究(Contrast-Associated Nephropathy After Endovascular Stroke Treatment)进行二次分析,该研究为回顾性多中心观察性队列,纳入2023年1月1日至12月31日期间16个国家73个中心的6638例接受EVT治疗的急性缺血性卒中成人。早期肌酐变化以48小时肌酐与基线肌酐比值的自然对数(ln[48小时/基线肌酐])量化,CA-AKI按KDIGO标准定义(48小时内≥0.3 mg/dL或≥基线1.5倍升高)。多变量logistic回归校正预设基线和围手术期协变量,分析其与90天改良Rankin量表移位和院内死亡的关系;线性与限制性立方样条设定通过似然比检验选择,并在±10%、±25%和±50%处估计对比。EVT后48小时内肌酐恶化程度越高,与不利的90天mRS移位独立相关(每1单位对数比增加的校正共同比值比1.48[95%CI 1.07-2.04];线性),并与院内死亡相关(非线性剂量反应,幅度更大)。48小时肌酐升高10%——远低于KDIGO阈值——与更差功能结局(校正共同OR 1.04[95%CI 1.01-1.07])和死亡(校正OR 1.22[95%CI 1.13-1.32])相关;48小时肌酐下降10%与两种结局更低的比值相关(校正共同OR 0.96[95%CI 0.93-0.99];校正OR 0.74[95%CI 0.65-0.86])。功能结局关联集中在上部mRS切点(严重残疾、死亡);基线肾功能效应修饰不显著。EVT后早期肌酐变化提供分级的、结局特异的预后信息,延伸至正式CA-AKI阈值以下,在低至±10%的变化即可检出剂量反应,可补充二分类CA-AKI作为EVT后肾脏风险评估框架。URL: https://www.clinicaltrials.gov;唯一标识符:NCT06596603。
Periprocedural flat-panel computed tomography (FPCT) may complement real-time decision-making during endovascular treatment for stroke. This study aims to summarize current evidence on diagnostic findings, prognostic associations, and clinical applications of periprocedural FPCT in the angiography suite. A systematic review and meta-analysis was preregistered (URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD420251142156), conducted and reported according to MOOSE guidelines (Meta-Analysis of Observational Studies in Epidemiology). Medline, Embase, and Scopus were searched for studies published between January 2019 and September 2025 reporting on periprocedural FPCT in endovascular treatment patients (noncontrast FPCT, 3-dimensional-digital subtraction angiography/contrast-enhanced FPCT, or FPCT perfusion). Random-effects models were used to calculate pooled prevalences and odds ratios for associations with outcomes, primarily functional status assessed via the 90-day modified Rankin Scale score. Forty studies comprising 4139 patients were included. For noncontrast FPCT, 3 distinct imaging biomarkers were identified. Intraparenchymal hyperattenuations were frequent (pooled prevalence 49% [95% CI, 42%-56%]) and associated with any intracranial hemorrhage (odds ratio, 10.4 [95% CI, 4.5-24.1]), parenchymal hematoma (odds ratio, 4.3 [95% CI, 2.2-8.7]) and lower rates of good outcomes (eg, 90-day modified Rankin Scale score 0-2; odds ratio, 0.35 [95% CI, 0.24-0.50]). Subarachnoid hyperattenuations occurred in 23% (95% CI, 14%-35%) of patients and were associated with distal occlusions, markers of procedural aggressiveness, and lower rates of good outcome (eg, 90-day modified Rankin Scale score 0-2; odds ratio, 0.69 [95% CI, 0.53-0.91]). Intravascular hyperattenuations (distal occlusion tracker sign; pooled prevalence 35%, [95% CI, 24%-49%]) showed high specificity (93%, 95% CI, 87%-96%) for residual distal occlusions after endovascular treatment. Advanced vessel imaging improved thrombus conspicuity and technical efficacy, while postoperative flat-panel computed tomography perfusion shows added value for the detection of residual hypoperfusion, diagnosis of hemodynamic alterations, and prediction of final infarct. There was evidence for selection bias, suggesting slight overreporting of the above imaging signs. Periprocedural FPCT may offer real-time neurovascular and parenchymal assessment when conventional 3-dimensional imaging is unavailable. In our cohort, FPCT findings were associated with clinical outcomes and improved recognition of complications. FPCT may hence assist intraprocedural decision-making regarding adjunctive manoeuvres or drug administrations if further prospective validation can be demonstrated.
中文摘要:围手术期平板CT(FPCT)可能补充卒中血管内治疗过程中的实时决策。本研究旨在总结血管造影室内围手术期FPCT在诊断发现、预后关联和临床应用方面的现有证据。该系统评价与荟萃分析已预注册(URL:https://www.crd.york.ac.uk/PROSPERO/;唯一标识:CRD420251142156),按照MOOSE指南(观察性研究流行病学荟萃分析)实施和报告。检索Medline、Embase和Scopus中2019年1月至2025年9月发表的研究,这些研究报道血管内治疗患者的围手术期FPCT(平扫FPCT、三维数字减影血管造影/增强FPCT或FPCT灌注)。采用随机效应模型计算合并患病率及与结局关联的比值比,主要结局为90天改良Rankin量表评分评估的功能状态。共纳入40项研究、4139例患者。平扫FPCT识别出3种不同的影像生物标志物。脑实质高密度影常见(合并患病率49%[95%CI,42%-56%]),与任何颅内出血(比值比10.4[95%CI,4.5-24.1])、脑实质血肿(比值比4.3[95%CI,2.2-8.7])及较低的良好结局率(如90天改良Rankin量表评分0-2;比值比0.35[95%CI,0.24-0.50])相关。蛛网膜下腔高密度影发生于23%(95%CI,14%-35%)的患者,与远端闭塞、操作侵袭性标志物及较低的良好结局率(如90天改良Rankin量表评分0-2;比值比0.69[95%CI,0.53-0.91])相关。血管内高密度影(远端闭塞追踪征;合并患病率35%[95%CI,24%-49%])对血管内治疗后的残余远端闭塞具有高特异性(93%,95%CI,87%-96%)。高级血管成像提高了血栓可见度和技术有效性,而术后平板CT灌注在检测残余低灌注、诊断血流动力学改变和预测最终梗死方面显示出附加价值。存在选择偏倚证据,提示上述影像征象可能被轻微过度报告。当常规三维成像不可用时,围手术期FPCT可提供实时神经血管和脑实质评估。在本队列中,FPCT发现与临床结局相关,并改善并发症识别。若进一步前瞻性验证能够证明,FPCT或可辅助关于辅助操作或药物给药的术中决策。
Stroke can occur at any age, and the effects can last for the remaining lifetime. To minimize the clinical and economic burden of stroke, we need to develop and test new treatments that have the potential to improve outcomes for people with stroke. Early-phase trials are foundational to testing new treatments in medicine. Early-phase trials encompass dose-ranging, dose-screening, and dose-finding noncomparative designs. A dose-ranging trial aims to establish the safe and tolerable dose range for a given investigational intervention in a target population to progress to a dose-screening or dose-finding trial that systematically identifies an intervention dose(s) in the target population that has signal of efficacy, feasibility, safety, and tolerability. Such designs originated in the oncology field and are gaining prominence in stroke literature. In this article, we first outline the features that differentiate the contribution of early-phase trials from late-phase trials and present a stepwise development program approach to frame our discussion. We then review early-phase trial terminology, discuss the characteristics of early-phase trials and high-quality reporting, and the role, value, and contribution of early-phase trials across the continuum of stroke care using published and ongoing trial examples. Finally, we highlight emerging innovations in early-phase trial design and application to inform future work in stroke.
中文摘要:卒中可发生于任何年龄,其影响可能持续余生。为减轻卒中的临床与经济负担,需要开发并检验有望改善卒中患者结局的新治疗。早期试验是医学中新治疗检验的基础,涵盖剂量范围、剂量筛选和剂量探索的非对照设计。剂量范围试验旨在确定某一研究性干预在目标人群中安全且可耐受的剂量范围,以便进入剂量筛选或剂量探索试验;后两类试验系统识别在目标人群中具有疗效信号、可行性、安全性和耐受性的干预剂量。此类设计源于肿瘤学领域,在卒中文献中日益受到重视。文章先说明早期试验与后期试验贡献的区分特征,并给出分阶段开发计划框架以组织讨论。随后回顾早期试验术语,讨论早期试验特征与高质量报告,并结合已发表和正在进行的试验案例,阐述早期试验在卒中照护连续体中的作用、价值与贡献。文末强调早期试验设计及应用中的新兴创新,为卒中领域未来工作提供参考。
Microvascular hemodynamic deterioration is a proposed mechanism underlying the no-reflow phenomenon in acute ischemic stroke. Experimental studies suggested that relative heterogeneity of capillary transit time (RTH) is a potential imaging biomarker of microvascular impairment. We investigated the relationship between peri-infarct RTH and infarct growth, measured on immediate post-thrombectomy (PT) perfusion magnetic resonance imaging (MRI), and functional outcomes in patients with acute ischemic stroke with successful reperfusion. In this retrospective case-control study from the University of California, Los Angeles, patients with acute ischemic stroke from 2015 to 2020 were included if they had excellent reperfusion (modified Thrombolysis in Cerebral Infarction score ≥2c) and diffusion- and perfusion-weighted MRIs at baseline, immediately PT, and 24 to 48 hours after thrombectomy. Peri-infarct regions were defined as time to maximum ≥6-second regions on baseline MRI that were not infarcted on immediate PT MRI. Following image coregistration, quantitative values of perfusion parameters, including RTH, were obtained from peri-infarct regions on immediate PT MRI. Two primary outcomes were assessed: (1) infarct growth ≥10 mL and (2) poor functional outcome (90-day modified Rankin Scale score >2). Associations between clinical and imaging parameters and outcomes were evaluated using univariate analysis. Age, sex, and covariates that were significant in univariate analysis were included in logistic regression analyses. Among 47 patients included in the analysis (62% women; mean age, 72±13 years; median National Institutes of Health Stroke Scale score, 14), 20 (43%) patients had substantial infarct growth and poor functional outcome. Peri-infarct RTH was significantly (P=0.005) higher in patients with infarct growth >10 mL than those without and remained as an independent predictor (odds ratio, 1.4 per 10% increase [95% CI, 1.0-2.0]; P=0.04). Similarly, the peri-infarct RTH was significantly higher (P<0.001) in patients with poor functional outcomes than those with good functional outcomes and remained as a significant predictor of poor functional outcome (odds ratio, 1.4 per 10% increase [95% CI, 1.0-1.9]; P=0.03). Increased peri-infarct RTH on immediate PT MRI predicts substantial infarct growth and poor functional outcomes in successfully reperfused patients with acute ischemic stroke. Results highlight the role of microvascular dysfunction depicted by elevated RTH as a potential marker of no-reflow phenomenon despite excellent macrovascular reperfusion.
中文摘要:微血管血流动力学恶化被认为是急性缺血性卒中无复流现象的一种机制。实验研究提示,毛细血管通过时间相对异质性(RTH)是微血管损伤的潜在影像生物标志物。本研究探讨成功再灌注的急性缺血性卒中患者中,梗死周围RTH与梗死增长及功能结局的关系,RTH在取栓后即刻灌注磁共振成像(MRI)上测量。这项来自加州大学洛杉矶分校的回顾性病例对照研究纳入2015至2020年的急性缺血性卒中患者,纳入条件为再灌注优良(改良脑梗死溶栓评分≥2c),并具有基线、取栓后即刻及取栓后24至48小时的弥散加权和灌注加权MRI。梗死周围区域定义为基线MRI上达峰时间≥6秒的区域,且取栓后即刻MRI上未梗死。图像配准后,从取栓后即刻MRI的梗死周围区域获取包括RTH在内的灌注参数定量值。评估两项主要结局:梗死增长≥10 mL和功能结局不良(90天改良Rankin量表评分>2)。采用单因素分析评估临床和影像参数与结局的关联。年龄、性别及单因素分析中显著的协变量纳入logistic回归分析。纳入分析的47例患者中(女性62%;平均年龄72±13岁;美国国立卫生研究院卒中量表评分中位数14),20例(43%)出现明显梗死增长和功能结局不良。梗死增长>10 mL患者的梗死周围RTH显著高于无梗死增长者(P=0.005),并仍为独立预测因素(每增加10%,比值比1.4[95% CI,1.0-2.0];P=0.04)。功能结局不良患者的梗死周围RTH也显著高于功能结局良好者(P<0.001),并仍为功能结局不良的显著预测因素(每增加10%,比值比1.4[95% CI,1.0-1.9];P=0.03)。成功再灌注的急性缺血性卒中患者取栓后即刻MRI上梗死周围RTH升高可预测明显梗死增长和功能结局不良。结果突出表明,RTH升高所反映的微血管功能障碍可能是大血管再灌注优良时仍出现无复流现象的潜在标志物。
Artificial intelligence is increasingly integrated into acute stroke management, demonstrating strong performance in tasks such as large vessel occlusion detection, Alberta Stroke Program Early Computed Tomography Score scoring, and functional outcome prediction. However, concerns persist regarding both the black-box nature of these models and algorithmic bias that may exacerbate disparities in stroke incidence, treatment, and outcomes across racial and socioeconomic subgroups. This review synthesizes the current literature on explainable artificial intelligence and fairness in artificial intelligence applications for acute stroke management, identifies persistent challenges, and outlines recommendations for the development of equitable and trustworthy systems in stroke care. Recent studies have increasingly adopted post hoc explainability methods, though these are limited by approximation and misleading interpretations, especially since explanations are rarely formally tested. Explainability and fairness remain largely disconnected, with fairness evaluation remaining uncommon due to limited demographic metadata, regulatory constraints, and the absence of stroke-specific fairness criteria. Generalizability also remains a concern due to suboptimal data set partitioning strategies and inadequate reporting practices. Responsible artificial intelligence for acute stroke management requires unified evaluation frameworks that jointly assess explainability, fairness, and generalizability.
中文摘要:人工智能正日益融入急性卒中管理,在大血管闭塞检测、Alberta卒中项目早期CT评分(ASPECTS)评分和功能结局预测等任务中表现良好。但这类模型的黑箱性质以及算法偏倚仍引发担忧,算法偏倚可能加剧不同种族和社会经济亚组在卒中发病率、治疗和结局方面的差异。本综述梳理关于可解释人工智能与人工智能公平性在急性卒中管理中应用的现有文献,识别持续存在的挑战,并提出在卒中照护中开发公平且可信系统的建议。近期研究越来越多采用事后可解释性方法,但这些方法受近似性和误导性解释限制,尤其因为解释很少经过正式检验。可解释性与公平性仍基本脱节,公平性评估并不常见,原因包括人口学元数据有限、监管限制以及缺乏卒中特异性公平性标准。由于数据集划分策略不理想和报告实践不足,泛化性也仍受关注。急性卒中管理的负责任人工智能需要统一评估框架,联合评估可解释性、公平性和泛化性。
Pediatric stroke is a significant cause of long-term disability worldwide, with outcomes influenced by age, stroke subtype, and access to care. Our objective was to define the global burden of pediatric stroke by its impact on mortality and disability. The Global Burden of Disease study uses advanced statistical modeling to analyze health across locations, synthesizing data on mortality, morbidity, and risk factors. We examined 2023 data from the study to assess deaths, years of life lost, and years lived with disability during 3 eras (1990-2001, 2002-2013, and 2014-2023) across high-income and low- and middle-income countries. We stratified the analysis by sex, age group, and stroke subtype. We calculated the proportion of burden attributable to disability (years lived with disability/[years lived with disability+years of life lost]) to assess shifts from fatal to nonfatal disease over time. Between 1990 and 2023, global age-standardized pediatric stroke incidence declined only modestly, whereas age-standardized years of life lost rates declined significantly, indicating that the lower mortality burden reflected better survival rather than a large reduction in disease occurrence. Because years lived with disability rates remained comparatively stable as mortality declined, the proportion of disease burden attributable to disability rose from 14.6% (1990-2001) to 21.7% (2014-2023). This transition was uneven across settings: high-income countries achieved faster mortality declines and reached a higher disability share, whereas low- and middle-income countries retained a higher mortality burden, reflecting a dual burden of ongoing premature death and rising disability. These patterns were consistent across age and sex strata. These data indicate that pediatric stroke is undergoing an epidemiological transition from a mortality-dominant burden to one increasingly driven by disability, reflecting improved survival but with uneven distribution worldwide. Reducing the disability burden, through better stroke recognition education and expanded access to prevention, acute stroke care systems, reperfusion, and rehabilitation, particularly in low- and middle-income countries, should be prioritized alongside efforts to close persistent global inequities in outcomes.
中文摘要:儿童卒中是全球长期残疾的重要原因,结局受年龄、卒中亚型与医疗可及性影响。本研究的目标是依据卒中对死亡与残疾的影响来界定儿童卒中的全球负担。全球疾病负担研究采用高级统计建模分析各地健康状况,汇总死亡、患病与危险因素数据。我们检视该研究2023年数据,评估1990—2001年、2002—2013年、2014—2023年三个时期在高收入国家与低中收入国家的死亡、寿命损失年与伤残生存年,并按性别、年龄组和卒中亚型分层。我们计算残疾所致负担占比(伤残生存年/[伤残生存年+寿命损失年]),以评估负担由致死向非致死转变的过程。1990年至2023年间,全球年龄标化儿童卒中发病率仅小幅下降,年龄标化寿命损失年率显著下降,说明死亡负担降低反映的是生存改善,而非疾病发生的大幅减少。由于死亡率下降过程中伤残生存年率相对稳定,残疾所致疾病负担占比由14.6%(1990—2001年)升至21.7%(2014—2023年)。这一转变在不同地区并不均衡:高收入国家死亡率下降更快、残疾占比更高;低中收入国家仍保有较高的死亡负担,呈现过早死亡与残疾上升并存的双重负担。上述模式在各年龄与性别分层中一致。这些数据表明,儿童卒中正经历流行病学转变,负担由死亡主导转向日益由残疾驱动,反映生存改善但全球分布不均。降低残疾负担应优先推进,包括改进卒中识别教育、扩大预防与急性卒中救治体系、再灌注治疗及康复的可及性,尤其是在低中收入国家,同时应着力缩小持续存在的全球结局不平等。
The CREST-2 trial (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial) demonstrated superiority of carotid artery stenting (CAS) over intensive medical management for asymptomatic carotid stenosis, but it did not evaluate transcarotid artery revascularization (TCAR). Herein, we compared ischemic stroke outcomes between TCAR and CAS among patients with asymptomatic carotid stenosis in contemporary real-world practice. We identified adults with asymptomatic carotid stenosis undergoing TCAR versus CAS using the 2016 to 2024 TriNetX database, which is a multicenter federated database of electronic health records. Propensity score matching was performed for demographics, laboratory values, risk factors, comorbidities, and medications. The primary outcome was ischemic stroke within 4 years. Among 7303 identified patients, 2207 patients remained in each group after matching. TCAR did not demonstrate a significantly different stroke risk compared with CAS (hazard ratio, 0.68 [95% CI, 0.44-1.06]). The absolute risk difference was numerically but nonsignificantly lower for patients with TCAR throughout the follow-up period, progressively widening over time: 0.35% at 6 months (0.61% versus 0.96%; P=0.18) to 1.55% at 4 years (3.26% versus 4.81%; P=0.086). TCAR did not significantly lower stroke risk compared with CAS for asymptomatic carotid stenosis. Although nonsignificant trends towards lower stroke risk were observed for TCAR, the widening of absolute risk differences over time suggests residual confounding rather than potential procedural benefit.
中文摘要:CREST-2试验(无症状颈动脉狭窄颈动脉血运重建与药物治疗试验)显示颈动脉支架置入术(CAS)在无症状颈动脉狭窄中优于强化药物治疗,但未评估经颈动脉血运重建(TCAR)。本研究在当代真实世界实践中比较无症状颈动脉狭窄患者接受TCAR与CAS的缺血性卒中结局。研究利用2016至2024年TriNetX数据库(多中心电子健康记录联合数据库)筛选接受TCAR或CAS的成人无症状颈动脉狭窄患者,并按人口学特征、实验室指标、危险因素、合并症及用药进行倾向评分匹配。主要结局为4年内缺血性卒中。共识别7303例患者,匹配后每组各2207例。TCAR与CAS相比卒中风险无显著差异(风险比0.68,95%CI 0.44-1.06)。TCAR组绝对风险差在整个随访期内数值上更低但无统计学意义,且随时间逐渐扩大:6个月时为0.35%(0.61%对0.96%,P=0.18),4年时为1.55%(3.26%对4.81%,P=0.086)。对于无症状颈动脉狭窄,TCAR并未较CAS显著降低卒中风险。尽管观察到TCAR卒中风险更低的非显著趋势,但绝对风险差随时间扩大提示为残余混杂而非手术本身的获益。
Although preclinical studies and limited clinical evidence suggest potential benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) after acute ischemic stroke, their effects in patients with moderate-to-severe acute ischemic stroke requiring endovascular thrombectomy remain unclear. This study aimed to evaluate whether SGLT2i use after endovascular thrombectomy is associated with improved 3-month functional outcomes in diabetic patients with acute ischemic stroke. This retrospective cohort study analyzed prospectively collected data from January 2020 to March 2025 across 4 comprehensive stroke centers in Korea, Italy, and Switzerland. Consecutive adult patients with diabetes were grouped according to whether SGLT2i was used after their endovascular thrombectomy. Propensity score-based methods-including overlap weighting, inverse probability of treatment weighting, and 1:1 propensity score matching-were applied. Outcomes included the shift in 3-month modified Rankin Scale score, favorable (modified Rankin Scale score 0-2), and excellent outcomes (modified Rankin Scale score 0-1) at 3 months. Ordinal and binary logistic regression analyses were performed. Of 429 eligible patients (mean [SD] age, 73.5 [11.1] years; 249 [58.0%] men; median [interquartile range] initial National Institutes of Health Stroke Scale score, 12 [6-18]), 51 (11.9%) received SGLT2i poststroke. Successful recanalization was achieved in 85.3%. In the overlap weighting model (weighted n=37 per group), SGLT2i use was associated with improved 3-month modified Rankin Scale score distribution (common odds ratio, 2.31; [95% CI, 1.30-4.10]) and higher odds of a favorable outcome (odds ratio, 2.26; [95% CI, 1.15-4.43]). Results were consistent across inverse probability of treatment weighting and propensity score matching models, with inverse probability of treatment weighting analyses additionally demonstrating significant associations with excellent outcomes. No significant effect modification was observed across key clinical subgroups. Poststroke SGLT2i therapy after endovascular thrombectomy was associated with improved 3-month functional outcomes in this multicenter retrospective analysis of diabetic patients. These findings suggest a potential therapeutic role for SGLT2i in poststroke diabetes management and support future prospective trials.
中文摘要:尽管临床前研究和有限的临床证据提示钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)在急性缺血性卒中后可能获益,但其在需血管内取栓的中重度急性缺血性卒中患者中的效果仍不明确。本研究旨在评估糖尿病急性缺血性卒中患者血管内取栓后使用SGLT2i是否与3个月功能结局改善相关。这项回顾性队列研究分析2020年1月至2025年3月韩国、意大利和瑞士4个综合卒中中心前瞻性收集的数据。连续纳入的成人糖尿病患者按血管内取栓后是否使用SGLT2i分组。采用基于倾向性评分的方法,包括重叠权重、逆概率治疗加权和1:1倾向性评分匹配。结局包括3个月改良Rankin量表评分的分布移位、3个月良好结局(改良Rankin量表评分0-2)和极好结局(改良Rankin量表评分0-1)。进行有序和二元logistic回归分析。429例符合条件患者(平均[SD]年龄73.5[11.1]岁;249例[58.0%]男性;初始美国国立卫生研究院卒中量表评分中位数[四分位距]为12[6-18])中,51例(11.9%)卒中后接受SGLT2i。85.3%实现成功再通。在重叠权重模型(每组加权n=37)中,使用SGLT2i与3个月改良Rankin量表评分分布改善相关(共同比值比2.31;95%CI 1.30-4.10),良好结局的比值更高(比值比2.26;95%CI 1.15-4.43)。逆概率治疗加权和倾向性评分匹配模型结果一致,逆概率治疗加权分析还显示与极好结局显著相关。关键临床亚组中未观察到显著效应修饰。在这项多中心回顾性分析中,糖尿病卒中患者血管内取栓后接受SGLT2i治疗与3个月功能结局改善相关。这些发现提示SGLT2i在卒中后糖尿病管理中可能具有治疗作用,并支持未来开展前瞻性试验。
Stratification of stroke risk remains challenging, but metabolomic profiling offers the potential to detect new biomarkers and to improve early risk assessment of incident stroke. The objective of this study was to evaluate the association between circulating metabolites and the incidence of stroke in a case-cohort study conducted across several large population-based European cohorts. Following the case-cohort design, a subset of 10 299 individuals, including all individuals with incident stroke, was selected from the original cohort of >70 000 individuals. The case-cohort design used a random subsample of the selected population cohorts, supplemented with cases not sampled in this random subcohort. A total of 141 circulating metabolites were measured from serum samples of the selected individuals, and associations of these metabolites with risk of incident stroke were estimated and compared with those of classic risk factors (sex, age at examination, systolic blood pressure, total cholesterol, body mass index, diabetes, daily smoking status, and antihypertensive treatment). Associations with time to stroke were assessed using weighted Cox proportional hazards models adjusted for the classic risk factors. Hazard ratios (HRs) for the log-transformed metabolites were reported per 1 SD increase. Of the 70 195 individuals in the original cohort, 1516 (2.2%) experienced incident strokes during a median follow-up time of 8.9 years (interquartile range, 4.4-14.7). Median age was 56.8 years (interquartile range, 49.5-62.4), and 39.5% were women. Six of the 141 metabolites (2 diacyl-phosphatidylcholines, 2 lyso-phosphatidylcholines, 1 hydroxysphingomyelin, and glutamic acid) remained significantly associated with incident stroke after correction for multiple comparisons (adjusted HRs [95% CIs] per SD: lyso-phosphatidylcholines a C18:2 HR, 0.88 [95% CI, 0.82-0.93], lyso-phosphatidylcholines a C17:0 HR, 0.88 [95% CI, 0.83-0.94], hydroxysphingomyelin C14:1 HR, 0.90 [95% CI, 0.85-0.94], diacyl-phosphatidylcholines C34:1 HR, 1.10 [95% CI 1.05-1.16], diacyl-phosphatidylcholines C32:1 HR, 1.14 [95% CI, 1.08-1.21], glutamic acid HR, 1.23 [95% CI 1.11-1.37]). The strengths of these associations were similar to those for classic cardiovascular risk factors (C statistics for 10-year prediction ranging from 0.782 to 0.785 for metabolites compared with 0.781 to 0.792 for classic cardiovascular risk factors). Among 10 299 individuals from the general European population, we identified 6 metabolites from 4 different metabolite classes that were associated with future risk of stroke. The application of specific circulating metabolites may improve early stroke risk prediction before the onset of potentially irreversible cerebrovascular pathological processes.
中文摘要:卒中风险分层仍具挑战,代谢组学分析有望发现新生物标志物并改善新发卒中的早期风险评估。本研究在多个欧洲大型人群队列中开展病例队列研究,评估循环代谢物与新发卒中之间的关联。按病例队列设计,从原始7万余人队列中选取10 299人,包括全部新发卒中个体。病例队列设计使用所选人群队列的随机子样本,并补充未纳入该随机子队列的病例。对所选个体血清样本测量141种循环代谢物,估计这些代谢物与新发卒中风险的关联,并与经典危险因素(性别、检查时年龄、收缩压、总胆固醇、体重指数、糖尿病、每日吸烟状态和降压治疗)比较。采用加权Cox比例风险模型评估与卒中时间的关联,并校正经典危险因素。报告对数转换代谢物每增加1个标准差的危险比。原始队列70 195人中,中位随访8.9年(四分位距4.4–14.7)期间有1516人(2.2%)发生新发卒中。中位年龄56.8岁(四分位距49.5–62.4),女性占39.5%。多重比较校正后,141种代谢物中有6种(2种二酰基磷脂酰胆碱、2种溶血磷脂酰胆碱、1种羟基鞘磷脂和谷氨酸)仍与新发卒中显著相关(每标准差校正HR [95% CI]:溶血磷脂酰胆碱a C18:2 HR 0.88 [95% CI 0.82–0.93],溶血磷脂酰胆碱a C17:0 HR 0.88 [95% CI 0.83–0.94],羟基鞘磷脂C14:1 HR 0.90 [95% CI 0.85–0.94],二酰基磷脂酰胆碱C34:1 HR 1.10 [95% CI 1.05–1.16],二酰基磷脂酰胆碱C32:1 HR 1.14 [95% CI 1.08–1.21],谷氨酸HR 1.23 [95% CI 1.11–1.37])。这些关联强度与经典心血管危险因素相似(代谢物10年预测C统计量0.782–0.785,经典心血管危险因素0.781–0.792)。在欧洲一般人群10 299人中,识别出4类共6种代谢物与未来卒中风险相关。特定循环代谢物的应用可能改善在可能不可逆脑血管病理过程发生前的早期卒中风险预测。
Acute basilar artery occlusion causes devastating strokes. Despite the benefit of endovascular treatment, the optimal management remains controversial in specific subgroups, particularly patients with mild deficits, and would benefit from robust prognostic tools. Given the dense white matter networks within the posterior fossa, we tested whether quantifying disconnections from acute diffusion-weighted imaging could improve outcome prediction and identify responders to recanalization compared with conventional metrics. We conducted a secondary analysis of a prospective multicenter stroke registry in France, including consecutive patients (2017-2024) with basilar artery occlusion and admission magnetic resonance imaging. Ultra-high-resolution diffusion magnetic resonance imaging was acquired in 2 healthy participants to build normative tractograms with optimized posterior fossa quality. Patient infarcts delineated on diffusion-weighted imaging were projected onto these tractograms to estimate disconnected fiber volume. The primary outcome was 90-day modified Rankin Scale score (0-3 versus 4-6). Predictive performance of disconnected fiber volume was compared with baseline National Institutes of Health Stroke Scale (NIHSS), infarct volume, and posterior circulation Alberta Stroke Program Early Computed Tomography Score using logistic regressions and area under the receiver operating characteristic curves. Ordinal regressions tested associations between dichotomized disconnection status and the full modified Rankin Scale spectrum, stratified by recanalization status. Analyses were repeated in patients with an NIHSS score ≤10. Among 201 patients (median age, 70; NIHSS score, 10), 97 (48.3%) had a poor outcome. Despite a small median infarct volume (4.75 mL), disconnected fiber volume was substantial (median 25.15 mL). Disconnected fiber volume achieved an area under the receiver operating characteristic curves of 0.84, outperforming NIHSS score (0.67; P<0.0001), infarct volume (0.75; P=0.00059), and posterior circulation Alberta Stroke Program Early Computed Tomography Score (0.76; P=0.0127). Patients without significant disconnection had better outcomes across the full modified Rankin Scale spectrum (odds ratio, 0.12 [95% CI, 0.065-0.204]) and derived greater benefit from successful recanalization (odds ratio, 0.33 [95% CI, 0.15-0.70]). In patients with an NIHSS score ≤10 (n=102), disconnected fiber volume remained the strongest predictor (area under the receiver operating characteristic curves of 0.83). Disconnected fiber volume derived indirectly is a robust prognostic marker of basilar artery occlusion outcomes that outperforms conventional predictors and may support future treatment decisions after prospective validation. URL: https://clinicaltrials.gov; Unique identifier: NCT03776877.
中文摘要:急性基底动脉闭塞可导致灾难性卒中。尽管血管内治疗有益,特定亚组的最佳管理仍存在争议,尤其是轻度神经功能缺损患者,这类人群需要可靠的预后工具。鉴于后颅窝内存在密集的白质网络,我们检验了基于急性弥散加权成像量化断连能否较常规指标改善结局预测并识别再通治疗应答者。本研究为法国一项前瞻性多中心卒中登记研究的二次分析,连续纳入2017—2024年因基底动脉闭塞入院并接受磁共振成像的患者。研究在2名健康参与者中采集超高分辨率弥散磁共振成像,用于构建后颅窝质量优化的正常参考纤维束图。将患者在弥散加权成像上勾画的梗死灶投影至这些纤维束图,以估计断连纤维体积。主要结局为90天改良Rankin量表评分(0—3分与4—6分)。采用logistic回归和受试者工作特征曲线下面积比较断连纤维体积与基线美国国立卫生研究院卒中量表评分、梗死体积及后循环Alberta卒中项目早期CT评分的预测性能。采用有序回归检验二分类断连状态与完整改良Rankin量表评分谱的关联,并按再通状态分层。在NIHSS评分≤10分的患者中重复分析。201例患者(中位年龄70岁;NIHSS评分10分)中,97例(48.3%)结局不良。尽管中位梗死体积较小(4.75 mL),断连纤维体积仍较大(中位25.15 mL)。断连纤维体积的受试者工作特征曲线下面积为0.84,优于NIHSS评分(0.67;P<0.0001)、梗死体积(0.75;P=0.00059)和后循环Alberta卒中项目早期CT评分(0.76;P=0.0127)。无显著断连的患者在完整改良Rankin量表评分谱上结局更好(比值比0.12[95% CI,0.065—0.204]),并从成功再通中获得更大获益(比值比0.33[95% CI,0.15—0.70])。在NIHSS评分≤10分的患者中(n=102),断连纤维体积仍是最强预测指标(受试者工作特征曲线下面积0.83)。间接得出的断连纤维体积是基底动脉闭塞结局的稳健预后标志物,优于常规预测指标,并可能在前瞻性验证后支持未来治疗决策。网址:https://clinicaltrials.gov;唯一标识:NCT03776877。
Vessel wall magnetic resonance imaging (VW-MRI) is a promising tool for evaluating intracranial arteriopathies in pediatric non-neonatal arterial ischemic stroke, but its diagnostic and prognostic roles remain underexplored. This study assesses the utility of VW-MRI in identifying arteriopathy subtypes and predicting clinical and radiological outcomes in children. We conducted an ancillary retrospective study using the national KidClot cohort and the stroke database at Necker-Enfants Malades Hospital (Paris). Children with arterial ischemic stroke who underwent VW-MRI within 3 months of onset and follow-up MRI at least 18 months later were included. Stroke causes were assessed according to the Childhood Arterial Ischemic Stroke Standardized Classification and Diagnostic Evaluation, and intracranial arterial vessel wall enhancement (VWE) was evaluated. Analyses focused on the focal cerebral arteriopathy (FCA) subgroup, comparing VWE-positive and VWE-negative patients and assessing correlations with clinical factors, imaging metrics, and outcomes. Categorical variables were compared using the χ2/Fisher exact test, qualitative/ordinal variables using the Mann-Whitney U test, and correlations were assessed using the Spearman rank correlation coefficient (ρ). From 193 children, 67 were included (median age, 4.1 years, interquartile range, 2.0-9.8; 61.1% male). Causes were FCA (42%, 28/67), bilateral cerebral arteriopathy (5%, 3/67), aortic/cervical arteriopathy (12%, 8/67), cardioembolic (7%, 5/67), other (22%, 15/67), and multifactorial (12%, 8/67). In FCA, 75% (21/28) showed concentric VWE, correlating with stenosis severity (ρ=0.31; P=0.001). VWE-positive patients with FCA had a higher initial focal cerebral arteriopathy severity score (median 5 versus 3; P=0.046) than VWE-negative patients, but no statistically significant differences were found in other evaluated factors, including initial Pediatric National Institutes of Health Stroke Scale (median 8.5 versus 8; P=0.5) and 12-month Pediatric Stroke Outcome Measure (median 0.5 versus 1; P=0.8). VW-MRI detects inflammatory arterial changes in pediatric FCA. However, its prognostic value is limited, suggesting enhancement reflects acute inflammation rather than long-term trajectory.
中文摘要:血管壁磁共振成像(VW-MRI)是评估儿童非新生儿动脉缺血性卒中颅内动脉病变的有前景工具,但其诊断和预后作用仍待阐明。该研究评估VW-MRI在识别动脉病变亚型及预测儿童临床与影像结局方面的效用。研究为一项辅助性回顾性研究,使用全国KidClot队列和巴黎Necker-Enfants Malades医院卒中数据库。纳入发病3个月内接受VW-MRI且至少18个月后接受随访MRI的动脉缺血性卒中患儿。卒中病因依据儿童动脉缺血性卒中标准化分类与诊断评估进行判定,并评估颅内动脉血管壁强化(VWE)。分析聚焦局灶性脑动脉病(FCA)亚组,比较VWE阳性与VWE阴性患者,并评估其与临床因素、影像指标和结局的相关性。分类变量采用χ2/Fisher精确检验比较,定性/有序变量采用Mann-Whitney U检验,相关性采用Spearman秩相关系数(ρ)评估。从193名儿童中纳入67名,中位年龄4.1岁,四分位距2.0-9.8岁,男性占61.1%。病因为FCA(42%,28/67)、双侧脑动脉病(5%,3/67)、主动脉/颈部动脉病(12%,8/67)、心源性栓塞(7%,5/67)、其他(22%,15/67)和多因素(12%,8/67)。FCA中75%(21/28)显示同心性VWE,与狭窄严重程度相关(ρ=0.31;P=0.001)。VWE阳性的FCA患者初始局灶性脑动脉病严重度评分高于VWE阴性患者(中位5对3;P=0.046),但其他评估因素未见统计学显著差异,包括初始儿童美国国立卫生研究院卒中量表评分(中位8.5对8;P=0.5)和12个月儿童卒中结局量表评分(中位0.5对1;P=0.8)。VW-MRI可检测儿童FCA中的炎性动脉改变。其预后价值有限,提示强化反映急性炎症而非长期病程轨迹。
Intravenous thrombolysis remains the standard treatment for distal and medium vessel occlusion (DMVO) strokes. However, unlike large vessel occlusions, whether tenecteplase achieves higher early successful recanalization rates than alteplase in DMVO strokes remains uncertain. This single-center observational cohort study included consecutive patients with magnetic resonance imaging (MRI)-confirmed DMVO stroke treated at Centre Hospitalier Sud-Francilien, France, according to an institutional thrombolysis protocol specifying alteplase (0.9 mg/kg, 2016-2018) or tenecteplase (0.25 mg/kg, 2018-2023), with follow-up MRI 1 to 2 hours after intravenous thrombolysis. Patients intended for endovascular thrombectomy or without diagnostic-quality follow-up MRI were excluded. Recanalization was blindly assessed using a modified Arterial Occlusion Lesion scale designed for MRI and DMVO. Early successful recanalization was defined as ≥50% recanalization on early follow-up MRI (grade ≥2b), and substantial early infarct growth, assessed using a semiautomatic segmentation technique, was defined as a ≥0.5 mL and ≥20% increase in lesion volume. Propensity-score weighting accounted for baseline imbalances, including age, sex, vascular risk factors, baseline National Institutes of Health Stroke Scale score, occlusion site, and time period (2020-2023 versus 2016-2019). Of the 319 included patients, 159 were treated with tenecteplase and 160 with alteplase. Median baseline National Institutes of Health Stroke Scale was 3 (1-7) in the tenecteplase group versus 4 (1-7.5) in the alteplase group, while M2 occlusions accounted for 54.1% versus 43.8% of cases. Early successful recanalization, assessed at a median postintravenous thrombolysis time of 80 (70-94) minutes, occurred in 72 (45.3%) and 53 (33.1%) patients treated with tenecteplase and alteplase, respectively (propensity-score weighting-odds ratio, 1.59 [95% CI, 1.15-2.20]; P=0.005). Substantial early infarct growth was observed in 42 (26.8%) and 64 (40.5%) patients, respectively (propensity-score weighting-odds ratio, 0.49 [95% CI, 0.35-0.69]; P<0.0001). Compared with alteplase, tenecteplase-treated patients with DMVO had higher early successful recanalization and a lower risk of substantial early infarct growth, supporting its preferential use in this setting. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05635786.
中文摘要:静脉溶栓仍是远端及中等血管闭塞(DMVO)卒中的标准治疗。与大血管闭塞不同,替奈普酶在DMVO卒中中能否比阿替普酶取得更高的早期成功再通率仍不确定。这项单中心观察性队列研究连续纳入法国Centre Hospitalier Sud-Francilien医院按机构溶栓方案治疗、经磁共振成像(MRI)确诊的DMVO卒中患者,方案规定使用阿替普酶(0.9 mg/kg,2016—2018年)或替奈普酶(0.25 mg/kg,2018—2023年),并在静脉溶栓后1至2小时复查MRI。拟行血管内取栓或缺乏诊断质量随访MRI的患者被排除。再通情况采用为MRI与DMVO设计的改良动脉闭塞病灶量表进行盲法评估。早期成功再通定义为早期随访MRI上再通≥50%(分级≥2b);早期梗死显著增长采用半自动分割技术评估,定义为病灶体积增加≥0.5 mL且≥20%。倾向评分加权用于校正基线不均衡,包括年龄、性别、血管危险因素、基线美国国立卫生研究院卒中量表评分、闭塞部位及时间段(2020—2023年与2016—2019年)。纳入的319例患者中,159例接受替奈普酶,160例接受阿替普酶。基线美国国立卫生研究院卒中量表评分中位数在替奈普酶组为3(1-7),在阿替普酶组为4(1-7.5);M2闭塞分别占54.1%与43.8%。在静脉溶栓后中位80(70-94)分钟评估,早期成功再通在替奈普酶组与阿替普酶组分别为72例(45.3%)与53例(33.1%)(倾向评分加权比值比1.59[95% CI 1.15-2.20],P=0.005)。早期梗死显著增长分别见于42例(26.8%)与64例(40.5%)(倾向评分加权比值比0.49[95% CI 0.35-0.69],P<0.0001)。与阿替普酶相比,接受替奈普酶治疗的DMVO患者早期成功再通率更高、早期梗死显著增长的风险更低,支持在该情形下优先使用替奈普酶。网址:https://www.clinicaltrials.gov;唯一标识:NCT05635786。
Acute ischemic stroke (AIS) survivors are at high risk of major adverse cardiovascular events (MACE), highlighting the need to identify modifiable secondary prevention targets. We assessed whether postacute discharge destination is associated with 1-year MACE risk among AIS survivors. In this retrospective cohort study, adult AIS survivors were identified from the state inpatient and emergency department databases of 5 US states (2016-2019) and categorized by discharge destination: home, inpatient rehabilitation facility (IRF), or skilled nursing facility (SNF). Other destinations were excluded. The primary outcome was 1-year MACE, defined as recurrent stroke, acute myocardial infarction, systemic embolism, or vascular death. Multivariable Cox models, adjusted for demographic and clinical factors, were used to evaluate the association between discharge disposition and MACE risk. Fine-Gray models were used for nonfatal secondary outcomes, and restricted mean survival time analyses were used to estimate absolute risk. Effect modification by age (<65 versus ≥65 years) was examined. Confounder-adjusted number-needed-to-be-exposed was estimated by marginal standardization. Among 213 511 AIS survivors (median age, 71 years), 16 237 (7.6%) experienced MACE within 1-year. MACE incidence was lowest after IRF discharge (6.6%) versus home (7.6%) or SNF (8.3%). In adjusted analyses, IRF discharge was associated with lower MACE risk versus home (adjusted hazard ratio, 0.88 [95% CI, 0.83-0.93]) and SNF (0.84 [95% CI, 0.79-0.89]). The association persisted across age strata but was more pronounced in patients <65 years (Pinteraction=0.014). Restricted mean survival time analyses indicated that IRF discharge was associated with 3.47 and 3.87 additional MACE-free days versus home and SNF discharge, respectively (both P<0.001). Adjusted number-needed-to-be-exposed were 115 (95% CI, 80-207) for IRF versus home and 87 (95% CI, 64-136) for IRF versus SNF. Postacute IRF discharge is associated with a lower 1-year MACE risk after AIS, highlighting the postacute care setting as a potentially modifiable system-level target for secondary prevention of long-term vascular outcomes.
中文摘要:急性缺血性卒中(AIS)存活者发生主要不良心血管事件(MACE)的风险较高,需要识别可干预的二级预防靶点。本研究评估AIS存活者急性期后出院去向是否与1年MACE风险相关。这项回顾性队列研究从美国5个州(2016—2019年)的住院和急诊数据库识别成人AIS存活者,并按出院去向分为家庭、住院康复机构(IRF)和专业护理机构(SNF),排除其他去向。主要结局为1年MACE,定义为复发性卒中、急性心肌梗死、系统性栓塞或血管性死亡。采用校正人口学和临床因素的多变量Cox模型评估出院去向与MACE风险的关联;非致死性次要结局采用Fine-Gray模型,绝对风险采用限制平均生存时间分析估计;并检验年龄(<65岁与≥65岁)的效应修饰。通过边际标准化估计混杂因素校正后的需暴露人数。在213 511例AIS存活者中(中位年龄71岁),16 237例(7.6%)在1年内发生MACE。IRF出院后的MACE发生率最低(6.6%),家庭出院为7.6%,SNF出院为8.3%。校正分析中,与家庭出院相比,IRF出院与更低的MACE风险相关(校正风险比0.88[95% CI,0.83—0.93]);与SNF出院相比亦更低(0.84[95% CI,0.79—0.89])。该关联在各年龄分层中持续存在,但在<65岁患者中更明显(交互作用P=0.014)。限制平均生存时间分析显示,与家庭和SNF出院相比,IRF出院分别与额外3.47天和3.87天无MACE生存时间相关(均P<0.001)。校正后的需暴露人数为IRF对家庭115(95% CI,80—207),IRF对SNF 87(95% CI,64—136)。AIS后急性期IRF出院与更低的1年MACE风险相关,提示急性期后照护环境可能是长期血管结局二级预防中可干预的系统层面靶点。
Despite increasing incidence of stroke among younger adults, the associations of social determinants of health (SDOH) and stroke among younger adults are not well known. This study investigates the associations between SDOH from early adulthood and stroke in a prospective longitudinal cohort. We studied participants enrolled in the CARDIA study (Coronary Artery Risk Development in Young Adults). Participants aged 18 to 30 years were enrolled in 1985 and followed through 2022. We investigated longitudinal, time-varying measures of SDOH classified into 5 distinct domains: economic (6 measures), education (1 measure), healthcare (4 measures), neighborhood (2 measures), and social/community (5 measures). The outcome was incident stroke or transient ischemic attack. We evaluated associations between individual SDOH and stroke using unadjusted Cox models. We then evaluated whether a greater cumulative number of adverse SDOH domains (each represented by 1 exposure selected by empirical techniques) was associated with stroke risk after adjustment for demographics. Among the 5114 participants (54.5% were female; baseline age, 25 years; and median follow-up, 37.9 years), 146 individuals experienced stroke or transient ischemic attack, all of which occurred <65 years. Household income (hazard ratio [HR], 1.24 per $10 000 lower [95% CI, 1.11-1.39]), education (HR, 0.93 per greater year [95% CI, 0.87-0.99]), neighborhood deprivation (HR, 1.21 [95% CI, 1.02-1.43]), and lacking health insurance (HR, 1.49 [95% CI, 1.05-2.11]) were associated with stroke risk. Those experiencing 2 adverse SDOH domains (HR, 1.65 [95% CI, 0.91-2.97]) or ≥3 adverse domains (HR, 2.00 [95% CI, 1.09-3.66]) had progressively higher stroke risk (Ptrend=0.005). In interaction analyses, the association between income and stroke appeared stronger in Black participants (Pinteraction=0.02) and women (Pinteraction=0.02). In this young cohort followed through midlife, SDOH spanning several domains were associated with stroke risk. We also observed a dose-dependent response with the number of adverse SDOH domains experienced. Our results suggest that SDOH experienced throughout adulthood are relevant to future stroke risk.
中文摘要:尽管年轻成人卒中发病率上升,年轻成人中健康社会决定因素(SDOH)与卒中的关联仍不清楚。该研究在前瞻性纵向队列中考察成年早期起SDOH与卒中的关联。研究纳入CARDIA研究(年轻成人冠状动脉风险发展研究)参与者,1985年入组时年龄18至30岁,随访至2022年。研究分析纵向、随时间变化的SDOH,分为5个域:经济(6项)、教育(1项)、医疗保健(4项)、社区邻里(2项)、社会/社区(5项)。结局为新发卒中或短暂性脑缺血发作。采用未校正Cox模型评估各SDOH与卒中的关联。随后在校正人口学特征后,评估累积不良SDOH域数量(每个域由经验方法选取的1项暴露代表)是否与卒中风险相关。5114名参与者中(54.5%为女性;基线年龄25岁;中位随访37.9年),146人发生卒中或短暂性脑缺血发作,均发生在65岁前。家庭收入(每低10000美元,风险比[HR] 1.24,95%CI 1.11-1.39)、教育(每多一年,HR 0.93,95%CI 0.87-0.99)、社区剥夺(HR 1.21,95%CI 1.02-1.43)和缺乏医疗保险(HR 1.49,95%CI 1.05-2.11)与卒中风险相关。经历2个不良SDOH域(HR 1.65,95%CI 0.91-2.97)或≥3个不良域(HR 2.00,95%CI 1.09-3.66)者卒中风险逐步升高(P趋势=0.005)。交互分析中,收入与卒中的关联在黑人参与者(P交互=0.02)和女性(P交互=0.02)中似乎更强。在这个随访至中年的年轻队列中,跨多个域的SDOH与卒中风险相关。还观察到与经历的不良SDOH域数量呈剂量依赖反应。结果提示,成年期经历的SDOH与未来卒中风险相关。
The utility-weighted approach to analyzing the modified Rankin Scale (mRS) is increasingly being utilized in acute stroke clinical trials. This analytic approach assigns a patient-centered utility weight-the desirability or value of a health state to patients-to each level of the mRS. The utility-weighted-mRS analysis converts the mRS from a scale reflecting only the rank order of functional outcome after stroke into one that quantifies the value of each poststroke mRS health state from patients' perspectives. The ability of the utility-weighted-mRS analysis to capture the unequal difference in patient health-related quality of life between each level of the mRS makes it an appealing patient-centered end point for acute stroke clinical trials. However, several concerns have historically raised skepticism regarding its value as a trial end point. Unfamiliarity with how utility weights are derived and used poses challenges to its use for shared decision-making between patients and clinicians. There are valid concerns that social, geographic, and demographic factors that differ between countries influence the mRS utility weights, so that use of uniform weights across all settings mildly reduces the precision of utility quantification, particularly in multinational stroke clinical trials. This narrative review aims to provide the clinical and research stroke community with a practical overview of key methodology in the utility-weighted-mRS analysis to aid in its interpretation, considers the advantages and challenges of using the utility-weighted-mRS analysis, and suggests future areas of study.
中文摘要:改良Rankin量表(mRS)的效用加权分析方法在急性卒中临床试验中的应用日益增多。该方法为mRS每一等级赋予以患者为中心的效用权重,即患者对某一健康状态的可取性或价值判断。效用加权mRS分析将mRS从仅反映卒中后功能结局等级顺序的量表,转变为可从患者视角量化卒中后每一mRS健康状态价值的工具。效用加权mRS分析能够捕捉mRS各等级之间患者健康相关生活质量差异的不均等性,使其成为急性卒中临床试验中具有吸引力的以患者为中心的终点。然而,历史上一些担忧曾使其作为试验终点的价值受到质疑。对效用权重如何推导和使用不熟悉,给患者与临床医生共同决策中的应用带来挑战。有合理担忧认为,国家间不同的社会、地理和人口学因素会影响mRS效用权重,因此在所有环境中使用统一权重会轻度降低效用量化的精确性,尤其是在跨国卒中临床试验中。该叙述性综述旨在为临床和研究卒中领域提供效用加权mRS分析关键方法的实用概览,以帮助解读,讨论使用效用加权mRS分析的优势与挑战,并提出未来研究方向。
Patients with medium or distal vessel occlusion stroke are heterogeneous. Randomized trials show no net benefit of endovascular treatment (EVT) over best medical treatment (BMT) alone, which may mask heterogeneity of treatment effect. We used an externally developed machine learning model to predict excellent early neurological outcome (EENO) with BMT alone and examined whether the effect of EVT differed across predicted risk. A Tabular Prior-Data Fitted Network (TabPFN) model was trained to predict EENO (24-hour National Institutes of Health Stroke Scale [NIHSS] score of 0-2) in patients with medium or distal vessel occlusion treated with BMT alone in a local Bernese Stroke Registry. This model was applied to patients from the DISTAL randomized trial (55 centers and 11 countries), who were randomized to EVT plus BMT or BMT alone. We tested for interaction between predicted EENO and treatment allocation on the primary outcome (90-day modified Rankin Scale shift), repeating this using admission NIHSS alone. In the development cohort (n=257, 42% female, and mean age 70.4±14.8 years), 54% achieved EENO. In the DISTAL cohort (270 BMT alone, 269 EVT plus BMT, 44% female, and mean age 74.9±12.0 years), the model showed moderate external discrimination (area under the receiver operating characteristic curve 0.73). A significant interaction was found between predicted EENO and treatment effect (Pinteraction=0.012): in 152 patients predicted to achieve EENO, EVT was associated with worse 90-day modified Rankin Scale score (common odds ratio, 0.48 [95% CI, 0.27-0.84]), whereas no treatment effect was seen in 387 patients predicted not to achieve EENO (common odds ratio 1.13 [95% CI, 0.79-1.60]). A model using admission NIHSS alone showed comparable discrimination (area under the receiver operating characteristic curve 0.71) and a common odds ratio for EVT of 0.47 (95% CI, 0.25-0.89) in patients with an NIHSS score of ≤4 and a common odds ratio of 1.05 (95% CI, 0.75-1.47) in patients with an NIHSS score of >4 (Pinteraction=0.029). EVT was harmful in patients with medium or distal vessel occlusion predicted to achieve EENO with BMT alone, and an NIHSS-alone model performed comparably to the multivariable model. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05029414.
中文摘要:中等或远端血管闭塞卒中患者具有异质性。随机试验显示血管内治疗(EVT)较单纯最佳药物治疗(BMT)无净获益,这可能掩盖治疗效应异质性。我们使用外部开发的机器学习模型预测单纯BMT下的优良早期神经功能结局(EENO),并检验EVT效应是否随预测风险不同。利用本地伯尔尼卒中登记中接受单纯BMT的中等或远端血管闭塞患者,训练表格先验数据拟合网络(TabPFN)模型预测EENO(24小时美国国立卫生研究院卒中量表[NIHSS]评分0-2分)。将该模型应用于DISTAL随机试验(55个中心、11个国家)中随机接受EVT联合BMT或单纯BMT的患者。检验预测EENO与治疗分配对主要结局(90天改良Rankin量表移位)的交互作用,并用入院NIHSS单独重复。开发队列(n=257,女性42%,平均年龄70.4±14.8岁)中54%达到EENO。DISTAL队列(单纯BMT 270例,EVT联合BMT 269例,女性44%,平均年龄74.9±12.0岁)中模型外部区分度中等(受试者工作特征曲线下面积0.73)。预测EENO与治疗效应存在显著交互(P交互=0.012):在预测可达到EENO的152例患者中,EVT与更差的90天改良Rankin量表评分相关(共同比值比0.48[95%CI 0.27-0.84]),而在预测未达到EENO的387例患者中未见治疗效应(共同比值比1.13[95%CI 0.79-1.60])。仅用入院NIHSS的模型区分度相当(曲线下面积0.71),NIHSS≤4分患者中EVT共同比值比0.47(95%CI 0.25-0.89),NIHSS>4分患者中1.05(95%CI 0.75-1.47)(P交互=0.029)。在预测单纯BMT可达到EENO的中等或远端血管闭塞患者中,EVT有害,仅用NIHSS模型与多变量模型表现相当。网址:https://www.clinicaltrials.gov;唯一标识:NCT05029414。
The ABCD2 score is widely used to stratify stroke risk after transient neurological events. We aimed to evaluate the association between the ABCD2 score and the risk of subsequent ischemic stroke among patients with diffusion-weighted imaging (DWI)-positive (DWI+) or DWI-negative (DWI-) findings for the index event. We pooled individual participant data from 3 multicenter cohorts including patients presenting with transient or minor neurological events. Patients presenting with transient neurological symptoms, a normal neurological examination, and available DWI for the index event were included. Associations between the ABCD2 score and 90-day ischemic stroke risk were analyzed separately in the DWI+ and DWI- groups using logistic regression models adjusted for sex, atrial fibrillation, and study source. Among 2014 patients (1143 [56.8%] men; median age 67 years), the median ABCD2 score was 4 (interquartile range, 3-5), and 504 (25.0%) were DWI+. Ischemic stroke occurred within 90 days in 20 patients (4.0%) in the DWI+ group and 33 (2.2%) in the DWI- group. The ABCD2 score was associated with stroke risk in the DWI- group (per 1-point increase, odds ratio, 1.36 [95% CI, 1.04-1.79]), but this relationship was not significant in the DWI+ group (per 1-point increase, odds ratio, 1.08 [95% CI, 0.76-1.53]). When stratified ABCD2 score into 0 to 3, 4 to 5, and 6 to 7, the predicted 90-day stroke risks were 3.2%, 3.9%, and 4.5% in the DWI+ group (per 1-category increase, odds ratio, 1.23 [95% CI, 0.63-2.40]) and 1.0%, 2.3%, and 4.1% in the DWI- group (per 1-category increase, odds ratio, 1.88 [95% CI, 1.11-3.20]), respectively. The ABCD2 score was associated with 90-day stroke risk among patients with DWI- findings. Patients with both a low ABCD2 score and DWI- findings had a particularly low risk of subsequent stroke, which may inform risk stratification and clinical decision-making after transient neurological events.
中文摘要:ABCD2评分广泛用于短暂神经事件后卒中风险分层。我们旨在评估在指数事件弥散加权成像阳性(DWI+)或阴性(DWI-)患者中,ABCD2评分与后续缺血性卒中风险的关系。我们汇总了3个多中心队列的个体参与者数据,纳入表现为短暂或轻微神经事件的患者。纳入标准为短暂神经症状、神经系统检查正常且指数事件有可用DWI。分别在DWI+和DWI-组中,用校正性别、心房颤动和研究来源的logistic回归模型分析ABCD2评分与90天缺血性卒中风险的关系。2014例患者(1143例[56.8%]男性;中位年龄67岁)中,ABCD2评分中位数为4(四分位距3-5),504例(25.0%)为DWI+。90天内发生缺血性卒中者DWI+组20例(4.0%),DWI-组33例(2.2%)。ABCD2评分与DWI-组卒中风险相关(每增加1分,比值比1.36[95%CI 1.04-1.79]),但该关系在DWI+组不显著(每增加1分,比值比1.08[95%CI 0.76-1.53])。将ABCD2评分分为0-3、4-5和6-7后,DWI+组预测90天卒中风险分别为3.2%、3.9%和4.5%(每增加1个类别,比值比1.23[95%CI 0.63-2.40]),DWI-组分别为1.0%、2.3%和4.1%(每增加1个类别,比值比1.88[95%CI 1.11-3.20])。ABCD2评分与DWI-患者的90天卒中风险相关。ABCD2评分低且DWI-的患者后续卒中风险特别低,这可能有助于短暂神经事件后的风险分层和临床决策。
基础研究 (7篇)
Flow disturbances in the smallest blood vessels of the brain, the capillaries, have long been considered a potential cause of brain dysfunction. However, owing to the technological challenge of studying blood flow in three-dimensional capillary networks, elucidating the incidence, causes, and consequences of capillary obstructions has been difficult. Advances in optical microscopes for in vivo imaging, primarily high-spatiotemporal-resolution optical coherence tomography and two-photon microscopy, have recently enabled detailed studies of these capillary stalling events in both healthy and diseased mice. In this review, we describe these imaging approaches to quantify capillary stalling, identifying strengths and weaknesses of different methods. We then review recent findings on the incidence, molecular and cellular causes, and physiological and neurological consequences of capillary stalling across multiple mouse models of brain disease, including Alzheimer's disease, stroke, and traumatic brain injury. We conclude by suggesting necessary next steps in instrumentation and analysis for studying capillary stalling, as well as how to address key unanswered questions about underlying mechanisms for capillary stalling in the brain and how this phenomenon may impact disease progression and cognitive function.
中文摘要:大脑最小血管即毛细血管内的血流紊乱长期被视为脑功能障碍的潜在原因。三维毛细血管网络血流研究存在技术困难,毛细血管阻塞的发生率、原因和后果一直难以阐明。活体成像光学显微镜的进展,主要是高时空分辨率光学相干断层扫描和双光子显微镜,近来使在健康和患病小鼠中详细研究毛细血管停滞事件成为可能。该综述介绍用于量化毛细血管停滞的成像方法,并指出不同方法的优势与不足。随后汇总多种脑疾病小鼠模型中的近期发现,涉及毛细血管停滞的发生率、分子与细胞原因以及生理和神经学后果,模型包括阿尔茨海默病、卒中和创伤性脑损伤。最后提出研究毛细血管停滞所需的仪器与分析下一步工作,并讨论如何回答关于脑内毛细血管停滞底层机制的关键未解问题,以及这一现象可能如何影响疾病进展和认知功能。
Ischemic stroke (IS) results from an acute interruption of cerebral blood flow and the ensuing collapse of energy metabolism. Although vascular recanalization can salvage the ischemic penumbra, its overall benefit remains constrained by a narrow therapeutic window and reperfusion injury. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, contributes to neuronal injury after IS and can amplify ischemia/reperfusion injury. By integrating energy metabolism, iron homeostasis, and redox balance, mitochondria can shape ferroptosis susceptibility within the energy-depleted, iron-dysregulated, and oxidatively stressed ischemic brain. However, most studies have examined iron metabolism and lipid peroxidation at the whole-cell level, leaving the temporal and interorganelle dimensions of mitochondrial regulation of ferroptosis insufficiently integrated. Here, we organize mitochondria-associated ferroptosis across the pathological course of IS, from metabolic reprogramming and substrate accumulation during ischemia to the reverse electron transport-associated reactive oxygen species burst during early reperfusion and subsequent disruption of mitochondrial quality control. We further examine mitochondrial crosstalk with the endoplasmic reticulum, lysosomes, lipid droplets, and nucleus, compare ferroptosis susceptibility across neurovascular unit cell populations, and map these mechanisms onto pharmacological interventions and mechanistically plausible therapeutic windows. Finally, we assess barriers to the clinical translation of mitochondria-targeted therapies and provide a stage-resolved framework for developing neuroprotective strategies in IS.
中文摘要:缺血性卒中(IS)由脑血流急性中断及随后的能量代谢崩溃引起。血管再通可挽救缺血半暗带,但总体获益受限于狭窄的治疗时间窗和再灌注损伤。铁死亡是一种由脂质过氧化驱动的铁依赖性调节性细胞死亡,参与IS后的神经元损伤,并可放大缺血/再灌注损伤。线粒体通过整合能量代谢、铁稳态和氧化还原平衡,影响能量匮乏、铁调控紊乱和氧化应激的缺血脑组织对铁死亡的易感性。现有研究多在整细胞水平考察铁代谢和脂质过氧化,线粒体调控铁死亡的时间维度与细胞器间维度尚未充分整合。本文按IS病理进程梳理线粒体相关铁死亡,从缺血期代谢重编程和底物蓄积,到再灌注早期反向电子传递相关活性氧爆发及随后的线粒体质量控制破坏。进一步审视线粒体与内质网、溶酶体、脂滴和细胞核的交互,比较神经血管单元各细胞群对铁死亡的易感性,并将这些机制对应到药理干预和机制上可行的治疗时间窗。最后评估线粒体靶向治疗临床转化的障碍,并提出面向IS神经保护策略开发的分阶段框架。
Cerebral ischemia-reperfusion injury (IRI) is a key driver of poor prognosis in ischemic stroke. Idebenone (IDBN) shows promise for mitigating IRI, but its efficacy is limited by poor brain accumulation. Moreover, IDBN cannot be visually tracked, making it difficult to confirm whether it reaches the ischemic brain and exerts therapeutic effects. Here, IDBN functionalized with a reactive oxygen species (ROS)-cleavable bond is grafted onto phosphorothioate-modified DNA strands and co-assembled with ultrasmall superparamagnetic iron oxide (USPIO) to form USPIO-IDBN-SNAs, where SNAs stands for spherical nucleic acids. Exploiting upregulated class A scavenger receptors, USPIO-IDBN-SNAs target the ischemic area without targeting modifications and increase local IDBN concentration. Hydrophobic IDBN inside the SNAs limits water access to USPIO clusters, suppressing their contrast-enhancing ability. Under oxidative stress, IDBN is rapidly released and exerts remarkable protection. This release allows USPIO clusters to re-establish contact with water, activating their contrast-enhancing ability on T2-weighted imaging. Collectively, USPIO-IDBN-SNAs provide significant neuroprotection against IRI and offer a magnetic resonance imaging (MRI)-visible platform to monitor IDBN release in the ischemic brain, presenting a promising theranostic approach for precise, trackable stroke therapy.
中文摘要:脑缺血再灌注损伤(IRI)是缺血性卒中预后不良的关键驱动因素。艾地苯醌(IDBN)具有减轻IRI的潜力,但脑内蓄积差限制了其疗效。IDBN也无法被可视化追踪,难以确认其是否到达缺血脑组织并发挥治疗作用。为此,将带活性氧(ROS)可裂解键的IDBN接枝到硫代磷酸修饰DNA链上,并与超小超顺磁性氧化铁(USPIO)共组装形成USPIO-IDBN-SNAs,其中SNAs指球形核酸。利用上调的A类清道夫受体,USPIO-IDBN-SNAs无需靶向修饰即可靶向缺血区,提高局部IDBN浓度。SNAs内部疏水性IDBN限制水接近USPIO簇,抑制其对比增强能力。在氧化应激下,IDBN快速释放并发挥显著保护作用;释放后USPIO簇重新与水接触,在T2加权成像上恢复对比增强能力。USPIO-IDBN-SNAs对IRI提供明显神经保护,并提供可在缺血脑内监测IDBN释放的磁共振成像(MRI)可视化平台,为精准、可追踪的卒中治疗提供有前景的诊疗一体化策略。
White matter preservation is a rate-limiting factor in neurological recovery after ischemic stroke and depends on efficient clearance of myelin debris by microglia/macrophages. Our prior work demonstrated that microglia/macrophage-specific SIK3 (salt-inducible kinase) knockout (SIK3-mKO) promotes an anti-inflammatory subset, enhances myelin phagocytosis, and limits white matter injury, yet the downstream molecular mechanisms remain undefined. Here, we elucidate a previously unrecognized signaling axis underlying these protective effects. SIK3-mKO mice (SIK3Flox+/+;CX3CR1CreER) were generated via tamoxifen-induced Cre recombination. Transient focal cerebral ischemia was induced by 60-minute transient middle cerebral artery occlusion. Neurological outcomes were assessed via Garcia, rotarod, foot-fault, and adhesive-removal tests. Immunofluorescence, flow cytometry, single-cell RNA sequencing, real-time quantitative polymerase chain reaction, ex vivo myelin phagocytosis assay, magnetic resonance imaging, and compound action potential recordings were used to characterize microglia/macrophage polarization, myelin phagocytic capacity, white matter integrity, and nerve conduction function. In the acute phase poststroke, SIK3-mKO selectively upregulated cluster of differentiation (CD)11c and its upstream complement initiator component 1q in anti-inflammatory microglia/macrophage subsets. Within the 400 to 800 µm peri-infarct zone, SIK3-mKO elevated the proportion of CD11c+ microglia/macrophage by 15.1% and C1q+ microglia/macrophage by 15.8% relative to wild-type controls. This CD11c-component 1q axis enhanced myelin debris clearance by 19.0% while constraining pathological engulfment of intact myelin, representing a balanced functional switch that mitigates severe demyelination. Conversely, myeloid-CD11c silencing using adeno-associated virus (AAV)-Itgax short hairpin RNA partially reversed SIK3-mKO-conferred protection. CD11c knockdown reduced anti-inflammatory microglia/macrophage proportions by 9.7%, attenuated physiological phagocytosis and lowered debris clearance efficiency by 7.5%, reduced MBP (myelin basic protein)-positive myelin preservation by 10.0%, and ultimately impaired white matter preservation and neurological recovery. We identify the SIK3-CD11c-component 1q axis as a novel pathway that orchestrates microglia/macrophage phagocytic homeostasis and preserves white matter integrity after ischemic stroke. These findings clarify SIK3 signaling in microglia/macrophage and highlight the CD11c-centered complement cascade as a promising therapeutic target for restoring white matter integrity in poststroke neurorepair.
中文摘要:白质保护是缺血性卒中后神经功能恢复的限制因素,依赖小胶质细胞/巨噬细胞对髓鞘碎片的有效清除。我们先前的工作显示,小胶质细胞/巨噬细胞特异性SIK3(盐诱导激酶)敲除(SIK3-mKO)促进抗炎亚群、增强髓鞘吞噬并减轻白质损伤,但下游分子机制尚未明确。在此,我们阐明一条此前未被认识、介导这些保护效应的信号轴。SIK3-mKO小鼠(SIK3Flox+/+;CX3CR1CreER)通过他莫昔芬诱导的Cre重组产生。采用60分钟短暂大脑中动脉闭塞诱导短暂性局灶性脑缺血。神经功能结局通过Garcia评分、转棒、足误和黏附物移除试验评估。使用免疫荧光、流式细胞术、单细胞RNA测序、实时定量聚合酶链反应、离体髓鞘吞噬实验、磁共振成像和复合动作电位记录来表征小胶质细胞/巨噬细胞极化、髓鞘吞噬能力、白质完整性和神经传导功能。卒中后急性期,SIK3-mKO在抗炎小胶质细胞/巨噬细胞亚群中选择性上调分化簇(CD)11c及其上游补体启动因子C1q。在梗死周围400至800 µm区域内,SIK3-mKO使CD11c+小胶质细胞/巨噬细胞比例较野生型对照提高15.1%,C1q+小胶质细胞/巨噬细胞提高15.8%。该CD11c-C1q轴使髓鞘碎片清除增强19.0%,同时限制对完整髓鞘的病理性吞噬,形成减轻严重脱髓鞘的平衡性功能转换。相反,使用腺相关病毒(AAV)-Itgax短发夹RNA沉默髓系CD11c可部分逆转SIK3-mKO带来的保护。CD11c敲低使抗炎小胶质细胞/巨噬细胞比例降低9.7%,削弱生理性吞噬并使碎片清除效率降低7.5%,减少MBP(髓鞘碱性蛋白)阳性髓鞘保留10.0%,最终损害白质保留和神经功能恢复。我们确定SIK3-CD11c-C1q轴是一条协调小胶质细胞/巨噬细胞吞噬稳态、保护缺血性卒中后白质完整性的新通路。这些发现阐明了小胶质细胞/巨噬细胞中的SIK3信号,并提示以CD11c为中心的补体级联可作为恢复卒中后神经修复中白质完整性的有希望治疗靶点。
The treatment of intracerebral hemorrhage (ICH) remains highly challenging, primarily due to its dynamic and multifaceted pathologies, which create a hostile microenvironment at the lesion site characterized by a ROS-inflammation-glial scar feedback loop and severely impaired neural regeneration. Herein, a dynamic protein-polysaccharide hydrogel is designed, constructed by a visible light-induced thiol-disulfide exchange reaction as a general strategy, and integrated with a spatiotemporal controlled delivery of chondroitinase ABC (ChABC) and insulin-like growth factor-1 (IGF-1) loaded in mesoporous silica nanoparticles (MSNs). Thiolated gelatin and thiolated hyaluronan were chosen to formulate the hydrogel that mimics brain ECM providing structure support with cell adhesion, infiltration, and tunable degradability, but also presents anti-swelling and pro-coagulant capacities. Importantly, the thiol-disulfide chemistry endowed the hydrogel efficient ROS scavenging and ROS-responsive on-demand release of ChABC, while MSNs loading achieved a sustained release of IGF-1. In vitro studies, the hydrogel is shown to reduce cellular ROS, regulate anti-inflammation polarization of macrophages via the MAPK signaling pathway, and promote neural stem cells (NSCs) proliferation, migration, differentiation and endothelial angiogenesis. Moreover, in an ICH mouse model, the hydrogel is demonstrated not only to enable efficient tissue ROS scavenging, anti-inflammation polarization of microglial/macrophages, and dynamical self-adaptive reduction of glial scar, achieving microenvironment remodeling, but also to regulate behaviors of endogenous NSCs and enhance angiogenesis, providing neural regeneration. Consequently, these effects enhanced neurons and myelin repair, ultimately contributing to synergistic recovery of neurological function. Overall, this dynamic hydrogel represents a promising strategy for simultanously remodeling the lesion site's microenvironment and promoting neural regeneration, thereby improving the treatment efficacy of ICH.
中文摘要:脑出血(ICH)的治疗仍极具挑战,主要因为其动态且多方面的病理过程在病灶部位形成恶劣微环境,特征为ROS-炎症-胶质瘢痕反馈环路和严重受损的神经再生。为此,设计了一种动态蛋白-多糖水凝胶,通过可见光诱导的硫醇-二硫键交换反应作为通用策略构建,并整合了负载于介孔二氧化硅纳米颗粒(MSNs)中的软骨素酶ABC(ChABC)和胰岛素样生长因子-1(IGF-1)的时空可控递送。选用硫醇化明胶和硫醇化透明质酸制备水凝胶,其模拟脑细胞外基质,提供具有细胞黏附、浸润和可调降解性的结构支持,并具有抗溶胀和促凝血能力。硫醇-二硫键化学赋予水凝胶高效的ROS清除能力和ROS响应性按需释放ChABC,而MSNs负载实现了IGF-1的持续释放。体外研究表明,该水凝胶可降低细胞ROS,通过MAPK信号通路调节巨噬细胞的抗炎极化,并促进神经干细胞(NSCs)增殖、迁移、分化及内皮血管生成。在ICH小鼠模型中,该水凝胶不仅能够有效清除组织ROS、促进小胶质细胞/巨噬细胞的抗炎极化,并动态自适应减少胶质瘢痕,实现微环境重塑,还能调控内源性NSCs的行为并增强血管生成,提供神经再生。这些作用促进了神经元和髓鞘修复,最终有助于神经功能的协同恢复。这种动态水凝胶代表了一种有前景的策略,可同时重塑病灶部位微环境并促进神经再生,从而提高ICH的治疗效果。
Proper cerebral artery function is essential for maintaining the brain's microenvironment. The multilayered organization of cellular and extracellular matrix (ECM) constituents enables large cerebral arteries to accommodate pulse pressure and ensure both effective blood distribution and protection of the microcirculation. However, aging and disease induce compositional and structural remodeling in cerebral arteries, such as the middle cerebral artery (MCA), which can alter biomechanical properties and increase susceptibility to cerebrovascular conditions including atherosclerosis and aneurysms, both major contributors to stroke. Understanding how age-related changes in arterial structure and composition influence biomechanical behavior is critical for improving prediction of cerebrovascular risk. In this study, we characterized the age-dependent elastic and viscoelastic properties of human MCAs and related these changes to ECM structure and composition using imaging and biochemical assays. Our results demonstrate that aging is associated with increased stiffness and stress relaxation in MCAs. Biochemical analyses revealed age-related increases in collagen and glycosaminoglycan (GAG) content, both of which correlated with altered mechanical properties. Histological staining further showed denser collagen organization within the adventitia and elevated GAG presence, consistent with mechanical and biochemical findings. Additionally, multiphoton imaging under mechanical loading provided insight into layer-specific collagen reorganization in the adventitia. Collectively, these findings elucidate key age-dependent alterations in the structure-function relationship of human cerebral arteries and provide a mechanistic basis for increased cerebrovascular risk with aging. STATEMENT OF SIGNIFICANCE: Age-related remodeling of the extracellular matrix is a fundamental driver of tissue dysfunction, yet its effects on human cerebral artery mechanics remain poorly understood. In this study, we combine biomechanical testing, biochemical assays, histology, and multiphoton microscopy to characterize structural and functional remodeling of human middle cerebral arteries across a broad age range. We demonstrate that aging is associated with increased arterial stiffness and viscoelastic relaxation, accompanied by elevated collagen and glycosaminoglycan content. By directly linking extracellular matrix composition and organization to biomechanical function, this work provides new insights into the mechanisms governing cerebrovascular aging. These findings establish an important structure function framework for understanding vascular tissue remodeling and have broader implications for age related vascular dysfunction, mechanobiology, and biomaterials research.
中文摘要:脑动脉的正常功能对维持脑微环境至关重要。细胞与细胞外基质(ECM)成分构成的多层组织,使大型脑动脉能够承受脉压,并保证有效的血液分配和对微循环的保护。衰老和疾病会诱发脑动脉(如大脑中动脉,MCA)的成分与结构重塑,改变其生物力学特性,并增加对动脉粥样硬化和动脉瘤等脑血管病变的易感性,这两者都是卒中的重要原因。理解动脉结构和成分的年龄相关变化如何影响生物力学行为,对于改进脑血管风险预测至关重要。研究利用影像学和生化检测表征了人MCA随年龄变化的弹性和黏弹性特性,并将这些变化与ECM结构和成分联系起来。结果显示,衰老与MCA刚度增加和应力松弛增强相关。生化分析发现胶原和糖胺聚糖(GAG)含量随年龄增加,二者均与力学特性改变相关。组织学染色还显示外膜内胶原组织更致密、GAG存在增加,与力学和生化结果一致。机械加载下的多光子成像进一步揭示了外膜中分层特异的胶原重组。这些结果阐明了人脑动脉结构-功能关系中关键的年龄相关改变,为衰老相关脑血管风险增加提供了机制基础。意义声明:ECM的年龄相关重塑是组织功能障碍的基本驱动因素,但其对人脑动脉力学的影响仍知之甚少。研究结合生物力学测试、生化检测、组织学和多光子显微镜,表征了广泛年龄范围内人MCA的结构和功能重塑。结果表明,衰老与动脉刚度增加和黏弹性松弛增强相关,并伴随胶原和GAG含量升高。通过将ECM成分和组织方式直接与生物力学功能联系起来,这项工作为脑血管衰老的机制提供了新认识。这些发现为理解血管组织重塑建立了重要的结构-功能框架,并对年龄相关血管功能障碍、力学生物学和生物材料研究具有更广泛的意义。
Recovery after ischemic stroke is limited by persistent cerebrovascular dysfunction, but the mechanisms regulating vascular repair remain poorly understood. Prnd (Prnd/Doppel) is a prion family protein expressed in the cerebrovascular endothelium during development. We tested the hypothesis that endothelial Prnd promotes vascular repair and functional recovery in the adult brain after stroke. Using middle cerebral artery occlusion in mice, we compared wild-type and Prnd-null mice and evaluated endothelial-specific Prnd overexpression. Functional recovery was assessed by behavioral testing, while infarct volume, brain atrophy, vascular architecture, blood-brain barrier integrity, and macrophage/microglia infiltration were evaluated histologically. Vascular signaling and endothelial cell junctional proteins were examined mechanistically. Acute infarct volumes were comparable between wild-type and Prnd-null mice, indicating that Prnd does not substantially affect initial ischemic injury. During recovery, however, Prnd-null mice exhibited disrupted cerebrovascular architecture, increased blood-brain barrier disruption, greater brain atrophy, and increased macrophage/microglial infiltration. Conversely, endothelial Prnd overexpression improved long-term functional recovery without altering acute infarct size and was associated with enhanced blood-brain barrier integrity and vascular remodeling. Mechanistically, Prnd manipulation was associated with enhanced VEGF-A (vascular endothelial growth factor-A) signaling and increased endothelial cell tight junction protein expression. Prnd is dispensable for acute ischemic injury but promotes cerebrovascular remodeling, blood-brain barrier restoration, and functional recovery after stroke. These findings identify endothelial Prnd as a regulator of poststroke vascular repair and a potential therapeutic target for enhancing long-term recovery.
中文摘要:缺血性卒中后恢复受持续性脑血管功能障碍限制,血管修复的调控机制仍不清楚。Prnd(Prnd/Doppel)是发育期脑血管内皮表达的朊蛋白家族蛋白。我们检验内皮Prnd促进成年脑卒中后血管修复和功能恢复的假设。采用小鼠大脑中动脉闭塞模型,比较野生型与Prnd缺失小鼠,并评估内皮特异性Prnd过表达。通过行为学测试评估功能恢复,组织学评估梗死体积、脑萎缩、血管结构、血脑屏障完整性和巨噬细胞/小胶质细胞浸润。机制上检测血管信号和内皮细胞连接蛋白。野生型与Prnd缺失小鼠急性梗死体积相当,提示Prnd对初始缺血损伤无显著影响。恢复期Prnd缺失小鼠出现脑血管结构破坏、血脑屏障破坏增加、脑萎缩加重和巨噬细胞/小胶质细胞浸润增加。相反,内皮Prnd过表达改善长期功能恢复且不改变急性梗死面积,并伴血脑屏障完整性和血管重塑增强。机制上,Prnd调控与VEGF-A信号增强及内皮细胞紧密连接蛋白表达增加相关。Prnd对急性缺血损伤非必需,但促进卒中后脑血管重塑、血脑屏障恢复和功能恢复。这些发现确定内皮Prnd是卒中后血管修复的调节因子和增强长期恢复的潜在治疗靶点。
3心力衰竭 (25篇)
临床研究 (14篇)
Cardiovascular disease remains the leading global cause of morbidity and mortality. Although advances in prevention, diagnostics, and disease-modifying therapies have prolonged survival, many individuals now live longer with high symptom burden, functional decline, and complex decisional needs. Palliative care (PC) for adults with advanced cardiovascular disease can improve quality of life, support caregivers, and align treatments with patient values and goals. Core elements include symptom management, effective communication, shared decision-making, advance care planning, and integration of psychosocial and spiritual support across the disease trajectory and different care settings. Current evidence demonstrates that early PC intervention can improve symptom control, enhance quality of life, reduce psychological distress, and decrease high-intensity yet low-value care near the end of life. Nevertheless, outside of heart failure populations, gaps in widespread PC implementation across populations supported with cardiac devices as well as across diverse cultural and health systems remain. This state-of-the-art review (i) synthesizes conceptual foundations, referral triggers, and delivery models for PC in cardiovascular medicine; (ii) reviews disease-specific considerations across heart failure, valvular disease, pulmonary hypertension, arrhythmias, and congenital heart disease; (iii) outlines ethical and legal issues including advance directives and device deactivation; (iv) provides practical guidance for symptom management and communication frameworks; and (v) proposes a pragmatic algorithm to support clinical integration of PC into cardiovascular medicine.
中文摘要:心血管疾病仍是全球发病和死亡的首要原因。预防、诊断和疾病修饰治疗的进展延长了生存,但许多人带病生存更久,伴随高症状负担、功能衰退和复杂的决策需求。对晚期心血管疾病成人提供姑息治疗可改善生活质量、支持照护者,并使治疗与患者价值观和目标一致。核心要素包括症状管理、有效沟通、共享决策、预立医疗照护计划,以及在疾病轨迹和不同照护场景中整合心理社会与精神支持。现有证据显示,早期姑息治疗干预可改善症状控制、提升生活质量、减轻心理痛苦,并减少生命末期高强度低价值照护。然而,除心力衰竭人群外,在依赖心脏装置支持的人群以及不同文化和卫生体系中,姑息治疗广泛实施仍存在缺口。本最新综述(i)整合心血管医学中姑息治疗的概念基础、转诊触发因素和提供模式;(ii)回顾心力衰竭、瓣膜病、肺动脉高压、心律失常和先天性心脏病中的疾病特异性考量;(iii)概述伦理和法律问题,包括预立医疗指示和装置停用;(iv)提供症状管理和沟通框架的实用指导;(v)提出一个务实算法,支持将姑息治疗融入心血管医学临床实践。
To define the impact of diastolic dysfunction (DD) on the response to empagliflozin treatment in patients with heart failure with preserved ejection fraction. Diastolic dysfunction was defined by left atrial volume index ≥34 ml/m2, the ratio of early diastolic mitral inflow velocity to early diastolic mitral annular tissue velocity (E/e) ≥ 13 or left ventricular mass index >115 (males) or >95 (females). We created three categories of increasing DD (0, 1, or ≥2 DD criteria at baseline) to describe the effect of DD on response to empagliflozin therapy and adverse effects. Of 5988 patients in the EMPEROR-Preserved trial, 3766 (63%) had no documented baseline DD, 1619 (27%) had one, and 603 (10%) had two or more measures. Baseline DD was associated with sex, race, ethnicity, and region and was more common with lower heart rate, DBP, body weight, and eGFR. Despite baseline DD not being significantly associated with the primary endpoint of hospitalization for heart failure or cardiovascular death within the placebo group, a progressive treatment effect across the three DD categories was seen (trend test P-value .0014), with estimated hazard ratios of empagliflozin vs placebo of 0.91 (none present), 0.64 (1 present), and 0.49 (≥2). A significant treatment-by-subgroup trend test was also observed for the total number of hospitalizations for heart failure. Both Kansas City Cardiomyopathy Questionnaire Clinical Summary Score improvement at week 52 and safety profile were consistent across DD categories. Baseline detection of echocardiographic DD predicted improved clinical response to empagliflozin in a graded fashion, but the reasons cannot be reliably determined from this analysis.
中文摘要:旨在明确舒张功能障碍对射血分数保留的心力衰竭患者接受恩格列净治疗反应的影响。舒张功能障碍定义为左心房容积指数≥34 ml/m2、早期二尖瓣流入速度与早期二尖瓣环组织速度比值≥13,或左心室质量指数男性>115、女性>95。研究按基线舒张功能障碍标准数目分为0项、1项、≥2项三组,以描述舒张功能障碍对恩格列净治疗反应及不良反应的影响。EMPEROR-Preserved试验共纳入5988例患者,3766例(63%)基线无舒张功能障碍记录,1619例(27%)有1项,603例(10%)有2项及以上。基线舒张功能障碍与性别、种族、族裔和地区相关,在心率、舒张压、体重和eGFR较低时更常见。尽管在安慰剂组中基线舒张功能障碍与心衰住院或心血管死亡这一主要终点无显著关联,但三个舒张功能障碍类别间可见逐渐增强的治疗效应(趋势检验P=0.0014),恩格列净相较安慰剂的估计风险比分别为0.91(无)、0.64(1项)和0.49(≥2项)。心衰住院总次数也观察到显著的治疗与亚组趋势检验。第52周堪萨斯城心肌病问卷临床总结评分改善及安全性特征在各舒张功能障碍类别间一致。基线超声心动图舒张功能障碍检测以分级方式预测对恩格列净更佳的临床反应,但本分析无法可靠确定其原因。
Obesity in patients supported by left ventricular assist devices (LVADs) is linked to excess mortality and haemocompatibility-related events. Whether this association persists with the fully magnetically levitated HeartMate 3 (HM3) pump is unknown. This analysis tested outcomes with obesity and the additive influence of co-existing frailty ('frail obesity') in the contemporary era. The study pooled 2200 HM3 recipients from the MOMENTUM 3 pivotal randomized trial (n = 515) and Continued Access Protocol (n = 1685). Obesity was defined as body mass index (BMI) ≥30 kg/m2 and frailty by a 40-item Rockwood cumulative-deficit frailty index (FI), with clinically relevant frailty defined as FI ≥0.325 (moderate-severe frailty); BMI was excluded from the FI to avoid mathematical coupling. The primary endpoint was survival to transplant, recovery, or 24 months of support free of disabling stroke (modified Rankin score >3) or pump replacement reoperation. Obese patients (n = 887, 40.3%) were younger, less often with ischaemic aetiology, and more frequently women, but more often had diabetes and hypertension, than non-obese patients. Unadjusted 2-year outcomes were similar between groups (freedom from the primary endpoint: 75.1% vs 77.1%, log-rank P = .34; survival: 79.9% vs 81.2%, P = .57). After covariate adjustment, obesity was independently associated with a higher risk of the primary endpoint (hazard ratio [HR] 1.30, 95% confidence interval [CI] 1.07-1.58) and all-cause mortality (HR 1.35, 95% CI 1.10-1.67), as well as heart failure hospitalization, infection, and arrhythmia, but not stroke, bleeding, or early right heart failure. Frailty affected 67.3% of obese recipients (571/849) and was associated with a higher adjusted risk of the primary endpoint (HR 1.51, 95% CI 1.09-2.10), overall mortality and non-haemocompatibilty-related morbidity endpoints. The obesity-by-frailty interaction was not significant for either the primary endpoint (P = .436) or mortality (P = .215), indicating additive rather than synergistic risk; frail-obese patients nonetheless carried the highest absolute risk of any subgroup. Frailty improved by at least one severity class by 6 months in 75.9% of frail-obese patients, and improvement was associated with better survival (adjusted HR 0.14, 95% CI 0.07-0.26). In the HM3 era, obese and non-obese recipients had similar unadjusted 2-year outcomes; however, after adjustment for baseline case-mix, obesity was independently associated with a higher risk of both the primary endpoint and all-cause mortality, together with heart failure hospitalization, infection, and arrhythmia. Frailty was independently associated with adverse outcomes across nearly all endpoints and was highly prevalent among obese recipients; the combination of obesity and frailty was additive but not synergistic, with frail-obese patients carrying the highest absolute risk. Frailty, however, proved substantially reversible after LVAD support, and its improvement was associated with markedly better survival. Obesity and frailty should therefore be assessed together, rather than through BMI thresholds alone, with recognition that frailty status is dynamic after implantation and that improvement in frailty is associated with markedly better survival.
中文摘要:在接受左心室辅助装置(LVAD)支持的患者中,肥胖与超额死亡及血液相容性相关事件相关。在全磁悬浮HeartMate 3(HM3)泵时代,这一关联是否仍然存在尚不清楚。本分析在当代人群中检验肥胖以及并存衰弱(「衰弱性肥胖」)叠加影响下的结局。研究汇总了MOMENTUM 3关键性随机试验(n=515)与继续准入方案(n=1685)中的2200例HM3植入者。肥胖定义为体质指数(BMI)≥30 kg/m2,衰弱采用40条目Rockwood累积缺陷衰弱指数(FI)评定,临床相关衰弱定义为FI≥0.325(中度至重度衰弱);为避免数学耦联,FI中未纳入BMI。主要终点为无致残性卒中(改良Rankin评分>3)或泵置换再手术的生存至移植、康复或支持满24个月。肥胖患者(n=887,40.3%)较非肥胖患者年轻、缺血性病因较少、女性更多,但糖尿病与高血压更多见。未校正的2年结局两组相似(主要终点无事件率75.1% vs 77.1%,log-rank P=0.34;生存率79.9% vs 81.2%,P=0.57)。校正协变量后,肥胖与主要终点风险升高独立相关(风险比[HR]1.30,95%置信区间[CI]1.07-1.58),与全因死亡(HR 1.35,95%CI 1.10-1.67)以及心力衰竭住院、感染和心律失常也独立相关,但与卒中、出血或早期右心衰无关。67.3%(571/849)的肥胖受者存在衰弱,且衰弱与主要终点校正后风险升高(HR 1.51,95%CI 1.09-2.10)、总体死亡及非血液相容性相关疾病终点相关。肥胖与衰弱的交互作用对主要终点(P=0.436)和死亡(P=0.215)均不显著,提示风险为相加而非协同;衰弱性肥胖患者在所有亚组中的绝对风险仍最高。75.9%的衰弱性肥胖患者在6个月时衰弱改善至少一个严重程度等级,且改善与更好的生存相关(校正HR 0.14,95%CI 0.07-0.26)。在HM3时代,肥胖与非肥胖受者未校正的2年结局相似;但校正基线病例构成后,肥胖与主要终点和全因死亡风险升高独立相关,并与心衰住院、感染及心律失常相关。衰弱在几乎所有终点上均与不良结局独立相关,且在肥胖受者中高度常见;肥胖与衰弱并存的风险为相加而非协同,衰弱性肥胖患者绝对风险最高。衰弱在LVAD支持后表现出实质性的可逆性,其改善与生存显著改善相关。因此,肥胖与衰弱应联合评估,而非仅凭BMI阈值判断,同时应认识到植入后衰弱状态是动态变化的,衰弱改善与生存显著改善相关。
Hydralazine-isosorbide dinitrate (H-ISDN) has shown benefit in earlier randomized trials of patients with reduced left ventricular ejection fraction (LVEF) and chronic heart failure. This trial tested if H-ISDN could reduce worsening heart failure or mortality in patients with chronic heart failure with reduced ejection fraction (HFrEF) receiving contemporary treatment. The Hydralazine-Isosorbide Dinitrate in Patients With Chronic Heart Failure Trial (H-HeFT) was a multicentre, randomized (1:1), double-blind, placebo-controlled trial in patients with HFrEF at 23 Danish hospitals (New York Heart Association class II-IV, elevated N-terminal pro-B-type natriuretic peptide and LVEF ≤40%). Target treatment was hydralazine 75 mg/isosorbide dinitrate 40 mg three times a day (t.i.d). The primary endpoint was a composite of hospitalization with worsening heart failure, an urgent outpatient visit resulting in intravenous/metolazone therapy for heart failure, heart transplantation, left ventricular assist device implantation, or death. Secondary endpoints included components of the primary outcome. Overall, 592 predominantly White patients (median age 72 years, 18% women) were randomized with a mean follow-up of 3.7 years. The primary outcome occurred in 90 of 294 patients (30.6%) in the H-ISDN group and in 91 of 298 patients (30.5%) in the placebo group [hazard ratio (HR) 0.90; 95% confidence interval (CI) 0.67-1.21; P = .48]. There were 57 deaths in the H-ISDN group vs 72 in the placebo group (HR 0.72; 95% CI 0.51-1.02); worsening heart failure events occurred in 52 vs 47 patients (HR 1.01; 95% CI 0.68-1.50). Hydralazine-isosorbide dinitrate did not change the incidence of the composite endpoint of heart failure events or death in patients with heart failure and LVEF ≤40%.
中文摘要:在射血分数降低且伴慢性心力衰竭的早期随机试验中,肼屈嗪-硝酸异山梨酯(H-ISDN)显示出获益。本试验检验在当代治疗背景下,H-ISDN能否减少慢性射血分数降低心力衰竭(HFrEF)患者的心衰恶化或死亡。H-HeFT为多中心、1:1随机、双盲、安慰剂对照试验,纳入丹麦23家医院的HFrEF患者(NYHA II-IV级、N末端B型利钠肽原升高且LVEF≤40%)。目标治疗为肼屈嗪75 mg/硝酸异山梨酯40 mg,每日三次。主要终点为因心衰恶化住院、因心衰急诊门诊并接受静脉或美托拉宗治疗、心脏移植、左心室辅助装置植入或死亡的复合终点。次要终点包括主要终点的各组成部分。共随机592例以白人为主的患者(中位年龄72岁,女性18%),平均随访3.7年。H-ISDN组294例中90例(30.6%)发生主要终点,安慰剂组298例中91例(30.5%)发生主要终点(风险比0.90;95%置信区间0.67-1.21;P=0.48)。H-ISDN组死亡57例,安慰剂组72例(风险比0.72;95%置信区间0.51-1.02);心衰恶化事件分别为52例和47例(风险比1.01;95%置信区间0.68-1.50)。在LVEF≤40%的心衰患者中,肼屈嗪-硝酸异山梨酯未改变心衰事件或死亡复合终点的发生率。
Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) have evolved from glucose-lowering agents to foundational therapies for the management of type 2 diabetes mellitus, heart failure, and chronic kidney disease, with substantial benefits for cardiovascular, kidney, and survival outcomes. As their indications continue to expand, a comprehensive understanding of their safety and tolerability has become increasingly important for optimizing patient care. Building on our recent state-of-the-art review of glucagon-like peptide-1 receptor agonists, this review provides a contemporary synthesis of the evidence on the safety and tolerability of SGLT-2is. We critically appraise data from randomized controlled trials, cardiovascular and kidney outcome trials, pharmacovigilance databases, large observational studies, and systematic reviews and meta-analyses. The available evidence demonstrates that SGLT-2is have a favorable overall safety profile, with genital mycotic infections representing the most consistently observed adverse event. Volume depletion and euglycemic diabetic ketoacidosis remain clinically important but are uncommon and are largely preventable through appropriate patient selection, patient education, and temporary treatment interruption during high-risk clinical situations. Fournier's gangrene should be regarded as a very rare but serious complication requiring prompt recognition and treatment. In contrast, randomized trials and meta-analyses generally indicate a reduced risk of acute kidney injury, while evidence concerning fracture, lower-limb amputation, hepatotoxicity, pancreatitis, and cancer is less definitive. Although consistent class-wide increases in these latter outcomes have not been established, uncommon or agent-specific risks cannot be excluded, particularly where event numbers are small or follow-up is limited. Overall, treatment discontinuation because of adverse events is low across major cardiovascular, heart failure, and kidney outcome trials, supporting the excellent tolerability of this therapeutic class. Comparative evidence suggests only modest differences among individual SGLT-2is, although definitive conclusions remain limited by the absence of direct, large, randomized head-to-head trials. We also summarize practical strategies for adverse-event mitigation, monitoring, temporary treatment interruption, and individualized patient selection. As the clinical applications of SGLT-2is continue to broaden, ongoing pharmacovigilance, inclusive clinical trials, and comparative safety studies will be essential to further refine their benefit-risk profile and optimize their safe use across diverse patient populations.
中文摘要:钠-葡萄糖协同转运蛋白2抑制剂(SGLT-2i)已从降糖药物发展为2型糖尿病、心力衰竭与慢性肾脏病管理的基础治疗,在心血管、肾脏及生存结局方面带来显著获益。随着适应证不断扩展,全面理解其安全性与耐受性对优化患者照护愈发重要。本综述承接我们近期关于胰高血糖素样肽-1受体激动剂的最新综述,对SGLT-2i安全性与耐受性证据作当代整合,系统评估随机对照试验、心血管与肾脏结局试验、药物警戒数据库、大型观察性研究及系统评价与荟萃分析的数据。现有证据显示SGLT-2i总体安全性良好,生殖器真菌感染是最稳定观察到的adverse event。容量不足与血糖正常的糖尿病酮症酸中毒在临床上仍需重视,但发生不常见,且通过合理选择患者、患者教育以及在高危临床情形下暂停用药大多可以预防。Fournier坏疽应视为极罕见但严重的并发症,需要及时识别与治疗。与之相对,随机试验与荟萃分析普遍提示急性肾损伤风险降低,而骨折、下肢截肢、肝毒性、胰腺炎与肿瘤方面的证据尚不够确定。这些结局未确立一致的类效应性升高,但少见或特定药物相关的风险无法排除,尤其当事件数较少或随访有限时。总体上,大型心血管、心力衰竭与肾脏结局试验中因adverse event停药的比例较低,支持该治疗类别耐受性良好。比较性证据提示各SGLT-2i之间差异有限,但缺乏直接、大型、随机头对头试验仍限制确定性结论。文中还归纳了adverse event减轻、监测、临时停药与个体化患者选择的实用策略。随着SGLT-2i临床应用持续拓宽,持续的药物警戒、具有包容性的临床试验与比较性安全研究对进一步完善其获益-风险特征、优化不同患者人群中的安全使用至关重要。
Evidence has shown an association of radon exposure with heart failure risk factors, but whether there is an association with heart failure remains unclear. To assess whether indoor radon concentrations are associated with incident heart failure among US postmenopausal women. This prospective cohort study used data from the Women's Health Initiative (WHI) observational study and clinical trials. Participants were postmenopausal women from 40 US clinical centers who were aged 50 to 79 years and did not have self-reported heart failure at enrollment or randomization (September 1993 to December 1998) but had physician adjudication of heart failure during follow-up through February 17, 2024. Geocoded participant address-based assignment of county-level, US Environmental Protection Agency-categorized indoor radon concentration (<2, 2-4, or >4 picocuries [pCi]/L). Incident hospitalization for acute decompensated heart failure was ascertained through physician adjudication of medical records. Hazard ratios (HRs) for heart failure by indoor radon concentration were estimated with Cox proportional hazards regression models. Among 43 188 postmenopausal women (mean [SD] age, 63 [7] years), 36% were exposed to a radon concentration less than 2 pCi/L; 41%, to a concentration of 2 to 4 pCi/L; and 23%, to a concentration of more than 4 pCi/L. Over a mean (SD) follow-up of 16.2 (8.4) years, 3446 incident heart failure events occurred. The fully adjusted HR for heart failure was 1.19 (95% CI, 1.07-1.33) at more than 4 pCi/L vs less than 2 pCi/L, changing little in sensitivity analyses. The HR was higher for heart failure with reduced ejection fraction (1.24; 95% CI, 1.04-1.49) and heart failure mortality (1.37; 95% CI, 1.12-1.69) at radon concentrations more than 4 pCi/L vs less than 2 pCi/L, but these HRs were not different from the null at concentrations of 2 to 4 pCi/L vs less than 2 pCi/L. The HR at concentrations greater than 4 pCi/L approximated that of a 16-mm Hg increase in systolic blood pressure or an increase of 4.8 in body mass index (calculated as weight in kilograms divided by height in meters squared). In this cohort study of US postmenopausal women, higher indoor radon concentrations were associated with an increased risk of incident heart failure, suggesting that radon may be a modifiable environmental determinant of heart failure.
中文摘要:已有证据显示氡暴露与心力衰竭危险因素相关,但氡暴露是否与心力衰竭相关仍不清楚。评估美国绝经后女性室内氡浓度是否与新发心力衰竭相关。这项前瞻性队列研究使用妇女健康倡议(WHI)观察性研究和临床试验的数据。参与者为来自美国40个临床中心的50至79岁绝经后女性,入组或随机分组时(1993年9月至1998年12月)无自报心力衰竭,且在截至2024年2月17日的随访期间有心力衰竭的医生裁定。根据参与者地址地理编码,按县水平、美国环境保护署分类的室内氡浓度(<2、2-4或>4皮居里[pCi]/L)进行分配。新发急性失代偿性心力衰竭住院通过病历的医生裁定确认。采用Cox比例风险回归模型估计不同室内氡浓度下心力衰竭的风险比(HR)。在43 188名绝经后女性(平均[SD]年龄63[7]岁)中,36%暴露于氡浓度低于2 pCi/L;41%暴露于2至4 pCi/L;23%暴露于高于4 pCi/L。平均(SD)随访16.2(8.4)年期间,发生3446例新发心力衰竭事件。与低于2 pCi/L相比,高于4 pCi/L时心力衰竭的完全校正HR为1.19(95% CI,1.07-1.33),敏感性分析中变化不大。与低于2 pCi/L相比,氡浓度高于4 pCi/L时,射血分数降低的心力衰竭HR更高(1.24;95% CI,1.04-1.49),心力衰竭死亡HR也更高(1.37;95% CI,1.12-1.69),但在2至4 pCi/L与低于2 pCi/L比较时,这些HR与无效值无差异。高于4 pCi/L时的HR大致相当于收缩压升高16 mm Hg或体重指数(以体重千克除以身高米平方计算)增加4.8。在这项美国绝经后女性队列研究中,较高的室内氡浓度与新发心力衰竭风险增加相关,提示氡可能是心力衰竭可改变的环境决定因素。
Hospitalizations are costly and may lead to adverse events. Some health systems offer treatment in alternative venues of care for select patients. To describe use and short-term outcomes of emergency department (ED) patients transitioned to noninpatient care settings (ambulatory treatment center [ATC], advanced care at home [ACAH], or emergency department observation unit [EDOU]) compared with inpatient care. This retrospective cohort study of ED patients aged 19 years or older was conducted from January 1, 2024, to June 30, 2025, at multisite community ED and inpatient medical centers within an integrated delivery system (Kaiser Permanente Northern California). Included patients had active health plan membership; had an ED visit for heart failure, pneumonia, cellulitis, urinary tract infection, COVID-19, or anemia; and had their care transitioned to an ATC, ACAH program (Kaiser Permanente Advanced Care at Home), EDOU, or inpatient bed. Treatment venue. The main outcomes were care escalation (inpatient admission) for patients treated in an ATC, ACAH program, or EDOU, as well as 7-day ED return visits, 30-day hospitalizations, and 30-day mortality following care completion across all venues. Unadjusted outcome rates are reported. This study included 26 618 ED encounters (median patient age, 77 years [IQR, 65-85 years]; 52.6% female). Among 22 755 unique patients, 87.4% had 1 encounter, 9.8% had 2 encounters, and 2.8% had more than 2 encounters. There were 728 (2.7%), 880 (3.3%), 5133 (19.3%), and 19 877 (74.7%) encounters in ATC, ACAH, EDOU, and hospital settings, respectively. One-quarter of patients (25.3%) received care in an ATC, ACAH program, or EDOU. Inpatient admission rates were lower for ATC and ACAH encounters than for EDOU encounters (4.3% [95% CI, 2.7%-5.8%], 5.3% [3.8%-6.8%], and 28.0% [26.8%-29.2%], respectively). Rates of 7-day ED visits were similar across venues (ATC: 10.4% [95% CI, 7.8%-12.9%]; ACAH: 5.3% [3.8%-6.8%]; EDOU: 9.2% [8.4%-10.0%]; and hospital: 8.5% [8.1%-8.9%]). In contrast, 30-day mortality and hospitalization rates were lower among ATC, ACAH, and EDOU encounters than in hospital encounters (30-day mortality: 2.1% [95% CI, 1.0%-3.2%], 1.7% [0.8%-2.6%], 2.8% [2.3%-3.2%], and 5.3% [5.0%-5.6%]; and 30-day hospitalization: 11.4% [95% CI, 8.8%-14.1%], 8.3% [6.3%-10.2%], 12.7% [11.7%-13.7%], and 15.3% [14.7%-15.8%], respectively). In this cohort study of patients treated in alternative venues of care, one-quarter received care in an ATC, ACAH program, or EDOU. These findings suggest that adoption of novel treatment spaces for appropriately selected patients may allow health systems to focus hospital resources on the patients with the most complex needs.
中文摘要:住院费用高且可能导致不良事件。部分医疗系统为特定患者在其他诊疗场所提供治疗。描述急诊科患者转入非住院诊疗环境(门诊治疗中心[ATC]、居家高级照护[ACAH]或急诊科观察病房[EDOU])与住院治疗的使用情况及短期结局。这项回顾性队列研究纳入2024年1月1日至2025年6月30日在Kaiser Permanente Northern California整合医疗系统内多站点社区急诊和住院医疗中心就诊、年龄19岁及以上的急诊患者。纳入患者为有效健保计划成员,因心力衰竭、肺炎、蜂窝织炎、尿路感染、COVID-19或贫血就诊,并转入ATC、ACAH项目(Kaiser Permanente Advanced Care at Home)、EDOU或住院床位。暴露为治疗场所。主要结局为在ATC、ACAH项目或EDOU治疗患者的照护升级(住院入院),以及所有场所在照护完成后7天急诊回访、30天住院和30天死亡。报告未调整结局率。研究纳入26618次急诊就诊(患者中位年龄77岁[IQR,65-85岁];52.6%女性)。在22755名唯一患者中,87.4%有1次就诊,9.8%有2次就诊,2.8%有超过2次就诊。ATC、ACAH、EDOU和医院环境分别有728次(2.7%)、880次(3.3%)、5133次(19.3%)和19877次(74.7%)就诊。四分之一患者(25.3%)在ATC、ACAH项目或EDOU接受照护。ATC和ACAH就诊的住院入院率低于EDOU就诊(分别为4.3%[95%CI,2.7%-5.8%]、5.3%[3.8%-6.8%]和28.0%[26.8%-29.2%])。7天急诊就诊率在各场所相近(ATC:10.4%[95%CI,7.8%-12.9%];ACAH:5.3%[3.8%-6.8%];EDOU:9.2%[8.4%-10.0%];医院:8.5%[8.1%-8.9%])。相反,ATC、ACAH和EDOU就诊的30天死亡率和住院率低于医院就诊(30天死亡率:2.1%[95%CI,1.0%-3.2%]、1.7%[0.8%-2.6%]、2.8%[2.3%-3.2%]和5.3%[5.0%-5.6%];30天住院:11.4%[95%CI,8.8%-14.1%]、8.3%[6.3%-10.2%]、12.7%[11.7%-13.7%]和15.3%[14.7%-15.8%])。在这项接受替代诊疗场所治疗患者的队列研究中,四分之一在ATC、ACAH项目或EDOU接受照护。这些发现提示,为经过适当选择的患者采用新的治疗空间,可使医疗系统将医院资源集中于需求最复杂的患者。
Chronic kidney disease is a frequent comorbidity in heart failure with preserved ejection fraction (HFpEF) and has been proposed as a contributor to its development. However, the spectrum of antecedent kidney function before incident HFpEF and its association with subsequent cardiovascular outcomes remains unclear. We conducted a multicenter cohort study across 170 US Veterans Affairs hospitals, including patients with incident HFpEF diagnosed between January 1, 2000, and June 30, 2025. HFpEF was ascertained using natural language processing-derived left ventricular ejection fraction ≥50% closest to the incident HF date and a validated HFpEF algorithm incorporating loop diuretic use, elevated natriuretic peptide levels, and an HFpEF-age, body mass index, and atrial fibrillation score >0.5. Antecedent kidney function was classified using 2 estimated glomerular filtration rate (eGFR) measurements obtained ≥90 days apart before incident HFpEF and urine albumin-to-creatinine ratio. We characterized antecedent kidney function, including albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g), and examined its associations with 5-year cardiovascular death and heart failure hospitalization. Competing-risk analysis was performed accounting for noncardiovascular death as a competing event for cardiovascular death. Of 304 712 patients meeting HFpEF ascertainment criteria, 236 910 comprised the final cohort; 51% had antecedent eGFR ≥60 mL/min per 1.73m2. Overall, 15% had an eGFR ≥90 mL/min per 1.73m2. Patients with eGFR <60 mL/min per 1.73m2 were older and had more diabetes and hypertension. 51% of the patients with eGFR <60 mL/min per 1.73m2 had body mass index <30 kg/m2, including 20% with body mass index <25 kg/m2. Progressively lower antecedent kidney function was associated with graded increases in cardiovascular death and heart failure hospitalization. Among decedents, the proportion of deaths attributed to cardiovascular causes increased from 25% in the preserved eGFR (≥90 mL/min per 1.73m2) without documented albuminuria to 32% with albuminuria and 38% with advanced kidney dysfunction (P<0.001). In this nationwide study of patients with incident HFpEF, antecedent kidney dysfunction was common but not uniformly present before HFpEF onset. Furthermore, among patients who developed HFpEF, antecedent kidney dysfunction identified a higher-risk phenotype, with progressively greater cardiovascular mortality and heart failure hospitalization with declining kidney function.
中文摘要:慢性肾脏病是射血分数保留的心力衰竭(HFpEF)常见合并症,并被认为参与其发生。但新发HFpEF之前肾功能的变化谱及其与后续心血管结局的关系仍不清楚。我们在美国170家退伍军人事务医院开展多中心队列研究,纳入2000年1月1日至2025年6月30日诊断的新发HFpEF患者。HFpEF通过自然语言处理获得的、最接近心衰发病日期的左心室射血分数≥50%,以及一个经验证的HFpEF算法确认,该算法包括袢利尿剂使用、利钠肽水平升高和HFpEF年龄、体重指数、心房颤动评分>0.5。既往肾功能采用新发HFpEF前间隔至少90天的2次估算肾小球滤过率(eGFR)测量和尿白蛋白肌酐比值分类。我们描述既往肾功能特征,包括白蛋白尿(尿白蛋白肌酐比值≥30 mg/g),并分析其与5年心血管死亡和心衰住院的关系。采用竞争风险分析,将非心血管死亡作为心血管死亡的竞争事件。304 712例符合HFpEF确认标准的患者中,236 910例构成最终队列;51%既往eGFR≥60 mL/min/1.73 m2。总体上,15%的eGFR≥90 mL/min/1.73 m2。eGFR<60 mL/min/1.73 m2者年龄更大,糖尿病和高血压更多。eGFR<60 mL/min/1.73 m2者中51%体重指数<30 kg/m2,其中20%体重指数<25 kg/m2。既往肾功能越低,心血管死亡和心衰住院呈分级增加。在死亡者中,归因于心血管原因的比例从无白蛋白尿且eGFR保留(≥90 mL/min/1.73 m2)者的25%升至有白蛋白尿者的32%和晚期肾功能不全者的38%(P<0.001)。在这项全国性新发HFpEF患者研究中,既往肾功能不全常见,但并非在HFpEF发病前普遍存在。此外,在发生HFpEF的患者中,既往肾功能不全识别出更高风险表型,随着肾功能下降,心血管死亡和心衰住院逐步增加。
The PREVENT-HF equations estimate 10-year risk of overall heart failure (HF), inclusive of both HF with preserved and reduced ejection fraction (HFpEF; HFrEF). Given differential risk factor profiles, pathophysiology, and therapeutic strategies for each HF subtype, we sought to examine the performance of PREVENT-HF for subtype-specific risk assessment. We included data from five pooled longitudinal cohort studies (baseline exam 1989 to 2013) and two longitudinal primary-care electronic health record-based samples (Beth Israel Deaconess Medical Center [BIDMC], baseline 2004 to 2014; Mass General Brigham [MGB], baseline 2001 to 2018). We assessed the performance of the PREVENT-HF equations in predicting 10-year incident HFrEF and HFpEF, including model discrimination (area under the receiver operating characteristic curve [AUROC]; average precision [AP]/event rate) and calibration (integrated calibration index [ICI]), in adults aged 30-79 years without prevalent cardiovascular disease or HF. The pooled cohort studies included 23,652 (55% women, age 60 ± 13 years), of whom 1,232 developed HF (432 [35%] HFpEF, 522 [42%] HFrEF). The BIDMC sample included 29,815 (55% women, 50 ± 13 years), of whom 259 (1%) developed HF (133 [51%] HFpEF, 101 [39%] HFrEF). MGB included 138,999 (62% women, 52 ± 13 years), of whom 1050 developed HF (586 [56%] HFpEF, 381 [36%] HFrEF). PREVENT-HF demonstrated better discrimination for HFpEF than HFrEF across all samples: in the pooled cohorts, the AUROC for HFpEF was 0.824 (95% CI 0.807, 0.839) versus 0.789 (95% CI 0.770, 0.807) for HFrEF; in BIDMC, the AUROC for HFpEF was 0.897 (95% CI 0.874, 0.918) versus 0.833 (95% CI 0.791, 0.869) for HFrEF; in MGB, the AUROC for HFpEF was 0.864 (95% CI 0.848, 0.880) versus 0.797 (95% CI 0.771, 0.820) for HFrEF. Similar results were reflected in the AP/event rate ratios: 2.92 (95% CI 2.47, 3.54) for HFpEF compared to 2.66 (95% CI 2.33, 3.14) for HFrEF in the pooled cohorts; 8.08 (95% CI 6.12, 12.30) for HFpEF compared to 5.12 (95% CI 3.84, 8.17) for HFrEF in BIDMC; and 6.84 (95% CI 5.66, 8.28) for HFpEF compared to 4.12 (95% CI 3.37, 5.16) for HFrEF in MGB. Calibration was similar for HFpEF and HFrEF across samples. For example, in the pooled cohorts, the ICI for HFpEF was 0.041 (95% CI 0.039, 0.043) and for HFrEF was 0.038 (95% CI 0.036, 0.040). PREVENT-HF demonstrated excellent discrimination for both HF subtypes across community-based cohorts and real-world samples, with consistently better discrimination for HFpEF as compared to HFrEF. Given PREVENT-HF was developed to estimate overall HF risk rather than subtype-specific risk, future studies are needed to establish subtype-specific risk thresholds.
中文摘要:PREVENT-HF方程用于估算总体心力衰竭(HF)的10年风险,涵盖射血分数保留型HF(HFpEF)和射血分数降低型HF(HFrEF)。鉴于各HF亚型的危险因素谱、病理生理和治疗策略存在差异,我们考察PREVENT-HF在亚型特异性风险评估中的表现。研究纳入五项汇总纵向队列研究(基线检查1989—2013年)和两个基于纵向初级保健电子健康记录样本(Beth Israel Deaconess Medical Center [BIDMC],基线2004—2014年;Mass General Brigham [MGB],基线2001—2018年)的数据。我们在30—79岁、无现患心血管疾病或HF的成人中评估PREVENT-HF方程预测10年新发HFrEF和HFpEF的表现,包括模型区分度(受试者工作特征曲线下面积[AUROC];平均精确率[AP]/事件率)和校准度(整合校准指数[ICI])。汇总队列研究纳入23,652人(女性55%,年龄60±13岁),其中1,232人发生HF(HFpEF 432人[35%],HFrEF 522人[42%])。BIDMC样本纳入29,815人(女性55%,50±13岁),其中259人(1%)发生HF(HFpEF 133人[51%],HFrEF 101人[39%])。MGB纳入138,999人(女性62%,52±13岁),其中1,050人发生HF(HFpEF 586人[56%],HFrEF 381人[36%])。PREVENT-HF在所有样本中对HFpEF的区分度均优于HFrEF:汇总队列中HFpEF的AUROC为0.824(95% CI 0.807, 0.839),HFrEF为0.789(95% CI 0.770, 0.807);BIDMC中HFpEF的AUROC为0.897(95% CI 0.874, 0.918),HFrEF为0.833(95% CI 0.791, 0.869);MGB中HFpEF的AUROC为0.864(95% CI 0.848, 0.880),HFrEF为0.797(95% CI 0.771, 0.820)。AP/事件率比值反映相似结果:汇总队列中HFpEF为2.92(95% CI 2.47, 3.54),HFrEF为2.66(95% CI 2.33, 3.14);BIDMC中HFpEF为8.08(95% CI 6.12, 12.30),HFrEF为5.12(95% CI 3.84, 8.17);MGB中HFpEF为6.84(95% CI 5.66, 8.28),HFrEF为4.12(95% CI 3.37, 5.16)。各样本中HFpEF与HFrEF的校准度相似。例如,汇总队列中HFpEF的ICI为0.041(95% CI 0.039, 0.043),HFrEF为0.038(95% CI 0.036, 0.040)。PREVENT-HF在社区队列和真实世界样本中对两种HF亚型均表现出优秀的区分度,对HFpEF的区分度持续优于HFrEF。鉴于PREVENT-HF用于估算总体HF风险而非亚型特异性风险,未来研究需要建立亚型特异性风险阈值。
Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce cardiovascular risk in patients with type 2 diabetes mellitus (T2D), evidence in heart failure (HF) has expanded across diverse trial populations and HF phenotypes but remains fragmented. We therefore performed an integrated systematic review and meta-analysis to evaluate the effects of GLP-1 RAs across the spectrum of HF using complementary trial-level and phenotype-based analyses. PubMed, Embase, and Web of Science were systematically searched for studies published from inception to August 10, 2025. To provide an integrated assessment across heterogeneous HF populations, treatment effects were evaluated using dual analytical frameworks: trial-level analyses according to study design (dedicated HF with preserved ejection fraction [HFpEF] trials, HF with reduced ejection fraction [HFrEF] trials, and HF subgroups from cardiovascular outcome trials [CVOTs]) and phenotype-based analyses according to left ventricular ejection fraction (HFpEF vs HFrEF using a pragmatic threshold of 40%). A prespecified targeted analysis was conducted to specifically assess the efficacy of semaglutide. The primary outcomes were major adverse cardiovascular events (MACE), and the secondary outcomes included hospitalization for HF (HHF), the composite of cardiovascular death or any worsening HF events, cardiovascular death alone, and all-cause mortality. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using random‑effects models. This meta-analysis included 14 trials, with a pooled total of 15,882 patients with HF. In phenotype‑based analyses for HFpEF, GLP‑1 RAs significantly reduced MACE (HR 0.79; 95% CI 0.66-0.94; p = 0.010), HHF (HR 0.48; 95% CI 0.27-0.85; p = 0.012), the composite of cardiovascular death or worsening HF (HR 0.57; 95% CI 0.37-0.89; p = 0.013), and all‑cause mortality (HR 0.75; 95% CI 0.62-0.89; p = 0.001). In contrast, in HFrEF, no significant reductions were observed for HHF, the composite of cardiovascular death or worsening HF, all-cause mortality, or MACE, although a reduction in cardiovascular death was noted (HR 0.71; 95% CI 0.54-0.95; p = 0.019). Trial-level analyses showed that cardiovascular benefits were primarily observed in HF subgroups from CVOTs, including reductions in MACE (HR 0.82; 95% CI 0.73-0.92; p = 0.001), cardiovascular death (HR 0.88; 95% CI 0.77-1.00; p = 0.05) and myocardial infarction (MI)/non-fatal MI (HR 0.84; 95% CI 0.70-1.00; p = 0.046). Semaglutide showed benefits in HHF and the composite of cardiovascular death or worsening HF events predominantly among overweight or obese patients with HFpEF. GLP-1 RAs also improved functional capacity and quality of life in HFpEF. GLP-1 RAs were associated with favorable cardiovascular and HF-related outcomes in HFpEF, predominantly among overweight or obese individuals, whereas evidence of benefit in HFrEF remains limited. In trial-level analyses, benefits were primarily observed for atherosclerotic endpoints in HF subgroups from CVOTs. By integrating evidence, this study provides a unified overview of the effects of GLP-1 RAs across the spectrum of HF and supports further phenotype-specific randomized trials, particularly dedicated studies in HFrEF. Protocol registration PROSPERO (CRD420251079970).
中文摘要:尽管胰高血糖素样肽-1受体激动剂(GLP-1 RAs)可降低2型糖尿病(T2D)患者的心血管风险,但其在心力衰竭(HF)中的证据虽已扩展到不同试验人群和HF表型,仍较为零散。为此开展整合性系统评价和荟萃分析,采用试验层面与表型分析两种互补框架评估GLP-1 RAs在整个HF谱中的效应。系统检索PubMed、Embase和Web of Science自建库至2025年8月10日发表的研究。为在异质性HF人群中提供整合评估,采用双重分析框架评价治疗效应:按研究设计进行试验层面分析(专门HFpEF试验、HFrEF试验及心血管结局试验CVOTs中的HF亚组),以及按左心室射血分数进行表型分析(以40%为实用阈值区分HFpEF与HFrEF)。预设靶向分析专门评估司美格鲁肽的疗效。主要结局为主要不良心血管事件(MACE),次要结局包括HF住院(HHF)、心血管死亡或任何HF恶化事件的复合终点、单纯心血管死亡和全因死亡。采用随机效应模型计算合并风险比(HR)及95%置信区间(CI)。该荟萃分析纳入14项试验,共15,882例HF患者。表型分析中,HFpEF患者使用GLP-1 RAs显著降低MACE(HR 0.79;95% CI 0.66-0.94;p=0.010)、HHF(HR 0.48;95% CI 0.27-0.85;p=0.012)、心血管死亡或HF恶化复合终点(HR 0.57;95% CI 0.37-0.89;p=0.013)和全因死亡(HR 0.75;95% CI 0.62-0.89;p=0.001)。相反,HFrEF患者中HHF、心血管死亡或HF恶化复合终点、全因死亡和MACE均未见显著降低,但观察到心血管死亡下降(HR 0.71;95% CI 0.54-0.95;p=0.019)。试验层面分析显示,心血管获益主要体现在CVOTs的HF亚组,包括MACE(HR 0.82;95% CI 0.73-0.92;p=0.001)、心血管死亡(HR 0.88;95% CI 0.77-1.00;p=0.05)和心肌梗死(MI)/非致死性MI(HR 0.84;95% CI 0.70-1.00;p=0.046)降低。司美格鲁肽在HHF及心血管死亡或HF恶化复合终点方面的获益主要见于超重或肥胖的HFpEF患者。GLP-1 RAs还改善HFpEF患者的功能能力和生活质量。GLP-1 RAs在HFpEF中与有利的心血管和HF相关结局相关,主要见于超重或肥胖个体,而HFrEF中的获益证据仍有限。试验层面分析中,获益主要体现为CVOTs的HF亚组中的动脉粥样硬化性终点。通过整合证据,该研究提供了GLP-1 RAs在整个HF谱中效应的统一概览,并支持进一步开展表型特异性随机试验,尤其是专门针对HFrEF的研究。方案注册于PROSPERO(CRD420251079970)。
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous multisystem syndrome characterized by diastolic dysfunction, metabolic inflexibility, and impaired mitochondrial reserve. Human myocardial metabolomic and proteomic studies support broad oxidative and mitochondrial remodeling, but they do not establish a uniform primary defect in ketone oxidation across HFpEF. Evidence for reduced MCT1, BDH1, or SCOT/OXCT1 and for a ketolytic bottleneck is strongest in selected experimental cardiometabolic or multifactorial models; direct human myocardial ketone flux data remain sparse. Circulating β-hydroxybutyrate (β-OHB), transcardiac extraction, myocardial uptake, and complete mitochondrial oxidation are distinct measurements and may change in different directions. We therefore propose a phenotype-dependent framework that interprets systemic ketone supply together with myocardial transport and ketolysis, mitochondrial oxidative reserve, and extra-cardiac comorbidity, rather than treating ketone metabolism as a single uniformly activated or impaired pathway. β-OHB may also influence redox, inflammatory, histone deacetylase (HDAC), and lysine β-hydroxybutyrylation (Kbhb) pathways, although these effects are metabolically coupled and direct causal evidence in human HFpEF is lacking. Acute and short-term ketone interventions have produced selected hemodynamic changes without consistent improvement in exercise capacity, and clinical trials have not established ketone metabolism as a mediator of sodium-glucose cotransporter 2 inhibitor benefit. Ketone-targeted strategies should therefore be tested in phenotype-stratified studies using direct flux and mechanism-specific functional endpoints.
中文摘要:射血分数保留型心力衰竭(HFpEF)是一种异质性多系统综合征,表现为舒张功能障碍、代谢灵活性下降和线粒体储备受损。人心肌代谢组学和蛋白质组学研究支持广泛的氧化与线粒体重塑,但并未确立HFpEF中存在统一的酮体氧化原发缺陷。MCT1、BDH1或SCOT/OXCT1降低以及酮解瓶颈的证据,在特定实验性心脏代谢或多因素模型中最为明确;直接的人心肌酮体通量数据仍然稀少。循环β-羟基丁酸(β-OHB)、经心脏提取、心肌摄取和线粒体完全氧化属于不同测量指标,变化方向可能不一致。因此提出依赖表型的框架,将全身酮体供应与心肌转运和酮解、线粒体氧化储备及心外合并症一并解释,而不把酮体代谢视为单一且统一激活或受损的通路。β-OHB还可能影响氧化还原、炎症、组蛋白去乙酰化酶(HDAC)和赖氨酸β-羟基丁酰化(Kbhb)通路,这些效应在代谢上相互耦联,且缺乏人心HFpEF中的直接因果证据。急性和短期酮体干预带来部分血流动力学改变,但未能一致改善运动能力,临床试验也未确立酮体代谢是钠-葡萄糖协同转运蛋白2抑制剂获益的中介。酮体靶向策略应在表型分层研究中检验,并采用直接通量测量和机制特异的 функциональные终点。
Heart failure (HF) is a common complication of diabetes, associated with a high mortality rate and a substantial healthcare burden. Residual HF risk persists despite achieving current treatment targets, suggesting a role for additional mechanisms beyond conventional risk factors. We sought to prospectively assess HF incidence and independent risk factors in individuals with new-onset diabetes. We used a prospective inception cohort (ANDIS, n=19,892) that included all individuals with newly diagnosed diabetes from southern Sweden between 2008 and 2021. Baseline clinical, biochemical and questionnaire data were linked to the Region Scania Care Database to obtain data on cardiovascular events and to the National Diabetes Registry to gather further data on cardiovascular risk factors that were not collected in the ANDIS study protocol. All-cause HF included all cases of HF regardless of underlying aetiology, whereas non-ischaemic HF was defined as HF occurring in individuals without prior acute myocardial infarction at baseline or during follow-up before the HF diagnosis. Cardiovascular disease incidence was estimated using the Kaplan-Meier method, and the associations with risk factors and incident HF were assessed using Cox proportional hazards regression. The median age of the overall population was 62.5 years (IQR 52.6-70.3), while the median age among individuals who developed incident all-cause HF was 69.8 years (IQR 62.7-76.7). A total of 819 individuals (4.1%) with prevalent HF were excluded. During up to 14 years of follow-up (median 5.0), the cumulative incidence of HF was 4.8%, exceeding that of myocardial infarction (3.0%). No individuals with type 1 diabetes developed HF, but the incidence was similar across those with type 2 diabetes, latent autoimmune diabetes in adults, and secondary diabetes. A lower eGFR and higher HOMA2-IR, were associated with increased risk of all-cause and non-ischaemic HF, independently of the presence of conventional risk factors. Insulin resistance predicted all-cause HF independently of the established SCORE2-Diabetes risk score. The hazard ratio (HR) per 1 SD increase in HOMA2-IR was highest in the low-risk group (HR 1.89; 95% CI 1.02, 3.48; p=4.3 × 10-2), with concordant results observed for non-ischaemic HF. The HF incidence was high, with approximately 1 in 20 individuals developing HF within 5 years after diagnosis of diabetes other than type 1, highlighting a notably high risk of developing HF soon after diabetes diagnosis. Beyond conventional risk factors, higher HOMA2-IR and lower renal function, but not hyperglycaemia or autoantibodies, were independent risk factors for HF. Measuring HOMA2-IR also provided prognostic information in addition to that provided by the SCORE2-Diabetes risk score, supporting its value in HF risk stratification.
中文摘要:心力衰竭是糖尿病的常见并发症,死亡率和医疗负担均较高。即使达到当前治疗目标,心衰残余风险仍存在,提示常规危险因素之外还有其他机制参与。旨在前瞻性评估新发糖尿病个体的心衰发生率和独立危险因素。研究使用前瞻性起始队列ANDIS(n=19,892),纳入2008年至2021年瑞典南部所有新诊断糖尿病个体。基线临床、生化和问卷数据与斯科讷地区医疗数据库链接以获取心血管事件数据,并与国家糖尿病登记链接以补充ANDIS研究方案未收集的心血管危险因素数据。全因心衰包括无论基础病因的所有心衰病例;非缺血性心衰定义为基线时或随访期间在心衰诊断前无急性心肌梗死的个体发生的心衰。心血管疾病发生率采用Kaplan-Meier法估计,危险因素与新发心衰的关联采用Cox比例风险回归评估。总人群中位年龄62.5岁(IQR 52.6-70.3),发生新发全因心衰的个体中位年龄69.8岁(IQR 62.7-76.7)。819例(4.1%)基线现患心衰个体被排除。随访最长14年(中位5.0年),心衰累积发生率为4.8%,高于心肌梗死(3.0%)。无1型糖尿病个体发生心衰,但2型糖尿病、成人隐匿性自身免疫糖尿病和继发性糖尿病个体的发生率相似。较低eGFR和较高HOMA2-IR与全因及非缺血性心衰风险增加相关,且独立于常规危险因素的存在。胰岛素抵抗可独立于已建立的SCORE2-Diabetes风险评分预测全因心衰。HOMA2-IR每增加1个标准差的危险比(HR)在低风险组最高(HR 1.89;95% CI 1.02, 3.48;p=4.3×10⁻²),非缺血性心衰观察到一致结果。心衰发生率较高,非1型糖尿病诊断后5年内约每20人中有1人发生心衰,凸显糖尿病诊断后不久发生心衰的风险显著偏高。在常规危险因素之外,较高HOMA2-IR和较低肾功能是心衰的独立危险因素,而高血糖或自身抗体不是。测定HOMA2-IR还提供了SCORE2-Diabetes风险评分之外的预后信息,支持其用于心衰风险分层。
Concern for ototoxicity hinders loop diuretic (LD) dosing in heart failure (HF); given the mechanism by which LDs affect the ear, high-dose LDs should produce transient, not permanent, hearing changes. To measure the association of LD dose with permanent and temporary ototoxicity. Cohort 1 received a randomized sequence of LD doses (bumetanide, 1.25-10 mg) across study visits with serial audiometry assessments. Cohort 2 received serial LD up to furosemide 500-mg doses during a HF hospitalization with audiometry at baseline and prior to discharge. Cohort 3 retrospectively characterized clinically diagnosed ototoxicity in HF hospitalizations was defined using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes. Cohorts 1 and 2 were single center, while cohort 3 was multicenter. Cohort 1 studied outpatient participants with stable HF, while cohort 2 (n = 40) and cohort 3 studied hospitalized patients with acute HF. Intravenous LD. The primary outcomes were clinically diagnosed ototoxicity and hearing changes via audiometry. Cohort 1 contained 50 participants, cohort 2 contained 40 participants, and cohort 3 contained 22 656 participants. In cohort 1, mean (SD) participant age was 63.2 (10.4) years, and 21 of 50 participants (42%) were women. In cohorts 1 and 2, clinically diagnosed ototoxicity was not observed. In cohort 1, at peak diuretic concentration, worsening hearing shifts were infrequent (24 ears of 400 doses [6%]) but were more common with higher doses (odds ratio [OR], 1.99; 95% CI, 1.21-3.28 per doubling dose; P = .007). Within hours, hearing shifts largely resolved and were absent in 98% of measurements (393 ears of 400 doses). No significant association between LD dose and hearing shifts was present at any time aside from peak LD concentration. In cohort 2, hearing shifts were not different across groups divided by the median daily LD dose and were not associated with LD dose (OR, 1.19; 95% CI, 0.71-1.98 per doubling dose; P = .52). In cohort 3, 608 HF hospitalizations (2.7%) had clinically diagnosed ototoxicity. In multivariable analyses, peak dose of 160 mg furosemide equivalents or greater (OR, 0.83; 95% CI, 0.52-1.31; P = .43) and 400 mg furosemide equivalents or greater (OR, 1.28; 95% CI, 0.71-2.31; P = .41) were not associated with greater clinically diagnosed ototoxicity risk relative to less than 160 mg. In this analysis of 2 small HF cohorts, short-term exposure to high-dose LD was not associated with permanent ototoxicity, although concomitant ototoxin use was excluded. Future studies are needed to understand the risk of ototoxicity with repeated LD exposure and in broader HF populations. ClinicalTrials.gov Identifiers: NCT04481919 and NCT05323487.
中文摘要:对耳毒性的担忧限制了心力衰竭患者袢利尿剂的剂量选择;鉴于袢利尿剂影响耳部的机制,高剂量袢利尿剂应引起暂时性而非永久性听力变化。评估袢利尿剂剂量与永久性和暂时性耳毒性的关联。队列1在多次研究访视中按随机顺序接受不同剂量袢利尿剂(布美他尼1.25~10 mg),并连续进行听力检测。队列2因心衰住院期间接受连续袢利尿剂治疗,直至呋塞米500 mg剂量,并在基线和出院前进行听力检测。队列3回顾性分析心衰住院中临床诊断的耳毒性,采用ICD-10编码定义。队列1和2为单中心,队列3为多中心。队列1研究稳定型心衰门诊患者,队列2(n=40)和队列3研究急性心衰住院患者。给予静脉袢利尿剂。主要结局为临床诊断的耳毒性和听力检测显示的听力变化。队列1有50例参与者,队列2有40例,队列3有22656例。队列1平均(SD)年龄63.2(10.4)岁,50例中21例(42%)为女性。队列1和2未观察到临床诊断的耳毒性。队列1在利尿剂浓度峰值时,听力恶化性偏移不常见(400次给药中24耳[6%]),但较高剂量时更常见(每倍剂量OR 1.99,95%CI 1.21~3.28,P=.007)。数小时内听力偏移大多恢复,98%的测量中不存在(400次给药中393耳)。除袢利尿剂浓度峰值外,其他时间点袢利尿剂剂量与听力偏移均无显著关联。队列2按每日袢利尿剂剂量中位数分组,各组听力偏移无差异,且听力偏移与袢利尿剂剂量无关(每倍剂量OR 1.19,95%CI 0.71~1.98,P=.52)。队列3中608次心衰住院(2.7%)出现临床诊断的耳毒性。多变量分析中,呋塞米等效剂量峰值≥160 mg(OR 0.83,95%CI 0.52~1.31,P=.43)和≥400 mg(OR 1.28,95%CI 0.71~2.31,P=.41)相对于<160 mg未与更高的临床诊断耳毒性风险相关。在这项2个小型心衰队列的分析中,短期暴露于高剂量袢利尿剂与永久性耳毒性无关,但排除了合并使用耳毒性药物者。未来研究需了解重复袢利尿剂暴露及更广泛心衰人群中的耳毒性风险。ClinicalTrials.gov注册号:NCT04481919和NCT05323487。
Rural-urban disparities in heart failure (HF) care delivery and outcomes are well documented. However, it remains unclear if differences in outcomes after HF hospitalization are primarily driven by patient rural residence, hospital resources, or both. To evaluate associations of patient and hospital rurality with quality of care and postdischarge outcomes after hospitalization for HF with reduced ejection fraction (HFrEF). This was a retrospective cohort study of Medicare beneficiaries in US hospitals with HFrEF with an index hospitalization from January 1, 2013, to December 31, 2021. Included were Medicare beneficiaries discharged alive after an index hospitalization for HFrEF. Participants were classified as rural patients hospitalized in rural hospitals (rural-rural), rural patients in urban hospitals (rural-urban), urban patients in urban hospitals (urban-urban), and urban patients in rural hospitals (urban-rural). Study data were analyzed from July to September 2026. Patient rural residence and hospital rurality. Primary outcome was 90-day all-cause mortality after hospitalization. Secondary outcomes included inpatient cardiology consultation, 90-day postdischarge guideline-directed medical therapy (GDMT) use based on prescription fills, and HF readmission at 30 days, 90 days, and 1 year. Among 735 460 beneficiaries (median [IQR] age, 77 [70-85] years; 415 077 male [56.4%]), 69 061 (9.4%) were rural-rural, 65 510 (8.9%) rural-urban, 582 947 (79.3%) urban-urban, and 17 942 (2.4%) urban-rural. Compared with rural patients treated in rural hospitals, rural patients treated in urban hospitals were more likely to receive inpatient cardiology consultation (odds ratio [OR], 2.02; 95% CI, 1.84-2.22) and initiation of several GDMT classes, including β-blockers (OR, 1.20; 95% CI, 1.16-1.25), ARNIs (OR, 1.23; 95% CI, 1.13-1.34), MRAs (OR, 1.23; 95% CI, 1.15-1.31), and SGLT2Is (OR, 1.48; 95% CI, 1.32-1.67). They also had lower rates of HF readmission and mortality at all time points (HF readmission 1-year: OR, 0.85; 95% CI, 0.82-0.88; mortality 1-year: OR, 0.91; 95% CI, 0.89-0.94) than rural-rural patients. Compared with urban patients hospitalized at urban hospitals, rural patients hospitalized at urban hospitals more often received inpatient cardiology consultation (OR, 1.38; 95% CI, 1.31-1.44), whereas postdischarge GDMT differences were modest (absolute difference in GDMT score 0.09 points; 95% CI, 0.05-0.14). Rural patients also had lower HF readmission (1-year OR, 0.81; 95% CI, 0.79-0.82) but higher 30- and 90-day mortality than urban patients (30-day OR, 1.10; 95% CI, 1.06-1.14; 90-day OR, 1.05; 95% CI, 1.02-1.08). Results suggest that hospital rurality was associated with lower odds of GDMT use and higher rates of all-cause mortality, whereas rural residence was associated with mortality differences despite treatment in urban hospitals. Interventions addressing both inpatient resource disparities and postdischarge transitions of care may reduce rural-urban inequities in HF outcomes.
中文摘要:心力衰竭照护和结局的城乡差异已有充分记录。但心衰住院后结局差异主要由患者农村居住地、医院资源还是两者共同驱动仍不清楚。评估患者和医院农村属性与射血分数降低心衰(HFrEF)住院后照护质量及出院后结局的关联。这项回顾性队列研究纳入2013年1月1日至2021年12月31日期间在美国医院因HFrEF指数住院的Medicare受益人,纳入出院时存活者。参与者分为农村患者在农村医院(农村-农村)、农村患者在城区医院(农村-城区)、城区患者在城区医院(城区-城区)、城区患者在农村医院(城区-农村)。研究数据分析时间为2026年7月至9月。暴露为患者农村居住地和医院农村属性。主要结局为住院后90天全因死亡。次要结局包括住院期间心内科会诊、基于处方配药的出院后90天指南导向药物治疗(GDMT)使用,以及30天、90天和1年心衰再住院。在735460名受益人(中位[IQR]年龄77[70-85]岁;415077名男性[56.4%])中,69061名(9.4%)为农村-农村,65510名(8.9%)为农村-城区,582947名(79.3%)为城区-城区,17942名(2.4%)为城区-农村。与在农村医院治疗的农村患者相比,在城区医院治疗的农村患者更可能接受住院心内科会诊(OR 2.02;95% CI 1.84-2.22)并启动多类GDMT,包括β受体阻滞剂(OR 1.20;95% CI 1.16-1.25)、ARNI(OR 1.23;95% CI 1.13-1.34)、MRA(OR 1.23;95% CI 1.15-1.31)和SGLT2抑制剂(OR 1.48;95% CI 1.32-1.67)。他们在所有时间点的心衰再住院率和死亡率也低于农村-农村患者(1年心衰再住院:OR 0.85;95% CI 0.82-0.88;1年死亡:OR 0.91;95% CI 0.89-0.94)。与在城区医院住院的城区患者相比,在城区医院住院的农村患者更常接受住院心内科会诊(OR 1.38;95% CI 1.31-1.44),出院后GDMT差异较小(GDMT评分绝对差0.09分;95% CI 0.05-0.14)。农村患者心衰再住院较低(1年OR 0.81;95% CI 0.79-0.82),但30天和90天死亡率高于城区患者(30天OR 1.10;95% CI 1.06-1.14;90天OR 1.05;95% CI 1.02-1.08)。结果提示医院农村属性与较低GDMT使用几率及较高全因死亡率相关,而患者农村居住地与死亡率差异相关,即使在城区医院治疗也是如此。针对住院资源差异和出院后照护衔接的干预可能减少心衰结局的城乡不平等。
基础研究 (11篇)
Accumulating evidence suggests that epitranscriptomic regulation, particularly the m6A modification, contributes to heart failure progression. However, modification dynamics are not yet mapped and studied at base resolution and transcript isoform level. Here we use Nanopore direct RNA sequencing to profile m6A remodeling at transcriptome-wide and site-specific resolution in a mouse heart failure model. We identify thousands of differentially methylated sites with distinct sequence motifs and associations with RNA regulatory and cardiac function processes. Cross-species comparison reveals conserved m6A regulatory features in mouse and human heart failure. Isoform-resolved analysis further uncovers co/posttranscriptional regulation events involving isoform switching and m6A regulation in the SYNPO2L transcript. Mechanistically, m6A modification, alternative promoter usage and associated regulatory elements collectively explain this observation. Overall, our study provides a comprehensive, high-resolution characterization of m6A landscape and its remodeling in heart failure. Isoform-level regulation exemplifies an underappreciated shaping of RNA expression and modification.
中文摘要:越来越多证据提示,表观转录组调控尤其是m6A修饰参与心力衰竭进展,但修饰动态尚未在碱基分辨率和转录本异构体水平得到定位与研究。本研究采用Nanopore直接RNA测序,在小鼠心力衰竭模型中于转录组范围和位点特异性分辨率刻画m6A重塑。我们鉴定出数千个差异甲基化位点,这些位点具有不同序列基序,并与RNA调控及心脏功能过程相关。跨物种比较显示小鼠与人类心力衰竭中存在保守的m6A调控特征。异构体分辨分析进一步揭示SYNPO2L转录本中涉及异构体转换与m6A调控的共转录/转录后调控事件。机制上,m6A修饰、可变启动子使用及相关调控元件共同解释这一现象。该研究提供了心力衰竭中m6A图谱及其重塑的全面高分辨率刻画。异构体水平调控体现了RNA表达与修饰中一种尚未被充分认识的塑造作用。
Clonal hematopoiesis (CH), the expansion of blood cell clones carrying acquired mutations, is an independent risk factor for cardiovascular disease. Although mutations in DNMT3A and TET2 are well studied, the cardiovascular consequences of KDM6A mutations remain unclear. KDM6A is an X-linked histone demethylase that is commonly mutated in patients with heart failure (HF). Here we performed multiomics profiling and functional characterization of mouse models and patient-derived data to show that hematopoietic KDM6A loss impairs cardiac recovery after myocardial infarction (MI). KDM6A deficiency increases myeloid cell recruitment to the injured heart and reprograms monocytes, macrophages and neutrophils toward inflammatory, migratory and glycolytic states. Patients with HF and KDM6A-driven CH show similar pro-inflammatory monocyte signatures. KDM6A-silenced macrophages promote cardiomyocyte hypertrophy and cardiac fibroblast activation. Notably, IL-1β blockade after MI rescued the adverse cardiac phenotype of hematopoietic KDM6A loss. These findings identify KDM6A-driven CH as a driver of immune dysregulation and IL-1β signaling as a potential therapeutic target in CH-associated HF.
中文摘要:克隆性造血(CH)指携带获得性突变的血细胞克隆扩增,是心血管疾病的独立危险因素。DNMT3A与TET2突变已被充分研究,而KDM6A突变的心血管后果仍不清楚。KDM6A是一种X连锁组蛋白去甲基化酶,在心力衰竭患者中常见突变。研究者对小鼠模型与患者来源数据开展多组学分析与功能鉴定,显示造血细胞KDM6A缺失损害心肌梗死后的心脏恢复。KDM6A缺陷使髓系细胞向受损心脏的募集增加,并使单核细胞、巨噬细胞和中性粒细胞向炎症性、迁移性和糖酵解状态重编程。合并KDM6A驱动CH的心力衰竭患者表现出相似的促炎性单核细胞特征。KDM6A沉默的巨噬细胞促进心肌细胞肥大与心脏成纤维细胞活化。心肌梗死后阻断IL-1β可逆转造血细胞KDM6A缺失所致的不良心脏表型。上述结果提示KDM6A驱动的CH是免疫失调的驱动因素,IL-1β信号通路可作为CH相关心力衰竭的潜在治疗靶点。
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are rising stars for treating heart failure as first-line drugs, but the mechanism remains elusive. In a recent issue of Science, Forelli and colleagues show that SGLT2i bind directly to cardiac pantothenate kinase 1, boosting coenzyme A biosynthesis to support energy metabolism and functional recovery.
中文摘要:钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)作为一线药物正成为治疗心力衰竭的新星,但其机制仍不明确。在近期一期Science中,Forelli及同事表明,SGLT2i直接结合心脏泛酸激酶1,促进辅酶A生物合成,从而支持能量代谢与功能恢复。
Protein S-nitrosylation (SNO), a reversible nitric oxide (NO)-dependent post-translational modification to reactive cysteine residues, finely tunes cardiac excitation-contraction coupling, mitochondrial function, and stress responses. In cardiomyocytes, compartmentalized NO signaling via neuronal (nNOS), endothelial (eNOS), and inducible (iNOS) isoforms regulates SNO of key proteins (e.g., RyR2, LTCC, SERCA2a, mitochondrial Complex I). Under physiological conditions, SNO modulates Ca2+ handling, myofilament sensitivity, and bioenergetics, while pathological SNO dysregulation, hypo-nitrosylation in heart failure (HF) with reduced ejection fraction or hypernitrosylation in HF with preserved ejection fraction, contributes to contractile dysfunction, arrhythmias, and mitochondrial impairment. Cardioprotective SNO (e.g., during ischemia-reperfusion) acts as a "redox shield", preventing irreversible oxidation of critical cysteines, whereas excessive or mislocalized SNO can be detrimental, this dynamic modification plays an essential role in maintaining cardiac function. However, disruption of NO bioavailability and redox balance during cardiovascular disease alters the cardiac S-nitrosoproteome, contributing to maladaptive signaling, mitochondrial dysfunction, contractile impairment, and pathological remodeling. Increasing evidence also highlights the dual nature of SNO exerts either protective or detrimental effects depending on the molecular context, subcellular localization, and disease stage. This review summarizes current knowledge on SNO mechanisms in the heart and discusses its roles in physiological cardiac function and major cardiac pathologies.
中文摘要:蛋白质S-亚硝基化(SNO)是一种可逆的、依赖一氧化氮(NO)的翻译后修饰,作用于反应性半胱氨酸残基,精细调节心脏兴奋-收缩耦联、线粒体功能和应激反应。在心肌细胞中,由神经元型(nNOS)、内皮型(eNOS)和诱导型(iNOS)NO合酶介导的区室化NO信号调控关键蛋白的SNO,例如RyR2、LTCC、SERCA2a和线粒体复合物I。生理条件下,SNO调节钙处理、肌丝敏感性和生物能量学;病理性的SNO失调,包括射血分数降低的心力衰竭(HFrEF)中的低亚硝基化和射血分数保留的心力衰竭(HFpEF)中的高亚硝基化,促进收缩功能障碍、心律失常和线粒体损伤。心脏保护性SNO(如缺血-再灌注期间)作为「氧化还原盾」,防止关键半胱氨酸发生不可逆氧化,而过度或定位错误的SNO可能有害,这种动态修饰在维持心脏功能中起重要作用。心血管疾病中NO生物利用度和氧化还原平衡的破坏改变心脏S-亚硝基化蛋白质组,导致适应不良信号、线粒体功能障碍、收缩受损和病理重塑。越来越多证据强调SNO的双重性质:其保护或有害效应取决于分子背景、亚细胞定位和疾病阶段。本综述总结心脏SNO机制的最新认识,并讨论其在生理性心脏功能和主要心脏病理中的作用。
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous and increasingly prevalent syndrome for which effective disease-modifying therapies remain limited, in part because its multicellular pathophysiology remains incompletely understood. Mitochondrial dysfunction has emerged as an important contributor to HFpEF, yet most studies have examined mitochondrial abnormalities within individual cell types rather than as part of an integrated cardiac microenvironment. This review discusses evidence that cell-type-specific mitochondrial alterations in cardiomyocytes, fibroblasts, and endothelial cells may interact through redox, metabolic, and paracrine signaling to promote diastolic dysfunction, myocardial stiffening, and impaired energetic reserve. In cardiomyocytes, disrupted mitochondrial calcium (mCa2+) handling and redox imbalance uncouple ATP production from energetic demand, contributing to Ca2+ overload, mitochondrial reactive oxygen species (mtROS) generation, and impaired relaxation. In fibroblasts, mitochondrial and metabolic reprogramming support profibrotic activation and extracellular matrix (ECM) deposition. In endothelial cells, mitochondrial dysfunction reduces nitric oxide bioavailability, enhances oxidative stress, and contributes to microvascular dysfunction. Together, these cell-type-specific mitochondrial abnormalities may converge on a redox-calcium-energetics axis that helps explain the dissociation between preserved systolic function and impaired diastolic performance in HFpEF. We further highlight mitochondrial heterogeneity and intercellular crosstalk as potential determinants of disease progression and discuss emerging therapeutic strategies targeting mitochondrial pathways as a rationale for precision approaches in HFpEF.
中文摘要:射血分数保留的心力衰竭(HFpEF)是一种异质性且日益常见的综合征,有效改善疾病进程的治疗仍有限,部分原因在于其多细胞病理生理尚未被充分理解。线粒体功能障碍已成为HFpEF的重要促进因素,但多数研究在单一细胞类型内考察线粒体异常,而非将其置于整合的心脏微环境中。讨论心肌细胞、成纤维细胞和内皮细胞的细胞类型特异性线粒体改变可能通过氧化还原、代谢和旁分泌信号相互作用,促进舒张功能障碍、心肌僵硬和能量储备受损的证据。在心肌细胞中,线粒体钙(mCa2+)处理紊乱和氧化还原失衡使ATP产生与能量需求脱耦联,促成Ca2+超载、线粒体活性氧(mtROS)生成和松弛受损。在成纤维细胞中,线粒体和代谢重编程支持促纤维化激活和细胞外基质(ECM)沉积。在内皮细胞中,线粒体功能障碍降低一氧化氮生物利用度,增强氧化应激,并促进微血管功能障碍。这些细胞类型特异性线粒体异常可能共同汇聚于氧化还原-钙-能量轴,有助于解释HFpEF中收缩功能保留与舒张性能受损之间的分离。进一步强调线粒体异质性和细胞间串话是疾病进展的潜在决定因素,并讨论靶向线粒体通路的新兴治疗策略,作为HFpEF精准治疗路径的依据。
Combination of genetic eNOS deficiency and high-fat diet induces reproducible cardiometabolic HFpEF.
Heart failure with preserved ejection fraction (HFpEF) is a complex, multi-organ cardiometabolic syndrome lacking universally effective therapies. We developed and validated a robust murine model leveraging complete, constitutive genetic endothelial nitric oxide synthase deficiency (eNOS KO) coupled with metabolic stress via a high-fat diet (HFD) in both male and female cohorts. eNOS KO mice subjected to HFD (10 weeks for males; 15 weeks for females) developed a severe and highly reproducible cardiometabolic HFpEF phenotype. Despite preserved left ventricular ejection fraction, both sexes exhibited profound diastolic dysfunction, characterized by elevated E/e' ratios and left ventricular end-diastolic pressures (LVEDP), alongside severe exercise intolerance. Consistent with the systemic clinical syndrome, pathological remodeling extended to multi-organ damage, featuring prominent cardiac fibrosis, severe hepatic steatosis, and renal tubulointerstitial fibrosis. Finally, chronic administration of the dual GIP/GLP-1 receptor agonist tirzepatide largely reversed the hemodynamic, functional, and systemic fibrotic derangements. In conclusion, this novel eNOS KO mouse + HFD model provides a rapidly developing, highly penetrant, and chemically unconfounded platform that ensures robust HFpEF induction across both sexes. This model can be readily adopted for the investigation of mechanistic insights into HFpEF pathobiology and for the study of novel HFpEF therapeutics.
中文摘要:射血分数保留的心力衰竭(HFpEF)是一种复杂的多器官心脏代谢综合征,缺乏普遍有效的治疗手段。我们建立并验证了一种稳健的小鼠模型,利用完全、组成性遗传性内皮型一氧化氮合酶缺失(eNOS KO)并通过高脂饮食(HFD)施加代谢应激,涵盖雄性和雌性队列。接受HFD的eNOS KO小鼠(雄性10周;雌性15周)出现了严重且高度可重复的心脏代谢HFpEF表型。尽管左心室射血分数保留,两种性别均表现出显著舒张功能障碍,特征为E/e'比值和左心室舒张末压(LVEDP)升高,并伴有严重运动不耐受。与系统性临床综合征一致,病理性重构扩展至多器官损伤,表现为明显心脏纤维化、严重肝脂肪变性和肾小管间质纤维化。长期给予双重GIP/GLP-1受体激动剂替尔泊肽在很大程度上逆转了血流动力学、功能和系统性纤维化异常。这种新的eNOS KO小鼠+HFD模型提供了快速发生、高外显率且不受化学因素混淆的平台,可确保在两种性别中稳定诱导HFpEF。该模型可直接用于研究HFpEF病理生物学的机制见解以及新型HFpEF治疗药物。
Loop diuretics are first-line therapy for hypervolemia. They block the sodium-potassium-2-chloride cotransporter type 1 on the renal afferent arteriole that mediates vasoconstriction and the sodium-potassium-2-chloride cotransporter type 2 on the macula densa cells that mediates the tubuloglomerular feedback response and raises intrarenal pressure that inhibits the myogenic response. These should reduce afferent arteriolar vasoconstriction and increase the glomerular filtration rate; however, more often, the glomerular filtration rate is reduced. This has been attributed to diuretic-induced extracellular volume depletion that activates a systemic neurohormonal response. Accordingly, a fall in glomerular filtration rate can lead to strategies to restore body fluid volumes while reducing the diuretic dosage. Here, we review the regulation of renal hemodynamics during loop diuretic therapy. We propose that a passive, obstructive component of reduced renal blood flow combines with activation of renal afferent nerves, macula densa-derived renin release with intrarenal Ang II (angiotensin II) formation, and generation of vasoconstrictor prostaglandins and thromboxane to provide intrarenal mechanisms of passive and active increases in renal vascular resistance that together can reduce the glomerular filtration rate. The hypothesis that a reduction in the glomerular filtration rate with loop diuretics can derive from intrarenal mechanisms of vasoconstriction rather than from volume depletion suggests novel approaches to manage diuretic resistance and worsening renal function in heart failure.
中文摘要:袢利尿剂是高容量状态的一线治疗。这类药物阻断肾入球小动脉上介导血管收缩的钠-钾-2氯共转运体1,也阻断致密斑细胞上介导管球反馈反应的钠-钾-2氯共转运体2,并升高肾内压以抑制肌源性反应。按此推断,应减少入球小动脉收缩并提高肾小球滤过率;但实际更多见的是肾小球滤过率下降。这一现象既往归因于利尿剂引起的细胞外容量减少激活全身神经激素反应。据此,肾小球滤过率下降可促使采取恢复体液容量并减少利尿剂剂量的策略。本综述讨论袢利尿剂治疗期间肾血流动力学的调节。我们提出,肾血流减少中的被动梗阻成分,与肾传入神经激活、致密斑来源肾素释放并伴肾内血管紧张素II生成、以及缩血管前列腺素和血栓素生成共同作用,构成被动与主动升高肾血管阻力的肾内机制,二者叠加可降低肾小球滤过率。袢利尿剂导致肾小球滤过率下降可由肾内血管收缩机制而非容量减少所致的假说,为管理心力衰竭中的利尿剂抵抗与肾功能恶化提示了新途径。
Female infertility occurs in ∼37% of infertile couples, while premature ovarian insufficiency (POI) impacts 1-3.7% of women under the age of 40. POI is clinically heterogeneous, with various genetic pathways associated with its pathogenesis. Mitochondrial diseases (MDs) are a broad group of clinically heterogeneous genetic conditions characterized by aberrantly functioning mitochondria. MDs have a disproportionate burden on organs and tissues with increased aerobic/energy demands, such as the heart, skeletal muscles, brain, and ovaries. The role of mitochondria in female fertility and ovarian reserve is increasingly being recognized. A comprehensive understanding of the role of mitochondria in the maintenance of female fertility is pertinent to better understanding female reproductive potential. In a world with increasing demand for assisted reproductive technologies (ART), due to a considerable rate of global infertility, there is a need to better understand the genes and pathways involved in female reproduction. This review summarizes, evaluates, and explores the current knowledge of mitochondria-associated genes and variants that are implicated in POI, including their function and dysfunction in female reproduction. We searched articles in the PubMed database, containing the following key words: premature ovarian insufficiency, mitochondria, mitochondrial, premature ovarian failure, genetics, mitochondrial DNA, mtDNA, mitochondrial protein, infertility, premature menopause, mitochondrial donation, assisted reproductive technologies, electron transport chain, oxidative phosphorylation (OXPHOS), mitochondrial disease, oocyte, oogenesis, meiosis, in vitro fertilization, mitoribosome, Perrault syndrome, and ovarioleukodystrophy, in the English-language literature until March 2026. Genetic variants that affect mitochondrial genes/proteins can negatively impact ovarian function. Various mitochondrial pathways are associated with female infertility, reflecting the broad sensitivity of ovarian reserve to mitochondrial dysfunction. Mitochondrial dysfunction and infertility can present in isolation or as part of a syndrome. Infertility in women may be the first clinical sign of a MD. Conversely, POI may be an underappreciated symptom of MDs. This review draws attention to the fact that females with MDs should be monitored for POI so it can be detected early for prompt and appropriate therapeutic interventions, such as hormone replacement therapy. This is known to mitigate the risk of comorbidities such as cardiovascular and bone disease and will optimize long-term health outcomes. Of equal importance, our review highlights the potential for girls and women presenting with apparently 'isolated' POI to harbour pathogenic variants in MD-associated genes, therefore putting these individuals at risk of developing further clinical manifestations of MDs. We emphasize the need for surveillance in these cases for hearing loss, vision disturbance, cardiomyopathy, muscle weakness and neurodegeneration, depending on the genetic cause. Given that mitochondrial function is essential to female fertility, future therapies for mitochondria-associated infertility could involve mitochondrial supplementation to improve the mitochondrial fraction or mitochondrial donation to optimize the likelihood of reproductive success. Finally, we also discuss the current landscape of biomarkers as potential early diagnostic tools for POI. Whilst currently rudimentary in their clinical utility, the further development of early screening methods will be invaluable for the detection, diagnosis, and early intervention of POI. N/A.
中文摘要:女性不孕约占不孕夫妇的37%,早发性卵巢功能不全(POI)影响1%至3.7%的40岁以下女性。POI在临床上具有异质性,多种遗传通路与其发病相关。线粒体病(MDs)是一组临床异质性遗传病,以线粒体功能异常为特征。MDs对有氧和能量需求较高的器官和组织造成不成比例的负担,如心脏、骨骼肌、脑和卵巢。线粒体在女性生育力和卵巢储备中的作用日益受到认识。全面理解线粒体在维持女性生育力中的作用,有助于更好理解女性生殖潜能。全球不孕率较高,辅助生殖技术(ART)需求不断增加,需要更好理解女性生殖相关的基因和通路。该综述总结、评价并探讨目前关于与POI相关的线粒体相关基因和变异的知识,包括其在女性生殖中的功能和功能障碍。检索PubMed数据库中截至2026年3月的英文文献,检索词包括早发性卵巢功能不全、线粒体、线粒体的、早发性卵巢衰竭、遗传学、线粒体DNA、mtDNA、线粒体蛋白、不孕、早绝经、线粒体捐赠、辅助生殖技术、电子传递链、氧化磷酸化(OXPHOS)、线粒体病、卵母细胞、卵子发生、减数分裂、体外受精、线粒体核糖体、Perrault综合征和卵巢脑白质营养不良等。影响线粒体基因或蛋白的遗传变异可对卵巢功能产生负面影响。多种线粒体通路与女性不孕相关,反映卵巢储备对线粒体功能障碍具有广泛敏感性。线粒体功能障碍和不孕可单独出现,也可作为综合征的一部分出现。女性不孕可能是MD的首个临床征象。反过来,POI可能是MDs一个未被充分认识的症状。该综述提请关注,患有MDs的女性应监测POI,以便早期发现并及时采取适当治疗干预,如激素替代治疗。已知这可降低心血管疾病和骨病等共病风险,并优化长期健康结局。同样重要的是,该综述强调,表现为看似「孤立性」POI的女孩和女性可能携带MD相关基因的致病变异,从而使这些个体面临出现MDs进一步临床表现的风险。我们强调这些病例需要根据遗传病因监测听力损失、视力障碍、心肌病、肌无力和神经退行性变。线粒体功能对女性生育力至关重要,未来针对线粒体相关不孕的治疗可能包括线粒体补充以改善线粒体组分,或线粒体捐赠以提高生殖成功的机会。目前生物标志物作为POI潜在早期诊断工具的状况也得到讨论。尽管其临床效用目前仍较初步,早期筛查方法的进一步发展将对POI的发现、诊断和早期干预具有重要价值。
Different pharmacological and non-pharmacological interventions have been suggested for the management of blood glucose, among which are sodium-glucose cotransporter-2 (SGLT-2) inhibitors and exercise. SGLT-2 inhibitors (-gliflozins) are a class of drugs that reduceglucose reabsorption from the proximal renal tubule, thereby decreasing its levels in the blood, while increasing its excretion in the urine. Several studies have demonstrated cardio-, neuro-, and renoprotective benefits of these drugs, including reduced cardiovascular deaths, hospitalizations due to heart failure, rate of progression of kidney disease, cognitive deficits, reactive oxygen species, and progression of amyloid beta (Aβ) formation. Several additional mechanisms of action have been proposed for the observed benefits of SGLT-2 inhibitors. Irisin is a myokine released by skeletal muscles in response to exercise that results in browning of adipose tissue, that has been shown to have similar benefits to SGLT-2 inhibitors. Recent studies have shown that SGLT-2 inhibitors upregulate fibronectin type III domain-containing protein 5 (FNDC5) expression, from which irisin is derived, presumably by activating upstream regulators, such as adenosine monophosphate-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α), thereby mimicking exercise-induced pathways, contributing to their protective benefits across various organ systems. We hypothesize that activation of the PGC-1α - FNDC5/irisin axis represents a previously unrecognized downstream mediator of the pleiotropic cardiorenal and neuroprotective effects of SGLT-2 inhibitors. While current evidence is largely preclinical and associative, this framework generates a testable mechanistic model in which circulating irisin could serve both as a mediator and biomarker of SGLT-2 inhibitor-induced tissue protection.
中文摘要:针对血糖管理已有多种药物与非药物干预措施,其中包括钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂和运动。SGLT-2抑制剂(-gliflozins)可减少近端肾小管对葡萄糖的重吸收,从而降低血糖水平并增加尿糖排泄。多项研究显示这类药物具有心脏、神经和肾脏保护获益,包括降低心血管死亡、因心力衰竭住院、肾病进展速度、认知缺陷、活性氧以及淀粉样β蛋白(Aβ)形成进展。针对SGLT-2抑制剂观察到的获益,已有若干其他作用机制被提出。鸢尾素是骨骼肌在运动刺激下释放的一种肌因子,可促进脂肪组织褐变,并已显示与SGLT-2抑制剂相似的获益。近期研究显示,SGLT-2抑制剂上调含Ⅲ型纤连蛋白结构域蛋白5(FNDC5)的表达,鸢尾素即由其衍生,推测这一过程通过激活上游调控因子如腺苷酸活化蛋白激酶(AMPK)和过氧化物酶体增殖物激活受体γ共激活因子1α(PGC-1α)实现,从而模拟运动诱导的通路,并参与其跨器官系统的保护获益。我们假设,PGC-1α-FNDC5/鸢尾素轴的激活是SGLT-2抑制剂多效性心肾和神经保护作用中一个此前未被认识的下游介质。当前证据主要来自临床前和相关性研究,这一框架提出了一个可检验的机制模型,其中循环鸢尾素既可作为SGLT-2抑制剂诱导组织保护的介质,也可作为其生物标志物。
Heart disease, including cardiac hypertrophy, ischemic heart disease, and heart failure, remains a global health challenge. Given the limitations of existing diagnostic and treatment methods, finding new biomarkers and therapies is essential. Non-coding RNAs (ncRNAs) are gaining prominence as key regulators in the medical field, playing a pivotal role in modulating the onset and progression of heart disease. Their significant potential as diagnostic biomarkers and therapeutic targets is increasingly recognized. This article comprehensively analyzes the basic characteristics of small nucleolar RNAs (snoRNAs), piwi-interacting RNAs (piRNAs), tRNA-derived small RNAs (tsRNAs), and circular RNAs (circRNAs), along with their recent research progress in cardiac hypertrophy, ischemic heart disease, and heart failure. By elucidating their functional mechanisms and clinical potential, this review provides foundational insights for translating ncRNA research into medical applications.
中文摘要:心脏病,包括心肌肥厚、缺血性心脏病和心力衰竭,仍是全球健康挑战。现有诊断和治疗手段存在局限,寻找新的生物标志物和治疗方式十分必要。非编码RNA(ncRNAs)在医学领域作为关键调控因子受到关注,在调节心脏病发生和进展中发挥核心作用。其作为诊断生物标志物和治疗靶点的显著潜力正得到越来越多认可。该综述全面分析小核仁RNA(snoRNAs)、piwi相互作用RNA(piRNAs)、tRNA来源小RNA(tsRNAs)和环状RNA(circRNAs)的基本特征,以及它们近期在心肌肥厚、缺血性心脏病和心力衰竭中的研究进展。通过阐明其功能机制和临床潜力,为将ncRNA研究转化为医学应用提供基础认识。
Cardiomyocyte senescence is a hallmark of cardiac aging and closely associated with diastolic dysfunction and heart failure in older adults. Strategies to effectively delay or reverse cardiomyocyte senescence in the aged heart remain limited. We investigated whether NAD+ replenishment regulates cardiomyocyte senescence and cardiac function in aging. Ventricular NAD+ metabolism, senescence markers, and cardiac function were assessed in young and aged mice of both sexes. Aged male mice exhibited reduced cardiac NAD+ levels due to impaired biosynthesis, limited mitochondrial mobilization, and increased consumption, leading to suppressed SIRT1 and SIRT6 activity and accumulation of senescent cardiomyocytes. These changes were accompanied by diastolic dysfunction, myocardial hypertrophy, and fibrosis. In cultured cardiomyocytes, NAD+ depletion induced cellular senescence, which was reversed by supplementation with the NAD+ precursors nicotinamide riboside (NR) and dihydronicotinamide riboside (NRH). In aged male mice, two months of NR or NRH treatment suppressed senescence markers, improved diastolic function, and reduced hypertrophy and fibrosis. Mechanistically, both NR and NRH activated SIRT1 and suppressed cell cycle arrest markers. NRH induced more robust SIRT1 activation, which deacetylated SIRT6, promoting its binding to histones and enhancing DNA damage repair. In contrast, aged female mice exhibited diastolic dysfunction without significant decline in cardiac NAD+ levels and did not respond to NR or NRH treatment. NAD+ is a critical regulator of cardiomyocyte senescence in aging male hearts. NAD+ replenishment, particularly with NRH, reverses senescence-associated cardiac dysfunction through coordinated activation of SIRT1 and SIRT6. The sex-specific differences observed highlight distinct mechanisms underlying cardiac aging and emphasize the importance of considering biological sex in the development of NAD+-based therapeutic strategies.
中文摘要:心肌细胞衰老是心脏衰老的标志性特征,与老年人的舒张功能障碍和心力衰竭密切相关。有效延缓或逆转衰老心脏中心肌细胞衰老的策略仍然有限。研究探讨了补充NAD+是否调控衰老过程中的心肌细胞衰老与心脏功能。在年轻和老年雌雄小鼠中评估了心室NAD+代谢、衰老标志物与心脏功能。老年雄性小鼠心脏NAD+水平降低,源于生物合成受损、线粒体动员受限和消耗增加,由此抑制SIRT1和SIRT6活性并造成衰老心肌细胞蓄积。这些变化伴随舒张功能障碍、心肌肥厚和纤维化。在培养的心肌细胞中,NAD+耗竭诱导细胞衰老,补充NAD+前体烟酰胺核糖(NR)和二氢烟酰胺核糖(NRH)可将其逆转。老年雄性小鼠接受NR或NRH治疗两个月后,衰老标志物受到抑制,舒张功能改善,肥厚和纤维化减轻。机制上,NR与NRH均激活SIRT1并抑制细胞周期停滞标志物。NRH引起的SIRT1激活更强,可使SIRT6去乙酰化,促进其与组蛋白结合并增强DNA损伤修复。相比之下,老年雌性小鼠存在舒张功能障碍,但心脏NAD+水平未见明显下降,对NR或NRH治疗无反应。NAD+是衰老雄性心脏中心肌细胞衰老的关键调控因子。补充NAD+,尤其是NRH,通过协同激活SIRT1与SIRT6逆转衰老相关的心脏功能障碍。所观察到的性别差异提示心脏衰老机制存在不同,也说明开发基于NAD+的治疗策略时需要考虑生物学性别。
4冠心病/PCI (12篇)
临床研究 (11篇)
Takotsubo syndrome (TTS) closely mimics acute coronary syndrome (ACS). Early differentiation remains challenging because diagnosis currently relies on medical, psychiatric, and neurological history, repeated cardiac imaging, and exclusion of a culprit epicardial coronary artery lesion, generally with invasive coronary angiography (ICA). The aim of this study was to develop and externally validate a biomarker-based diagnostic score supporting the early differentiation of TTS from ACS before ICA. In this study, 3615 patients with ACS or TTS from overlapping registries were investigated. Circulating levels of established and emerging cardiovascular biomarkers were measured before ICA. A biomarker-based diagnostic score for TTS (BioTAK) was developed in a cohort of 1823 patients (ACS n = 1754; TTS n = 69) using machine learning-guided feature selection and logistic regression and externally validated in an independent cohort of 1792 patients (ACS n = 1715; TTS n = 77). The final five-item score incorporated biomarkers reflecting myocardial stress (N-terminal pro-B-type natriuretic peptide), vasoconstriction and anxiety regulation (peptidylglycine α-amidating monooxygenase), atherosclerotic plaque instability (soluble lectin-like oxidized low-density lipoprotein receptor-1), and lipid metabolism (low-density lipoprotein cholesterol), along with sex. BioTAK demonstrated excellent discrimination between TTS and ACS in the development cohort [area under the receiver operating characteristic curve (AUC) .97, 95% confidence interval (CI) .95-.98] and maintained high performance on external validation (AUC .93, 95% CI .90-.96), with good calibration. Using predefined rule-in and rule-out thresholds, the score stratified almost 90% of patients to a likely diagnosis prior to ICA. TTS is characterized by a distinct biomarker profile reflecting pathophysiological differences from ACS. The non-subjective biomarker-based BioTAK score can support the early identification of TTS, help streamline diagnostic pathways, and might reduce potentially avoidable invasive procedures in patients presenting with suspected ACS. NCT01000701, NCT01947621.
中文摘要:Takotsubo综合征(TTS)在临床上与急性冠脉综合征(ACS)高度相似。早期鉴别仍很困难,因为目前的诊断依赖内科、精神科和神经系统病史,反复的心脏影像检查,以及在一般情况下通过有创冠状动脉造影(ICA)排除导致病变的心外膜冠状动脉狭窄。本研究旨在建立并外部验证一个基于生物标志物的诊断评分,用于在ICA之前早期区分TTS与ACS。研究纳入来自相互重叠登记库的3615例ACS或TTS患者,在ICA之前测定已知和新型心血管循环生物标志物水平。基于生物标志物的TTS诊断评分(BioTAK)在1823例患者(ACS 1754例,TTS 69例)的队列中,采用机器学习引导的特征筛选与logistic回归建立,并在1792例患者(ACS 1715例,TTS 77例)的独立队列中进行外部验证。最终的五项评分纳入反映心肌应激(N末端B型利钠肽原)、血管收缩与焦虑调节(肽酰甘氨酸α酰胺化单加氧酶)、动脉粥样硬化斑块不稳定(可溶性凝集素样氧化低密度脂蛋白受体-1)和脂质代谢(低密度脂蛋白胆固醇)的生物标志物,以及性别。BioTAK在建立队列中对TTS与ACS的区分能力优秀(受试者工作特征曲线下面积AUC 0.97,95%置信区间0.95–0.98),在外部验证中保持高性能(AUC 0.93,95%置信区间0.90–0.96),校准良好。按预设的纳入与排除阈值,该评分在ICA之前将近90%的患者归入可能的诊断。TTS具有独特的生物标志物谱,反映其与ACS不同的病理生理差异。这一非主观的、基于生物标志物的BioTAK评分可支持早期识别TTS,有助于简化诊断路径,并可能减少疑似ACS患者中原本可以避免的有创操作。NCT01000701,NCT01947621。
Delirium is a common yet underrecognized neuropsychiatric syndrome in cardiovascular medicine associated with prolonged hospitalization, increased mortality, and long-term cognitive decline. Patients undergoing interventional or surgical cardiovascular procedures-such as transcatheter aortic valve replacement, surgical aortic valve replacement, coronary artery bypass grafting, or percutaneous coronary interventions-may be particularly vulnerable to its development. Delirium incidence varies widely across cardiovascular procedures, influenced by patient characteristics, procedural invasiveness, and diagnostic methodology. Risk factors include advanced age, baseline cognitive impairment, cerebrovascular disease, extended operative times, perioperative complications, and systemic inflammation. Diagnostic tools such as the Confusion Assessment Method (CAM) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) score are established but underutilized in the diagnosis of delirium. While preventive strategies emphasizing non-pharmacological, multicomponent approaches-such as early mobilization, cognitive stimulation, and sleep hygiene-are supported by strong evidence, preventive use of pharmacologic agents remains controversial. Pharmacologic treatment is reserved for select cases; dexmedetomidine shows benefits in intensive care unit settings, while antipsychotics like quetiapine and risperidone may be used cautiously. Overall, delirium poses a significant clinical challenge in cardiovascular medicine and requires a proactive, interdisciplinary approach. Systematic risk assessment and multimodal preventive strategies should be the standard of care, while pharmacologic treatment should be symptom- and context-specific. Further high-quality studies are needed to inform evidence-based guidelines tailored to cardiovascular populations. The present state-of-the-art review summarizes the current literature on the epidemiology, mechanisms, clinical manifestations, diagnosis, prevention, and treatment of delirium in cardiovascular medicine. By integrating findings and interdisciplinary expert discussions from interventional cardiology, cardiac surgery, and psychiatry, it aims to define the unique vulnerability of this patient population, highlight critical knowledge gaps, and lay the foundation for developing targeted, evidence-based management strategies.
中文摘要:谵妄是心血管医学中常见却常被低估的神经精神综合征,与住院时间延长、死亡率升高及长期认知功能下降相关。接受心血管介入或外科手术的患者,例如经导管主动脉瓣置换、外科主动脉瓣置换、冠状动脉旁路移植或经皮冠状动脉介入治疗,可能尤其易发生谵妄。不同心血管操作中的谵妄发生率差异很大,受患者特征、操作创伤程度和诊断方法影响。危险因素包括高龄、基线认知障碍、脑血管病、手术时间延长、围术期并发症和全身炎症。意识模糊评估法(CAM)和重症监护室意识模糊评估法(CAM-ICU)评分等诊断工具已经确立,但在谵妄诊断中应用不足。强调非药物、多组分策略的预防措施,如早期活动、认知刺激和睡眠卫生,已有较强证据支持,而药物预防仍存在争议。药物治疗仅用于特定病例;右美托咪定在重症监护环境中显示获益,喹硫平和利培酮等抗精神病药可谨慎使用。总体而言,谵妄是心血管医学中的重大临床挑战,需要主动、跨学科的处理方式。系统风险评估和多模式预防策略应成为标准诊疗,药物治疗应针对症状和具体情境。仍需高质量研究为针对心血管人群的循证指南提供依据。本现状综述总结心血管医学中谵妄的流行病学、机制、临床表现、诊断、预防和治疗的最新文献。通过整合介入心脏病学、心脏外科和精神科的研究发现及跨学科专家讨论,旨在界定该患者人群的独特易感性,突出关键知识空白,并为制定有针对性的循证管理策略奠定基础。
The best management approach for renin-angiotensin system (RAS) inhibitor use before surgery is controversial. Some studies have suggested that continuation could increase the risk of clinically significant peri-operative hypotension and, thus, organ injury. By contrast, others believe that withholding them significantly increases the risk of severe hypertension and heart failure. To determine the most effective strategy, this systematic review and meta-analysis of randomized controlled trials compared discontinuation vs continuation of RAS inhibitors in patients undergoing non-cardiac and non-vascular surgeries. PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched for randomized controlled trials that compared discontinuation vs continuation of RAS inhibitors in patients undergoing non-cardiac and non-vascular surgery. Five randomized controlled trials (n = 10 773 patients; 5388 randomized to discontinuation) were included. Discontinuation of an RAS inhibitor probaby reduced peri-operative hypotension (27.66% vs 34.06%; risk ratio [RR] 0.81, 95% confidence interval [CI] 0.73-0.89; moderate certainty). The evidence is very uncertain about effects on peri-operative hypertension (9.46% vs 8.05%; RR 1.38, 95% CI 0.66-2.89; very low certainty). For major clinical outcomes, discontinuation suggested little to no difference in acute kidney injury (10.45% vs 10.69%; RR 0.98, 95% CI 0.66-1.45; low certainty), acute heart failure (5.38% vs 5.32%; RR 1.00, 95% CI 0.76-1.31; low certainty), myocardial infarction (1.22% vs 1.00%; RR 1.19, 95% CI 0.60-2.39; low certainty), stroke (0.42% vs 0.40%; RR 1.04, 95% CI 0.56-1.93; low certainty), and arrhythmias (1.80% vs 1.40%; RR 1.28, 95% CI 0.69-2.38; low certainty). These findings suggest that discontinuation of RAS inhibitors is likely to reduce peri-operative hypotension in patients undergoing non-cardiac, non-vascular surgery, but the evidence is very uncertain about effects on peri-operative hypertension and major clinical outcomes.
中文摘要:肾素-血管紧张素系统(RAS)抑制剂术前最佳管理策略仍有争议。部分研究提示继续用药可能增加有临床意义的围手术期低血压及由此导致的器官损伤风险。相反,另一些研究认为停药会显著增加严重高血压和心力衰竭风险。为确定更有效策略,这项系统综述与荟萃分析纳入随机对照试验,比较接受非心脏、非血管手术患者停用与继续使用RAS抑制剂。检索PubMed、Embase和Cochrane Central Register of Controlled Trials(CENTRAL)数据库,纳入比较非心脏、非血管手术患者停用与继续使用RAS抑制剂的随机对照试验。共纳入5项随机对照试验(n=10 773例患者;5388例随机分配至停药组)。停用RAS抑制剂可能降低围手术期低血压(27.66% vs 34.06%;风险比[RR] 0.81,95%置信区间[CI] 0.73-0.89;中等确定性)。有关围手术期高血压影响的证据很不确定(9.46% vs 8.05%;RR 1.38,95% CI 0.66-2.89;极低确定性)。主要临床结局方面,停药提示急性肾损伤(10.45% vs 10.69%;RR 0.98,95% CI 0.66-1.45;低确定性)、急性心力衰竭(5.38% vs 5.32%;RR 1.00,95% CI 0.76-1.31;低确定性)、心肌梗死(1.22% vs 1.00%;RR 1.19,95% CI 0.60-2.39;低确定性)、卒中(0.42% vs 0.40%;RR 1.04,95% CI 0.56-1.93;低确定性)和心律失常(1.80% vs 1.40%;RR 1.28,95% CI 0.69-2.38;低确定性)差异很小或没有差异。这些发现提示,在非心脏、非血管手术患者中停用RAS抑制剂可能降低围手术期低血压,但有关围手术期高血压和主要临床结局影响的证据很不确定。
The prognostic significance of longitudinal changes in the cardio-ankle vascular index (CAVI) remains unclear. We investigated the association between 1-year changes in CAVI and subsequent cardiovascular events according to age. A total of 4032 participants with cardiovascular risk factors who were enrolled in the prospective multicenter Coupling Registry and had undergone CAVI measurements at baseline and 1 year were classified into four groups using a CAVI cutoff of 9: good ( < 9 at both time points, n = 1841), improved ( ≥ 9 to <9, n = 268), worsened ( < 9 to ≥9, n = 408), and persistently high ( ≥ 9 at both time points, n = 1515). The primary outcome was a composite of stroke, coronary artery disease, sudden cardiac death, heart failure, and aortic dissection. Multivariable Cox proportional hazards models assessed associations between CAVI changes and outcomes. CAVI increased from 8.80 ± 1.34 at baseline to 8.88 ± 1.35 at 1 year (P < 0.001). During a median 60-month follow-up (49-63 months), 155 cardiovascular events occurred. In the overall cohort, neither the worsened group (HR, 1.56; 95% CI, 0.93-2.62) nor the persistently high group (HR, 1.10; 95% CI, 0.72-1.68) was significantly associated with cardiovascular events compared with the good group. Among participants aged <65 years, the worsened group (HR, 3.36; 95% CI, 1.18-9.58) and persistently high group (HR, 2.68; 95% CI, 1.11-6.50) had higher cardiovascular risk. No significant associations were observed among participants aged ≥65 years. In conclusion, among patients aged <65 years with cardiovascular risk factors, both worsening and persistently elevated CAVI were independently associated with increased cardiovascular risk.
中文摘要:心血管-踝血管指数(CAVI)纵向变化的预后意义仍不明确。我们按年龄探讨CAVI 1年变化与随后心血管事件的关联。共4032名具有心血管危险因素、纳入前瞻性多中心Coupling Registry且在基线和1年时接受CAVI测量的参与者,以CAVI切点9分为四组:良好(两个时间点均<9,n=1841)、改善(≥9至<9,n=268)、恶化(<9至≥9,n=408)和持续偏高(两个时间点均≥9,n=1515)。主要结局为卒中、冠状动脉疾病、心源性猝死、心力衰竭和主动脉夹层的复合终点。多变量Cox比例风险模型评估CAVI变化与结局的关联。CAVI从基线8.80±1.34升至1年时8.88±1.35(P<0.001)。中位随访60个月(49-63个月)期间发生155例心血管事件。总体队列中,与良好组相比,恶化组(HR 1.56;95% CI 0.93-2.62)和持续偏高组(HR 1.10;95% CI 0.72-1.68)均未与心血管事件显著相关。在<65岁参与者中,恶化组(HR 3.36;95% CI 1.18-9.58)和持续偏高组(HR 2.68;95% CI 1.11-6.50)心血管风险更高。≥65岁参与者中未观察到显著关联。在<65岁具有心血管危险因素的患者中,CAVI恶化与持续升高均与心血管风险增加独立相关。
Non-healing diabetic foot ulcers are a major precursor to lower-extremity amputation (LEA) in diabetes, and gout may be an overlooked contributor. We hypothesised that individuals with both diabetes and gout have a higher risk of LEA than those with diabetes alone, with the strongest effect at more distal amputation levels. In a nationwide case-control study of 601,541 individuals with type 2 diabetes, we identified 4912 cases with LEA and 39,101 age- and sex-matched control participants. Gout exposure was determined using ICD-10 diagnoses and Anatomical Therapeutic Chemical codes for urate-lowering therapy. Associations were estimated using conditional logistic regression, adjusting for diabetes duration, peripheral arterial disease, acute myocardial infarction and late diabetes complications. Gout was associated with an increased risk of LEA (OR 1.85, 95% CI 1.69, 2.02) in unadjusted analyses, and the association remained significant after full adjustment (OR 1.53, 95% CI 1.37, 1.69). A significant trend (p=0.03) was observed across amputation levels, with potentially higher risk at more anatomically distal sites although no statistically significant differences were observed between individual amputation levels: OR 1.37 (95% CI 1.12, 1.68) for above-knee amputations, increasing to OR 1.65 (95% CI 1.32, 2.05) for toe amputations. Co-existing gout is an independent risk factor for LEA in individuals with type 2 diabetes. The risk is elevated across all amputation levels, with the most pronounced effect potentially being at distal anatomical sites. These findings highlight the need for increased awareness of gout when managing individuals with type 2 diabetes at risk of LEA.
中文摘要:不愈合的糖尿病足溃疡是糖尿病患者下肢截肢(LEA)的主要前驱因素,而痛风可能是被忽视的促发因素。我们假设同时患糖尿病和痛风者比单纯糖尿病者LEA风险更高,且效应在更远端截肢水平最强。在一项纳入601,541例2型糖尿病患者的全国性病例对照研究中,我们识别出4912例LEA病例和39,101名年龄、性别匹配的对照。痛风暴露依据ICD-10诊断和降尿酸治疗的ATC编码确定。采用条件logistic回归估计关联,并校正糖尿病病程、外周动脉疾病、急性心肌梗死和晚期糖尿病并发症。未校正分析中痛风与LEA风险升高相关(OR 1.85,95% CI 1.69, 2.02),充分校正后关联仍显著(OR 1.53,95% CI 1.37, 1.69)。截肢水平间观察到显著趋势(p=0.03),更远端部位风险可能更高,但各截肢水平间未见统计学显著差异:膝上截肢OR 1.37(95% CI 1.12, 1.68),趾截肢升至OR 1.65(95% CI 1.32, 2.05)。合并痛风是2型糖尿病个体LEA的独立危险因素。风险在所有截肢水平均升高,远端解剖部位效应可能最明显。这些发现提示管理有LEA风险的2型糖尿病患者时需提高对痛风的关注。
Alström syndrome (AS) is a rare multisystemic disorder frequently associated with respiratory complications, which are a major cause of premature death. While fibrosis in multiple organs has been historically suggested as a hallmark of AS, including the lungs, definitive evidence in adult patients remains limited. We conducted a retrospective study of adult patients diagnosed as AS seen in our National Multidisciplianry AS clinic from 2010 to 2024. Lung function test and high-resolution computed tomography (HRCT) of the thorax was performed in a subset of patients. Postmortem lung tissue analysis was available from four patients. A total of 25/41 (61%) of the patients were unable to complete full lung function testing. Among those who did, 67% exhibited reduced lung volumes, with 47% showing decreased diffusing capacity of the lung for carbon monoxide but normal or elevated transfer coefficient for carbon monoxide, indicating extrapulmonary restrictive physiology. HRCT scans in 39 patients showed no evidence of diffuse interstitial lung fibrosis; however, breathing artefacts were common. Historical infantile cardiomyopathy was identified as a risk factor for adult pulmonary dysfunction. Post-mortem pathology reports were obtained from four patients and no diffuse fibrosis in the lung tissue was identified in any of the patients. Pulmonary hypertension and Acute Respiratory Distress Syndrome were identified as potential causes of respiratory morbidity and mortality, despite the absence of intrinsic interstitial lung disease. This is the first large cohort study to depict the lung in adult patients with AS. This study provides no evidence for diffuse interstitial lung fibrosis in adult patients with AS, challenging prior assumptions. Pulmonary dysfunction appears mainly due to extrapulmonary restrictive physiology, with infantile cardiomyopathy as a possible risk factor. Pulmonary hypertension and acute respiratory distress syndrome, rather than intrinsic lung disease, likely underlie respiratory morbidity and mortality, highlighting the need for focused cardiopulmonary care. Although this study represents one of the largest single-centre cohorts of patients with AS reported to date, the overall sample size remains limited due to the ultra-rare nature of the disease and findings should be interpreted with caution. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
中文摘要:Alström综合征(AS)是一种罕见的累及多系统的疾病,常合并呼吸系统并发症,而呼吸系统并发症是其早死的主要原因之一。既往一直认为多器官纤维化是AS的标志性表现,肺也包括在内,但成年患者中的确凿证据仍然有限。我们对2010年至2024年在本中心全国性多学科AS门诊确诊的成年患者进行了回顾性研究,其中部分患者完成了肺功能检查与胸部高分辨率计算机断层扫描(HRCT),另有4例患者具备尸检肺组织分析资料。41例患者中有25例(61%)无法完成全套肺功能检查;在完成者中,67%存在肺容积下降,47%的一氧化碳弥散量降低但一氧化碳转移系数正常或升高,提示肺外限制性生理。39例患者的HRCT未见弥漫性间质性肺纤维化证据,但呼吸伪影较为常见。既往婴儿期心肌病被识别为成年期肺功能障碍的危险因素。4例患者的尸检病理报告均未发现肺组织弥漫性纤维化。尽管不存在固有的间质性肺疾病,肺动脉高压与急性呼吸窘迫综合征仍是呼吸系统致病与致死的原因。这是首个描绘成年AS患者肺部情况的大型队列研究,未发现成年AS患者存在弥漫性间质性肺纤维化的证据,与既往假设不同。肺功能障碍主要源于肺外限制性生理,婴儿期心肌病可能是危险因素。呼吸系统致病与致死更可能来自肺动脉高压与急性呼吸窘迫综合征,并非肺部本身疾病,提示需要针对心肺的重点照护。本研究是迄今报道的规模最大的AS单中心队列之一,但受疾病超罕见性所限,总体样本量仍然有限,结果解读需谨慎。本研究未获得公共、商业或非营利部门任何资助机构的专项资助。
One in four surgical patients carries a drug allergy label, of which an estimated 90% are incorrect. Avoidance of first-choice drug therapies can lead to worse postoperative outcomes. We sought to determine the nature and extent of any association between drug allergy labels and postoperative complications. A multicentre observational study was performed in 21 UK National Health Service hospitals. Eligible patients were ≥18 yr of age and undergoing common surgical procedures: primary hip or knee replacement, internal fixation of closed long bone fracture, colorectal resection, transurethral resection of prostate or bladder tumour, Caesarean delivery, or hysterectomy. Exclusion criteria were the use of antibiotics in the two weeks before surgery or previous participation in the study. The primary outcome was postoperative complications within 30 days after surgery, a composite outcome comprising all postoperative infections, anastomotic leak, acute respiratory distress syndrome, myocardial infarction, postoperative bleeding, pulmonary embolism, stroke, antimicrobial side-effects, and death. Among 13 646 patients, 3924 (29%) carried ≥1 drug allergy label. Labelled patients were more likely to develop postoperative complications (989/3924 [25%] vs 1926/9722 [20%]; odds ratio [OR] 1.21 [1.10-1.34]; P<0.001). They were more likely to develop surgical site infections (337/3924 [9%] vs 760/9722 [8%]; OR 1.19 [1.03-1.38]; P<0.018), and any postoperative infection (750/3924 [19%] vs 1472/9722 [15%]; OR 1.24 [1.11-1.38]; P<0.001). Labelled patients experienced an increased risk of allergic drug reactions (31/3924 [0.01%] vs 29/9722 [<0.01%]; OR 3.00 [1.77-5.09]; P<0.001), but no increase in mortality. Drug allergy labels are common, but often incorrect. Patients with drug allergy labels experience worse postoperative outcomes, including infective and noninfective complications and an increased risk of allergic drug reactions. ISRCTN Registry (ISRCTN15775657).
中文摘要:四分之一的外科患者带有药物过敏标签,其中估计90%不正确。回避首选药物治疗可能导致术后结局更差。研究旨在确定药物过敏标签与术后并发症之间关联的性质和程度。在英国21家国民健康服务体系医院开展多中心观察性研究。纳入标准为年龄≥18岁并接受常见外科手术:初次髋或膝关节置换、闭合性长骨骨折内固定、结直肠切除、经尿道前列腺或膀胱肿瘤切除、剖宫产或子宫切除术。排除标准为术前两周内使用抗生素或既往参加本研究。主要结局为术后30天内并发症,为复合结局,包括所有术后感染、吻合口漏、急性呼吸窘迫综合征、心肌梗死、术后出血、肺栓塞、卒中、抗菌药物不良反应和死亡。13646例患者中,3924例(29%)带有至少1个药物过敏标签。带标签患者更易发生术后并发症(989/3924[25%] vs 1926/9722[20%];比值比[OR]1.21[1.10-1.34];P<0.001)。他们更易发生手术部位感染(337/3924[9%] vs 760/9722[8%];OR 1.19[1.03-1.38];P<0.018),以及任何术后感染(750/3924[19%] vs 1472/9722[15%];OR 1.24[1.11-1.38];P<0.001)。带标签患者发生过敏性药物反应风险增加(31/3924[0.01%] vs 29/9722[<0.01%];OR 3.00[1.77-5.09];P<0.001),但死亡率未增加。药物过敏标签常见但常不正确。带药物过敏标签患者术后结局更差,包括感染性和非感染性并发症以及过敏性药物反应风险增加。ISRCTN注册库(ISRCTN15775657)。
Vasomotor symptoms in perimenopause are associated with increased future cardiovascular (CVD) risk. Most clinical trials on menopausal hormone therapy (MHT) and CVD risk have focused on postmenopausal women, with limited study of the perimenopausal period when hormonal fluctuations and symptoms are greatest. Moreover, these trials were not designed to evaluate CVD risk with MHT among women with vasomotor symptoms. To estimate the effect of MHT on CVD risk among perimenopausal and recently postmenopausal women with vasomotor symptoms and assess the extent to which timing of MHT use relative to menopause and race and ethnicity modify this effect. Cohort data from the Study of Women's Health Across the Nation (SWAN, 1997-2017)-a multiethnic, multicenter, longitudinal study of the menopause transition-were used to emulate a sequence of target trials. Eligible participants were women who self-reported any vasomotor symptoms (ie, hot flashes and/or night sweats over the past 2 weeks) and who were CVD-free, with no prior MHT use. Data were analyzed from January 2023 to December 2025. MHT use (systemic estrogen with/without progestogens, verified from medication containers). CVD events (myocardial infarction, stroke, heart failure, and revascularization) were self-reported. CVD-related death was recorded from death certificates. Of 2737 women who reported any vasomotor symptoms, 755 initiated MHT (mean [SD] age, 53.7 [4.6] years) over the 20-year follow-up period, during which 224 fatal and nonfatal CVD events occurred. Overall, the estimated adjusted hazard ratio (aHR) of CVD events for MHT initiation vs noninitiation was 0.78 (95% CI, 0.62-0.98). The estimated aHR was 0.73 (95% CI, 0.58-0.93) and 1.53 (95% CI, 0.66-3.52) among women initiating MHT 10 or fewer years vs more than 10 years from the onset of menopause, respectively (P value for interaction: .02). Race and ethnicity modified the MHT initiation effect, with Black women showing protective effect (aHR, 0.51; 95% CI, 0.33-0.81), while no clear effects were observed in White women or women of other races (P value for interaction = .007). The presented results are pooled from all target trials and found that MHT initiation during perimenopause or recently postmenopausal women with vasomotor symptoms was estimated to reduce CVD risk by 22%. Benefits were more pronounced in Black women and women who initiated MHT within 10 years of menopause onset. However, all estimates warrant caution given the potential for residual confounding. Given the inconsistency of the cardiovascular benefits and the need to consider overall risk-benefit balance, these findings should not be used to support MHT for CVD prevention.
中文摘要:围绝经期血管舒缩症状与未来心血管(CVD)风险升高相关。关于绝经激素治疗(MHT)与CVD风险的临床试验多集中于绝经后女性,对激素波动和症状最明显的围绝经期研究有限。这些试验也未设计用于评估有血管舒缩症状女性接受MHT的CVD风险。本研究旨在估计有血管舒缩症状的围绝经期和近期绝经后女性中MHT对CVD风险的影响,并评估MHT使用相对于绝经的时间以及种族和民族对该效应的修饰程度。研究使用全国女性健康研究(SWAN,1997-2017)的队列数据,该研究是多民族、多中心、纵向的绝经过渡研究,用以模拟一系列目标试验。合格参与者为自我报告过去2周内出现任何血管舒缩症状(即潮热和/或盗汗)、无CVD且既往未使用MHT的女性。数据分析时间为2023年1月至2025年12月。MHT使用(全身雌激素联合或不联合孕激素,经药盒核实)。CVD事件(心肌梗死、卒中、心力衰竭和血运重建)为自我报告。CVD相关死亡从死亡证明记录。在2737名报告任何血管舒缩症状的女性中,755人在20年随访期间开始MHT(平均[SD]年龄53.7[4.6]岁),期间发生224例致死和非致死性CVD事件。总体而言,MHT启动与非启动相比,CVD事件的估计校正风险比(aHR)为0.78(95% CI,0.62-0.98)。在绝经开始后10年及以内与超过10年开始MHT的女性中,估计aHR分别为0.73(95% CI,0.58-0.93)和1.53(95% CI,0.66-3.52)(交互作用P值:.02)。种族和民族修饰MHT启动效应,黑人女性显示保护效应(aHR,0.51;95% CI,0.33-0.81),白人女性或其他种族女性未观察到明确效应(交互作用P值=.007)。所呈现结果汇总自所有目标试验,发现有血管舒缩症状的围绝经期或近期绝经后女性启动MHT估计可使CVD风险降低22%。黑人女性和绝经开始后10年内启动MHT的女性获益更明显。然而,鉴于潜在残余混杂,所有估计均需谨慎解读。鉴于心血管获益不一致以及需要考虑总体风险-获益平衡,这些发现不应被用于支持MHT预防CVD。
Individuals with chronic kidney disease are at increased risk for herpes zoster, cardiovascular events, kidney failure, and premature mortality. Although the recombinant zoster vaccine effectively prevents herpes zoster, its broader systemic effects in this population remain unclear. We conducted a retrospective cohort study of adults aged 50 years or older with incident chronic kidney disease using the U.S.-based TriNetX network from 2017 to 2024. A total of 13,218 vaccine recipients were propensity score-matched to 13,218 unvaccinated controls. The primary outcome was a kidney event, defined as progression to end-stage kidney disease or initiation of dialysis. Secondary outcomes included cardiovascular events and all-cause mortality. Cox proportional hazards models were used to estimate hazard ratios, with additional analyses of restricted mean survival time over five years and incidence rate differences. After a median follow-up of 3.0 years (IQR, 1.5-4.9), recombinant zoster vaccination was associated with significantly lower risks of kidney events (hazard ratio, 0.63; 95% CI, 0.57-0.70), cardiovascular events (hazard ratio, 0.74; 95% CI, 0.68-0.80), and all-cause mortality (hazard ratio, 0.51; 95% CI, 0.48-0.54). Greater risk reductions were observed among individuals who completed the two-dose series. These findings suggest that recombinant zoster vaccination in patients with chronic kidney disease is associated with substantial and sustained reductions in kidney disease progression, cardiovascular events, and mortality, supporting a potential role for vaccination in long-term cardiorenal protection.
中文摘要:慢性肾脏病患者发生带状疱疹、心血管事件、肾衰竭和过早死亡的风险升高。重组带状疱疹疫苗能有效预防带状疱疹,但其在该人群中的系统性作用仍不清楚。本研究基于美国 TriNetX 网络 2017 至 2024 年数据,对 50 岁及以上新发慢性肾脏病成人开展回顾性队列研究,将 13218 名接种者与 13218 名未接种对照进行倾向评分匹配。主要结局为肾脏事件,定义为进展至终末期肾病或开始透析;次要结局包括心血管事件和全因死亡。采用 Cox 比例风险模型估计风险比,并补充分析五年限制性平均生存时间及发病率差。中位随访 3.0 年(IQR 1.5–4.9)后,接种重组带状疱疹疫苗与肾脏事件(风险比 0.63;95% CI 0.57–0.70)、心血管事件(风险比 0.74;95% CI 0.68–0.80)及全因死亡(风险比 0.51;95% CI 0.48–0.54)风险显著降低相关。完成两剂次接种者风险下降幅度更大。这些结果提示,慢性肾脏病患者接种重组带状疱疹疫苗与肾病进展、心血管事件和死亡的大幅且持续下降相关,支持疫苗在长期心肾保护中的潜在作用。
Bipolar disorder, major depressive disorder, and schizophrenia are associated with substantial excess mortality, principally from cardiovascular disease. Identifying strategies to reduce this burden is a critical psychiatric priority. To evaluate associations between initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) vs sodium-glucose cotransporter-2 (SGLT2) inhibitors and all-cause mortality and major adverse cardiovascular events (MACEs) among adults with and without serious mental illness (SMI). This was a retrospective target trial emulation within the TriNetX Analytics Network, a multinational federated electronic health record network. Adults initiating GLP-1 RAs or SGLT2 inhibitors were included using a new-user, active-comparator design with propensity score matching and separate psychiatric and nonpsychiatric cohorts. The study included all available data in the TriNetX network through the most recent database refresh. Data were queried and analyzed in March 2026, with prespecified follow-up intervals of 1, 4, and 10 years. Additional subgroup analyses were conducted following peer review in May 2026. First-recorded GLP-1 RA vs SGLT2 inhibitor prescription. The primary outcome was 4-year all-cause mortality; the key secondary outcome, 1-year mortality. Additional outcomes included 3- and 5-point MACEs and individual cardiovascular end points. Sensitivity analyses included diabetes stratification, exclusion of baseline heart failure and chronic kidney disease, and censoring at crossover. Exploratory analyses examined SMI subgroups, agent-specific effects, and combination therapy. For the primary 4-year analysis, 1 528 230 adults were propensity score matched (764 115 pairs; 195 184 pairs with serious mental illness [SMI] and 568 931 pairs without SMI). The mean [SD] age in the GLP-1RA and SGLT2 inhibitor groups was 60.5 [12.0] and 60.2 [13.3] years, respectively, in the SMI cohort and 60.9 [12.2] and 60.6 [13.0] years, respectively, in the non-SMI cohort; 112 911 [57.8%], 113 488 [58.1%], 251 679 [44.2%], and 260 480 [45.8%] were female, respectively. Among participants with SMI, mortality was lower with GLP-1RA initiation than with SGLT2 inhibitor initiation (9585 of 195 184 [4.91%] vs 12 584 of 195 184 [6.45%]; hazard ratio [HR], 0.76; 95% CI, 0.74-0.78; absolute risk difference [ARD], -1.54 percentage points; 95% CI, -1.68 to -1.39; P < .001). Among participants with SMI and type 2 diabetes, semaglutide initiation, compared with SGLT2 inhibitor initiation, was associated with lower risks of 3-point MACE (HR, 0.77; 95% CI, 0.76-0.79), 5-point MACE, myocardial infarction, stroke, heart failure, and coronary artery bypass grafting. In a separately matched 1-year SMI cohort, mortality was lower with GLP-1RA initiation than with SGLT2 inhibitor initiation (2898 of 198 065; 1.46% vs 5624 of 198 065; 2.84%; RR, 0.52; 95% CI, 0.49-0.54; ARD, -1.38 percentage points; 95% CI, -1.47 to -1.29; P < .001). In 10-year exploratory analyses among participants with type 2 diabetes, semaglutide initiation, compared with SGLT2 inhibitor initiation, was associated with lower mortality in the major depressive disorder (RR, 0.55; 95% CI, 0.53-0.56), bipolar disorder (RR, 0.57; 95% CI, 0.51-0.63), and schizophrenia (RR, 0.67; 95% CI, 0.59-0.75) groups (all P < .001). The primary mortality association persisted across prespecified sensitivity analyses. In this study, GLP-1 RA initiation was associated with lower mortality and cardiovascular events compared to SGLT2 inhibitor initiation, with greater absolute reductions in SMI. Benefits were evident within 1 year, consistent across SMI subgroups, and driven by semaglutide and tirzepatide. Prospective randomized trials are warranted.
中文摘要:双相障碍、重性抑郁障碍和精神分裂症与显著的超额死亡相关,主要来自心血管疾病。识别减轻这一负担的策略是精神病学的重要优先事项。评估在有或无严重精神疾病(SMI)的成人中,启动胰高血糖素样肽-1受体激动剂(GLP-1 RA)与钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂相比,与全因死亡和主要不良心血管事件(MACE)之间的关联。本研究为TriNetX Analytics Network内的回顾性目标试验模拟,该网络为跨国联邦电子健康记录网络。采用新使用者、活性对照设计,并进行倾向评分匹配,分别纳入精神疾病和非精神疾病队列,纳入启动GLP-1 RA或SGLT2抑制剂的成人。研究纳入TriNetX网络中截至最近一次数据库刷新时的全部可用数据。数据于2026年3月查询和分析,预设随访间隔为1年、4年和10年。同行评审后于2026年5月进行额外亚组分析。暴露为首次记录的GLP-1 RA与SGLT2抑制剂处方。主要结局为4年全因死亡;关键次要结局为1年死亡。其他结局包括3项和5项MACE及个体心血管终点。敏感性分析包括糖尿病分层、排除基线心力衰竭和慢性肾病、交叉换药时删失。探索性分析考察SMI亚组、药物特异性效应和联合治疗。主要4年分析中,1 528 230名成人经倾向评分匹配(764 115对;195 184对有SMI,568 931对无SMI)。GLP-1RA组和SGLT2抑制剂组在SMI队列中的平均[SD]年龄分别为60.5[12.0]岁和60.2[13.3]岁,在非SMI队列中分别为60.9[12.2]岁和60.6[13.0]岁;女性分别为112 911[57.8%]、113 488[58.1%]、251 679[44.2%]和260 480[45.8%]。在SMI参与者中,启动GLP-1RA者的死亡低于启动SGLT2抑制剂者(195 184例中9585例[4.91%]对195 184例中12 584例[6.45%];风险比[HR]0.76;95%CI 0.74-0.78;绝对风险差[ARD]-1.54个百分点;95%CI -1.68至-1.39;P<.001)。在合并2型糖尿病的SMI参与者中,与启动SGLT2抑制剂相比,启动司美格鲁肽与较低3项MACE(HR 0.77;95%CI 0.76-0.79)、5项MACE、心肌梗死、卒中、心力衰竭和冠状动脉旁路移植术风险相关。在另一个匹配的1年SMI队列中,启动GLP-1RA者的死亡低于启动SGLT2抑制剂者(198 065例中2898例,1.46%对198 065例中5624例,2.84%;RR 0.52;95%CI 0.49-0.54;ARD -1.38个百分点;95%CI -1.47至-1.29;P<.001)。在合并2型糖尿病参与者的10年探索性分析中,与启动SGLT2抑制剂相比,启动司美格鲁肽与重性抑郁障碍(RR 0.55;95%CI 0.53-0.56)、双相障碍(RR 0.57;95%CI 0.51-0.63)和精神分裂症(RR 0.67;95%CI 0.59-0.75)组较低死亡相关(均P<.001)。主要死亡关联在预设敏感性分析中持续存在。本研究中,与启动SGLT2抑制剂相比,启动GLP-1 RA与较低死亡和心血管事件相关,在SMI中绝对降低更大。获益在1年内显现,在SMI亚组中一致,并由司美格鲁肽和替尔泊肽驱动。有必要开展前瞻性随机试验。
Twin studies reveal high genetic overlap between anxiety disorders and depression, contributing to the internalising spectrum. Some genetic specificity for fear-based anxiety disorders (fear), distinct from general anxiety and depression (distress), has also emerged. Limited datasets with detailed phenotyping across anxiety disorders have restricted most genome-wide association studies (GWAS) to "any anxiety diagnosis". Additional genome-wide evidence to discern genetic differences between fear and distress is required. We conducted GWAS meta-analyses of fear (panic, agoraphobia, specific phobia, social anxiety disorder) and generalised anxiety disorder (GAD), measured using brief single-item and detailed symptom-based diagnoses from three datasets. We explored two control group criteria: phenotype-specific (fear/GAD) or broader anxiety/depression screening. We identified one independent genome-wide significant locus and three gene-level associations with fear (up to 35,523 Ncases; 157,447 Ncontrols). Four genome-wide significant loci and three gene-level associations were identified for GAD (up to 60,879 Ncases; 117,064 Ncontrols). The genetic correlation between fear and GAD was significantly different from unity only when excluding a depression-enriched dataset and using phenotype-specific control screening (rg = 0.87; P = 9.32 × 10-3). Most complex traits had statistically similar genetic correlations with fear and GAD, including depression. Exceptions included general cognitive ability, educational attainment, and coronary artery disease, showing statistically stronger genetic correlations with fear than GAD, while bipolar disorder type I, anorexia nervosa, and neuroticism displayed the opposite pattern. Our findings partially support a distress-fear genetic distinction, but show stronger evidence for an overarching genetic liability to internalising psychopathology driving comorbidity across anxiety disorders and depression.
中文摘要:双生子研究表明焦虑障碍与抑郁之间存在高度遗传重叠,构成内化谱系的一部分。也出现了恐惧型焦虑障碍(恐惧)与广泛焦虑和抑郁(苦恼)不同的部分遗传特异性。由于缺乏在焦虑障碍中进行详细表型分型的数据集,多数全基因组关联研究(GWAS)局限于「任何焦虑诊断」。需要更多全基因组证据来辨别恐惧与苦恼之间的遗传差异。我们对恐惧(惊恐障碍、广场恐惧症、特定恐惧症、社交焦虑障碍)和广泛性焦虑障碍(GAD)开展了GWAS荟萃分析,测量来自三个数据集的简短单条目诊断和详细症状诊断。我们探索了两种对照组标准:表型特异性(恐惧/GAD)或更广泛的焦虑/抑郁筛查。我们识别出1个独立的恐惧全基因组显著位点和3个基因水平关联(最多35,523例病例;157,447例对照)。GAD识别出4个全基因组显著位点和3个基因水平关联(最多60,879例病例;117,064例对照)。恐惧与GAD的遗传相关性仅在排除一个抑郁富集数据集并采用表型特异性对照筛查时才显著异于1(rg=0.87;P=9.32×10-3)。多数复杂性状与恐惧和GAD的遗传相关性在统计上相似,包括抑郁。例外包括一般认知能力、教育程度和冠状动脉疾病,它们与恐惧的遗传相关性在统计上强于与GAD的相关性,而双相I型障碍、神经性厌食和神经质则呈相反模式。我们的发现部分支持苦恼-恐惧的遗传区分,但更有力地支持内化精神病理的总体遗传易感性驱动焦虑障碍与抑郁共病的证据。
基础研究 (1篇)
Reticulon-3 (RTN3) was initially studied as an endoplasmic reticulum (ER)-resident reticulon family protein involved in membrane shaping, apoptosis, and amyloid precursor protein processing. More recent work has considerably expanded this view and now places RTN3 at the intersection of ER remodeling, selective ER-phagy, cargo trafficking, lipid handling, and stress signaling. This shift is especially relevant to pharmacology, because RTN3 appears to exhibit heterogeneous effects across tissues and disease states: RTN3 upregulation is maladaptive in obesity, nonalcoholic fatty liver disease, cardiac lipotoxicity, post-myocardial infarction heart failure, and some vascular conditions, whereas RTN3 loss aggravates renal injury, renal fibrosis, and pulmonary fibrosis. Viral infection and hepatocellular carcinoma further illustrate that RTN3 can either support membrane remodeling programs or constrain disease progression, depending on the biological environment. In this review, we reorganize RTN3 biology around mechanism-driven processes and discuss how these processes converge on cardiometabolic, fibrotic, infectious, and oncologic phenotypes. Current evidence suggests that RTN3 is better regarded as a membrane organizing regulator with therapeutic potential rather than a disease specific marker. However, future efforts to target RTN3 will likely need to consider tissue type and pathway specificity.
中文摘要:Reticulon-3(RTN3)最初作为内质网驻留的reticulon家族蛋白被研究,参与膜塑形、细胞凋亡及淀粉样前体蛋白加工。较新的工作显著拓展了这一认识,将RTN3置于内质网重塑、选择性内质网自噬、货物运输、脂质处理与应激信号的交汇点。这一转变对药理学尤为重要,因为RTN3在不同组织和疾病状态下呈现异质性效应:RTN3上调在肥胖、非酒精性脂肪性肝病、心脏脂毒性、心肌梗死后心力衰竭及部分血管病变中呈适应不良,而RTN3缺失会加重肾损伤、肾纤维化和肺纤维化。病毒感染与肝细胞癌进一步说明,RTN3既可支持膜重塑程序,也可限制疾病进展,取决于生物学环境。本综述围绕机制驱动过程重新组织RTN3生物学,并讨论这些过程如何汇聚于心脏代谢、纤维化、感染和肿瘤表型。当前证据提示,将RTN3视为具有治疗潜力的膜组织调控因子比视为疾病特异性标志物更为合适。未来靶向RTN3的努力可能需要考虑组织类型与通路特异性。
5心肌梗死/ACS (12篇)
临床研究 (1篇)
Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for ST-segment elevation myocardial infarction (STEMI), rapidly restoring coronary blood flow, limiting infarct size, improving survival, and reducing recurrent ischemic events. Advances in interventional techniques and adjunctive therapies have enhanced its safety and efficacy over time, with high rates of successful epicardial reperfusion, however large intracoronary thrombus burden remains a major challenge during primary PCI. Extensive thrombus promotes distal embolization of platelet-fibrin aggregates and atherothrombotic debris, which mechanically occlude the downstream capillary bed during reperfusion triggering microvascular obstruction, inflammation, endothelial dysfunction, and the no-reflow phenomenon. Consequently, restoration of epicardial patency does not always translate into effective myocardial tissue perfusion or myocardial salvage, resulting in larger infarcts and worse clinical outcomes. Contemporary management strategies aim to reduce thrombus burden, preserve microvascular integrity, and improve myocardial salvage through adjunctive pharmacologic therapies, selective mechanical interventions, and optimized procedural techniques. Although routine use of aspiration thrombectomy and many adjunctive intracoronary therapies have not consistently improved clinical outcomes, selective use in carefully chosen patients remains an important component of contemporary practice. Emerging strategies are shifting the focus beyond restoration of epicardial flow toward preservation of the coronary microcirculation. Advances in intracoronary imaging, precision PCI, and therapies targeting inflammation, reperfusion injury, and microvascular dysfunction offer promising opportunities to individualize treatment and further improve outcomes in patients with STEMI and large thrombus burden.
中文摘要:直接经皮冠状动脉介入治疗(PCI)是ST段抬高型心肌梗死(STEMI)首选的再灌注策略,可迅速恢复冠状动脉血流、限制梗死面积、提高生存率并减少复发性缺血事件。随着介入技术与辅助治疗的发展,其安全性和有效性不断提高,心外膜再灌注成功率高,但较大的冠状动脉内血栓负荷仍是直接PCI期间的主要难题。大量血栓促使血小板-纤维蛋白聚集体和动脉粥样硬化血栓碎屑向远端栓塞,在再灌注时机械性阻塞下游毛细血管床,引发微血管阻塞、炎症、内皮功能障碍和无复流现象。因此,心外膜血管开通并不总能转化为有效的心肌组织灌注或心肌挽救,导致梗死面积更大、临床结局更差。当代管理策略通过辅助药物治疗、选择性机械干预和优化的操作技术,旨在减轻血栓负荷、保护微血管完整性并提高心肌挽救。尽管常规使用血栓抽吸和多种冠状动脉内辅助治疗并未一致改善临床结局,但在经过仔细选择的患者中选择性应用仍是当代实践的重要组成部分。新兴策略正把关注点从恢复心外膜血流转向保护冠状动脉微循环。冠状动脉内影像、精准PCI以及针对炎症、再灌注损伤和微血管功能障碍的治疗进展,为个体化治疗并进一步改善伴大血栓负荷STEMI患者的结局提供了有前景的机会。
基础研究 (11篇)
Cardiac patches implanted onto the heart surface are a prospective treatment for myocardial infarction. In this issue of Cell Stem Cell, Xie et al. provide evidence that patches matching myocardial electroconductivity not only reestablish cardiac conduction after injury but also induce endothelial differentiation of epicardial cells to promote heart repair.
中文摘要:植入心脏表面的心脏补片是心肌梗死的一种前瞻性治疗手段。在本期Cell Stem Cell中,Xie等提供证据表明,与心肌电导性相匹配的补片不仅能在损伤后重建心脏传导,还能诱导心外膜细胞的内皮分化以促进心脏修复。
While ferroptosis is demonstrated to be involved in myocardial ischemia/reperfusion (I/R) injury, the detailed mechanism is yet to be fully elucidated. Since the zinc transporter ZIP7 (Slc39a7) contributes to myocardial I/R injury by targeting mitochondria and inhibition of ZIP7 attenuates erastin-induced cell death, we hypothesized that upregulation of ZIP7 induces ferroptosis by targeting mitochondria in mouse hearts subjected to I/R. Mouse hearts or cardiomyocytes were subjected to I/R or hypoxia/reoxygenation (H/R). Doxorubicin (DOX) or I/R upregulated ZIP7and induced ferroptosis. DOX or I/R-induced ferroptosis and cardiac injury were attenuated by ZIP7 cKO (cardiac-specific conditional knockout). I/R resulted in downregulation of mitochondrial GPX4 (mtGPX4) and guanine-rich RNA sequence binding factor 1 (GRSF1) in a ZIP7 dependent manner. GRSF1 knockout (KO) or its shRNA inhibited mtGPX4 expression or activity, and the protective effect of ZIP7 cKO on I/R-induced ferroptosis and myocardial infarction was abolished by GRSF1 shRNA or ZIP7/mtGPX4 double knockout (DKO). Moreover, the mitochondrial iron importers SLC25A28 and SLC25A37 were upregulated by I/R, which was reversed by ZIP7 cKO. We further found that ZIP7 upregulates SLC25A28 and SLC25A37 by inhibiting PINK1-mediated mitophagy. In support, the protective effects of ZIP7 cKO on mitochondrial Fe2+ accumulation, ferroptosis, and cardiac injury were blocked by PINK1 siRNA or SLC25A37 siRNA. Finally, the anti-infarct effect of ZIP7 cKO was not improved by the ferroptosis inhibitor ferrostatin-1. ZIP7 upregulation triggers ferroptosis in I/R hearts through the antioxidant axis (GRSF1-mtGPX4) and the mitophagic axis (PINK1-SLC25A28/37). The inhibition of GRSF1 may lead to the downregulation of mtGPX4, whereas suppression of mitophagy may result in mitochondrial iron accumulation through the upregulation of SLC25A28 and SLC25A37.
中文摘要:铁死亡已被证实参与心肌缺血/再灌注(I/R)损伤,但其具体机制尚未完全阐明。鉴于锌转运体ZIP7(Slc39a7)通过靶向线粒体参与心肌I/R损伤,且抑制ZIP7可减轻erastin诱导的细胞死亡,我们假设在经受I/R的小鼠心脏中,ZIP7上调通过靶向线粒体诱导铁死亡。对小鼠心脏或心肌细胞进行I/R或缺氧/复氧(H/R)处理。多柔比星(DOX)或I/R上调ZIP7并诱导铁死亡。ZIP7 cKO(心脏特异性条件性敲除)减轻了DOX或I/R诱导的铁死亡和心脏损伤。I/R以ZIP7依赖的方式导致线粒体GPX4(mtGPX4)和富含鸟嘌呤RNA序列结合因子1(GRSF1)下调。GRSF1敲除(KO)或其shRNA抑制mtGPX4表达或活性,而GRSF1 shRNA或ZIP7/mtGPX4双敲除(DKO)取消了ZIP7 cKO对I/R诱导铁死亡和心肌梗死的保护作用。线粒体铁输入体SLC25A28和SLC25A37被I/R上调,并被ZIP7 cKO逆转。我们进一步发现ZIP7通过抑制PINK1介导的线粒体自噬上调SLC25A28和SLC25A37。支持这一点的结果是,PINK1 siRNA或SLC25A37 siRNA阻断了ZIP7 cKO对线粒体Fe2+积累、铁死亡和心脏损伤的保护作用。铁死亡抑制剂ferrostatin-1未能进一步改善ZIP7 cKO的抗梗死作用。ZIP7上调通过抗氧化轴(GRSF1-mtGPX4)和线粒体自噬轴(PINK1-SLC25A28/37)触发I/R心脏中的铁死亡。抑制GRSF1可能导致mtGPX4下调,而抑制线粒体自噬可能通过上调SLC25A28和SLC25A37导致线粒体铁积累。
Electroconductive patch promotes heart repair by directing epicardial cells toward endothelial fate.
Whether epicardium-derived cells (EPDCs) can differentiate into endothelial cells after myocardial infarction (MI) remains unclear. Considering the heart's electrical dependence, we asked if restoring electrical conduction could direct this potential. Using cardiac patches with tunable electroconductivity and genetic fate-mapping approaches in mice, we found that patches matching native myocardial electroconductivity (10-4-10-3 S/cm) specifically promoted proliferation and endothelial differentiation of WT1+ EPDCs, rescuing cardiac function. Single-cell transcriptomic sequencing revealed that electroconductive patches drove WT1+ EPDCs into a distinct WT1+TRPC3+CD93+ transitional state. These cells differentiated into endothelial cells via TRPC3-Ca2+ signaling and integrated into functional vessels. Inhibiting TRPC3 blocked differentiation and reduced infarct vascularization. Thus, improving electrical conduction unlocks and directs the endothelial differentiation of WT1+ EPDCs, offering a strategy for post-MI repair.
中文摘要:心肌梗死后心外膜来源细胞(EPDCs)能否分化为内皮细胞仍不清楚。考虑到心脏对电活动的依赖,我们探讨恢复电传导能否引导这一潜能。利用电导率可调的心脏补片和小鼠遗传命运图谱方法,我们发现与天然心肌电导率(10^-4–10^-3 S/cm)匹配的补片特异性促进WT1+ EPDCs增殖并向内皮分化,从而挽救心脏功能。单细胞转录组测序显示,导电补片驱动WT1+ EPDCs进入一种独特的WT1+TRPC3+CD93+过渡状态。这些细胞通过TRPC3-Ca2+信号分化为内皮细胞,并整合入功能血管。抑制TRPC3可阻断分化并减少梗死区血管化。改善电传导可开启并引导WT1+ EPDCs的内皮分化,为梗死后修复提供了一种策略。
Myocardial ischemia-reperfusion injury (MIRI) remains a major obstacle to functional recovery after myocardial infarction, primarily driven by excessive reactive oxygen species (ROS) generation, mitochondrial dysfunction, and apoptosis. In this study, we developed a straightforward hydrothermal method to synthesize Astragalus membranaceus-derived carbon dots (AM-CDs), using this medicinal herb, known for its cardiovascular protective effects, as a biomass precursor. The resulting AM-CDs exhibited broad-spectrum ROS-scavenging activity and pronounced biological effects against oxidative stress, inflammation, and apoptosis. In vitro experiments revealed that AM-CDs restored mitochondrial membrane potential and reduced DNA damage, as indicated by decreased γ-H2AX expression. Furthermore, AM-CDs downregulated pro-inflammatory cytokine mRNA expression in LPS-stimulated macrophages. In a rat model of MIRI, direct intramyocardial administration of AM-CDs resulted in a significant reduction in infarct size, improved left ventricular ejection fraction and fractional shortening in a dose-dependent manner, and exhibited no notable systemic toxicity. Transcriptomic and protein analyses further demonstrated that AM-CDs downregulate pro-apoptotic proteins and modulate the PI3K-AKT and NF-κB-apoptosis signaling pathways, thereby disrupting the vicious cycle of oxidative stress, inflammation, and cell death. Collectively, these findings indicate that AM-CDs offer a promising therapeutic approach that integrates traditional medicine with nanotechnology to provide effective cardioprotection against MIRI.
中文摘要:心肌缺血再灌注损伤(MIRI)仍是心肌梗死后功能恢复的主要障碍,主要驱动因素包括活性氧(ROS)过度生成、线粒体功能障碍和细胞凋亡。本研究采用简便水热法,以具有心血管保护作用的中药黄芪为生物质前体,合成黄芪来源碳点(AM-CDs)。所得AM-CDs表现出广谱ROS清除活性,并对氧化应激、炎症和凋亡具有明显生物学作用。体外实验显示,AM-CDs恢复线粒体膜电位,并通过降低γ-H2AX表达减少DNA损伤。AM-CDs还下调LPS刺激巨噬细胞中促炎细胞因子mRNA表达。在大鼠MIRI模型中,心肌内直接给予AM-CDs显著缩小梗死面积,呈剂量依赖性改善左心室射血分数和缩短分数,未见明显全身毒性。转录组和蛋白分析进一步表明,AM-CDs下调促凋亡蛋白,调控PI3K-AKT与NF-κB-凋亡信号通路,从而打断氧化应激、炎症和细胞死亡之间的恶性循环。这些结果共同表明,AM-CDs将传统医学与纳米技术结合,为MIRI提供有效心脏保护的有前景治疗策略。
Myocardial infarction (MI) initiates a wound-healing response where immune cells shape inflammation, tissue repair, and long-term remodeling. Although CD4+ T cells are increasingly recognized as contributors to post-MI healing, the transcriptional reprogramming defining their early pro-reparative functions remains incompletely resolved. Here, RNA sequencing of cardiac CD4+ T cells isolated 1 week after MI found that a substantial post-MI transcriptional fraction lay outside canonical cytokine-induced T helper subset polarization, including type 1 T helper cell (Th1), Th2, Th17, nature-occurring CD4+ regulatory T cell (nTreg), and peripherally induced Treg (iTreg) reference transcriptomic programs. Instead, this response was organized into a distinct CD4+ Th tissue injury-polarized (CD4+/TIP) transcriptomic module enriched for extracellular matrix organization, adhesion, vascular, and developmental programs, with a coordinated downregulated arm involving RNA metabolism, chromatin regulation, and protein catabolic processes. Within the CD4+/TIP population, MI induced and polarized at least 10 transcriptionally distinct CD4+ Th subsets at 1 week post-MI. Integration with curated transcription factors, epigenetic, reduction-oxidation (redox), and unfolded protein response (UPR) datasets identified a stress-adaptive architecture, in which regulatory subsets and the CD4+/TIP population shared redox attenuation features, while the CD4+/TIP state showed the strongest coupling to reparative tissue interaction programs, predominant Activating Transcription Factor 6 (ATF6)-aligned UPR structure, restrained proteostasis related outputs, and an innate-adjacent immune and secretome signature enriched for complement-associated, inflammatory recruitment, and extracellular communication genes. These findings identify a specific MI-associated CD4+ T-cell transcriptomic state during early MI inflammation and tissue repair. They establish a coordinated framework in which redox control, UPR, and tissue-injury-polarized CD4+ T-cell immune programs converge outside traditional Th and Treg lineages, offering new targets for CD4+ T-cell-mediated tissue repair after MI.
中文摘要:心肌梗死(MI)启动伤口愈合反应,免疫细胞在其中塑造炎症、组织修复与长期重构。CD4+ T细胞参与MI后愈合日益受到重视,但界定其早期促修复功能的转录重编程仍未完全阐明。对MI后1周分离的心脏CD4+ T细胞进行RNA测序发现,MI后相当一部分转录特征落在经典细胞因子诱导的T辅助细胞亚群极化程序之外,包括1型T辅助细胞(Th1)、Th2、Th17、天然CD4+调节性T细胞(nTreg)和外周诱导Treg(iTreg)参考转录组程序。该反应反而组织为一个独特的CD4+ Th组织损伤极化(CD4+/TIP)转录组模块,富集细胞外基质组织、黏附、血管和发育程序,并伴有一个协调下调的分支,涉及RNA代谢、染色质调控和蛋白分解代谢过程。在CD4+/TIP群体内,MI后1周诱导并极化了至少10个转录上不同的CD4+ Th亚群。与整理过的转录因子、表观遗传、氧化还原(redox)和未折叠蛋白反应(UPR)数据集整合后,识别出一种应激适应架构:调节性亚群与CD4+/TIP群体共享氧化还原衰减特征,而CD4+/TIP状态与修复性组织相互作用程序耦合最强,以激活转录因子6(ATF6)对齐的UPR结构为主,蛋白稳态相关输出受限,并呈现先天免疫邻近的免疫与分泌组特征,富集补体相关、炎症招募和细胞外通讯基因。这些发现确定了早期MI炎症与组织修复期间一个特定的MI相关CD4+ T细胞转录组状态,建立了一个协调框架:氧化还原控制、UPR和组织损伤极化的CD4+ T细胞免疫程序在传统Th和Treg谱系之外汇聚,为MI后CD4+ T细胞介导的组织修复提供了新靶点。
Myocardial infarction (MI) disrupts immune homeostasis by impairing the recruitment and suppressive function of regulatory T cells (Tregs), which are hard to restore to date. In this study, a dual-functional platform based on core-shell microgels (Ab/HAPA C-S MGs) was developed to enhance Tregs homing and function within the post-infarct environment. The surface-modified C-C motif chemokine ligand 17 (CCL17) antibody neutralized excess CCL17, thereby enabling targeted Tregs recruitment. Propionic acid (PA) was released via hydrolytic cleavage of an encapsulated prodrug precursor (HAPA) within the core to promote Tregs immunosuppressive activity through fatty acid oxidation. The platform ensured localized retention and release of PA, addressing the pharmacokinetic limitations characteristic of short-chain fatty acid (SCFAs). The Ab/HAPA@C-S MGs enhanced Tregs recruitment by 4.2-fold through CCL17 neutralization, while enzymatically released PA boosted Tregs immunosuppression with 1.8-fold higher Foxp3 expression in vitro. In MI models, treatment with Ab/HAPA@C-S MGs promoted a 2.4-fold increase in Tregs infiltration while reducing Th17 cells in infarcted region, ultimately improving cardiac functions and attenuating myocardial fibrosis. These findings show potential of the SCFA-based C-S MGs system on regulating the immunomodulation and cardiac tissue repair.
中文摘要:心肌梗死(MI)通过损害调节性T细胞(Tregs)的招募和抑制功能破坏免疫稳态,目前难以恢复。本研究开发了一种基于核壳微凝胶(Ab/HAPA C-S MGs)的双功能平台,以增强梗死后环境中Tregs的归巢和功能。表面修饰的C-C趋化因子配体17(CCL17)抗体中和过量CCL17,从而实现Tregs靶向招募。核心内包封的前药前体(HAPA)经水解裂解释放丙酸(PA),通过脂肪酸氧化促进Tregs免疫抑制活性。该平台确保PA的局部滞留和释放,解决短链脂肪酸(SCFAs)的药代动力学局限。Ab/HAPA@C-S MGs通过中和CCL17使Tregs招募提高4.2倍,酶解释放的PA在体外增强Tregs免疫抑制,Foxp3表达提高1.8倍。在MI模型中,Ab/HAPA@C-S MGs治疗使Tregs浸润增加2.4倍,同时减少梗死区Th17细胞,最终改善心功能并减轻心肌纤维化。这些发现显示基于SCFA的C-S MGs系统在调节免疫调节和心脏组织修复方面的潜力。
Precise management of the inflammatory response after myocardial infarction necessitates targeted engagement of cellular drivers. Here, we report a pathophysiology-guided theranostic platform that exploits two defining features of pro-inflammatory macrophages, their high-output nitric oxide (NO) production and localized acidic microenvironment, to enable concurrent sensing, quantification, and modulation of post-infarction inflammation. The platform, PM720@NRP, is engineered from platelet membranes encapsulating an NO-responsive NIR-II fluorophore and the immunomodulator FTY720. It delivers three integrated functions: (i) specific, NO-activated NIR-II imaging of inflammatory foci; (ii) machine learning-powered translation of imaging signals into quantitative maps of pro-inflammatory macrophage activity; (iii) acid-triggered release of FTY720 to reprogram macrophages toward a reparative phenotype, synergizing with platelet-derived factors to stimulate angiogenesis. This strategy provided real-time visualization and non-invasive quantification of inflammation, while improving cardiac function and repair. By repurposing pathological biomarkers as intrinsic triggers for diagnosis and treatment, this work establishes a closed-loop, biology-inspired paradigm that autonomously adapts to dynamic disease activity.
中文摘要:心肌梗死后炎症反应的精准管理需要靶向干预细胞驱动因素。我们报道一种由病理生理学引导的诊疗一体化平台,利用促炎巨噬细胞的两个关键特征,即高水平一氧化氮(NO)生成和局部酸性微环境,实现对梗死后炎症的同步传感、定量和调控。该平台PM720@NRP由血小板膜包封NO响应型近红外二区荧光团和免疫调节剂FTY720构建而成。它提供三项整合功能:(i)对炎症灶进行特异性、NO激活的近红外二区成像;(ii)以机器学习将成像信号转化为促炎巨噬细胞活性的定量图谱;(iii)酸触发释放FTY720,使巨噬细胞重编程为修复表型,并与血小板来源因子协同刺激血管生成。该策略实现炎症的实时可视化和无创定量,同时改善心脏功能与修复。通过将病理生物标志物重新用作诊断和治疗的内源性触发因素,这项工作建立了一种闭环、受生物学启发的范式,可自主适应动态疾病活动。
Myocardial patches, particularly collagen-based systems, have emerged as promising therapeutic platforms for repairing injured cardiac tissue after myocardial infarction (MI). However, their clinical translation remains constrained by insufficient wet-tissue adhesion, mechanical mismatch with the native myocardium, and limited regenerative bioactivity. Inspired by the interpenetrating rigid-flexible architecture of deep-sea glass sponge spicules, we developed a biomimetic hydrogel cardiac patch (PCH@D) designed to address these challenges in an integrated manner. The patch is constructed as a multi-component interpenetrating network, in which diatom-derived biosilica serves as a rigid skeletal framework and silicate ion reservoir, while a dual-network matrix of acrylated collagen and poly(acrylic acid), reinforced by catechol-functionalized hyperbranched polymers, forms a flexible organic phase that mediates wet-tissue adhesion through cooperative hydrophobic-catechol interactions by actively displacing interfacial water and forming stable covalent bonds with tissues. As a result, the PCH@D patch achieves rapid and robust adhesion to wet myocardium (40.59 ± 3.30 kPa), exhibits mechanical properties well matched to native myocardium, and offers sustained silicate ion release over 28 days. In a murine MI model, implantation of the PCH@D patch reduced cardiomyocyte apoptosis, promoted M2 macrophage polarization, enhanced angiogenesis, and effectively mitigated adverse ventricular remodeling, leading to improved cardiac function. This work highlights a bioinspired materials design strategy for cardiac patches that integrates mechanical compatibility with active biological regulation.
中文摘要:心肌补片尤其是胶原基系统已成为修复心肌梗死(MI)后受损心肌组织的潜力治疗平台。其临床转化仍受湿组织黏附不足、与天然心肌力学失配以及再生生物活性有限等因素制约。受深海玻璃海绵骨针互穿刚柔结构启发,我们构建了仿生水凝胶心脏补片PCH@D,以一体化方式应对上述挑战。该补片为多组分互穿网络,其中硅藻来源生物硅作为刚性骨架和硅酸根离子储库,丙烯酰化胶原与聚丙烯酸的双网络基质由儿茶酚功能化超支化聚合物增强,形成柔性有机相,通过疏水-儿茶酚协同作用主动置换界面水并与组织形成稳定共价键,从而介导湿组织黏附。PCH@D补片对湿心肌实现快速而稳固的黏附(40.59 ± 3.30 kPa),力学性能与天然心肌良好匹配,并可在28天内持续释放硅酸根离子。在小鼠MI模型中,植入PCH@D补片减少心肌细胞凋亡,促进M2巨噬细胞极化,增强血管生成,并有效减轻不良心室重构,改善心脏功能。该工作提出了一种将力学相容性与主动生物调控整合的心脏补片仿生材料设计策略。
Myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide, and current therapeutic strategies offer limited efficacy in promoting long-term cardiac repair. miRNAs have emerged as promising therapeutic agents owing to their capacity to modulate gene networks involved in cardiomyocyte apoptosis, mitochondrial dysfunction, and extracellular matrix (ECM) remodeling. Herein, we identified miR-30d as a potential therapeutic target, exhibiting dynamic expression changes in plasma extracellular vesicles (EVs) from MI patients before and after percutaneous coronary intervention (PCI). To facilitate targeted delivery, we developed an engineered milk-derived EV-like vehicle (mELV) system in which endogenous RNAs were depleted via sonication to reduce off-target effects and improve cargo uniformity. These mELVs were further loaded with miR-30d and subsequently functionalized with an ischemic myocardium targeting peptide (IMTP). Intravenous administration of miR30d-mELVsIMTP in murine MI model conferred both acute cardioprotection and sustained improvements in cardiac function, accompanied by reduced pathological remodeling. Mechanistically, miR-30d directly targets Thbs2, leading to suppression of downstream MMP2 expression, attenuation of mitochondrial reactive oxygen species production, and inhibition of ECM degradation. Collectively, these findings underscore the therapeutic potential of miR-30d and establish programmable RNA-depleted, IMTP-conjugated mELVs as a safe, targeted, and effective platform for miRNA delivery in post-MI gene therapy.
中文摘要:心肌梗死(MI)仍是全球发病和死亡的主要原因,现有治疗策略在促进长期心脏修复方面效果有限。miRNA能够调控参与心肌细胞凋亡、线粒体功能障碍和细胞外基质(ECM)重塑的基因网络,因而成为有前景的治疗药物。我们确定miR-30d为潜在治疗靶点,其在MI患者经皮冠状动脉介入治疗(PCI)前后血浆细胞外囊泡(EVs)中呈动态表达变化。为实现靶向递送,我们构建了工程化乳源EV样载体(mELV)系统,通过超声处理去除内源性RNA以降低脱靶效应并提高货物均一性。这些mELV进一步负载miR-30d,并用缺血心肌靶向肽(IMTP)进行功能化。在小鼠MI模型中静脉给予miR30d-mELVsIMTP可产生急性心脏保护作用,并持续改善心功能,同时减轻病理性重塑。机制上,miR-30d直接靶向Thbs2,抑制下游MMP2表达,减弱线粒体活性氧产生,并抑制ECM降解。这些发现支持miR-30d的治疗潜力,并将可编程的RNA去除、IMTP偶联mELV确立为MI后基因治疗中安全、靶向且有效的miRNA递送平台。
Ischemic heart disease, which leads to the loss of functional myocardium, remains the leading cause of death in late adulthood. Epicardial patches have emerged as a promising adjunctive strategy for myocardial repair. However, owing to the thick epicardial barrier (epicardial adipose tissue), only a select few approaches have demonstrated reduced scarring and improved heart function in large animal models and early-stage human trials. In this opinion article, we examine the different mechanisms and approaches to overcome the epicardial barrier. We further discuss key design and material considerations to improve safety and efficacy in clinical applications. Finally, we provide a summary of current regulatory and clinical challenges, together with proposed future research directions and foci in the translation of epicardial patches.
中文摘要:缺血性心脏病导致功能性心肌丢失,仍是成年晚期人群的首要死因。心外膜补片已成为心肌修复的一种有前景的辅助策略。然而,由于厚实的心外膜屏障(心外膜脂肪组织),仅有少数方法在大动物模型和早期人体试验中显示出减少瘢痕形成和改善心脏功能的效果。这篇观点文章考察克服心外膜屏障的不同机制和途径。文中还讨论改善临床应用安全性和有效性的关键设计与材料考量。文章梳理当前监管与临床挑战,并提出心外膜补片转化研究的未来方向与重点。
β3 adrenergic receptor (ADRB3) has recently emerged as an important regulator of cardiovascular homeostasis. However, the role of endothelial ADRB3 in cardiac repair after myocardial infarction (MI) remains unclear. As endothelial dysfunction critically drives post-MI remodeling, we hypothesized that ADRB3 preserves endothelial integrity and protects the heart from ischemic injury. Endothelial cell-specific ADRB3 knockout mice and adeno-associated virus serotype 9 (AAV9)-mediated endothelial ADRB3 overexpression mice were subjected to MI. Single-cell RNA sequencing (scRNA-seq) was performed to characterize cellular heterogeneity and endothelial phenotypic changes. scRNA-seq revealed enhanced EndoMT and activated TGFβ signaling in ADRB3-deficient hearts, accompanied by accelerated fibrotic remodeling and exacerbated ischemic injury. In contrast, endothelial ADRB3 overexpression suppressed EndoMT, reduced fibrosis, and improved cardiac function following MI. In vitro, ADRB3 knockdown induced EndoMT and endothelial dysfunction, whereas ADRB3 overexpression attenuated hypoxia-induced mesenchymal activation. Mechanistically, proximity ligation assay, co-immunoprecipitation, and mass spectrometry identified TGFβ receptor 2 (TGFβR2) as an endogenous binding partner of ADRB3. ADRB3 interaction with TGFβR2 prevented SMAD2 recruitment to TGFβR1 and inhibited downstream SMAD2 phosphorylation. Moreover, endothelial-specific TGFβR2 knockdown using AAV9 mitigated cardiac injury in ADRB3-deficient mice following MI. These findings demonstrate that endothelial ADRB3 protects against ischemic heart injury by limiting TGFβR2-SMAD2-dependent EndoMT, highlighting its role as a critical endothelial regulator and a potential therapeutic target for myocardial repair.
中文摘要:β3肾上腺素能受体(ADRB3)近来被认为是心血管稳态的重要调节因子。但内皮ADRB3在心肌梗死(MI)后心脏修复中的作用仍不清楚。内皮功能障碍是MI后重构的关键驱动因素,因此我们假设ADRB3可维持内皮完整性并保护心脏免受缺血性损伤。研究对血管内皮细胞特异性ADRB3敲除小鼠和AAV9介导内皮ADRB3过表达小鼠实施MI。采用单细胞RNA测序(scRNA-seq)刻画细胞异质性和内皮表型变化。scRNA-seq显示ADRB3缺失心脏中EndoMT增强、TGFβ信号激活,并伴有纤维化重构加速和缺血性损伤加重。相反,内皮ADRB3过表达抑制EndoMT、减少纤维化并改善MI后心脏功能。体外实验中,ADRB3敲低诱导EndoMT和内皮功能障碍,而ADRB3过表达减轻缺氧诱导的间充质活化。机制上,邻近连接实验、免疫共沉淀和质谱鉴定TGFβ受体2(TGFβR2)为ADRB3的内源性结合伙伴。ADRB3与TGFβR2相互作用阻止SMAD2募集至TGFβR1并抑制下游SMAD2磷酸化。此外,AAV9介导内皮特异性TGFβR2敲低减轻ADRB3缺失小鼠MI后心脏损伤。这些发现表明内皮ADRB3通过限制TGFβR2-SMAD2依赖的EndoMT防止缺血性心脏损伤,凸显其作为关键内皮调节因子和心肌修复潜在治疗靶点的作用。
6卒中/脑血管 (12篇)
临床研究 (10篇)
Clinical research evaluating mechanical ventilation liberation in patients with acute brain injury (ABI) shows substantial outcome heterogeneity, limiting evidence synthesis. We aimed to develop an internationally endorsed core outcome set (COS) and a hierarchical composite endpoint for ventilation trials in neurocritical care. Following COS-STAD/COS-STAP standards, we conducted a 4-round international Delphi study. Candidate outcomes were identified via a scoping review. A multidisciplinary panel from 31 countries scored outcomes using a 9-point GRADE scale. Inclusion required >70% rating as "critical" (score 7-9) and ≤15% as "not important" (1-3). Two consensus meetings were held to categorize outcomes, select representative measures, and ratify a hierarchical composite endpoint. 78 stakeholders participated in Round 1; 60 completed all rounds (23.1% attrition). Fifty-four outcomes achieved Delphi consensus. At Consensus Meeting 1, these were organized into 16 categories; the highest-scoring outcome per category was selected. Three outcomes were not ratified due to disease-specificity (NIH Stroke Scale) or lack of universal applicability (brain death, coma-free days). The final COS comprised 13 outcomes across 5 domains: respiratory function, survival, complications, functional status, and quality of life. A 3-level hierarchical composite endpoint was ratified at Consensus Meeting 2: (1) intensive care unit survival, (2) no reintubation within 72 hours, and (3) days alive without mechanical ventilation. This study establishes the first COS for ventilation weaning trials in ABI patients. Widespread adoption of these 13 outcomes and the hierarchical composite endpoint will standardize reporting, enable meaningful evidence synthesis, and facilitate clinical translation in neurocritical care. Core Outcome Measures in Effectiveness Trials (COMET) Initiative, registration number 2320.
中文摘要:针对急性脑损伤患者机械通气撤机开展的临床研究,结局指标差异很大,证据整合因此受限。研究目标是建立一套国际认可的核心结局指标集,并为神经重症监护中的通气试验制定分层复合终点。研究遵循COS-STAD/COS-STAP标准,开展4轮国际德尔菲研究。候选结局通过范围综述确定。来自31个国家的多学科专家组采用9分GRADE量表对结局评分。纳入标准为超过70%的专家评为关键(7–9分),且不超过15%评为不重要(1–3分)。举行两次共识会议,对结局进行分类、选择代表性测量指标并批准分层复合终点。第1轮有78名利益相关者参与,60名完成全部轮次,脱落率23.1%。54个结局达成德尔菲共识。第1次共识会议将其归入16个类别,并选择每类中评分最高的结局。3个结局未获批准,原因分别是疾病特异性(NIH卒中量表)或缺乏普遍适用性(脑死亡、无昏迷天数)。最终核心结局指标集包含5个领域的13个结局:呼吸功能、生存、并发症、功能状态和生活质量。第2次共识会议批准了3级分层复合终点:(1)重症监护室生存;(2)72小时内无再插管;(3)无机械通气存活天数。该研究建立了首个用于急性脑损伤患者通气撤机试验的核心结局指标集。广泛采用这13个结局和分层复合终点,将统一报告方式,支持有意义的证据整合,并促进神经重症监护中的临床转化。COMET注册号2320。
Cardiac troponin is increasingly used for cardiovascular risk prediction. While abnormal values often reflect subclinical cardiovascular disease, they can be raised due to interference, where antibodies influence the assay or clearance of troponin from the circulation by forming macrotroponin complexes. The frequency of macrotroponins and its association with future risk are unknown. In a general population cohort, participants with both cardiac troponin I and T measurements available (n=19 499, median 49 [25th-75th percentile, 36-58] years of age, 58.3% women) were categorized into 3 groups: no myocardial injury (neither cardiac troponin I or T was elevated), suspected macrotroponin (either cardiac troponin was elevated and discordant with a >3-fold difference in concentration), and myocardial injury (either cardiac troponin was elevated without discordance). Macrotroponin complex formation was verified in a subset of samples (n=203) using immunoglobulin depletion and ultracentrifugation. Associations with future myocardial infarction, ischemic stroke, or cardiovascular death were evaluated using Cox proportional hazards models adjusted for known cardiovascular risk factors. The generalizability of our findings was determined through replication in a second general population cohort study. Elevated cardiac troponin I was present in 1% (193 of 19 499) of participants and elevated cardiac troponin T in 6% (1159 of 19 499). Among those, 48% and 57% were discordant, respectively. Biochemical testing attributed 92.5% of discordant troponin I and 15.4% of discordant troponin T to macrotroponin complexes. Participants with myocardial injury were at increased risk of future cardiovascular events compared with those without (cardiac troponin I: adjusted hazard ratio [HR], 2.90 [95% CI, 1.99-4.22]; cardiac troponin T: adjusted HR, 1.99 [95% CI, 1.63-2.42]), whereas those with suspected macrotroponin had similar risk as those without elevated values for suspected macrotroponin I (adjusted HR, 1.59 [95% CI, 0.94-2.70]) and T (adjusted HR, 1.27 [95% CI, 1.00-1.61]). Findings were similar in the replication cohort. Assay interference due to macrotroponin complex formation is common in individuals with elevated cardiac troponin concentrations in the general population, particularly for cardiac troponin I. This has important implications for the use of cardiac troponin testing for cardiovascular risk assessment in the general population.
中文摘要:心脏肌钙蛋白越来越多用于心血管风险预测。异常值常反映亚临床心血管病,但也可能因干扰而升高,即抗体影响检测或通过形成巨肌钙蛋白复合物改变肌钙蛋白从循环中的清除。巨肌钙蛋白的出现频率及其与未来风险的关系尚不清楚。在一个一般人群队列中,同时具有心肌肌钙蛋白I和T检测结果的参与者(n=19 499,中位年龄49岁,25th-75th百分位36-58岁,女性58.3%)被分为3组:无心肌损伤组,即心肌肌钙蛋白I和T均未升高;疑似巨肌钙蛋白组,即任一肌钙蛋白升高且两者浓度差异超过3倍而不一致;心肌损伤组,即任一肌钙蛋白升高且无不一致。在部分样本(n=203)中通过免疫球蛋白去除和超速离心验证巨肌钙蛋白复合物形成。采用校正已知心血管危险因素的Cox比例风险模型评估与未来心肌梗死、缺血性卒中或心血管死亡的关系。通过在第二个一般人群队列研究中重复分析确定结果的普遍性。心肌肌钙蛋白I升高见于1%(193/19 499)的参与者,心肌肌钙蛋白T升高见于6%(1159/19 499)。其中分别有48%和57%存在不一致。生化检测将92.5%的不一致肌钙蛋白I和15.4%的不一致肌钙蛋白T归因于巨肌钙蛋白复合物。与无心肌损伤者相比,心肌损伤参与者未来心血管事件风险增加(心肌肌钙蛋白I:校正风险比[HR] 2.90,95% CI 1.99-4.22;心肌肌钙蛋白T:校正HR 1.99,95% CI 1.63-2.42),而疑似巨肌钙蛋白者的风险与相应肌钙蛋白未升高者相似(疑似巨肌钙蛋白I:校正HR 1.59,95% CI 0.94-2.70;疑似巨肌钙蛋白T:校正HR 1.27,95% CI 1.00-1.61)。重复队列中的结果相似。在一般人群中,肌钙蛋白浓度升高者因巨肌钙蛋白复合物形成导致检测干扰较常见,尤其是心肌肌钙蛋白I。这对在一般人群中使用心脏肌钙蛋白检测进行心血管风险评估具有重要意义。
Preeclampsia remains a leading cause of maternal mortality, particularly in low-resource settings. We aimed to develop a dynamic prediction model accommodating repeated measurements for predicting adverse maternal outcomes in preeclampsia. We utilized data from 7283 women with preeclampsia from the PIERS studies (Preeclampsia Integrated Estimate of Risk). Data from 6548 women were randomly split into a training set (80%) and an internal validation set (20%), while an independent cohort of 735 women was used for external validation. The outcome was a composite of maternal mortality and severe maternal morbidity. The mini PIERSdynamic model was fitted with the binary mixed model random forest algorithm. Threshold probabilities were calculated for 5 risk strata, ranging from very low to very high risk. Model performance was externally validated. In the development cohort, 785 (12.0%) women experienced an adverse maternal outcome, compared with 91 (12.4%) women in the external validation cohort. The final model retained all candidate predictors. Model performance was similar in internal and external validation. The daily area under the receiver-operating-characteristics curve remained around 0.75 on days 0 to 9 in internal validation and 0.70 in external validation, with peak values of 0.92 and 0.94, respectively. The area under the precision-recall curve declined over time as outcome incidence decreased. Observed daily event rates corresponded closely with the assigned risk strata. We developed the mini PIERSdynamic model and performed external validation, demonstrating its potential for dynamic prediction of adverse maternal outcomes in preeclampsia for up to 10 days after initial presentation. Further evaluation is required to verify its generalizability and clinical utility.
中文摘要:子痫前期仍是孕产妇死亡的主要原因之一,在资源匮乏环境中尤为突出。研究旨在建立可处理重复测量的动态预测模型,用于预测子痫前期的不良孕产妇结局。研究使用PIERS(子痫前期风险综合评估)研究中7283例子痫前期妇女的数据。6548例妇女的数据被随机分为训练集(80%)和内部验证集(20%),另有一个735例妇女的独立队列用于外部验证。结局为孕产妇死亡和严重孕产妇疾病的复合结局。mini PIERSdynamic模型采用二分类混合模型随机森林算法拟合。计算5个风险分层的阈值概率,风险从极低到极高。模型性能接受外部验证。开发队列中785例(12.0%)妇女发生不良孕产妇结局,外部验证队列中为91例(12.4%)。最终模型保留了所有候选预测因子。模型性能在内部和外部验证中相似。每日受试者工作特征曲线下面积在内部验证第0至9天维持在0.75左右,外部验证为0.70,峰值分别为0.92和0.94。随着结局发生率下降,精确率-召回率曲线下面积随时间降低。观察到的每日事件率与所分配风险分层密切对应。研究建立了mini PIERSdynamic模型并完成外部验证,显示其在子痫前期患者初次就诊后最长10天内动态预测不良孕产妇结局的潜力。仍需进一步评估以验证其可推广性和临床实用性。
Hemodynamic insufficiency may contribute to the development of neuroimaging signs of cerebral small vessel disease (SVD). The arterial spin labeling (ASL) spatial coefficient of variation (ASL-sCoV) is a proxy marker of arterial transit time and may better capture SVD-related hemodynamic disturbances compared with ASL-derived cerebral blood flow. We investigated ASL-derived hemodynamic indices in relation to cognition and neuroimaging markers of SVD over an 11-year follow-up period. Participants without dementia or stroke were enrolled in the Vanderbilt Memory and Aging Project, a longitudinal observational cohort study in Nashville, TN. Participants underwent serial multimodal 3T brain magnetic resonance imaging to quantify SVD burden and neuropsychological assessment from 2012 to 2024 (4.9±3.5 years mean follow-up). Pseudo-continuous ASL assessed cerebral blood flow and ASL-sCoV in total gray matter. Baseline ASL-sCoV and cerebral blood flow were individually related to the cross-sectional burden and longitudinal trajectory of each SVD neuroimaging marker (white matter hyperintensities, enlarged perivascular spaces, cerebral microbleeds, and lacunar infarcts) and cognitive performances using linear and linear mixed-effects regression models. Models were adjusted for demographics, cognitive status, Framingham Stroke Risk Profile (minus age), apolipoprotein E-ε4 status, intracranial volume (for SVD outcomes), and follow-up time (for longitudinal models). Among participants (n=667, 68±9 years, 18% mild cognitive impairment, 51% female), higher ASL-sCoV was cross-sectionally associated with SVD markers, including white matter hyperintensities and enlarged perivascular spaces (pFDR-values<0.006). Higher baseline ASL-sCoV was associated with a faster longitudinal increase in the burden of white matter hyperintensities (pFDR=0.03) and accelerated decline in executive function, information processing, language, and visuospatial performances (P<0.05). Gray matter cerebral blood flow was not associated with SVD burden or cognition cross-sectionally (pFDR-values>0.05) or longitudinally (pFDR-values>0.06). ASL-sCoV may serve as an important hemodynamic measure for identifying perfusion deficits tied to SVD burden and progression. Readily derived from existing ASL data sets, ASL-sCoV could provide substantial insight into the longitudinal clinical consequences of SVD.
中文摘要:血流动力学储备不足可能促进脑小血管病(SVD)神经影像征象的出现。动脉自旋标记(ASL)空间变异系数(ASL-sCoV)可反映动脉通过时间,与ASL衍生的脑血流量相比,可能更好地捕捉SVD相关血流动力学紊乱。本研究在11年随访期内考察ASL衍生的血流动力学指标与认知及SVD神经影像标志物的关系。研究纳入无痴呆或卒中的参与者,来自Vanderbilt Memory and Aging Project,一项位于田纳西州纳什维尔的纵向观察性队列研究。2012至2024年,参与者接受系列多模态3T脑磁共振成像以量化SVD负担,并接受神经心理学评估(平均随访4.9±3.5年)。伪连续ASL测量全灰质脑血流量和ASL-sCoV。采用线性回归和线性混合效应回归模型,分别分析基线ASL-sCoV和脑血流量与各SVD神经影像标志物(白质高信号、扩大的血管周围间隙、脑微出血和腔隙性梗死)横断面负担及纵向轨迹以及认知表现的关系。模型校正人口学特征、认知状态、Framingham卒中风险谱(不含年龄)、载脂蛋白E-ε4状态、颅内体积(针对SVD结局)和随访时间(针对纵向模型)。在参与者中(n=667,68±9岁,18%轻度认知障碍,51%女性),较高的ASL-sCoV与SVD标志物横断面相关,包括白质高信号和扩大的血管周围间隙(pFDR值<0.006)。较高的基线ASL-sCoV与白质高信号负担纵向增长更快相关(pFDR=0.03),并与执行功能、信息处理、语言和视空间表现加速下降相关(P<0.05)。灰质脑血流量与SVD负担或认知在横断面(pFDR值>0.05)或纵向上(pFDR值>0.06)均无关联。ASL-sCoV可作为识别与SVD负担和进展相关灌注缺损的重要血流动力学指标。ASL-sCoV可从现有ASL数据集中便捷获得,可能为理解SVD的纵向临床后果提供重要线索。
To directly compare the predictive ability of carotid-femoral pulse wave velocity (cf-PWV) and brachial-ankle pulse wave velocity (ba-PWV) for cardiovascular events within the same population. This is a community-based prospective cohort study that included older adults (>65 years). The primary end point was major adverse cardiovascular events (MACEs), including cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke. A total of 3309 participants (median age [quartiles], 70 [67-75] years; 1434 [43.3%] men) were included. The median follow-up time was 6.40 [6.37-6.41] years. Cf-PWV and ba-PWV were moderately correlated (R=0.588; P<0.001). Participants were divided into 4 groups by quartiles or 2 groups using cutoff values. Aalen-Johansen estimators and Cox regression analyses indicated that both cf-PWV and ba-PWV were associated with an increased rate of MACEs. When cf-PWV and ba-PWV were cross-adjusted, only cf-PWV remained significantly associated with MACEs and mortality (hazard ratio, 1.12 [95% CI, 1.00-1.25]; P=0.048 and 1.16 [95% CI, 1.03-1.29]; P=0.032, respectively) in both full-model and stepwise regressions. Stratification based on cf-PWV and ba-PWV cutoff values further revealed that elevated cf-PWV was associated with a higher risk of MACEs, independent of baseline ba-PWV. Concordance index, net reclassification improvement, and integrated discrimination improvement analyses confirmed the additive value of cf-PWV to conventional cardiovascular risk factors. Other stiffness-related parameters, including pulse pressure and its amplification, were not independently associated with MACEs. Both cf-PWV and ba-PWV are associated with cardiovascular events, and cf-PWV demonstrates a higher predictive value compared with ba-PWV. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02368938.
中文摘要:在同一个社区人群中直接比较颈-股脉搏波传导速度(cf-PWV)与肱-踝脉搏波传导速度(ba-PWV)对心血管事件的预测能力。这项基于社区的前瞻性队列研究纳入年龄>65岁的老年人。主要终点为主要不良心血管事件(MACEs),包括心血管死亡、非致死性心肌梗死和非致死性卒中。共纳入3309名参与者(中位年龄[四分位数]70[67-75]岁;男性1434名[43.3%])。中位随访时间为6.40[6.37-6.41]年。cf-PWV与ba-PWV呈中度相关(R=0.588;P<0.001)。按四分位数将参与者分为4组,或按切点值分为2组。Aalen-Johansen估计和Cox回归分析显示,cf-PWV和ba-PWV均与MACEs发生率升高相关。对cf-PWV和ba-PWV进行相互校正后,在全模型和逐步回归中,仅cf-PWV仍与MACEs和死亡显著相关(风险比分别为1.12[95% CI,1.00-1.25];P=0.048和1.16[95% CI,1.03-1.29];P=0.032)。按cf-PWV和ba-PWV切点值分层进一步显示,cf-PWV升高与MACEs风险较高相关,且不依赖基线ba-PWV。一致性指数、净重分类改善和综合判别改善分析证实cf-PWV对传统心血管危险因素具有增量价值。其他僵硬度相关参数,包括脉压及其放大,与MACEs无独立关联。cf-PWV和ba-PWV均与心血管事件相关,cf-PWV的预测价值高于ba-PWV。URL: https://www.clinicaltrials.gov;唯一标识符:NCT02368938。
Nearly 40% of African adults with type 2 diabetes are lean (BMI <25 kg/m2). Emerging evidence suggests that type 2 diabetes in African individuals who are lean may represent a distinct phenotype driven by impaired insulin secretion rather than insulin resistance, raising concerns about treatment mismatch and divergent disease outcomes. We examined complication profiles in Africans with type 2 diabetes who are lean vs overweight/obese. We analysed harmonised, individual-level cross-sectional data from two large, well-characterised African cohorts (Africa America Diabetes Mellitus study, n=2790; Research on Obesity and Diabetes among African Migrants study, n=541; total n=3331) of adults with type 2 diabetes from Ghana, Nigeria and Kenya. Participants were classified as lean (BMI <25 kg/m2) or overweight/obese (BMI ≥25 kg/m2). Robust Poisson regression, adjusted for age, sex, education and treatment, assessed associations with retinopathy, chronic kidney disease, stroke, hypertension and 10-year cardiovascular disease risk. Cohort-specific estimates were pooled using random effects, followed by mediation analysis examining contributions of lifestyle and metabolic markers to observed differences. Type 2 diabetes in Africans who are lean was characterised by lower beta cell function and low insulin levels. Compared with individuals who are overweight/obese, adults who are lean showed a higher prevalence of retinopathy (pooled prevalence ratio [pPR] 1.36 [95% CI 1.13, 1.63]) and stroke (pPR 1.41 [95% CI 1.01, 1.99]), but lower hypertension (pPR 0.77 [95% CI 0.71, 0.85]) and 10-year cardiovascular disease risk (pPR 0.85 [95% CI 0.74, 0.97]). Chronic kidney disease prevalence did not differ between groups. Body fat percentage accounted for most differences (up to 92%). Complication patterns in Africans with type 2 diabetes who are lean vs overweight/obese follow divergent paths. In Africa, where nearly 24 million people have type 2 diabetes, two-fifths of whom are lean, our findings add to growing evidence that lean type 2 diabetes may be a distinct phenotype, underscoring the urgent need for investigation into better-targeted management for this large, potentially mistreated, population.
中文摘要:非洲2型糖尿病成人中近40%体型偏瘦(BMI<25 kg/m2)。新出现的证据提示,非洲瘦型个体的2型糖尿病可能是一种由胰岛素分泌受损而非胰岛素抵抗驱动的独立表型,这引发了对治疗不匹配与疾病结局差异的担忧。我们比较了非洲瘦型与超重/肥胖2型糖尿病患者的并发症谱。分析数据来自两个大型、特征明确的非洲队列,即非洲裔美国人糖尿病研究(n=2790)与非洲移民肥胖与糖尿病研究(n=541),合计n=3331,均为加纳、尼日利亚和肯尼亚的2型糖尿病成人,采用经统一处理的个体水平横断面资料。参与者按瘦型(BMI<25 kg/m2)或超重/肥胖(BMI≥25 kg/m2)分组。采用稳健泊松回归,校正年龄、性别、教育程度与治疗后,评估与视网膜病变、慢性肾脏病、卒中、高血压及10年心血管病风险的关联。各队列的估计值以随机效应模型合并,随后进行中介分析,考察生活方式与代谢指标对所见差异的贡献。非洲瘦型2型糖尿病的特征为β细胞功能较低、胰岛素水平偏低。与超重/肥胖者相比,瘦型成人视网膜病变(合并患病率比1.36[95%CI 1.13,1.63])与卒中(1.41[95%CI 1.01,1.99])的患病率更高,高血压(0.77[95%CI 0.71,0.85])与10年心血管病风险(0.85[95%CI 0.74,0.97])更低。慢性肾脏病患病率两组无差异。体脂百分比解释了大部分差异(最高达92%)。非洲瘦型与超重/肥胖2型糖尿病患者的并发症模式走向不同路径。非洲有近2400万2型糖尿病患者,其中五分之二为瘦型;这些结果进一步支持瘦型2型糖尿病可能是独立表型,也提示亟需研究针对这一庞大、可能治疗不当人群的更精准管理策略。
This systematic review investigates the mediating factors in the relationship between ambient air pollution exposure and cognitive aging. We identified 16 studies examining 72 unique exposure-mediator-outcome associations for six pollutants (PM2.5, PM10, NO2, NOX, black carbon, and PM1 components). The most studied pollutant was PM2.5 (65% of analyses). Cognitive outcomes included memory, cognitive processing speed, and clinically diagnosed conditions such as dementia incidence. Potential mediators spanned mental health outcomes (depression, anxiety, stress), lung function (FEV1, FVC, PEF), vascular diseases (stroke, hypertension), inflammation (CRP), metabolic factors (type 2 diabetes), sleep, and neuroanatomical changes. The quality of mediation analysis reporting was generally good, but most studies had some risk of bias, particularly in outcome assessment and confounding adjustment. Cardio and Cerebro-vascular diseases emerged as a potential key mediator. Mental health outcomes, sleep, and lung function also showed mediating potential, but further research is needed to confirm these findings. This review highlights the need for rigorous causal mediation analyses and standardized reporting to better understand the complex pathways linking air pollution to cognitive aging, in order to identify targeted preventive measures to reduce the negative impact of ambient air pollution on cognitive health.
中文摘要:本系统综述考察环境空气污染暴露与认知老化关系中的中介因素。共纳入16项研究,涉及6种污染物(PM2.5、PM10、NO2、NOX、黑碳及PM1组分)的72条暴露—中介—结局关联。研究最多的污染物为PM2.5,占全部分析的65%。认知结局包括记忆、认知加工速度以及痴呆发病等临床诊断疾病。潜在中介因素涵盖心理健康结局(抑郁、焦虑、应激)、肺功能(FEV1、FVC、PEF)、血管性疾病(脑卒中、高血压)、炎症(CRP)、代谢因素(2型糖尿病)、睡眠及神经解剖改变。中介分析的报告质量总体较好,但多数研究存在一定偏倚风险,尤见于结局评估与混杂因素调整。心脑血管疾病成为潜在的关键中介。心理健康结局、睡眠与肺功能也显示中介作用,尚需进一步研究确认。本综述提示,需要严格的因果中介分析与规范化报告,以更好理解空气污染通向认知老化的复杂路径,从而识别有针对性的预防措施,减轻环境空气污染对认知健康的负面影响。
The human brain exhibits a complex and hierarchical organization that supports efficient information integration across local and global scales. Accurately characterizing such topological organization from neuroimaging data remains challenging. Conventional graph neural networks (GNNs) effectively capture local dependencies through neighborhood aggregation but often overlook higher-order topological structures that reflect the brain's small-world organization. Although Transformer architectures enable global dependency modeling, their high computational cost limits scalability for large connected brain networks. To address these challenges, we propose a Topology-Constrained Graph Transformer Network (TC-GTN) that explicitly integrates brain network topology into graph learning. TC-GTN combines two complementary modules: a cycle-constrained graph convolution, which captures localized edge aggregation and models modular brain organization, and an MST-guided Transformer, which constrains global attention along minimum spanning tree (MST) pathways to efficiently model long-range dependencies while reducing redundant communication. Moreover, we introduce cycle-based edge positional encodings (CEPE) that provide a topological coordinate system for distinguishing edges with similar local structures but different cycle-level contexts. We evaluate TC-GTN on both structural and functional brain networks, extracted from diffusion-weighted imaging (DWI) and functional MRI (fMRI) respectively, using large-scale datasets, including UK Biobank (38557 participants; 18100 females/20457 males; age 40-70 years) and ABCD (7684 participants; 3782 females/3902 males; age 9-10 years). Experiments on sex classification and brain-age estimation demonstrate that TC-GTN consistently outperforms state-of-the-art graph network approaches, achieving superior accuracy, interpretability, and generalizability. Clinical significance analysis further demonstrates that the model accurately characterizes neuroanatomical divergence across pathological states. Using the brain age gap (BAG) as a biomarker, systemic accelerated aging is identified in multiple sclerosis and dementia, alongside heterogeneous structural alterations in stroke and Parkinson's disease. Our code is available at https://github.com/bieqa/TC-GTN.
中文摘要:人脑表现出复杂的分层组织,支持局部与全局尺度上的高效信息整合。从神经影像数据准确刻画这种拓扑组织仍具挑战。传统图神经网络(GNN)通过邻域聚合有效捕获局部依赖,却常忽略反映脑小世界组织的高阶拓扑结构。Transformer架构虽能建模全局依赖,但其高计算成本限制了对大规模连接脑网络的可扩展性。为应对这些挑战,我们提出拓扑约束图Transformer网络(TC-GTN),将脑网络拓扑显式整合到图学习中。TC-GTN结合两个互补模块:循环约束图卷积,捕获局部边聚合并建模模块化脑组织;最小生成树引导的Transformer,沿最小生成树(MST)路径约束全局注意力,在高效建模长程依赖的同时减少冗余通信。我们引入基于循环的边位置编码(CEPE),提供拓扑坐标系统,以区分局部结构相似但循环层级上下文不同的边。我们在分别由弥散加权成像(DWI)和功能磁共振成像(fMRI)提取的结构与功能脑网络上评估TC-GTN,使用大规模数据集,包括UK Biobank(38557名参与者;18100名女性/20457名男性;年龄40-70岁)和ABCD(7684名参与者;3782名女性/3902名男性;年龄9-10岁)。性别分类与脑龄估计实验表明,TC-GTN持续优于最先进的图网络方法,在准确性、可解释性和泛化性上更优。临床意义分析表明,该模型能准确刻画不同病理状态下的神经解剖差异。以脑龄差(BAG)作为生物标志物,在多发性硬化与痴呆中识别出系统性加速老化,并在卒中与帕金森病中伴随异质性结构改变。代码见https://github.com/bieqa/TC-GTN。
Accelerated brain aging is increasingly recognized as a transdiagnostic risk factor for neuropsychiatric and neurodegenerative disorders, yet its metabolic underpinnings remain poorly understood. Here we integrated multimodal neuroimaging (MRI), plasma metabolomics, and genomic data from the UK Biobank to identify metabolic markers of brain aging and evaluate their causal relevance. Using 1079 imaging-derived phenotypes (IDPs) from 4333 healthy participants, we trained and validated machine learning models for brain age prediction, with a least absolute shrinkage and selection operator (LASSO) regression model achieving the best performance (mean absolute error = 3.26 years, R² = 0.68). Brain age gap (BAG) was then estimated in 37,458 participants. Association analyses in 21,780 individuals identified nine plasma metabolites significantly linked to BAG after Bonferroni correction, with glucose showing the strongest effect (β = 0.32, P = 9.90 × 10⁻¹²). Genome-wide association studies (GWAS) identified 392 BAG-associated single-nucleotide polymorphisms (SNPs) (P < 5 × 10⁻⁸), and two-sample Mendelian randomization (MR) provided evidence supporting a potential causal role of glucose in accelerating brain aging. Clinically, elevated plasma glucose was positively associated with seven brain disorders, including all-cause dementia, Alzheimer's disease, vascular dementia, Parkinson's disease, stroke, depression, and anxiety, and negatively associated with cognitive performance, movement function, and mental health outcomes. Higher glucose concentrations were also associated with reduced regional brain volumes across 80 cortical, subcortical, and cerebellar regions. These findings implicate glucose metabolism as a modifiable pathway in brain aging, with implications for early intervention strategies aimed at preserving brain health across the lifespan.
中文摘要:加速脑衰老日益被视为神经精神和神经退行性疾病的跨诊断风险因素,其代谢基础仍不清楚。该研究整合英国生物银行的多模态神经影像(MRI)、血浆代谢组学和基因组数据,以识别脑衰老的代谢标志物并评估其因果相关性。利用4333名健康参与者的1079个影像衍生表型(IDP),训练并验证了脑年龄预测的机器学习模型,最小绝对收缩和选择算子(LASSO)回归模型表现最佳(平均绝对误差=3.26年,R²=0.68)。随后在37,458名参与者中估计脑年龄差(BAG)。在21,780名个体中进行的关联分析经Bonferroni校正后识别出9种与BAG显著相关的血浆代谢物,其中葡萄糖效应最强(β=0.32,P=9.90×10⁻¹²)。全基因组关联研究(GWAS)识别出392个与BAG相关的单核苷酸多态性(SNP)(P<5×10⁻⁸),两样本孟德尔随机化(MR)提供了支持葡萄糖在加速脑衰老中可能具有因果作用的证据。在临床层面,血浆葡萄糖升高与七种脑部疾病呈正相关,包括全因痴呆、阿尔茨海默病、血管性痴呆、帕金森病、卒中、抑郁和焦虑,并与认知表现、运动功能和心理健康结局呈负相关。较高的葡萄糖浓度还与80个皮层、皮层下和小脑脑区的区域脑体积减小相关。这些发现提示葡萄糖代谢是脑衰老中的可干预通路,对旨在全生命周期维护脑健康的早期干预策略具有意义。
The plasma proteomic signatures of sleep disturbance remain poorly characterized. Using data from 43,709 predominantly European-ancestry, middle-aged and older UK Biobank participants, we depict a large-scale atlas of plasma proteomic signatures of seven self-reported sleep traits (sleep duration, chronotype, insomnia symptoms, daytime napping, daytime sleepiness, snoring, and ease of getting up in the morning) and a derived sleep health score. We identify 935 proteins associated with at least one sleep trait, converging on lipid metabolism, immune function and inflammation, cell adhesion, and neurochemical signaling. Leveraging genomic structural equation modeling to define three latent sleep factors, namely circadian preference, daytime sleep burden, and nighttime sleep adequacy, bidirectional Mendelian randomization (MR) identifies one protein (LTA) with robust cis-instrument and strong colocalization support (PP.H4 = 0.98) for a putative causal effect on nighttime sleep adequacy. Sixteen additional genetically supported candidate proteins rely primarily on trans-pQTL instruments or weaker colocalization. These genetically supported candidates are prospectively associated with incident cardiovascular disease, stroke, type 2 diabetes, dementia, chronic kidney disease, depression, and mortality over a median 13.6-year follow-up, with the strongest per-SD hazard ratio (HR) associations observed for chronic kidney disease (e.g., BTN2A1: HR = 2.33) and type 2 diabetes (e.g., RBP5: HR = 1.58). Collectively, these findings highlight the potential of large-scale proteomics in elucidating sleep pathogenesis, and generate testable hypotheses for validation in independent cohorts and experimental models.
中文摘要:睡眠障碍的血浆蛋白质组特征仍缺乏充分刻画。基于43,709名以欧洲血统为主的中老年英国生物银行参与者数据,我们绘制了七项自报睡眠特征(睡眠时长、昼夜节律类型、失眠症状、日间小睡、日间嗜睡、打鼾、晨起难易程度)及一个衍生睡眠健康评分的血浆蛋白质组特征大规模图谱。我们识别出935种与至少一项睡眠特征相关的蛋白质,这些蛋白质汇聚于脂质代谢、免疫功能与炎症、细胞黏附和神经化学信号传导。利用基因组结构方程模型定义三个潜在睡眠因子,即昼夜偏好、日间睡眠负担和夜间睡眠充足性,双向孟德尔随机化(MR)识别出一种蛋白质(LTA),其顺式工具变量稳健且共定位支持强(PP.H4=0.98),提示对夜间睡眠充足性具有推定因果效应。另外16种遗传学支持的候选蛋白质主要依赖反式pQTL工具变量或较弱的共定位支持。这些遗传学支持的候选蛋白质在中位13.6年随访中与新发心血管疾病、卒中、2型糖尿病、痴呆、慢性肾脏病、抑郁和死亡前瞻性相关,其中每SD风险比(HR)关联最强见于慢性肾脏病(如BTN2A1:HR=2.33)和2型糖尿病(如RBP5:HR=1.58)。这些发现凸显大规模蛋白质组学在阐明睡眠发病机制方面的潜力,并产生可在独立队列和实验模型中验证的可检验假设。
基础研究 (2篇)
Traumatic brain injury (TBI) accelerates bone healing and induces heterotopic ossification, raising the question of whether an injured brain benefits from bone. Here we reveal that dynamic compressive tibial axial loading (DCTAL), a model of tibial bone compression, increased survival and promoted motor and cognitive recovery after stroke and TBI in mice, as well as in pig TBI models. DCTAL reduced neuron loss, attenuated chronic inflammation and astrogliosis and stimulated neuronal regeneration after TBI. Deletion of the mechanosensory channel Piezo1 in osteocytes reversed these benefits, while serum from DCTAL mice recapitulated them. Osteocytes transduced mechanical signals to directly secrete factors such as IL-1R2, APOL11a and HSP70, while indirectly increasing serum levels of BDNF, PF4 and dopamine. These factors synergistically protected against TBI. Altogether, we establish a bone-brain axis in which bone endocrine function can be modulated by mechanical forces to enhance brain repair after injury.
中文摘要:创伤性脑损伤(TBI)会加速骨愈合并诱导异位骨化,由此引出受损大脑是否可从骨骼获益的问题。本研究发现,胫骨动态轴向压缩加载(DCTAL)这一胫骨压缩模型,可提高小鼠卒中与TBI后的存活率并促进运动与认知恢复,在猪TBI模型中亦如此。DCTAL减少TBI后神经元丢失,减轻慢性炎症与星形胶质细胞增生,并刺激神经元再生。敲除骨细胞中的机械感受通道Piezo1可逆转这些获益,而DCTAL小鼠血清可重现上述获益。骨细胞将机械信号转导为直接分泌IL-1R2、APOL11a和HSP70等因子,同时间接提高血清BDNF、PF4和多巴胺水平。这些因子协同发挥抗TBI保护作用。研究确立了骨-脑轴,即骨骼内分泌功能可受机械力调控,从而增强损伤后脑修复。
Mitochondrial F1FO-ATPase is classically viewed as the "splendid" rotary nanomachine that sustains life by converting the proton-motive force (pmf) into ATP. Yet this same complex can adopt a second, context-dependent function that links bioenergetics to cell fate. When oxygen becomes limiting during ischemia, stroke, hypoxia, or anoxia, respiratory chain activity declines, pmf collapses, and the enzyme reverses direction: ATP hydrolysis drives rotor turnover and pumps H+ across the inner mitochondrial membrane to partially restore pmf. This reverse mode can be protective by preserving membrane potential and basic mitochondrial homeostasis, but it also imposes a severe energetic burden on the cell. A key determinant of whether F1FO-ATPase acts as an energy-conserving or energy-dissipating machine is the identity of the catalytic divalent cation. Under physiological conditions, Mg2+ supports efficient, reversible ATP synthesis/hydrolysis. In pathology, mitochondrial Ca2+ overload may replace Mg2+ at catalytic sites, shifting catalysis toward ATP hydrolysis and promoting an ATP-wasting state that triggers mitochondrial permeability transition pore (mPTP) formation and regulated cell death. Thus, ATP hydrolysis by F1FO-ATPase beyond regulation by pmf and inhibitory proteins such as IF1, cation cofactor selection emerges as a decisive switch that repurposes the enzyme from "enzyme of life" to "enzyme of death." Here, this cofactor-dependent reversibility is framed as a moonlighting role of F1FO-ATPase, integrating energy conversion with death signaling. Conceptual questions are outlined to resolve current debate and to exploit this switch for therapeutic insight.
中文摘要:线粒体F1FO-ATP酶通常被视为维持生命的「卓越」旋转纳米机器,通过将质子动力势(pmf)转化为ATP。该复合物也可采用第二种依赖情境的功能,把生物能量学与细胞命运联系起来。缺血、卒中、缺氧或无氧时氧供受限,呼吸链活性下降,pmf崩溃,酶反向运转:ATP水解驱动转子转动并跨线粒体内膜泵出H+,以部分恢复pmf。反向模式可通过维持膜电位和基本线粒体稳态发挥保护作用,但也给细胞带来严重能量负担。F1FO-ATP酶作为保能机器还是耗能机器的关键决定因素,是催化二价阳离子的种类。生理条件下,Mg2+支持高效、可逆的ATP合成与水解。病理情况下,线粒体Ca2+超载可在催化位点取代Mg2+,使催化偏向ATP水解并促进耗ATP状态,触发线粒体通透性转换孔(mPTP)形成和调节性细胞死亡。因此,除受pmf和IF1等抑制蛋白调控外,F1FO-ATP酶的ATP水解还受阳离子辅因子选择的影响,后者成为决定性的开关,使该酶从「生命之酶」转变为「死亡之酶」。这里将这种依赖辅因子的可逆性视为F1FO-ATP酶的兼职功能,将能量转换与死亡信号整合起来,并提出若干概念性问题,以化解当前争议并利用该开关获得治疗启示。
7心房颤动 (8篇)
临床研究 (6篇)
To characterize sex-specific differences in clinical presentation, evaluate progression through the atrial fibrillation (AF) care pathway from diagnosis to catheter ablation (CA) and assess long-term outcomes. This was a retrospective cohort study of patients with incident AF at Northwell Health between 2015 and 2024 from the ITHACA-database. Sex-specific differences in clinical presentation were examined. The AF care pathway was operationalized as a stepwise cascade, modelling conditional drop-off to identify care gaps. Sex-specific CA risk ratios were assessed via Poisson regression. Incident AF was identified among 165 563/655 459 patients (71.4 ± 11.6 years, 32% non-white, 45% female) with a recorded diagnosis of AF. Women were older (73.3 ± 10.6 vs. 69.8 ± 12.1 years, P < 0.001), had higher rates of dementia (9.1% vs. 5.2%), stroke (8.6% vs. 7.4%) and congestive heart failure (21.5% vs. 20.8%) at diagnosis. Transfer-of-care gaps [median 3.6 years follow-up, 96% retention] were identified at every level: 31.5% of women vs. 35.3% of men were evaluated by cardiology, 16.2% vs. 21.6% by electrophysiology, and 3.5% vs. 5.7% underwent CA (all P < 0.001). Women were 16% less likely to receive CA (RR 0.84 95% CI 0.77-0.91). In cause-specific Cox models, female sex was associated with incident stroke (aHR 1.24, 95% CI 1.18-1.30) and dementia (aHR 1.30, 95% CI 1.24-1.35), but modestly lower mortality after adjustment (aHR 0.96, 95% CI 0.94-0.99). In this real-world analysis, significant sex-specific differences in clinical phenotype at presentation, progression through the AF care pathway and clinical outcomes were observed.
中文摘要:旨在刻画心房颤动(AF)患者在临床表现上的性别差异,评估从诊断到导管消融(CA)的AF诊疗路径进展,并分析长期结局。该研究为回顾性队列研究,数据来自ITHACA数据库,纳入Northwell Health在2015—2024年间的新发AF患者。研究考察临床表现的性别差异,并将AF诊疗路径设为阶梯式级联,通过条件脱落建模识别诊疗缺口。采用Poisson回归评估性别相关的CA风险比。在655459例有AF诊断记录的患者中识别出165563例新发AF(71.4±11.6岁,32%为非白人,45%为女性)。女性诊断时年龄更大(73.3±10.6岁对69.8±12.1岁,P<0.001),痴呆(9.1%对5.2%)、卒中(8.6%对7.4%)和充血性心力衰竭(21.5%对20.8%)比例更高。中位随访3.6年、96%保留率下,各层级均存在诊疗转接缺口:女性31.5%对男性35.3%接受心内科评估,16.2%对21.6%接受电生理评估,3.5%对5.7%接受CA(均P<0.001)。女性接受CA的可能性低16%(RR 0.84,95%CI 0.77-0.91)。在病因特异性Cox模型中,女性与发生卒中(aHR 1.24,95%CI 1.18-1.30)和痴呆(aHR 1.30,95%CI 1.24-1.35)相关,但校正后死亡率略低(aHR 0.96,95%CI 0.94-0.99)。在这项真实世界分析中,观察到临床表现、AF诊疗路径进展及临床结局存在显著性别差异。
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].
中文摘要:GIM/FP/GP:[公式:见正文]。心脏病学:[公式:见正文]。
AbstractAtrial fibrillation is the most common cardiac arrhythmia in the world. In clinical trials evaluating interventions for atrial fibrillation, outcomes have been traditionally defined using a thirty second arrhythmia end point. In this Clinical Trials Workshop, we evaluate the role of atrial fibrillation burden as a primary outcome for atrial fibrillation intervention trials. In particular, we evaluate key considerations for ascertainment, definition, and analysis of atrial fibrillation burden while further considering regulatory implications of its use as a primary end point.
中文摘要:心房颤动是全球最常见的心律失常。在评估心房颤动干预措施的临床试验中,结局传统上采用30秒心律失常终点来定义。本次临床试验研讨会评估心房颤动负荷作为心房颤动干预试验主要结局的作用,重点讨论心房颤动负荷的确认、定义和分析中的关键考量,并进一步思考将其用作主要终点的监管含义。
Ninety percent of left atrial thrombi in nonvalvular atrial fibrillation arise in the left atrial appendage, which can be occluded percutaneously (left atrial appendage closure [LAAC]). Two 2026 trials (CHAMPION-AF [Watchman Flx Versus Non-Vitamin K Antagonist Oral Anticoagulant for Embolic Protection in the Management of Patients With Non-Valvular Atrial Fibrillation] and CLOSURE-AF [Left Atrial Appendage Closure in Patients With Atrial Fibrillation Compared to Medical Therapy]) more than doubled the available randomized evidence comparing LAAC with oral anticoagulation. We evaluated pooled effects of LAAC on stroke, bleeding, and mortality by bleeding risk, anticoagulation eligibility, and comparator. In this systematic review and meta-analysis, we searched PubMed, Scopus, and Embase from inception to April 15, 2026, for randomized controlled trials comparing percutaneous LAAC with oral anticoagulation in nonvalvular atrial fibrillation. Risk of bias was assessed with the Cochrane Risk of Bias 2 tool. Cumulative-incidence outcomes were pooled as odds ratios using random-effects models, with prediction intervals, prespecified subgroups, and trial sequential analysis. Six randomized controlled trials (2014-2026; 358 sites in North America, Europe, and Asia; 7028 patients) compared LAAC with warfarin (2 trials) or a direct oral anticoagulant (4 trials); populations were predominantly anticoagulation-eligible with low prior-stroke prevalence, plus 2 high-bleeding-risk and 1 postablation trial. Overall stroke rates were similar between arms (odds ratio, 1.10 [95% CI, 0.78-1.56]). Ischemic stroke was more frequent with LAAC (odds ratio, 1.41 [95% CI, 1.07-1.86]) but did not reach the required information size. Nonprocedural bleeding was lower with LAAC (odds ratio, 0.58 [95% CI, 0.35-0.96]), the only outcome reaching a sufficient information size, in standard-risk and postablation but not high-bleeding-risk patients. LAAC is best positioned to reduce nonprocedural bleeding in anticoagulation-eligible patients at standard-to-moderate bleeding risk, rather than as a stroke-equivalent substitute for oral anticoagulation. URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD420261370546.
中文摘要:非瓣膜性心房颤动中90%的左心房血栓起源于左心耳,左心耳可经皮封堵(LAAC)。2026年的两项试验(CHAMPION-AF 和 CLOSURE-AF)使比较LAAC与口服抗凝的随机证据增加了一倍以上。我们按出血风险、抗凝适应证和对照措施评估LAAC对卒中、出血和死亡率的汇总效应。在这项系统综述和荟萃分析中,检索PubMed、Scopus和Embase自建库至2026年4月15日,纳入比较经皮LAAC与口服抗凝治疗非瓣膜性心房颤动的随机对照试验。使用Cochrane Risk of Bias 2工具评估偏倚风险。累积发生率结局以随机效应模型合并为比值比,并计算预测区间、预设亚组和试验序贯分析。六项随机对照试验(2014-2026;北美、欧洲和亚洲358个中心;7028例患者)比较LAAC与华法林(2项试验)或直接口服抗凝药(4项试验);人群以抗凝适应证为主,既往卒中患病率低,另有2项高出血风险和1项消融后试验。总体卒中率两组相似(比值比1.10 [95% CI 0.78-1.56])。LAAC组缺血性卒中更常见(比值比1.41 [95% CI 1.07-1.86]),但未达到所需信息量。LAAC组非手术相关出血较低(比值比0.58 [95% CI 0.35-0.96]),这是唯一达到足够信息量的结局,在标准风险及消融后患者中可见,高出血风险患者中未见。LAAC最适合用于降低抗凝适应证且标准至中度出血风险患者的非手术相关出血,而非作为口服抗凝的等效卒中替代。URL: https://www.crd.york.ac.uk/PROSPERO/;注册号:CRD420261370546。
Atrial fibrillation (AF) is frequently accompanied by hypertension; however, the relationship between mid-term blood pressure variability (BPV) assessed using home blood pressure (BP) measurements and prognosis in patients with AF remains unclear. We examined the association between home BPV and cardiovascular outcomes in elderly patients with non-valvular AF using data from the ANAFIE (All Nippon AF In the Elderly) Registry. This post hoc analysis of a prospective registry included 4885 patients aged ≥75 years who performed standardized home BP measurements in the morning and evening (two measurements at each time point) over seven consecutive days. Mid-term BPV was quantified using the coefficient of variation of systolic home BP and categorized into quartiles. The primary endpoint was a net cardiovascular outcome, defined as a composite of stroke, systemic embolism, and major bleeding. Associations were assessed using multivariable Cox proportional hazards models adjusted for mean BP and established risk factors. Over a median follow-up of two years, the net cardiovascular outcome occurred in 171 patients. Compared with the lowest BPV quartile, patients in the highest quartile had a significantly higher risk of the net cardiovascular outcome (HR 2.03, 95% CI 1.21-3.40). Higher risks were also observed for stroke/systemic embolism, intracranial hemorrhage, and bleeding. Findings were consistent when BPV was assessed using the standard deviation and across subgroups. In conclusion, greater mid-term home BPV was independently associated with increased cardiovascular risk beyond average BP in elderly patients with non-valvular AF.
中文摘要:心房颤动常伴高血压;但通过家庭血压测量评估的中期血压变异性(BPV)与房颤患者预后的关系仍不明确。利用ANAFIE(All Nippon AF In the Elderly)注册研究数据,分析老年非瓣膜性房颤患者家庭BPV与心血管结局的关联。这项前瞻性注册研究的事后分析纳入4885例年龄≥75岁患者,患者连续7天于早晚进行标准化家庭血压测量(每个时间点测量两次)。中期BPV以家庭收缩压变异系数量化,并按四分位数分组。主要终点为净心血管结局,定义为卒中、系统性栓塞和大出血的复合终点。采用多变量Cox比例风险模型评估关联,并校正平均血压及已确定危险因素。中位随访两年期间,171例患者发生净心血管结局。与BPV最低四分位组相比,最高四分位组净心血管结局风险显著升高(HR 2.03,95% CI 1.21-3.40)。卒中/系统性栓塞、颅内出血和出血风险也升高。以标准差评估BPV及进行亚组分析时,结果一致。结论:在老年非瓣膜性房颤患者中,较高的中期家庭BPV与心血管风险增加独立相关,且这一关联超出平均血压的影响。
Recent clinical trials have reported an increased risk for atrial fibrillation (AF) in individuals treated with omega-3 fatty acids (FA). As virtually all these studies were conducted with pharmaceutical omega-3 FA preparations in populations at higher risk for cardiovascular disease (CVD), it is unclear to what extent these findings apply to the general population consuming omega-3 FA either from oily fish or from omega-3 FA supplements. Based on an updated meta-analysis reviewed here, consumption of up to 1500 mg/day (and possibly 2400 mg/day) of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) from food or dietary supplements in the general adult population does not appear to significantly increase risk for AF. Indeed, the preponderance of the evidence suggests that chronic intakes in this range are associated with lower risk for AF (and other CVD outcomes) in the general population. For individuals at high risk for CVD, treatment with EPA+DHA doses of >1500 mg/day might increase the absolute risk for AF (by <1%) and the relative risk (by ∼43%). Because of the favorable effects of EPA+DHA on CVD (and other health) outcomes, our view is that, for the general population, intakes of EPA+DHA afford several health benefits and do not meaningfully increase the risk for AF. For patients with prevalent CVD or at high risk for CVD, the risk-benefit ratio for EPA+DHA intake is favorable, especially for intakes up to 1500 mg/day, but also at higher doses where there may be increased risk for AF.
中文摘要:近期临床试验报告,接受omega-3脂肪酸治疗的人群房颤风险增加。这些研究几乎均使用药用omega-3脂肪酸制剂,且人群心血管病风险较高,因此尚不清楚这些发现能在多大程度上适用于通过油性鱼或omega-3脂肪酸补充剂摄入omega-3脂肪酸的一般人群。基于本文综述的一项更新meta分析,一般成年人群从食物或膳食补充剂摄入每日至多1500 mg(可能至2400 mg)二十碳五烯酸(EPA)加二十二碳六烯酸(DHA),似乎并未显著增加房颤风险。多数证据提示,这一范围内的长期摄入与一般人群较低的房颤风险及其他心血管结局风险相关。对于心血管病高风险个体,每日EPA+DHA剂量超过1500 mg可能增加房颤绝对风险(不足1%)和相对风险(约43%)。鉴于EPA+DHA对心血管及其他健康结局的有利作用,我们认为一般人群摄入EPA+DHA可获得多项健康获益,且不会实质性增加房颤风险。对于已有心血管病或心血管病高风险患者,EPA+DHA摄入的风险获益比有利,尤其是每日至多1500 mg的摄入;更高剂量下房颤风险可能增加,但风险获益比仍有利。
基础研究 (2篇)
Atrial fibrillation (AF) often progresses from paroxysmal to more stable forms. It is well-recognized that patients vary in their AF progression, but the underlying mechanisms remain unclear. This work, performed in a sheep AF-model, aimed to identify atrial redox and energetic status differences between animals developing stable AF (AF-S) versus those resistant to AF-stabilization (AF-R). AF was induced with bursts of atrial tachystimulation, maintained whenever sinus rhythm resumed, and monitored with telemetry. Electrophysiological and structural remodeling were assessed via contact mapping, and histology, respectively. Proteomic, metabolomic, enzymatic, and bioenergetic remodeling were evaluated using left atrial appendage (LAA) tissues and isolated LAA mitochondria. Healthy rats were used to investigate whether a metabolic challenge stabilizes electrically induced AF episodes. AF-S (N = 12) sheep developed stable AF after 13 days on average, whereas AF-R (N = 8) sheep failed to develop self-sustained AF despite 120 days of tachypacing. Contact mapping and histological analysis revealed that AF-S animals presented reduced atrial conduction velocity, and increased endomysial fibrosis. Metabolic analysis showed significant differences in tricarboxylic acid cycle (TCA) enzymes activities and a 45% succinate content increase in AF-S LAA versus AF-R. AF-S mitochondria showed abnormal succinate oxidation, decreased ATP synthesis rate, and increased ROS emission. The ratios of ATP/ADP, NAD+/NADH, and Complex I/II activities were disturbed in AF-S compared to AF-R. Calculated mitochondrial NAD+/NADH ratios suggest an oxidized state in AF-S while AF-R showed a reduced state. Exogenous succinate was metabolized when incubated with rat atrial cardiomyocytes, while intravenous succinate injection stabilized atrial arrhythmias electrically-induced in vivo. AF-S sheep showed TCA cycle, energetic and redox adaptations compared to AF-R. In this animal model, TCA cycle remodeling and associated redox and energetic responses determined the resistance to AF domestication, with potential relevance to identify new mechanistic determinants of AF progression in humans.
中文摘要:心房颤动(AF)常由阵发性进展为更稳定的形式。患者AF进展存在差异已获广泛认识,但其机制仍不清楚。本研究在绵羊AF模型中开展,旨在识别发展为稳定AF(AF-S)与对AF稳定化抵抗(AF-R)动物之间心房氧化还原和能量状态的差异。AF以心房快速起搏串刺激诱发,窦性心律恢复时继续维持起搏,并用遥测监测。分别通过接触标测和组织学评估电生理与结构重构。利用左心耳组织和分离的左心耳线粒体评估蛋白质组、代谢组、酶学和生物能量学重构。使用健康大鼠研究代谢挑战是否稳定电诱发AF发作。AF-S(N=12)绵羊平均13天后发展为稳定AF,而AF-R(N=8)绵羊尽管快速起搏120天仍未发展为自维持AF。接触标测和组织学分析显示AF-S动物心房传导速度降低,肌内膜纤维化增加。代谢分析显示AF-S与AF-R相比左心耳三羧酸循环(TCA)酶活性存在显著差异,琥珀酸含量增加45%。AF-S线粒体表现为琥珀酸氧化异常、ATP合成速率降低和ROS释放增加。与AF-R相比,AF-S中ATP/ADP、NAD+/NADH比值及复合体I/II活性发生紊乱。计算得到的线粒体NAD+/NADH比值提示AF-S处于氧化状态,而AF-R处于还原状态。外源性琥珀酸与大鼠心房心肌细胞孵育时可被代谢,静脉注射琥珀酸则可稳定体内电诱发的心房心律失常。与AF-R相比,AF-S绵羊表现出TCA循环、能量和氧化还原适应。在该动物模型中,TCA循环重构及相关氧化还原与能量反应决定了对AF稳定化的抵抗,这可能有助于识别人类AF进展的新机制决定因素。
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is promoted by atrial fibrosis, a form of structural remodelling for which effective therapies are lacking. MicroRNA-31-5p (miR-31-5p), an aging-associated, atrial-enriched microRNA, has been linked to AF, but its role in atrial fibrosis is unknown. Here we show that atrial fibroblasts from patients with persistent AF exhibit increased miR-31-5p expression and reduced expression of the calcitonin receptor (CTR, encoded by CALCR). MiR-31-5p directly represses CTR and promotes pro-fibrotic fibroblast responses, whereas its inhibition restores CTR expression. Fibroblast-specific overexpression of miR-31 in mice reduces atrial CTR expression, increases atrial fibrosis and enhances arrhythmia susceptibility. Selective disruption of miR-31-5p-CALCR binding using a locked nucleic acid target site blocker restores atrial CTR expression, prevents fibrosis progression and reduces arrhythmia burden. In mice with established atrial remodeling, this strategy promotes fibrosis regression, identifying the miR-31-5p-CTR axis as a potential therapeutic target in AF.
中文摘要:心房颤动(AF)是最常见的持续性心律失常,受心房纤维化促进,后者是一种结构性重构,缺乏有效治疗。microRNA-31-5p(miR-31-5p)是一种与衰老相关、在心房富集的microRNA,已被与AF联系起来,但其在心房纤维化中的作用尚不清楚。这里显示,持续性AF患者的心房成纤维细胞中miR-31-5p表达增加,降钙素受体(CTR,由CALCR编码)表达降低。MiR-31-5p直接抑制CTR并促进促纤维化成纤维细胞反应,而抑制miR-31-5p可恢复CTR表达。小鼠成纤维细胞特异性过表达miR-31会降低心房CTR表达、增加心房纤维化并增强心律失常易感性。使用锁核酸靶位点阻断剂选择性破坏miR-31-5p-CALCR结合可恢复心房CTR表达、阻止纤维化进展并降低心律失常负荷。在已建立心房重构的小鼠中,该策略促进纤维化消退,确定miR-31-5p-CTR轴是AF的潜在治疗靶点。
8心肌病/心肌炎 (6篇)
临床研究 (3篇)
Fulminant myocarditis (FM) is a complex clinical syndrome characterized by acute myocardial inflammation and cardiogenic shock. Evidence on long-term outcomes, mortality risk factors, and targeted treatment options remains limited. This retrospective analysis included consecutive adult patients admitted for FM between January 2012 and November 2022 at 26 European tertiary centres. According to endomyocardial biopsy (EMB) findings, patients were categorized as lymphocytic (LM), eosinophilic (EM), necrotizing eosinophilic (NEM), and giant-cell myocarditis (GCM) for the main analyses. Patients with inconclusive histopathology and those who did not undergo EMB were analysed separately. Primary outcomes were in-hospital and 1-year mortality. Multivariable logistic regression models were employed as generalized linear models to analyse the association of prespecified risk factors with mortality. Estimated associations are reported as odds ratios, generalized marginal effects, and adjusted prediction plots. A total of 271 patients [median age 43 years (interquartile range: 33-55 years), 58% male] were included in the analysis, of whom 146 fulfilled histopathologic criteria of LM (n = 99), EM (n = 18), NEM (n = 3), or GCM (n = 26). In the remaining 125 cases, EMB was inconclusive (n = 48) or not performed (n = 77). While there were no significant differences in cardiac arrest rate, admission Simplified Acute Physiology Score (SAPS) II, ventricular function, initial pH, and liver and kidney function parameters between histopathologic subgroups, the use of immunosuppressive medications and need for organ replacement varied. In the overall population, in-hospital and 1-year mortality were 31% and 34%, respectively. The highest 1-year mortality rate was observed among patients with GCM (LM: 25%, EM: 28%, NEM: 33%, GCM: 54%, P = .04). Patients who survived to discharge had an excellent functional outcome and long-term recovery of ventricular function. In total, 17 patients (6%) received a heart transplant during follow-up. Older age, lower pH, and histopathologic diagnosis of GCM were independently associated with in-hospital and 1-year mortality. In-hospital mortality among patients with FM remains high. Age, pH, and histopathological findings may serve as prognostic markers to identify high-risk patients and to guide treatment strategies. Long-term outcomes are excellent among those who survive to discharge.
中文摘要:暴发性心肌炎(FM)是一种以急性心肌炎症和心源性休克为特征的复杂临床综合征,长期结局、死亡危险因素及针对性治疗选择的证据仍有限。本回顾性分析纳入2012年1月至2022年11月在26家欧洲三级中心连续收治的成年FM患者。依据心内膜心肌活检(EMB)结果,将患者分为淋巴细胞性(LM)、嗜酸性(EM)、坏死性嗜酸性(NEM)和巨细胞性心肌炎(GCM)用于主要分析;组织病理学结果不确定及未行EMB者单独分析。主要结局为院内死亡率和1年死亡率。采用多变量logistic回归模型作为广义线性模型分析预设危险因素与死亡率的关联,估计关联以比值比、广义边际效应和调整预测图报告。共纳入271例患者,中位年龄43岁(四分位距33-55岁),男性占58%,其中146例符合LM(n=99)、EM(n=18)、NEM(n=3)或GCM(n=26)的组织病理学标准;其余125例中,EMB结果不确定48例,未行EMB 77例。各组织病理学亚组间心脏骤停发生率、入院简化急性生理评分(SAPS)II、心室功能、初始pH及肝肾功能指标无显著差异,但免疫抑制药物使用和器官替代治疗需求存在差异。总体人群中,院内死亡率和1年死亡率分别为31%和34%。1年死亡率最高者为GCM患者(LM:25%,EM:28%,NEM:33%,GCM:54%,P=0.04)。存活至出院的患者功能结局良好,心室功能长期恢复。随访期间共17例(6%)接受心脏移植。较高年龄、较低pH及GCM的组织病理学诊断与院内死亡率和1年死亡率独立相关。FM患者院内死亡率仍较高,年龄、pH和组织病理学发现可作为预后标志物用于识别高危患者并指导治疗策略;存活至出院者长期结局良好。
In HELIOS-B (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy), vutrisiran reduced the risk of all-cause mortality (ACM) and recurrent cardiovascular events and slowed disease progression measures versus placebo in patients with TTR (transthyretin) amyloidosis with cardiomyopathy after 33 to 36 months. We report the long-term efficacy and safety of vutrisiran from an ongoing open-label extension of HELIOS-B. Patients who completed HELIOS-B could enroll in the open-label extension, continuing with vutrisiran 25 mg every 3 months (continuous vutrisiran) or, if previously receiving placebo, initiating vutrisiran 25 mg every 3 months (placebo/vutrisiran). Prespecified end points assessed in the open-label extension are the composite of ACM and cardiovascular events, ACM, Kansas City Cardiomyopathy Questionnaire-Overall Summary score, New York Heart Association class, and NT-proBNP (N-terminal pro-B-type natriuretic peptide) and troponin I levels. Outcomes were assessed through month 48 in this analysis. Of 654 participants in HELIOS-B (vutrisiran, n=326; placebo, n=328), 478 completed double-blind treatment and 466 (vutrisiran, n=243; placebo, n=223) entered the open-label extension. In the continuous vutrisiran group, the risk of first cardiovascular event or ACM was reduced by 37% (hazard ratio, 0.63 [95% CI, 0.51, 0.79]; P=0.0001) and ACM by 37% (hazard ratio, 0.63 [95% CI, 0.46, 0.84]; P=0.0023) versus the placebo/vutrisiran group. Through month 48, patients in the continuous vutrisiran group had preserved health status and quality of life per Kansas City Cardiomyopathy Questionnaire-Overall Summary score (least squares mean difference, 9.0 [95% CI, 5.3, 12.6]; P<0.0001) and more patients had improved or stable New York Heart Association class (odds ratio, 1.6 [95% CI, 1.1, 2.2]; P=0.0084) versus the placebo/vutrisiran group. Benefits in the continuous vutrisiran group were maintained for NT-proBNP and troponin I levels (adjusted geometric mean fold change ratios, 0.66 [95% CI, 0.58, 0.74]; P<0.0001; and 0.71 [95% CI, 0.64, 0.79]; P<0.0001, respectively) versus the placebo/vutrisiran group. Similar benefits were observed in the vutrisiran monotherapy population. No new safety signals were observed. Long-term vutrisiran resulted in clinically meaningful benefits across mortality, cardiovascular events, cardiac biomarkers, functional status, and quality of life in patients with TTR amyloidosis with cardiomyopathy through month 48. Patients initially treated with vutrisiran had better outcomes than those first receiving placebo, highlighting the importance of early diagnosis and treatment in TTR amyloidosis with cardiomyopathy. URL: https://www.clinicaltrials.gov; Unique identifier: NCT04153149.
中文摘要:HELIOS-B 研究在转甲状腺素蛋白(TTR)淀粉样变性伴心肌病患者中评估了 vutrisiran,33 至 36 个月时,与安慰剂相比,vutrisiran 降低了全因死亡(ACM)与复发性心血管事件的风险,并延缓了疾病进展指标。本文报告 HELIOS-B 正在进行的开放标签延伸期中长期疗效与安全性。完成 HELIOS-B 的患者可进入开放标签延伸期,继续使用 vutrisiran 25 mg 每 3 个月一次(持续 vutrisiran 组),或若先前使用安慰剂则开始 vutrisiran 25 mg 每 3 个月一次(安慰剂/vutrisiran 组)。开放标签延伸期的预设终点包括 ACM 与心血管事件的复合终点、ACM、堪萨斯城心肌病问卷总体汇总评分、纽约心功能分级,以及 NT-proBNP 和肌钙蛋白 I 水平。本次分析评估至第 48 个月的结果。HELIOS-B 共纳入 654 例受试者(vutrisiran 组 n=326,安慰剂组 n=328),478 例完成双盲治疗,466 例进入开放标签延伸期(vutrisiran 组 n=243,安慰剂组 n=223)。与安慰剂/vutrisiran 组相比,持续 vutrisiran 组首次心血管事件或 ACM 风险降低 37%(风险比 0.63,95% CI 0.51–0.79;P=0.0001),ACM 风险降低 37%(风险比 0.63,95% CI 0.46–0.84;P=0.0023)。至第 48 个月,持续 vutrisiran 组按堪萨斯城心肌病问卷总体汇总评分评估的健康状况与生活质量得以维持(最小二乘均值差 9.0,95% CI 5.3–12.6;P<0.0001),纽约心功能分级改善或稳定的患者比例更高(比值比 1.6,95% CI 1.1–2.2;P=0.0084)。持续 vutrisiran 组在 NT-proBNP 与肌钙蛋白 I 水平上的获益也得以保持(校正几何均值倍数变化比分别为 0.66,95% CI 0.58–0.74;P<0.0001,以及 0.71,95% CI 0.64–0.79;P<0.0001)。vutrisiran 单药治疗人群观察到相似获益。未发现新的安全性信号。长期 vutrisiran 治疗至第 48 个月在 TTR 淀粉样变性伴心肌病患者的死亡、心血管事件、心脏生物标志物、功能状态与生活质量方面带来具有临床意义的获益。最初即接受 vutrisiran 治疗的患者结局优于先接受安慰剂者,提示早期诊断与治疗在 TTR 淀粉样变性伴心肌病中的重要性。URL: https://www.clinicaltrials.gov;唯一标识:NCT04153149。
Fibrosis assessed through late gadolinium enhancement (LGE) in cardiac magnetic resonance imaging and genetics have emerged as risk markers of ventricular arrhythmias in nonischemic dilated cardiomyopathy. Conduction corridors detected within LGE (ie, LGE corridors) have been associated with ventricular arrhythmias in ischemic cardiomyopathy. This study sought to evaluate major ventricular arrhythmic events (MVAs) according to the presence of LGE corridors combined with high-risk genotypes (HRGs) in nonischemic dilated cardiomyopathy. We studied consecutive patients with nonischemic dilated cardiomyopathy from 22 European centers who had undergone genetic testing and cardiac magnetic resonance imaging. Among 925 patients (mean age, 54.5 years [interquartile range, 43.7-63.9 years]; 64% men; mean left ventricular ejection fraction, 37.6% [26.9%-44.8%]; LGE in 24.3%), LGE corridors were present in 160 patients (17.3%), and HRG in 119 (12.9%). After a median follow-up of 5.4 years (interquartile range, 3.3-7.7), 95 patients (10.3%) experienced an MVA. In multivariable competing-risk analysis adjusted for left ventricular ejection fraction and extent of LGE, the number of LGE corridors and HRGs were independently associated with MVA (subdistribution hazard ratio, 1.25 [95% CI, 1.11-1.42]; P<0.001; and subdistribution hazard ratio, 2.28 [95% CI, 1.32-3.96]; P=0.003, respectively). An optimal cutoff of ≥4 LGE corridors predicted MVA. A stepwise risk stratification algorithm to predict MVA integrating LGE, the presence of ≥4 LGE corridors, and HRG outperformed left ventricular ejection fraction ≤35%-based classification proposed in guidelines (5-year time-dependent area under the curve, 0.72 [95% CI, 0.65-0.78] versus 0.57 [95% CI, 0.51-0.64]; P=0.001), showing a progressive increase in arrhythmic risk across categories (Gray test P<0.001), and allowing clinically meaningful arrhythmic risk classification. LGE corridors and HRGs provide additive value for arrhythmic risk stratification in patients with nonischemic dilated cardiomyopathy. These findings support MVA multiparametric prediction over the traditional left ventricular ejection fraction ≤35% threshold.
中文摘要:通过心脏磁共振晚期钆增强评估的纤维化与遗传学已成为非缺血性扩张型心肌病室性心律失常的风险标志物。在LGE范围内检测到的传导走廊(即LGE走廊)与缺血性心肌病室性心律失常相关。本研究旨在评估非缺血性扩张型心肌病中依据LGE走廊存在情况及高风险基因型(HRG)分层的重大室性心律失常事件(MVA)。我们研究了来自22个欧洲中心的连续非缺血性扩张型心肌病患者,这些患者接受了基因检测和心脏磁共振检查。925例患者中(平均年龄54.5岁[四分位距43.7-63.9岁];64%男性;平均左心室射血分数37.6%[26.9%-44.8%];24.3%存在LGE),160例(17.3%)存在LGE走廊,119例(12.9%)存在HRG。中位随访5.4年(四分位距3.3-7.7年)后,95例(10.3%)发生MVA。在调整左心室射血分数和LGE范围的多变量竞争风险分析中,LGE走廊数量和HRG与MVA独立相关(亚分布风险比1.25[95% CI 1.11-1.42];P<0.001;亚分布风险比2.28[95% CI 1.32-3.96];P=0.003)。≥4条LGE走廊的最佳截断值可预测MVA。整合LGE、≥4条LGE走廊和HRG的逐步风险分层算法预测MVA优于指南提出的基于左心室射血分数≤35%的分类(5年时间依赖曲线下面积0.72[95% CI 0.65-0.78]对0.57[95% CI 0.51-0.64];P=0.001),显示各分类间心律失常风险逐步升高(Gray检验P<0.001),并可实现具有临床意义的心律失常风险分类。LGE走廊和HRG为非缺血性扩张型心肌病患者心律失常风险分层提供附加价值。这些发现支持采用MVA多参数预测,而非传统的左心室射血分数≤35%阈值。
基础研究 (3篇)
Fulminant myocarditis (FM) is an acute inflammatory cardiomyopathy with high risk of cardiogenic shock. Current management relies largely on circulatory support, while mechanism-based pharmacological targets remain poorly defined. Cardiac CD45+ single-cell RNA sequencing, whole-heart single-nucleus RNA sequencing, ligand-target inference, spatial validation, and human plasma/myocardial analyses were integrated to define disease-associated cellular interactions. CCR2+ macrophage sorting, macrophage depletion, CVB3-stimulated BMDMs, transcription-factor perturbation, ChIP-qPCR, and promoter assays defined the source and regulation of OSM. OSM signaling was examined using recombinant OSM, OSM-neutralizing antibody, macrophage Osm knockdown, cardiomyocyte Osmr silencing, and STAT3/ERK1/2 inhibition, followed by transcriptomic, mitochondrial, contractile, and in vivo analyses. FM featured expansion of CCR2+ inflammatory macrophages, cardiomyocyte inflammatory/stress remodeling, and enhanced macrophage-to-cardiomyocyte OSM-OSMR signaling. Circulating OSM was increased in patients with FM and correlated with higher NT-proBNP and cTnI and lower LVEF. OSM was produced predominantly by CCR2+ macrophages and transcriptionally induced by IRF1 after CVB3 stimulation. Recombinant OSM aggravated mortality, systolic dysfunction, myocardial inflammation, and cardiac injury. In cardiomyocytes, OSM activated OSMR-dependent STAT3/ERK1/2 signaling and impaired mitochondrial bioenergetics, contractility, and Ca²+ handling. OSM neutralization and macrophage Osm knockdown improved cardiomyocyte respiration and sarcomere shortening after exposure to CVB3-activated macrophage conditioned medium. In vivo, OSM neutralization improved survival, cardiac function, myocardial inflammation, mitochondrial integrity, and ATP content. Macrophage OSM links inflammatory myeloid activation to cardiomyocyte mitochondrial and contractile failure in experimental FM. OSM-OSMR signaling is a candidate mechanism-based pharmacological target for acute inflammatory cardiac dysfunction.
中文摘要:暴发性心肌炎(FM)是一种急性炎症性心肌病,心源性休克风险高。当前治疗主要依赖循环支持,基于机制的药物靶点仍不明确。研究整合心脏CD45+单细胞RNA测序、全心脏单核RNA测序、配体-靶点推断、空间验证以及人血浆/心肌分析,以界定疾病相关细胞互作。通过CCR2+巨噬细胞分选、巨噬细胞清除、CVB3刺激的骨髓来源巨噬细胞(BMDMs)、转录因子扰动、ChIP-qPCR和启动子实验,明确OSM的来源与调控。利用重组OSM、OSM中和抗体、巨噬细胞Osm敲低、心肌细胞Osmr沉默和STAT3/ERK1/2抑制检查OSM信号,随后进行转录组、线粒体、收缩功能及体内分析。FM表现为CCR2+炎症巨噬细胞扩增、心肌细胞炎症/应激重塑以及巨噬细胞向心肌细胞OSM-OSMR信号增强。FM患者循环OSM升高,并与较高NT-proBNP和cTnI及较低LVEF相关。OSM主要由CCR2+巨噬细胞产生,并在CVB3刺激后由IRF1转录诱导。重组OSM加重死亡、收缩功能障碍、心肌炎症和心脏损伤。在心肌细胞中,OSM激活OSMR依赖的STAT3/ERK1/2信号,并损害线粒体生物能量学、收缩力和Ca²⁺处理。暴露于CVB3激活的巨噬细胞条件培养基后,OSM中和与巨噬细胞Osm敲低改善心肌细胞呼吸和肌节缩短。体内,OSM中和改善生存、心脏功能、心肌炎症、线粒体完整性和ATP含量。巨噬细胞OSM将炎症髓系激活与实验性FM中心肌细胞线粒体和收缩衰竭联系起来。OSM-OSMR信号是急性炎症性心脏功能障碍的候选机制型药物靶点。
Sepsis-induced cardiomyopathy (SICM) is an acute, often reversible myocardial depression driven by the host response to infection. Cardiac macrophages are central signaling hubs that integrate systemic danger signals and orchestrate myocardial dysfunction. We introduce a "Macrophage Functional Continuum" model, conceptualizing macrophages as dynamic signal integrators undergoing three interconnected phases: sensing and initiation, intrinsic reprogramming and fate determination, and multicellular network execution. Conceptually, these phases represent functional modules that may overlap in time and vary across organs, rather than a rigid chronological sequence. Stage-matched strategies-including immunometabolic modulation, checkpoint control, nanomedicine, and macrophage-based therapies-may provide a more context-sensitive therapeutic framework than conventional anti-inflammatory approaches. This review aims to reframe macrophage biology in SICM and provide a roadmap for translational research.
中文摘要:脓毒症诱导的心肌病(SICM)是由宿主对感染的反应驱动的急性、常可逆的心肌抑制。心脏巨噬细胞是整合全身危险信号并协调心肌功能障碍的核心信号枢纽。提出「巨噬细胞功能连续体」模型,将巨噬细胞视为动态信号整合者,其经历三个相互关联的阶段:感知与启动、内在重编程与命运决定、多细胞网络执行。概念上,这些阶段是功能模块,可在时间上重叠、随器官不同而变化,并非严格的时间顺序。与阶段匹配的策略包括免疫代谢调节、检查点控制、纳米医学和基于巨噬细胞的治疗,可能比传统抗炎方法提供更贴合情境的治疗框架。本综述旨在重新界定SICM中的巨噬细胞生物学,并为转化研究提供路线图。
Sepsis-induced cardiomyopathy (SIC) markedly increases the overall mortality among patients with sepsis. The pathogenesis of SIC remains incompletely elucidated; specifically, the role of protein lactylation in the onset and progression of SIC awaits further investigation. Using lactylome profilinganalysis, bioinformatics and molecular biology methods, the key proteins and lactylation sites involved in the development of SIC were identified. Amino acid point mutations, molecular dynamic simulation, and biochemical experiments were performed to investigate their biological roles and underlying mechanisms. The lactylome analysis revealed 439 differentially lactylated sites in the myocardium of septic mice compared with control group.Through integrated bioinformatic analysis and molecular validation, we demonstrated that lactylation of ubiquinol-cytochrome c reductase core protein 2 (Uqcrc2) plays a pivotal role in SIC, andidentified K109 as the critical lactylation site. Mechanistically,Uqcrc2 K109 lactylation disrupts mitochondrial respiratory chain function and exacerbates cardiomyocyte apoptosis. Importantly,inhibition of Uqcrc2 K109 lactylation attenuates this apoptotic process. Furthermore, we identifiedlysine acetyltransferase 6A (KAT6A) as a novel lactyltransferase, mediating Uqcrc2 lactylation. Our study reveals that the lactate-KAT6A-Uqcrc2 lactylation-mitochondrial apoptosis axis plays a pivotal role in SIC.
中文摘要:脓毒症诱导的心肌病(SIC)显著增加脓毒症患者总体死亡率。SIC 的发病机制尚未完全阐明,蛋白乳酸化在 SIC 发生和进展中的作用仍待进一步研究。利用乳酸化蛋白组学分析、生物信息学与分子生物学方法,识别了参与 SIC 发展的关键蛋白及乳酸化位点。通过氨基酸点突变、分子动力学模拟和生化实验,研究了其生物学作用及潜在机制。乳酸化蛋白组分析显示,与对照组相比,脓毒症小鼠心肌中有 439 个差异乳酸化位点。通过整合生物信息学分析与分子验证,证实泛醇-细胞色素 c 还原酶核心蛋白 2(Uqcrc2)的乳酸化在 SIC 中起关键作用,并确定 K109 为关键乳酸化位点。机制上,Uqcrc2 K109 乳酸化破坏线粒体呼吸链功能并加重心肌细胞凋亡。抑制 Uqcrc2 K109 乳酸化可减轻这一凋亡过程。进一步确定赖氨酸乙酰转移酶 6A(KAT6A)是一种新的乳酸转移酶,介导 Uqcrc2 乳酸化。研究揭示乳酸-KAT6A-Uqcrc2 乳酸化-线粒体凋亡轴在 SIC 中起关键作用。
9冠心病/心绞痛 (6篇)
临床研究 (6篇)
Atherosclerotic plaque healing is a dynamic biological mechanism that occurrs after plaque disruption and represents an endogenous reparative response within the atherosclerotic lesion. This process unfolds through three partially overlapping phases: endogenous thrombus lysis, granulation tissue formation, and re-endothelialization. Through the coordinated interaction of circulating cells, vascular wall components, and soluble mediators, plaque healing promotes fibrous repair and structural stabilization of the disrupted plaque. For many years, plaque healing remained primarily a histopathological observation described in post-mortem studies. The advent of high-resolution intracoronary imaging, particularly optical coherence tomography, has enabled in vivo visualization of the characteristic layered morphology of healed plaques, providing direct clinical confirmation of these early pathological findings. These observations have significantly improved our understanding of the clinical significance of plaque healing. Healed plaques are more frequently observed in patients with chronic coronary syndromes, supporting the concept that healing contributes to plaque stabilization. At the same time, recurrent cycles of plaque disruption followed by repair may lead to progressive luminal narrowing, thereby contributing to the long-term progression of coronary atherosclerosis. This review provided an updated overview of the clinical significance and implications of healed plaques in coronary artery disease, the mechanisms underlying plaque healing, and examines emerging intracoronary and non-invasive imaging modalities that allow their in vivo identification.
中文摘要:斑块愈合是斑块破裂后发生的动态生物学机制,属于动脉粥样硬化病变内的内源性修复反应。该过程经历三个部分重叠的阶段:内源性血栓溶解、肉芽组织形成和再内皮化。循环细胞、血管壁成分和可溶性介质协同作用,促进纤维性修复和破裂斑块的结构稳定。多年来,斑块愈合主要是尸检研究描述的组织病理学观察。高分辨率冠状动脉内成像尤其光学相干断层扫描的出现,使愈合斑块特征性分层形态能够在体内可视化,为早期病理发现提供了直接临床证据。这些观察显著提升了对斑块愈合临床意义的认识。愈合斑块在慢性冠脉综合征患者中更常见,支持愈合促进斑块稳定的观点。斑块破裂与修复反复循环可导致管腔逐渐狭窄,推动冠状动脉粥样硬化的长期进展。该综述更新了愈合斑块在冠心病中的临床意义与启示、斑块愈合机制,并审视可用于体内识别的冠状动脉内及无创成像新技术。
Familial hypercholesterolaemia (FH) leads to lifelong elevated low-density lipoprotein (LDL) cholesterol and increased risk of coronary artery disease. We tested the hypothesis that elevated remnant cholesterol additionally increases cardiovascular risk in FH. In the Copenhagen General Population Study (CGPS) and UK Biobank, 108,751 and 428,625 individuals were classified as with or without FH according to clinical scores and genetic mutations. In the two cohorts, 7,708 and 50,997 experienced coronary artery disease, respectively. In CGPS and UK Biobank, remnant cholesterol ≥1 mmol/L (39 mg/dL) was observed in 12% and 11% of individuals without FH (N = 104,226 and 403,172), in 33% and 40% with Simon Broome FH (N = 3,923 and 23,860), in 44% and 78% with MEDPED FH (N = 1,005 and 2,465), in 33% and 34% with DLCN FH (N = 744 and 1,207), and in 12% and 21% of individuals with genetic FH (N = 188 and 875). Likewise in the CGPS and UK Biobank, the multivariable adjusted hazard ratios for coronary artery disease by remnant cholesterol ≥1 vs. < 1 mmol/L (39 mg/dL) were 1.49 (95% CI: 1.39-1.59) and 1.47 (1.43-1.52) in individuals without FH, 1.59 (1.31-1.93) and 1.18 (1.10-1.27) in Simon Broome FH, 1.50 (1.08-2.08) and 1.14 (0.89-1.45) in MEDPED FH, 1.60 (1.17-2.21) and 1.59 (1.20-2.09) in DLCN FH, and 1.48 (0.59-3.69) and 1.39 (0.88-2.19) in genetic FH. In familial hypercholesterolaemia, remnant cholesterol ≥1 mmol/L (39 mg/dL) vs below is associated with ≈50% higher risk of coronary artery disease, that is, above the already high risk due to lifelong genetically elevated LDL cholesterol.
中文摘要:家族性高胆固醇血症(FH)导致低密度脂蛋白(LDL)胆固醇终身升高并增加冠心病风险。我们检验了残粒胆固醇升高会进一步增加FH患者心血管风险的假设。在Copenhagen General Population Study(CGPS)和UK Biobank中,依据临床评分和基因突变将108,751人和428,625人分为有或无FH;两个队列中分别有7,708人和50,997人发生冠心病。CGPS和UK Biobank中,残粒胆固醇≥1 mmol/L(39 mg/dL)见于无FH者的12%和11%(N=104,226和403,172),Simon Broome FH者的33%和40%(N=3,923和23,860),MEDPED FH者的44%和78%(N=1,005和2,465),DLCN FH者的33%和34%(N=744和1,207),以及遗传性FH者的12%和21%(N=188和875)。同样,在CGPS和UK Biobank中,残粒胆固醇≥1 mmol/L(39 mg/dL)与低于1 mmol/L(39 mg/dL)相比,冠心病多变量校正风险比分别为:无FH者1.49(95% CI: 1.39-1.59)和1.47(1.43-1.52),Simon Broome FH者1.59(1.31-1.93)和1.18(1.10-1.27),MEDPED FH者1.50(1.08-2.08)和1.14(0.89-1.45),DLCN FH者1.60(1.17-2.21)和1.59(1.20-2.09),遗传性FH者1.48(0.59-3.69)和1.39(0.88-2.19)。在家族性高胆固醇血症中,残粒胆固醇≥1 mmol/L(39 mg/dL)相较低于该水平与冠心病风险约高50%相关,即高于因终身遗传性LDL胆固醇升高本已较高的风险。
PCSK9-Targeting Therapies and Mortality: A Systematic Review and Meta-Analysis of Randomized Trials.
To evaluate the association of PCSK9-targeting therapies with mortality and cardiovascular events in stable or clinically stabilized randomized trial populations. We systematically reviewed randomized trials comparing alirocumab, evolocumab or inclisiran with placebo or active control. The review was registered in PROSPERO (CRD420261395609). Treatment effects were pooled as incidence rate ratios (IRRs) using random-effects models. The primary outcome was all-cause mortality. Prespecified subgroup analyses were based on trial-level known atherosclerosis status, as defined by enrollment criteria. Thirty-two trials enrolled 77,178 participants. Individual atherosclerosis status could not be determined beyond trial-level eligibility criteria. Mortality estimates were predominantly informed by large cardiovascular outcome trials. All-cause mortality was lower with PCSK9-targeting therapy (IRR 0.88, 95% CI 0.82-0.95). Estimates favored PCSK9-targeting treatment in both trials requiring known atherosclerosis for enrollment (IRR 0.90, 95% CI 0.83-0.98) and trials without such an enrollment requirement (IRR 0.78, 95% CI 0.62-0.97; interaction p = 0.21). PCSK9-targeting treatment additionally reduced myocardial infarction, stroke, and coronary revascularization rates. Leave-one-out estimates remained directionally consistent. PCSK9-targeting therapies were associated with lower all-cause mortality and fewer ischemic events across trial populations. The predominant contribution of large cardiovascular outcome trials enrolling populations with known atherosclerosis and using PCSK9 antibodies limits the ability to infer a survival benefit in populations not selected on the basis of atherosclerosis status and across individual therapies, particularly inclisiran.
中文摘要:评估PCSK9靶向治疗与稳定或临床稳定随机试验人群中死亡和心血管事件的关联。系统检索比较alirocumab、evolocumab或inclisiran与安慰剂或活性对照的随机试验。综述在PROSPERO注册(CRD420261395609)。采用随机效应模型将治疗效应合并为发生率比(IRR)。主要结局为全因死亡。预设亚组分析基于试验层面已知的动脉粥样硬化状态,由入组标准定义。32项试验纳入77,178名参与者。除试验层面入组标准外,无法确定个体动脉粥样硬化状态。死亡估计主要来自大型心血管结局试验。PCSK9靶向治疗的全因死亡率较低(IRR 0.88,95% CI 0.82-0.95)。在要求入组时已知动脉粥样硬化的试验(IRR 0.90,95% CI 0.83-0.98)和无此入组要求的试验(IRR 0.78,95% CI 0.62-0.97;交互作用p=0.21)中,估计均支持PCSK9靶向治疗。PCSK9靶向治疗还降低心肌梗死、卒中和冠状动脉血运重建率。留一法估计方向一致。PCSK9靶向治疗与试验人群中较低的全因死亡率和较少的缺血事件相关。大型心血管结局试验主要纳入已知动脉粥样硬化人群并使用PCSK9抗体,这一主导贡献限制了对非按动脉粥样硬化状态选择人群以及各单个治疗(尤其inclisiran)推断生存获益的能力。
Coronary microvascular dysfunction (CMD) is highly prevalent in patients with angina and nonobstructive coronary arteries (ANOCA). Microvascular resistance reserve (MRR) is a novel index to assess CMD independently of epicardial disease and driving pressures, but the long-term prognostic value of continuous thermodilution-derived MRR in patients with ANOCA is unknown. To assess the prognostic value of continuous thermodilution-derived MRR and its association with clinical outcomes and symptom burden in patients with ANOCA. This prospective, multicenter cohort study within the Netherlands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT) included patients between July 2020 and June 2025 in 4 clinical centers in the Netherlands. Follow-up for clinical events and patient-reported symptoms was completed for up to 3 years. Clinical events were adjudicated by investigators blinded to CFT results. Consecutive patients with ANOCA who underwent continuous thermodilution were included. Abnormal MRR (CMD) was defined as less than 2.1, gray zone as 2.1 to 2.7, and normal microvascular function as 2.7 or greater. The primary clinical outcome was a composite of all-cause death, acute coronary syndrome, stroke, clinically indicated revascularization, repeat angiography without intervention, and unplanned hospital admittance or emergency department visit due to angina or heart failure. Secondary outcomes included angina at baseline and follow-up. Symptoms were assessed using the patient-reported Seattle Angina Questionnaire (SAQ) scores. Among 553 included patients (mean [SD] age, 59.1 [9.6] years; 459 female [83.0%]) with a mean (SD) follow-up of 27.5 (16.1) months, CMD was observed in 94 patients (17.0%). The main composite outcome did not differ across the 3 MRR categories (18 of 94 patients with abnormal [19.1%] vs 21 of 98 patients with gray zone [21.4%] vs 76 of 361 patients with normal [21.1%] MRR; log-rank P = .85). Individual outcomes did not differ between groups. There was no overall longitudinal interaction between MRR and SAQ summary scores. While low MRR (abnormal vs normal groups) was not associated with an increased symptom burden at baseline, it was associated with worse angina at follow-up (mean [SD] SAQ summary score, 53.0 [16.7] vs 60.1 [16.6]; P = .04) and less clinically relevant improvement (9 of 30 patients [30.0%] vs 52 of 88 patients [59.1%]; P = .02). In this study, CMD assessed by continuous thermodilution-derived MRR was not associated with clinical outcomes.
中文摘要:冠状动脉微血管功能障碍(CMD)在心绞痛和非阻塞性冠状动脉(ANOCA)患者中很常见。微血管阻力储备(MRR)是一种可在不受心外膜病变和驱动压影响的情况下评估CMD的新指标,但基于连续热稀释法的MRR在ANOCA患者中的长期预后价值尚不清楚。该研究评估基于连续热稀释法的MRR的预后价值及其与ANOCA患者临床结局和症状负担的关系。这项前瞻性、多中心队列研究属于荷兰侵入性冠状动脉血管舒缩功能检测登记(NL-CFT),于2020年7月至2025年6月在荷兰4个临床中心纳入患者,随访临床事件和患者报告症状最长3年。临床事件由对CFT结果不知情的研究者裁定。连续纳入接受连续热稀释法检查的ANOCA患者。MRR异常(CMD)定义为小于2.1,灰区为2.1至2.7,微血管功能正常为2.7或更高。主要临床结局为全因死亡、急性冠脉综合征、卒中、有临床指征的血运重建、未干预的重复血管造影,以及因心绞痛或心力衰竭导致的非计划住院或急诊就诊的复合终点。次要结局包括基线和随访时的心绞痛。症状采用患者报告的西雅图心绞痛问卷(SAQ)评分评估。共纳入553例患者(平均[标准差]年龄59.1[9.6]岁;女性459例[83.0%]),平均(标准差)随访27.5(16.1)个月,94例(17.0%)存在CMD。主要复合结局在3个MRR分类间无差异(MRR异常组94例中18例[19.1%],灰区组98例中21例[21.4%],正常组361例中76例[21.1%];log-rank P=.85)。各单项结局在组间无差异。MRR与SAQ总结评分之间无总体纵向交互作用。低MRR(异常组与正常组比较)与基线症状负担增加无关,但与随访时心绞痛更重相关(平均[标准差]SAQ总结评分53.0[16.7]比60.1[16.6];P=.04),且有临床意义的改善较少(30例中9例[30.0%]比88例中52例[59.1%];P=.02)。该研究中,以连续热稀释法MRR评估的CMD与临床结局无关。
Coronary artery disease (CAD) remains the leading cause of global mortality. Multi-omics integration offers unprecedented opportunities for precision risk stratification beyond conventional approaches. However, comprehensive integration of genomic, proteomic, and metabolomic data for CAD prediction remains underexplored. We integrated genomic (n = 442,574), proteomic (n = 54,219 with 1472 proteins), and metabolomic (n = 121,249 with 249 metabolites) data from UK Biobank. Multi-omics integration employed similarity network fusion combined with elastic net regularization in the 23,776 participants with complete multi-omics data, with a late integration (stacking) strategy applied for prediction modeling across the full cohort. Internal validation encompassed temporal split (2006-2008 vs. 2009-2010), geographical split (England vs. Scotland/Wales), 10-fold cross-validation, and bootstrap resampling (1000 iterations). Among 442,574 participants (34,241 CAD cases, 7.74%), we identified 241 independent genomic loci and integrated 1472 proteins with 249 metabolites. Network analysis revealed four major biological modules: vascular dysfunction (37.8% variance), lipid metabolism (25.4%), inflammatory response (19.2%), and cardiac remodeling (13.6%). The integrated multi-omics model achieved superior discrimination (C-statistic: 0.798, 95% CI: 0.793-0.803) compared to clinical factors alone (0.741) and genomics-only approaches (0.704, P < 0.001), with net reclassification improvement of 10.34% (95% CI: 8.92-11.77%). Temporal validation demonstrated robust transportability (C-statistic: 0.791) with consistent calibration (Hosmer-Lemeshow χ²=8.73, P = 0.366). Individuals in the highest risk quintile exhibited 4.52-fold increased CAD odds (95% CI: 4.28-4.78) with 10-year incidence of 11.24% compared to 2.51% in the lowest quintile. Drug target analysis identified 8 proteins targeted by approved cardiovascular drugs and 5 additional targets in Phase II/III clinical trials, supporting translational potential. Multi-omics integration substantially enhances CAD risk prediction with robust internal validation, enabling targeted precision medicine strategies through successful intermediate-risk reclassification. These findings establish a framework for clinical translation of multi-omics risk assessment.
中文摘要:冠状动脉疾病(CAD)仍是全球死亡的首位原因。多组学整合为超越传统手段的精准风险分层带来了前所未有的机会,但基因组、蛋白质组与代谢组数据的综合整合用于CAD预测仍缺乏充分探索。本研究整合了英国生物银行(UK Biobank)的基因组数据(n=442,574)、蛋白质组数据(n=54,219,含1472种蛋白)与代谢组数据(n=121,249,含249种代谢物)。在具有完整多组学数据的23,776名参与者中,采用相似性网络融合结合弹性网正则化进行多组学整合,并在全队列中以晚期整合(stacking)策略构建预测模型。内部验证包括时间切分(2006—2008年与2009—2010年)、地域切分(英格兰与苏格兰/威尔士)、10折交叉验证以及自助重抽样(1000次迭代)。在442,574名参与者(34,241例CAD,占7.74%)中,识别出241个独立基因组位点,并将1472种蛋白与249种代谢物进行整合。网络分析显示四个主要生物学模块:血管功能障碍(方差占37.8%)、脂质代谢(25.4%)、炎症反应(19.2%)与心脏重构(13.6%)。整合多组学模型的判别能力优于仅用临床因素(0.741)和仅用基因组学(0.704,P<0.001),C统计量为0.798(95% CI:0.793—0.803),净重分类改善为10.34%(95% CI:8.92—11.77%)。时间验证显示良好的可迁移性(C统计量0.791),校准一致(Hosmer-Lemeshow χ²=8.73,P=0.366)。风险最高五分位人群的CAD比值比为4.52(95% CI:4.28—4.78),10年发病率为11.24%,而最低五分位为2.51%。药物靶点分析识别出8种已有获批心血管药物作用的蛋白,以及5个处于II/III期临床试验的靶点,支持其转化潜力。多组学整合经稳健的内部验证显著提升了CAD风险预测,并通过成功重分类中等风险人群为靶向精准医学策略提供了条件。这些结果建立了多组学风险评估临床转化的框架。
Prior imaging studies (predominantly using intravascular ultrasound) have demonstrated modest plaque regression with lipid-lowering therapy in stable coronary artery disease (CAD). The effect of initiating intensive lipid-lowering therapy on coronary plaque regression across the entire coronary tree in treatment-naive patients remains uncertain. To report the prespecified secondary imaging end points of the FLOWPROMOTE trial by comparing the effects of intensive vs more intensive lipid-lowering therapy on plaque regression in statin-naive patients with stable CAD and to assess the association between achieved low-density lipoprotein cholesterol (LDL-C) levels and plaque regression. FLOWPROMOTE was a multicenter randomized clinical trial enrolling statin-naive patients with newly diagnosed stable CAD, defined by a coronary computed tomography angiography (CTA) stenosis greater than 50% and fractional flow reserve CT less than or equal to 0.80. Coronary CTA was performed at baseline and repeated at 9 and 18 months. Study data were analyzed from February 2025 to January 2026. Patients were randomized to intensive lipid-lowering therapy (atorvastatin 40 mg) or more intensive lipid-lowering therapy (rosuvastatin 40 mg plus ezetimibe 10 mg) for 18 months. Prespecified secondary end points included changes in total plaque volume (TPV), noncalcified plaque volume (NCPV), and calcified plaque volume (CPV) across all coronary vessels at 9 and 18 months compared with baseline. A total of 104 patients (mean [SD] age, 64 [9] years; 82 male [79%]) were included in this analysis, with 52 patients in the intensive group and 52 patients in the more intensive group. LDL-C levels decreased from 119.7 to 69.5 mg/dL (-38%) with intensive therapy and from 127.4 to 42.5 mg/dL (-65%) with more intensive therapy (between-group P < .001). At 18 months, both TPV and NCPV decreased in both groups, with significantly greater regression in the more intensive-therapy group. TPV was reduced by -69.8 mm3 (-21.1%) with more intensive therapy vs -39.0 mm3 (-13.6%) with intensive therapy (between-group difference, -30.9 mm3; 95% CI, -57.2 to -4.5 mm3; P = .02), and NCPV was reduced by -82.3 mm3 (-28.2%) vs -53.5 mm3 (-20.0%), respectively (between-group difference, -28.9 mm3; 95% CI, -53.2 to -4.6 mm3; P = .02). CPV increased similarly in both groups. Regression of TPV occurred in 90% of patients receiving more intensive therapy compared with 76% receiving intensive therapy (47 of 52 [90%] vs 38 of 51 [75%]; P = .05), and regression of NCPV was observed in 98% vs 77% (51 of 52 [98%] vs 39 of 51 [77%]; P =.001). Lower achieved LDL-C levels were linearly associated with greater regression of TPV and NCPV. This secondary analysis of the FLOWPROMOTE randomized clinical trial demonstrated that in statin-naive patients with CAD, more intensive lipid-lowering therapy was associated with significantly greater regression of total and noncalcified coronary plaque burden compared with intensive therapy. The extent of plaque regression was related to achieved LDL-C levels, supporting the potential for partial reversal of coronary atherosclerosis with intensive lipid reduction. ClinicalTrials.gov Identifier: NCT04737408.
中文摘要:既往影像学研究(主要采用血管内超声)显示,稳定型冠心病患者接受降脂治疗后可出现轻度斑块消退。对于未接受过他汀治疗的患者,启动强化降脂治疗对整个冠状动脉树斑块消退的影响仍不确定。报告FLOWPROMOTE试验预设的次要影像学终点,比较强化降脂与更强效降脂对未接受过他汀治疗的稳定型冠心病患者斑块消退的影响,并评估达到的低密度脂蛋白胆固醇(LDL-C)水平与斑块消退之间的关联。FLOWPROMOTE是一项多中心随机临床试验,纳入新诊断稳定型冠心病且未接受过他汀治疗的患者,定义为冠状动脉计算机断层扫描血管造影(CTA)狭窄大于50%且CT血流储备分数小于或等于0.80。基线时行冠状动脉CTA,并在9个月和18个月重复检查。研究数据于2025年2月至2026年1月分析。患者随机接受强化降脂治疗(阿托伐他汀40 mg)或更强效降脂治疗(瑞舒伐他汀40 mg联合依折麦布10 mg),疗程18个月。预设次要终点包括9个月和18个月时与基线相比所有冠状动脉血管的总斑块体积(TPV)、非钙化斑块体积(NCPV)和钙化斑块体积(CPV)变化。本分析共纳入104例患者(平均[SD]年龄64[9]岁;男性82例[79%]),强化治疗组52例,更强效治疗组52例。LDL-C水平在强化治疗组从119.7降至69.5 mg/dL(-38%),在更强效治疗组从127.4降至42.5 mg/dL(-65%)(组间P<.001)。18个月时,两组的TPV和NCPV均下降,更强效治疗组消退幅度显著更大。TPV在更强效治疗组减少-69.8 mm3(-21.1%),强化治疗组减少-39.0 mm3(-13.6%)(组间差异-30.9 mm3;95%CI -57.2至-4.5 mm3;P=.02);NCPV分别减少-82.3 mm3(-28.2%)和-53.5 mm3(-20.0%)(组间差异-28.9 mm3;95%CI -53.2至-4.6 mm3;P=.02)。CPV在两组均相似增加。更强效治疗组90%的患者出现TPV消退,强化治疗组为76%(47/52[90%]对38/51[75%];P=.05);NCPV消退分别为98%和77%(51/52[98%]对39/51[77%];P=.001)。达到的LDL-C水平越低,TPV和NCPV消退幅度越大,呈线性关联。这项FLOWPROMOTE随机临床试验的次要分析显示,在未接受过他汀治疗的冠心病患者中,与强化降脂治疗相比,更强效降脂治疗与总斑块和非钙化冠状动脉斑块负荷的显著更大消退相关。斑块消退程度与达到的LDL-C水平相关,支持强化降脂可能使冠状动脉粥样硬化部分逆转。ClinicalTrials.gov注册号:NCT04737408。
10肺动脉高压 (4篇)
临床研究 (2篇)
In pulmonary hypertension (PH), risk assessment focuses on right ventricular function and may overlook exercise-related right atrial (RA) functional limitation. We investigated whether RA stiffness during exercise reflects impaired right-heart filling reserve and is associated with prognosis beyond conventional measures. We prospectively enrolled 68 participants in this observational study, including 42 with precapillary PH. Participants who had PH ruled out and patients with postcapillary PH formed reference groups. Participants underwent 3-dimensional echocardiography, right heart catheterization, and invasive RA pressure-volume loop analysis at rest and during standardized semisupine exercise. RA filling stiffness was derived from the reservoir phase. Patients with precapillary PH were stratified by median exercise RA filling stiffness. At rest, high- and low-stiffness groups had comparable right ventricular function, afterload, and cardiac index, but the high-stiffness group exhibited impaired phasic RA strain and venous congestion (median [interquartile range] liver stiffness, 7.1 [6.0-8.8] versus 5.2 [4.8-5.8] kPa; P=0.021). During exercise, mean RA pressure increased similarly, but the high-stiffness group had impaired peak cardiac index (3.3±1.0 versus 4.1±0.9 L/min per m2; P=0.015) and RA strain. Unlike resting RA stiffness, high exercise RA stiffness was independently associated with mortality (adjusted hazard ratio, 4.37 [95% CI, 1.20-15.96]). A model including RA conduit strain and right ventricular functional reserve discriminated high RA stiffness (area under the receiver operating characteristic curve, 0.90). RA stiffness during exercise integrates resting congestion with limited cardiac reserve and unmasks mortality risk missed by resting metrics. RA conduit strain and right ventricular functional reserve noninvasively identify the high-stiffness subgroup.
中文摘要:在肺动脉高压(PH)中,风险评估聚焦右心室功能,可能忽略运动相关右心房(RA)功能受限。我们探讨运动时RA僵硬是否反映右心充盈储备受损,并与超越常规指标的预后相关。本观察性研究前瞻性纳入68名参与者,其中42例为毛细血管前PH。排除PH者及毛细血管后PH患者构成参照组。参与者在静息和标准化半仰卧运动时接受三维超声心动图、右心导管检查及有创RA压力-容积环分析。RA充盈僵硬由储器期得出。毛细血管前PH患者按运动RA充盈僵硬中位数分层。静息时,高僵硬组与低僵硬组右心室功能、后负荷和心指数相当,但高僵硬组时相性RA应变受损并存在静脉淤血(肝硬度中位数[四分位距]7.1[6.0-8.8]对5.2[4.8-5.8] kPa;P=0.021)。运动时平均RA压升高相似,但高僵硬组峰值心指数(3.3±1.0对4.1±0.9 L/min/m²;P=0.015)和RA应变受损。与静息RA僵硬不同,高运动RA僵硬与死亡率独立相关(校正风险比4.37[95% CI,1.20-15.96])。包含RA管道应变和右心室功能储备的模型可区分高RA僵硬(受试者工作特征曲线下面积0.90)。运动时RA僵硬整合静息淤血与心脏储备受限,并揭示静息指标遗漏的死亡风险。RA管道应变与右心室功能储备可无创识别高僵硬亚组。
Pulmonary hypertension (PH), a progressive and life-threatening condition with rising prevalence among older adults, frequently coexists with systemic hypertension, the prognostic impact of which is poorly understood. To evaluate the association between systemic hypertension and survival in patients with PH. This multicenter cohort study analyzed data from the Pulmonary Vascular Research Institute GoDeep meta-registry, integrating global retrospective and prospective PH cohorts (n = 3238 in Europe, n = 3014 in North America, n = 96 in Africa, n = 802 in Asia, and n = 851 in Oceania). Survival was assessed using multivariable Cox proportional hazards models and adjusted for key confounders, with sensitivity analyses to validate robustness. Independent external validation was performed in a cohort in the UK. A total of 12 771 patients with incident PH (median [IQR] age, 65 [53-73] years; 7372 [58%] female) were diagnosed via right heart catheterization and comprehensive clinical data, encompassing PH groups 1-5 and all age categories. The study spans diagnosis decades from 1980 to 2020. Data were analyzed from February 2025 until September 2026. Center-reported diagnosis of systemic hypertension, baseline systolic systemic arterial pressure (sSAP), and heart rate as well as longitudinal sSAP and heart rate trajectories. All-cause mortality, adjusted for confounding variables, including age, PH group, antihypertensive and PH-specific medications, and cardiac index. Higher baseline sSAP and preexisting systemic hypertension were independently associated with improved survival. Patients with hypertension exhibited a 26% reduced mortality hazard (hazard ratio [HR], 0.74; 95% CI, 0.68-0.79) compared to their counterparts without hypertension. Survival benefits correlated positively with increasing sSAP (80-180 mm Hg), remained consistent across PH groups and age groups, and were independent of antihypertensive and PH-specific medications. Elevated heart rate was associated with higher mortality. sSAP increments correlated with improved cardiac index and tricuspid annular plane systolic excursion. Decreased sSAP and higher heart rate during follow-up correlated with higher mortality. External validation in a separate UK cohort confirmed these findings. In this global PH cohort, higher sSAP was associated with enhanced survival, while a higher baseline heart rate and declining systemic blood pressure during follow-up were significantly associated with increased mortality risk.
中文摘要:肺动脉高压(PH)是一种进行性、危及生命的疾病,在老年人中患病率上升,常与系统性高血压并存,后者对预后的影响尚不明确。为评估系统性高血压与PH患者生存的关系,这项多中心队列研究分析了肺血管研究所GoDeep元登记数据,整合全球回顾性与前瞻性PH队列(欧洲n=3238,北美n=3014,非洲n=96,亚洲n=802,大洋洲n=851)。生存分析采用多变量Cox比例风险模型并校正关键混杂因素,以敏感性分析验证稳健性,并在英国一个队列中独立外部验证。共纳入12771例新诊断PH患者(中位[IQR]年龄65[53-73]岁;7372例[58%]女性),均经右心导管诊断并有完整临床数据,涵盖PH 1-5组及所有年龄类别。研究覆盖1980至2020年诊断年代。数据分析时间为2025年2月至2026年9月。暴露包括中心报告的系统性高血压诊断、基线收缩期体循环动脉压(sSAP)和心率,以及纵向sSAP和心率轨迹。结局为全因死亡,校正年龄、PH组别、降压药与PH特异性药物、心脏指数等混杂变量。较高的基线sSAP和既存系统性高血压与生存改善独立相关。与无高血压者相比,高血压患者的死亡风险降低26%(风险比[HR]0.74;95%CI 0.68-0.79)。生存获益随sSAP升高(80-180 mmHg)呈正相关,在PH各组和年龄组中保持一致,且独立于降压药和PH特异性药物。心率升高与死亡风险增加相关。sSAP升高与心脏指数和三尖瓣环收缩期位移改善相关。随访期间sSAP下降和心率升高与死亡风险增加相关。英国独立队列的外部验证证实了这些发现。在这个全球PH队列中,较高sSAP与生存改善相关,而较高的基线心率和随访期间体循环血压下降与死亡风险增加显著相关。
基础研究 (2篇)
Maladaptive vascular remodeling is a hallmark of pulmonary hypertension (PH), and therapeutic strategies directly targeting the pathological activity of smooth muscle cells remain limited. Metabolic and epigenetic dysregulation are established drivers of PH, and lysine lactylation has emerged as a novel posttranslational modification implicated in diverse diseases; however, its direct contribution to PH progression remains undefined. Integrated lactylomic and proteomic profiling was performed in hypoxic human pulmonary arterial smooth muscle cells. The functional role of ALDOA (aldolase A) lactylation at lysine 42 (K42) was assessed using site-specific mutant virus and smooth muscle cell-specific inducible ALDOA knockout mice in 2 established PH models: SU5416+hypoxia in mice and monocrotaline in rats. We identified ALDOA as a prominent lactylation target in hypoxic pulmonary arterial smooth muscle cells, with K42 lactylation consistently elevated in primary pulmonary arterial smooth muscle cells derived from PH rodent models and human PH tissues. Mechanistically, AARS1 (alanyl-tRNA synthetase 1)-mediated ALDOA K42 lactylation enhanced its binding to γ-actin, independent of glycolytic activity. This lactylation-enhanced interaction promoted F-actin polymerization and activated YAP (Yes-associated protein) signaling via LATS1 (large tumor suppressor kinase 1) inhibition, thereby driving pulmonary arterial smooth muscle cell proliferation and phenotypic switching. Moreover, YAP/TEAD4 (TEA domain transcription factor 4)-mediated transcriptional upregulation of AARS1 established a positive feedback loop reinforcing ALDOA K42 lactylation under hypoxia. In vivo, ALDOA inducible knockout or reconstitution with the lactylation-deficient K42R (lysine 42 mutant to arginine) mutant attenuated experimental PH progression, with suppressed F-actin/YAP activation and reduced vascular remodeling. Furthermore, competitive inhibition of lactylation through β‑alanine reduced ALDOA K42 lactylation and ameliorated vascular remodeling in ALDOA-overexpressing rodent PH models. Translationally, pharmacological disruption of the ALDOA/γ-actin interaction by raltegravir suppressed cytoskeletal reorganization and YAP signaling, mitigating PH progression in both mouse and rat models. AARS1-mediated ALDOA K42 lactylation drives pulmonary vascular remodeling through a mechanism independent of ALDOA's catalytic activity, promoting F-actin polymerization and YAP activation. Precision targeting of this modification selectively inhibits pathological signaling while preserving metabolic homeostasis, highlighting a translational potential for precision intervention in PH.
中文摘要:适应不良性血管重塑是肺动脉高压(PH)的标志,直接靶向平滑肌细胞病理活动的治疗策略仍有限。代谢与表观遗传失调是PH的已知驱动因素,赖氨酸乳酸化作为一种新型翻译后修饰已涉及多种疾病,但其对PH进展的直接贡献尚未明确。研究对缺氧人肺动脉平滑肌细胞进行乳酸化组和蛋白质组整合分析。利用位点特异性突变病毒和平滑肌细胞特异性诱导性ALDOA敲除小鼠,在两种已建立的PH模型(小鼠SU5416+缺氧和大鼠野百合碱)中评估ALDOA赖氨酸42(K42)乳酸化的功能作用。研究确定ALDOA是缺氧肺动脉平滑肌细胞中显著的乳酸化靶点,K42乳酸化在来源于PH啮齿动物模型的原代肺动脉平滑肌细胞及人PH组织中持续升高。机制上,AARS1(丙氨酰-tRNA合成酶1)介导的ALDOA K42乳酸化增强其与γ-肌动蛋白结合,且不依赖糖酵解活性。这种乳酸化增强的相互作用促进F-肌动蛋白聚合,并通过抑制LATS1(大肿瘤抑制激酶1)激活YAP(Yes相关蛋白)信号,从而驱动肺动脉平滑肌细胞增殖和表型转换。YAP/TEAD4(TEA结构域转录因子4)介导的AARS1转录上调形成正反馈环路,在缺氧下强化ALDOA K42乳酸化。体内,诱导性敲除ALDOA或用乳酸化缺陷的K42R(赖氨酸42突变为精氨酸)突变体重建可减轻实验性PH进展,并抑制F-肌动蛋白/YAP激活、减少血管重塑。通过β-丙氨酸竞争性抑制乳酸化可降低ALDOA K42乳酸化,并改善ALDOA过表达啮齿动物PH模型中的血管重塑。转化方面,raltegravir药理性破坏ALDOA/γ-肌动蛋白相互作用可抑制细胞骨架重排和YAP信号,减轻小鼠和大鼠模型中的PH进展。AARS1介导的ALDOA K42乳酸化通过不依赖ALDOA催化活性的机制驱动肺血管重塑,促进F-肌动蛋白聚合和YAP激活。精准靶向该修饰可选择性地抑制病理信号,同时维持代谢稳态,显示PH精准干预的转化潜力。
Metabolic reprogramming, impaired mitochondrial quality control, and mitochondrial redox imbalance are increasingly recognized as central drivers of pulmonary arterial hypertension (PAH). Spermidine (SPD) has been reported to exert cardiovascular protective effects; however, its effects on endothelial metabolism and redox homeostasis in PAH remain incompletely characterized. HADHA, the α-subunit of mitochondrial trifunctional protein, participates in long-chain fatty acid β-oxidation (FAO) and provides a potential link between fatty acid utilization, mitochondrial respiration, mitophagy-related quality control, and redox homeostasis. Here, using integrated metabolomics, lipidomics, and molecular biology approaches in monocrotaline (MCT)-induced PAH rats and palmitic acid-stimulated pulmonary microvascular endothelial cells (PMVECs), we examined the contribution of HADHA to the effects of SPD on endothelial FAO and mitochondrial redox homeostasis. SPD treatment markedly attenuated pulmonary hypertension and vascular remodeling, accompanied by reduced inflammatory activation and endothelial injury. Metabolomic and lipidomic profiling indicated that SPD partially corrected pathological lipid-metabolic remodeling, including phosphatidylethanolamine-associated lipid alterations, and improved FAO-related mitochondrial function under lipotoxic stress. SPD reduced lipid accumulation and lipotoxic mitochondrial injury, inhibited PLIN2-vimentin-associated endothelial-to-mesenchymal transition (EndMT) marker changes, and increased PINK1/Parkin-related mitophagy markers together with TOM20/LC3B/LAMP2 colocalization, consistent with improved mitophagy-related mitochondrial quality control. Molecular dynamics simulation, cellular thermal shift assay, and microscale thermophoresis supported SPD-HADHA binding and SPD-associated HADHA stabilization. Importantly, HADHA knockdown markedly attenuated several effects of SPD on FAO-related function, mitochondrial redox balance, and lipotoxic phenotypes in PMVECs. These findings suggest that HADHA may contribute to the effects of SPD on fatty acid oxidation, redox homeostasis, and endothelial protection in PAH.
中文摘要:代谢重编程、线粒体质量控制受损以及线粒体氧化还原失衡日益被视为肺动脉高压(PAH)的核心驱动因素。亚精胺(SPD)已被报道具有心血管保护作用;但其对PAH中内皮代谢和氧化还原稳态的影响仍未充分阐明。HADHA是线粒体三功能蛋白的α亚基,参与长链脂肪酸β氧化(FAO),并将脂肪酸利用、线粒体呼吸、线粒体自噬相关质量控制与氧化还原稳态联系起来。研究在野百合碱(MCT)诱导的PAH大鼠和棕榈酸刺激的肺微血管内皮细胞(PMVECs)中,采用代谢组学、脂质组学和分子生物学相结合的方法,考察HADHA在SPD影响内皮FAO和线粒体氧化还原稳态中的作用。SPD处理显著减轻肺动脉高压和血管重构,并伴随炎症激活和内皮损伤减少。代谢组学和脂质组学分析表明,SPD部分纠正病理性脂质代谢重塑,包括磷脂酰乙醇胺相关脂质改变,并改善脂毒性应激下FAO相关线粒体功能。SPD减少脂质蓄积和脂毒性线粒体损伤,抑制PLIN2-波形蛋白相关的内皮-间质转化(EndMT)标志物变化,并增加PINK1/Parkin相关线粒体自噬标志物以及TOM20/LC3B/LAMP2共定位,这与线粒体自噬相关线粒体质量控制改善一致。分子动力学模拟、细胞热位移实验和微量热泳动支持SPD与HADHA结合以及SPD相关的HADHA稳定化。HADHA敲低显著减弱SPD对PMVECs中FAO相关功能、线粒体氧化还原平衡和脂毒性表型的多种作用。这些发现提示,HADHA可能参与SPD在PAH中对脂肪酸氧化、氧化还原稳态和内皮保护的作用。
11基础/转化 (3篇)
基础研究 (3篇)
Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder characterized by progressive skeletal muscle degeneration, chronic inflammation, fibrosis, and mitochondrial dysfunction. Although gene- and cell-based therapies hold great promise, significant limitations still restrict their broad application, highlighting the need for complementary pharmacological approaches targeting secondary pathological mechanisms. Histone deacetylase (HDAC) inhibitors and Sirtuin 1 (SIRT1) activators represent promising therapeutic strategies, as HDAC8 is involved in cytoskeletal remodeling, whereas SIRT1 mainly regulates mitochondrial metabolism and energy homeostasis. In this study, we investigated the therapeutic efficacy of combining selective HDAC8 inhibition (PCI-34051) with SIRT1 activation (SRT2104) in a zebrafish model of DMD. Combined treatment significantly improved muscle structure and function, reduced inflammatory cell recruitment, and enhanced mitochondrial activity compared with single-drug administration. Importantly, comparable therapeutic efficacy was achieved using reduced doses of both compounds. Proteomic and acetylomic analyses revealed distinct but complementary molecular signatures induced by the two treatments. HDAC8 inhibition predominantly modulated pathways associated with cytoskeletal organization, epigenetic regulation, ribosome biogenesis, and muscle structural remodeling, whereas SIRT1 activation mainly affected mitochondrial function, oxidative metabolism, amino acid catabolism, and cellular bioenergetics. Overall, these findings demonstrate that combined HDAC8 inhibition and SIRT1 activation effectively ameliorate key pathological features of DMD in zebrafish and provide mechanistic insights into the complementary pathways targeted by the two compounds. This work supports the development of combinatorial epigenetic strategies as potential therapeutic approaches for DMD.
中文摘要:杜氏肌营养不良症(DMD)是一种严重遗传病,表现为进行性骨骼肌变性、慢性炎症、纤维化和线粒体功能障碍。基因和细胞治疗虽前景可观,但明显局限仍限制其广泛应用,因此需要针对继发性病理机制的补充药物策略。组蛋白去乙酰化酶(HDAC)抑制剂和Sirtuin 1(SIRT1)激活剂是有前景的治疗策略,HDAC8参与细胞骨架重塑,SIRT1主要调节线粒体代谢和能量稳态。本研究在DMD斑马鱼模型中考察选择性HDAC8抑制(PCI-34051)与SIRT1激活(SRT2104)联合的治疗效果。与单药给药相比,联合治疗显著改善肌肉结构和功能,减少炎症细胞募集,增强线粒体活性。降低两种化合物剂量仍可获得相近疗效。蛋白质组学和乙酰化组学分析显示,两种处理诱导的分子特征不同但互补。HDAC8抑制主要调节与细胞骨架组织、表观遗传调控、核糖体生物发生和肌肉结构重塑相关的通路,SIRT1激活主要影响线粒体功能、氧化代谢、氨基酸分解代谢和细胞生物能量学。这些发现表明,HDAC8抑制与SIRT1激活联合可有效改善斑马鱼DMD的关键病理特征,并为两种化合物所靶向的互补通路提供机制认识。这项工作支持将组合表观遗传策略发展为DMD的潜在治疗方法。
Cardiovascular ageing is accompanied by progressive impairment of redox buffering, mitochondrial quality control, proteostasis and metal homeostasis. Iron and copper homeostasis, together with cystine-glutathione and thiol/disulfide redox metabolism, are increasingly recognized as interconnected determinants of metabolic vulnerability and regulated cell death (RCD) in age-related cardiovascular diseases. Ferroptosis, defined by iron-dependent lipid peroxidation and impaired anti-peroxidative defence, has a substantial evidence base in myocardial ischaemia/reperfusion injury, atherosclerosis, heart failure and cardiac fibrosis. By contrast, cuproptosis is supported by emerging but still limited cardiovascular mechanistic evidence, whereas disulfidptosis in cardiovascular tissues is supported mainly by cross-system mechanistic extrapolation and pathway-associated transcriptomic signatures rather than demonstration of canonical cell-death execution. This review integrates iron-, copper-, and sulfur-metabolism-related RCD programmes across shared pathological interfaces, disease-specific contexts, and translational opportunities. We highlight circulating metal and thiol/disulfide indices, transcriptomic signatures, lesion-responsive nanomedicine, and imaging platforms as candidate routes for risk stratification and intervention. A layered interpretation of evidence is essential for translating iron-, copper-, and sulfur-metabolism-related RCD mechanisms into ageing-focused cardiovascular medicine. Here, "metal-sulfur metabolic derangement" is used as an evidence-stratified conceptual framework for partially intersecting stress programmes, not as a unitary mechanism or evidence that the three death modes have equivalent cardiovascular importance.
中文摘要:心血管衰老伴随氧化还原缓冲、线粒体质量控制、蛋白稳态和金属稳态的进行性受损。铁和铜稳态,连同胱氨酸-谷胱甘肽及硫醇/二硫化物氧化还原代谢,日益被视为年龄相关心血管疾病中代谢脆弱性和调节性细胞死亡(RCD)的相互关联决定因素。铁死亡以铁依赖性脂质过氧化和抗过氧化防御受损为定义,在心肌缺血/再灌注损伤、动脉粥样硬化、心力衰竭和心肌纤维化中已有较充分证据基础。相比之下,铜死亡得到新近但仍有限的心血管机制证据支持,而心血管组织中的二硫死亡主要由跨系统机制外推和通路相关转录组特征支持,而非经典细胞死亡执行过程的证实。本综述整合铁、铜和硫代谢相关RCD程序,涵盖共享病理界面、疾病特异情境和转化机会。我们强调循环金属及硫醇/二硫化物指标、转录组特征、病灶响应性纳米药物和成像平台作为风险分层与干预的候选途径。对证据进行分层解读,对于将铁、铜和硫代谢相关RCD机制转化为以衰老为中心的心血管医学至关重要。此处,「金属-硫代谢紊乱」被用作针对部分交叉应激程序的按证据分层的概念框架,而非单一机制,也不表示三种死亡方式具有同等心血管重要性。
Cardiovascular disease is currently a major global challenge, and its causes are complex, encompassing genetic, lifestyle, environmental, and other factors. Ubiquitination, an important post-translational protein modification, is closely associated with cardiovascular disease and is involved in the regulation of protein degradation, signaling, and gene expression. An increasing number of studies have shown that ubiquitination plays a key regulatory role in the development and progression of cardiovascular disease. Recent research has elucidated the crucial role of ubiquitination modifications in governing various cellular processes, signaling pathways, and protein homeostasis within cardiovascular contexts. Specifically, these modifications have been implicated in cardiomyocyte injury and hypertrophy, macrophage inflammation, phenotypic changes in smooth muscle cells, and activation of fibroblasts. This review summarizes the role of ubiquitination modifications in recent years, focusing on the recognition of different substrate proteins by E3 ubiquitin ligases. These ligases are involved in the regulation of various cardiovascular disorders, such as atherosclerosis, myocardial ischemia/reperfusion injury, cardiac remodeling, cardiac arrhythmia, and hypertension. The findings provide new insights into the prevention and treatment of cardiovascular disease.
中文摘要:心血管疾病是当前全球重大挑战,其病因复杂,涉及遗传、生活方式、环境等因素。泛素化是一种重要的蛋白质翻译后修饰,与心血管疾病密切相关,参与蛋白质降解、信号传导和基因表达调控。越来越多研究表明,泛素化在心血管疾病发生发展中起关键调控作用。近期研究阐明泛素化修饰在心血管环境中调控多种细胞过程、信号通路和蛋白质稳态的关键作用。具体而言,这些修饰参与心肌细胞损伤与肥大、巨噬细胞炎症、平滑肌细胞表型改变以及成纤维细胞活化。综述总结近年来泛素化修饰的作用,重点讨论E3泛素连接酶对不同底物蛋白的识别。这些连接酶参与动脉粥样硬化、心肌缺血/再灌注损伤、心脏重构、心律失常和高血压等多种心血管疾病的调控。这些发现为心血管疾病的预防和治疗提供新见解。
12心脏瓣膜病/TAVR (3篇)
临床研究 (3篇)
Severe aortic regurgitation (AR) causes characteristic peripheral hemodynamic changes. This study aimed to evaluate the association between vascular parameters and AR severity and determine whether ankle-brachial index (ABI) and brachial-ankle pulse wave velocity (baPWV) reflect these changes and can serve as markers for identifying severe AR. We retrospectively analyzed 6769 patients undergoing echocardiography and vascular function testing, excluding patients with peripheral artery disease, dialysis, atrial fibrillation, or moderate or severe non-AR valvular disease. Participants were stratified by AR grade (0-4). Associations were examined using multivariable logistic regression. Receiver operating characteristic (ROC) curve analysis was performed for ABI and baPWV, and an optimal cutoff-based four-group classification was constructed. ABI remained stable across AR grades 0-3 and sharply increased in AR 4 (median 1.35), whereas baPWV was lowest in AR 4 (1307 cm/s). ABI (per 0.01 increase; odds ratio [OR] 1.16, 95% confidence interval [CI] 1.13-1.18) and baPWV (per 100 cm/s increase; OR 0.80, 95% CI 0.74-0.86) were independently associated with AR 4. Area under the curve was 0.88 and 0.75 for ABI and baPWV, increasing to 0.90 in the combined model. In a combined model using ROC-derived cutoffs (ABI ≥ 1.26 and baPWV <1330 cm/s), the high-ABI/low-baPWV group showed independently increased odds of AR 4 after adjustment for age, sex, and brachial pulse pressure (OR 49.71, 95% CI 22.15-88.54). Elevated ABI and reduced baPWV served as complementary markers of severe AR, and their combined assessment may facilitate early identification and prompt referral for echocardiographic evaluation.
中文摘要:重度主动脉瓣反流(AR)会引起特征性外周血流动力学改变。本研究旨在评估血管参数与AR严重程度的关联,并确定踝臂指数(ABI)和臂踝脉搏波传导速度(baPWV)是否反映这些改变,能否作为识别重度AR的标志物。回顾性分析6769例接受超声心动图和血管功能检测的患者,排除外周动脉疾病、透析、心房颤动或中重度非AR瓣膜病患者。按AR分级(0-4级)分层。采用多变量logistic回归分析关联。对ABI和baPWV进行ROC曲线分析,并构建基于最佳截断值的四组分类。ABI在AR 0-3级保持稳定,在AR 4级急剧升高(中位数1.35),baPWV在AR 4级最低(1307 cm/s)。ABI(每增加0.01;OR 1.16,95%CI 1.13-1.18)和baPWV(每增加100 cm/s;OR 0.80,95%CI 0.74-0.86)与AR 4级独立相关。ABI和baPWV的曲线下面积分别为0.88和0.75,联合模型增至0.90。在使用ROC推导截断值(ABI≥1.26且baPWV<1330 cm/s)的联合模型中,高ABI/低baPWV组在调整年龄、性别和肱动脉脉压后,AR 4级的比值比独立升高(OR 49.71,95%CI 22.15-88.54)。ABI升高和baPWV降低可作为重度AR的互补标志物,二者联合评估可能有助于早期识别并促使及时转诊进行超声心动图评估。
For patients with severe pure aortic regurgitation (AR) at high surgical risk, guideline-directed medical therapy (GDMT) is often the only available option. Transfemoral transcatheter aortic valve replacement (TAVR) is an established treatment for aortic stenosis and has also been evaluated in patients with pure AR. However, no adequately powered randomized trial has compared TAVR with GDMT alone in this population. We conducted a prospective, investigator-initiated, multicenter, randomized, open-label trial in China. Patients with severe pure AR for whom surgery was considered difficult or unacceptable by the local heart team or who persistently declined surgery were randomly assigned at a 1:1 ratio to receive transfemoral TAVR with the VitaFlow system plus GDMT or GDMT alone. The primary end point was a composite of all-cause death, disabling stroke, or heart failure rehospitalization at 1 year. We assigned 210 patients with severe pure AR to the TAVR group (n=109) or GDMT group (n=101) at 18 centers. At 1-year follow-up, the Kaplan-Meier estimate of the primary end point was significantly lower in the TAVR group than in the GDMT group (8.3% vs 24.8%; hazard ration [HR], 0.31 [95% CI, 0.14-0.66]; P=0.001), driven primarily by a reduction in heart failure rehospitalization (3.7% vs 21.3%; HR, 0.16 [95% CI, 0.06-0.47]; P < 0.001). TAVR was associated with higher rates of major or life-threatening bleeding and new permanent pacemaker implantation, most of which occurred within 30 days after the procedure. Among patients with severe pure AR, TAVR plus GDMT significantly reduced the rate of all-cause death, disabling stroke, or heart failure rehospitalization at 1 year compared with GDMT alone despite higher 30-day rates of major or life-threatening bleeding and new permanent pacemaker implantation. URL: https://www.clinicaltrials.gov; Unique identifier: NCT04864145.
中文摘要:对于外科手术高风险的重度单纯性主动脉瓣反流(AR)患者,指南导向药物治疗(GDMT)常常是唯一可选方案。经股动脉经导管主动脉瓣置换术(TAVR)是主动脉瓣狭窄的成熟治疗方式,也已在单纯性AR患者中接受评估。然而,尚无足够把握度的随机试验在该人群中比较TAVR与单纯GDMT。我们在中国开展了一项前瞻性、研究者发起、多中心、随机、开放标签试验。对于当地心脏团队认为手术困难或不可接受,或持续拒绝手术的重度单纯性AR患者,按1:1比例随机接受VitaFlow系统经股动脉TAVR联合GDMT或单纯GDMT。主要终点为1年全因死亡、致残性卒中或心力衰竭再住院的复合终点。我们在18个中心将210例重度单纯性AR患者分配至TAVR组(n=109)或GDMT组(n=101)。1年随访时,TAVR组主要终点的Kaplan-Meier估计值显著低于GDMT组(8.3% vs 24.8%;风险比[HR],0.31[95% CI,0.14-0.66];P=0.001),主要归因于心力衰竭再住院减少(3.7% vs 21.3%;HR,0.16[95% CI,0.06-0.47];P<0.001)。TAVR与较高的重大或危及生命出血及新发永久起搏器植入率相关,其中多数发生在术后30天内。在重度单纯性AR患者中,与单纯GDMT相比,TAVR联合GDMT显著降低了1年全因死亡、致残性卒中或心力衰竭再住院发生率,尽管30天内重大或危及生命出血及新发永久起搏器植入率较高。URL: https://www.clinicaltrials.gov;唯一标识符:NCT04864145。
Pre-procedural nutritional status has been proposed as a prognostic marker in transcatheter aortic valve replacement (TAVR), although most studies rely on isolated nutrition scores. This study examined how multiple serum-based nutritional scores influence post-TAVR survival. Consecutive patients undergoing TAVR between December 2021 and December 2023 were retrospectively analyzed. Eight serum biomarker-based scores were calculated for each patient (GNRI, PNI, CONUT, PALBI, TCBI, PACI, AGR, ALBI). Associations with overall survival were assessed with Kaplan-Meier curves and adjusted multivariable Cox regression. Principal component analysis (PCA) evaluated relationships among scores. A total of 459 patients were included (mean age 81.7 ± 7.1 years, 45.8% female, median STS 2.8 [1.8-4.4]). The eight scores frequently classified the same patients into different risk strata. Significant survival differences were observed for all scores' most severe stratification except CONUT (p = 0.083) and PNI (p = 0.133). In adjusted Cox models, most scores showed a statistically significant association with overall mortality, except for GNRI (p = 0.237), PALBI (p = 0.378) and TCBI (p = 0.125). PCA demonstrated substantial collinearity among several scores and highlighted a dominant first principal component (PC), PC1 = 54%, without improved discrimination compared to STS score. In the adjusted Cox model, PC1 was also significantly associated with overall mortality (p < 0.001). Despite capturing overlapping biological domains, serum-based nutritional scores inconsistently classify TAVR patients. PCA suggests that a single underlying biomarker dimension explains most of the variability among scores, highlighting overlap and inconsistency across them and supporting the need for a more integrated approach to nutritional assessment rather than single metrics.
中文摘要:术前营养状态被认为是经导管主动脉瓣置换术(TAVR)的预后标志,但多数研究仅依赖单一营养评分。本研究考察多种基于血清生物标志物的营养评分如何影响TAVR术后生存。回顾性分析2021年12月至2023年12月连续接受TAVR的患者,计算每例患者的8种基于血清生物标志物的评分(GNRI、PNI、CONUT、PALBI、TCBI、PACI、AGR、ALBI),采用Kaplan-Meier曲线和校正多变量Cox回归评估其与总生存的关联,并用主成分分析(PCA)评价各评分之间的关系。共纳入459例患者(平均年龄81.7±7.1岁,女性45.8%,STS中位数2.8[1.8-4.4])。8种评分常将同一批患者归入不同的风险分层。除CONUT(p=0.083)和PNI(p=0.133)外,各评分最不利分层均观察到显著的生存差异。在校正Cox模型中,除GNRI(p=0.237)、PALBI(p=0.378)和TCBI(p=0.125)外,多数评分与总死亡率呈统计学显著关联。PCA显示若干评分之间存在明显共线性,并突出一个占主导的第一主成分(PC),PC1=54%,但相较STS评分未改善判别能力。在校正Cox模型中,PC1亦与总死亡率显著相关(p<0.001)。尽管这些基于血清的营养评分覆盖重叠的生物学维度,其对TAVR患者的分类并不一致。PCA提示单一潜在生物标志物维度可解释各评分的大部分变异,反映评分间存在重叠和不一致,支持采用更整合的营养评估方法而非单一指标。
13PCI/血运重建 (2篇)
临床研究 (2篇)
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Hematology: [Formula: see text].
中文摘要:GIM/FP/GP:[公式见正文]。心脏病学:[公式见正文]。血液学:[公式见正文]。
Patients with anatomically complex coronary artery disease may be considered more suitable for coronary artery bypass grafting (CABG) than percutaneous coronary intervention (PCI), but some undergo PCI because of clinical constraints and experience higher long-term cardiovascular risk. The physiological rationale underlying this excess post-PCI risk remains unclear. From the perspective of post-PCI revascularization completeness and physiological results, we sought to explain the drivers of excess long-term adverse risk among patients with Favor CABG anatomy undergoing PCI. Coronary physiology based on quantitative flow ratio (QFR) was retrospectively evaluated in the randomized PANDA III trial in which all patients underwent PCI. Patients were stratified into 2 predefined groups by baseline SYNTAX score: Favor PCI or Favor CABG. Functional revascularization completeness was assessed using classic residual functional SYNTAX score (c-rFSS). Final physiological results were quantified by post-PCI QFR. Causal mediation analyses used 2-year major adverse cardiovascular events (MACE) excluding periprocedural MI as the outcome to estimate the proportion of the group-outcome association statistically accounted for by residual coronary physiological profiles. The primary endpoint was 2-year MACE, defined as the composite of all-cause death, all MI, or any ischemia-driven revascularization. A total of 1555 patients with complete post-PCI physiological assessment constituted the final study cohort, among whom 269 (17.3%) individuals were stratified to Favor CABG group by baseline SYNTAX score. The 2-year MACE rate was significantly higher in the Favor CABG than the Favor PCI group (18.6% vs 9.2%; adjusted HR: 1.78; 95% CI: 1.27-2.50). Functional incomplete revascularization (c-rFSS >0) was substantially more prevalent among patients in the Favor CABG group (53.2% vs. 15.1%, P < 0.001). Suboptimal post-PCI physiology defined by QFR <0.90 was more frequent in Favor CABG cohort (32.0% vs 11.8%, P < 0.001). In analyses using MACE excluding periprocedural MI, the estimated proportions mediated by functional incomplete revascularization and suboptimal post-PCI physiology were 49.4% and 47.8%, respectively, and their estimated joint proportion mediated was 79.8%. Integrating c-rFSS or post-PCI QFR into clinical-anatomic risk models significantly improved discrimination and reclassification capacity for 2-year MACE (all P < 0.05). In this post hoc analysis of an all-comers PCI trial, approximately one-fifth of patients presented with anatomic complexity warranting CABG as the preferred revascularization strategy. Favor CABG anatomy was associated with higher 2-year MACE than Favor PCI anatomy. This association may be partly explained by the higher prevalence of residual functional incomplete revascularization and suboptimal post-PCI physiology. These findings between Favor CABG and Favor PCI anatomy do not represent a head-to-head comparison and should not be interpreted as a direct comparison of revascularization modalities. URL: https://www. gov; Unique Identifier: NCT02017275.
中文摘要:解剖学复杂的冠心病患者可能更适合冠状动脉旁路移植术(CABG)而非经皮冠状动脉介入治疗(PCI),但部分患者受临床条件限制仍接受PCI,其长期心血管风险更高。这种PCI后超额风险的生理学依据尚不清楚。研究从PCI后血运重建完整性与生理学结果的角度,尝试解释具备CABG优势解剖特征却接受PCI的患者长期不良风险升高的驱动因素。基于定量血流分数(QFR)的冠状动脉生理学在PANDA III随机试验中做了回顾性评估,该试验全部患者均接受PCI。按基线SYNTAX评分将患者分为两个预设组:Favor PCI组与Favor CABG组。功能学血运重建完整性用经典残余功能SYNTAX评分(c-rFSS)评估,最终生理学结果用PCI后QFR量化。因果中介分析以2年主要不良心血管事件(MACE,排除围术期心肌梗死)为结局,估算残余冠状动脉生理学特征在组别与结局关联中所能统计解释的比例。主要终点为2年MACE,即全因死亡、任何心肌梗死或任何缺血驱动血运重建的复合终点。1555例完成PCI后生理学评估的患者构成最终研究队列,其中269例(17.3%)按基线SYNTAX评分归入Favor CABG组。Favor CABG组2年MACE率显著高于Favor PCI组(18.6%对9.2%;校正HR 1.78;95%CI 1.27-2.50)。功能性血运重建不完整(c-rFSS>0)在Favor CABG组更为多见(53.2%对15.1%,P<0.001)。以QFR<0.90定义的PCI后生理学结果欠佳在Favor CABG队列中更常见(32.0%对11.8%,P<0.001)。在排除围术期心肌梗死的MACE分析中,功能性血运重建不完整与PCI后生理学欠佳所中介的估计比例分别为49.4%和47.8%,两者联合中介的估计比例为79.8%。将c-rFSS或PCI后QFR纳入临床-解剖风险模型,显著改善了对2年MACE的区分度与重分类能力(均P<0.05)。在这项不设严格筛选的PCI试验的事后分析中,约五分之一的患者其解剖复杂度提示CABG为优选血运重建策略。Favor CABG解剖与高于Favor PCI解剖的2年MACE相关,这种关联可能部分由功能性血运重建不完整和PCI后生理学结果欠佳的高发生率解释。Favor CABG与Favor PCI解剖之间的这些发现并非头对头比较,不应解读为血运重建方式的直接比较。网址:https://www. gov;唯一标识符:NCT02017275。
14心脏移植 (1篇)
临床研究 (1篇)
The increasing age of heart donors in Europe raises concerns about undetected coronary artery disease (CAD), a contributor to early graft dysfunction and long-term complications. This study examined the association between donor coronary angiography (CA) and heart transplant utilization, particularly in donors aged >40 years. A total of 20 681 donor heart offers reported to Eurotransplant between 2004 and 2020 were analysed. The use of CA, donor characteristics, and acceptance rates were assessed. CAD status was imputed for donors without angiography using logistic regression based on clinical risk factors. Transplantation probabilities were modelled using observed and imputed CAD severity to explore potential differences under a scenario of broader CA availability. CA was performed in 23.5% of cases, predominantly in older donors and those with cardiovascular risk factors. Among donors with CA, 37.5% had CAD, which was significantly associated with age, male sex, hypertension, and smoking. Donors with normal CA findings had lower odds of rejection compared with those without CA (odds ratio 0.36, P < .0001). In a counterfactual model, broader CA availability in donors aged >40 years was associated with a higher estimated transplant utilization (56.4%-67.1%), corresponding to a model-based increase of ∼535 transplants. In this observational cohort, CA availability was associated with differences in donor heart utilization, particularly when findings were normal or showed non-significant CAD. These findings suggest that angiographic information may reduce diagnostic uncertainty and support clinical decision-making in older donors. A risk-adapted, resource-sensitive approach to CA use is warranted.
中文摘要:欧洲心脏供体年龄上升,使未被发现的冠状动脉疾病(CAD)受到关注,而CAD可导致早期移植物功能障碍和长期并发症。该研究分析供体冠状动脉造影(CA)与心脏移植利用之间的关系,重点在年龄>40岁的供体。研究纳入2004年至2020年向Eurotransplant报告的20681例供体心脏提供记录,评估CA使用、供体特征和接受率。对未接受造影的供体,依据临床危险因素用逻辑回归插补CAD状态。利用观察到的和插补的CAD严重程度建立移植概率模型,以探索CA可及性更广情形下可能出现的差异。23.5%的病例实施了CA,主要集中在年龄较大的供体和具有心血管危险因素者。接受CA的供体中37.5%存在CAD,CAD与年龄、男性、高血压和吸烟显著相关。CA结果正常的供体相比未接受CA者,排斥反应的几率更低(比值比0.36,P < .0001)。在反事实模型中,年龄>40岁供体的CA可及性更广时,估计移植利用率更高(56.4%-67.1%),对应模型估计增加约535例移植。在这个观察性队列中,CA可及性与供体心脏利用差异相关,尤其在结果正常或显示无显著意义CAD时。这些发现提示,造影信息可能减少诊断不确定性,并支持年龄较大供体的临床决策。需要采用风险适配且考虑资源条件的方法来使用CA。
15心血管疾病 (1篇)
临床研究 (1篇)
The extent to which whole-blood NAD levels are altered in human disease or ageing remains controversial. Here we conducted 1,340 measurements in 1,068 adults, and found that whole-blood NAD levels do not decline with age in healthy individuals; they remain stable in males and increase in females, but are reduced in chronic diseases, specifically cardiovascular disease and hypertension. These findings indicate that whole-blood NAD levels track cardiovascular disease rather than chronological age. As this research was not designed to investigate causality, these data do not provide direct evidence that NAD supplementation may serve as a treatment for cardiovascular disease or hypertension.
中文摘要:全血NAD水平在人类疾病或衰老中改变的程度仍有争议。我们对1,068名成年人进行了1,340次检测,发现健康个体的全血NAD水平不随年龄下降;男性保持稳定,女性升高,但在慢性疾病中降低,尤其是心血管疾病和高血压。这些发现表明,全血NAD水平反映的是心血管疾病而非实际年龄。由于本研究并非为探讨因果关系而设计,这些数据不能直接证明NAD补充剂可作为心血管疾病或高血压的治疗手段。
16先天性心脏病 (1篇)
临床研究 (1篇)
The aim of the study was to assess the effect of guideline-directed medical therapy (GDMT) on cardiac function, neurohormonal activation, and mortality in adults with congenitally corrected transposition of the great arteries (cc-TGA) presenting with systemic right ventricular (RV) systolic dysfunction. The study hypothesis was that GDMT use (assessed using the GDMT score) was associated with improved cardiac function (higher RV free wall strain [RVFWS]), less neurohormonal activation (lower N-terminal pro-B-type natriuretic peptide [NT-proBNP] levels), and lower mortality. GDMT score, RVFWS, and NT-proBNP levels were assessed at baseline and 1-year follow-up. GDMT uptitration was assessed using ΔGDMT (GDMT at 1-year minus GDMT at baseline). Improvements in RV systolic function and neurohormonal activation were defined as a relative increase in RVFWS of >20% and a relative decrease in NT-proBNP levels of >20%, respectively. Of 213 patients (age 43 ± 15 years; 54% male), baseline GDMT score was 1.97 ± 1.27, and ΔGDMT score was 0.74 ± 0.39. Baseline RVFWS was -18 ± 5%; 25% had improved RV systolic function. Baseline NT-proBNP was 369 (142, 1004) pg/mL; 56% had improved neurohormonal activation. Higher baseline GDMT score and ΔGDMT score were associated with improvement in RV systolic function and neurohormonal activation. Overall, 34 (16%) patients died, and higher baseline GDMT score and ΔGDMT score were associated with a lower risk of mortality and of the composite adverse event endpoint (heart failure hospitalization, death, and heart transplantation). Clinical benefits of GDMT use were observed only in patients with moderate/severe RV systolic dysfunction, and not in patients with mild RV systolic dysfunction. GDMT use was associated with improved outcomes in patients with moderate/severe RV systolic dysfunction.
中文摘要:研究旨在评估指南导向药物治疗(GDMT)对以体循环右心室收缩功能障碍为表现的成人先天性矫正型大动脉转位(cc-TGA)患者心功能、神经激素激活和死亡率的影响。研究假设为,GDMT使用情况(以GDMT评分评估)与心功能改善(右心室游离壁应变[RVFWS]更高)、神经激素激活减轻(N末端B型利钠肽原[NT-proBNP]水平更低)和死亡率降低相关。基线及1年随访时评估GDMT评分、RVFWS和NT-proBNP水平。GDMT上调以ΔGDMT评估(1年时GDMT减基线GDMT)。RV收缩功能改善定义为RVFWS相对增加>20%,神经激素激活改善定义为NT-proBNP水平相对下降>20%。213例患者(年龄43±15岁;54%男性)中,基线GDMT评分为1.97±1.27,ΔGDMT评分为0.74±0.39。基线RVFWS为-18±5%;25%的患者RV收缩功能改善。基线NT-proBNP为369(142,1004)pg/mL;56%的患者神经激素激活改善。较高的基线GDMT评分和ΔGDMT评分与RV收缩功能及神经激素激活改善相关。总体34例(16%)患者死亡,较高的基线GDMT评分和ΔGDMT评分与较低死亡风险及复合不良事件终点(心力衰竭住院、死亡和心脏移植)风险相关。GDMT的临床获益仅见于中度/重度RV收缩功能障碍患者,轻度RV收缩功能障碍患者未见获益。GDMT使用与中度/重度RV收缩功能障碍患者结局改善相关。
17胃癌 (1篇)
临床研究 (1篇)
This single-center randomized controlled trial assessed the efficacy and safety of the ramucirumab plus nab-paclitaxel, lobaplatin, and S-1(RNPLS) regimen for conversion therapy in unresectable advanced gastric cancer. Seventy patients were equally assigned to receive either ramucirumab, nab-paclitaxel, lobaplatin, and S-1(RNPLS) therapy or nab-paclitaxel, lobaplatin, and S-1(NPLS) chemotherapy alone. Primary endpoints included pathological complete response (pCR) and secondary endpoints encompassed R0 resection rate, objective response rate (ORR), the disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and adverse events (AE). Although the difference in pCR rate was statistically insignificant between the two groups, the RNPLS group achieved significantly higher ORR, DCR, and R0 resection rate. Moreover, the RNPLS regimen yielded prolonged PFS, longer duration of response, and promising preliminary OS. While hypertension occurred more frequently in the RNPLS group, the incidence of grade ≥3 AEs was low and comparable in both cohorts. This exploratory single-center randomized trial showed preliminary favorable efficacy of RNPLS regimen for conversion therapy in unresectable advanced gastric cancer with manageable toxicity. ClinicalTrials.gov: NCT06169410.
中文摘要:这项单中心随机对照试验评估了雷莫西尤单抗联合白蛋白结合型紫杉醇、洛铂和替吉奥(RNPLS)方案用于不可切除晚期胃癌转化治疗的有效性和安全性。70例患者等量分配接受RNPLS治疗或仅接受白蛋白结合型紫杉醇、洛铂和替吉奥(NPLS)化疗。主要终点包括病理完全缓解(pCR),次要终点包括R0切除率、客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS)、缓解持续时间(DOR)和不良事件(AE)。两组pCR率差异无统计学意义,RNPLS组ORR、DCR和R0切除率显著更高。RNPLS方案还带来更长的PFS、更长的缓解持续时间和初步有希望的OS。RNPLS组高血压发生率更高,但≥3级AE发生率低且两组相当。这项探索性单中心随机试验显示,RNPLS方案用于不可切除晚期胃癌转化治疗具有初步良好疗效,毒性可管理。ClinicalTrials.gov:NCT06169410。
18抗栓治疗不足 (1篇)
临床研究 (1篇)
Antithrombotic therapy undertreatment includes omission, nonadherence, underdosing, and clinical circumstances that result in subtherapeutic antithrombotic levels. Antithrombotic undertreatment has profound implications for patient safety, public health, and healthcare costs. Due to deviation from evidence-based clinical practice, misperceptions of bleeding versus thrombotic risk, and inequities in healthcare access, many patients with atrial fibrillation, venous thromboembolism, or peripheral artery disease remain untreated or receive suboptimal anticoagulant dosing. Antithrombotic undertreatment has been shown to increase rates of ischemic stroke, systemic embolism, recurrent thrombosis, and mortality. Real-world data continue to highlight substantial gaps in care, which appear to be magnified in patients with inequity in social determinants of health. The emergence of antithrombotic stewardship, in concert with growing bodies of literature on antithrombotic agent underdosing, represents a transformative opportunity to address these gaps through structured, interprofessional, and evidence-based approaches. Through interdisciplinary collaboration, healthcare professionals are well positioned to enhance patient health and safety by recognizing and recommitting to reducing antithrombotic undertreatment.
中文摘要:抗栓治疗不足包括遗漏用药、不依从、剂量不足,以及导致抗栓水平低于治疗剂量的临床情形。抗栓治疗不足对患者安全、公共卫生和医疗费用有深远影响。由于偏离循证临床实践、对出血风险与血栓风险的误判,以及医疗可及性方面的不公平,许多心房颤动、静脉血栓栓塞症或外周动脉疾病患者仍未接受治疗,或接受次优的抗凝剂量。抗栓治疗不足已被证明会增加缺血性卒中、系统性栓塞、血栓复发和死亡的发生率。真实世界数据不断凸显诊疗中的巨大差距,而在健康社会决定因素方面处于不公平境地的患者中,这一差距似乎被放大。抗栓管理理念的出现,连同关于抗栓药物剂量不足的文献日益增多,为解决这些差距提供了变革性机会,可通过结构化、跨专业和循证的方法实现。通过跨学科协作,医疗专业人员完全有能力识别并重新致力于减少抗栓治疗不足,从而增进患者健康与安全。
19心肌梗死 (1篇)
基础研究 (1篇)
Direct reprogramming of cardiac fibroblasts (CFs) into induced cardiomyocytes (iCMs) holds promise as a therapeutic strategy for heart regeneration. After myocardial infarction (MI), resident quiescent CFs (QCFs) activate and differentiate into myofibroblasts (MFs) in the infarcted region that drive pathological cardiac fibrosis. Converting these injury-activated MFs into iCMs could simultaneously alleviate fibrosis and replenish lost cardiomyocytes. However, whether the marked heterogeneity of CFs in the infarcted heart, and in particular the activation of QCFs into MFs, creates an intrinsic barrier that limits the reprogramming of these injury-activated MFs remains unknown. To define the molecular basis of this heterogeneity, we purified PDGFRα+ CFs and used Postn lineage tracing to distinguish injury-activated MFs from quiescent CFs, enabling matched comparison of their reprogramming competence and single-cell RNA sequencing (scRNA-seq) profiling of post-MI CF subpopulations. A targeted in vitro shRNA screen was conducted against 9 MF-enriched TFs as candidate molecular barriers for cardiac reprogramming. The lead candidate was validated in mouse MFs, human iPSC-derived MFs, primary human MFs, and in vivo using dual-recombinase-mediated lineage tracing. Mechanistic insights were gained through integrated bulk RNA-seq, scRNA-seq and Cleavage Under Targets and Tagmentation (CUT&Tag), together with functional assays including DNA-binding-deficient and domain-swap MEOX1 mutants. We identified the upregulated transcription factor MEOX1, a known fibrosis determinant downstream of the key post-MI cytokines transforming growth factor-beta 1 and interleukin-1 beta, as the principal molecular barrier responsible for the profound reprogramming resistance of MFs. MEOX1 knockdown markedly enhanced reprogramming efficiency in both mouse and human MFs and enabled GATA4-free reprogramming combinations. This inhibition depended on the transcriptional activation activity of MEOX1, as disrupting its DNA-binding domain or fusing it to a repressor domain rescued reprogramming. Integrated scRNA-seq and CUT&Tag analyses revealed that MEOX1 binds and stabilizes a fibrotic, MF-defining transcriptional program that antagonizes the cardiogenic program while also modulating the inflammatory response; its knockdown disrupted this fibrotic network to favor iCM fate acquisition. Using stringent dual-recombinase lineage tracing, we demonstrated that MEOX1 knockdown enables highly efficient in vivo MF-to-iCM conversion, leading to significant reductions in cardiac fibrosis and substantial improvement in cardiac function after MI. Our study identifies pathological MEOX1 upregulation as a key mechanism underlying the reprogramming resistance of post-MI mouse MFs and activated human MFs. Overcoming this barrier achieves unprecedented, lineage-confirmed in vivo reprogramming efficiency, thereby addressing a significant obstacle for the clinical translation of in situ reprogramming therapies.
中文摘要:将心脏成纤维细胞(CFs)直接重编程为诱导性心肌细胞(iCMs)有望成为心脏再生的治疗策略。心肌梗死后,梗死区驻留的静息CFs活化并分化为肌成纤维细胞,驱动病理性心脏纤维化。把这些损伤活化的MFs转化为iCMs可同时减轻纤维化并补充丢失的心肌细胞。然而,梗死心脏中CFs的显著异质性、尤其QCFs向MFs的活化,是否构成限制这些损伤活化MFs重编程的内在屏障仍不清楚。为界定这种异质性的分子基础,我们纯化PDGFRα+ CFs,并用Postn谱系追踪区分损伤活化MFs与静息CFs,从而配对比较其重编程能力,并对梗死后CF亚群进行单细胞RNA测序。针对9个MF富集转录因子开展体外靶向shRNA筛选,作为心脏重编程的候选分子屏障。先导候选在小鼠MFs、人iPSC来源MFs、原代人MFs及双重组酶介导谱系追踪的体内实验中验证。机制通过整合bulk RNA-seq、scRNA-seq和CUT&Tag,以及DNA结合缺陷和结构域互换MEOX1突变体等功能实验获得。我们发现上调的转录因子MEOX1——梗死后关键细胞因子TGF-β1和IL-1β下游已知的纤维化决定因子——是MFs重编程抵抗的主要分子屏障。MEOX1敲低显著提高小鼠和人MFs的重编程效率,并实现无GATA4的重编程组合。该抑制作用依赖MEOX1的转录激活活性,破坏其DNA结合域或将其融合到抑制域可挽救重编程。整合scRNA-seq和CUT&Tag分析显示,MEOX1结合并稳定一个纤维化、MF定义的转录程序,该程序拮抗心脏发生程序并调节炎症反应;敲低MEOX1破坏该纤维化网络,利于iCM命运获得。用严格的双重组酶谱系追踪,我们证明MEOX1敲低可实现高效的体内MF向iCM转化,显著减少梗死后心脏纤维化并大幅改善心功能。该工作确定病理性MEOX1上调是梗死后小鼠MFs和活化人MFs重编程抵抗的关键机制。克服该屏障获得前所未有的、谱系确认的体内重编程效率,从而解决原位重编程治疗临床转化的重要障碍。
20胸腺癌 (1篇)
临床研究 (1篇)
Advanced thymic carcinoma is a rare, aggressive malignancy with limited treatment options after chemotherapy failure. This randomized, double-blind, placebo-controlled trial (AL3810-202) aimed to evaluate lucitanib, a novel, orally potent tyrosine kinase inhibitor targeting VEGFR1‒3, FGFR1‒3, and PDGFRα/β in patients with advanced thymic carcinoma progressing after chemotherapy. Sixty-eight patients were randomized (2:1) to receive 10 mg lucitanib daily (n = 46) or placebo (n = 22). Although this study did not meet its primary endpoint of independent review committee (IRC)-assessed progression-free survival (PFS) (median 5.8 vs. 3.7 months; hazard ratio [HR]: 0.60; p = 0.1050), the prespecified log-rank test may have underestimated the treatment effect due to an observed non-proportional hazards pattern. Subsequent restricted mean survival time analysis demonstrated a statistically significant PFS benefit (p < 0.05), which was further supported by significantly prolonged investigator-assessed PFS (6.6 vs. 1.9 months; HR: 0.53; p = 0.0306). The most common grade 3 treatment-related adverse events (TRAEs) were hypertension (50%), proteinuria (15.2%), and thrombocytopenia (8.7%), with no grade 4/5 events. Considering the totality of the evidence and an acceptable safety profile, lucitanib may confer a meaningful clinical benefit for patients with advanced thymic carcinoma, warranting further investigation.
中文摘要:晚期胸腺癌是一种罕见且侵袭性强的恶性肿瘤,化疗失败后治疗选择有限。这项随机、双盲、安慰剂对照试验(AL3810-202)旨在评估lucitanib——一种新型口服强效酪氨酸激酶抑制剂,靶向VEGFR1‒3、FGFR1‒3和PDGFRα/β——在化疗后进展的晚期胸腺癌患者中的疗效。68例患者按2:1随机接受lucitanib 10 mg每日一次(n=46)或安慰剂(n=22)。研究未达到独立评审委员会(IRC)评估的无进展生存期(PFS)主要终点(中位5.8个月 vs 3.7个月;风险比[HR]:0.60;p=0.1050),预设的log-rank检验可能因观察到非比例风险模式而低估了治疗效应。随后进行的限制性平均生存时间分析显示PFS获益具有统计学显著性(p<0.05),研究者评估的PFS显著延长(6.6个月 vs 1.9个月;HR:0.53;p=0.0306)进一步支持这一结果。最常见的3级治疗相关不良事件(TRAE)为高血压(50%)、蛋白尿(15.2%)和血小板减少(8.7%),未发生4/5级事件。综合全部证据及可接受的安全性特征,lucitanib可能为晚期胸腺癌患者带来有临床意义的获益,值得进一步研究。
21子宫内膜癌 (1篇)
临床研究 (1篇)
Patients with advanced endometrial cancer (EC) have a poor prognosis and limited therapeutic options after failure of prior systemic therapy. In this multi-cohort Phase II study (ETER200), patients with metastatic or recurrent EC who had received at least one chemotherapy regimen were enrolled. Based on MSI/MMR status, patients received benmelstobart plus anlotinib (Cohort 1), benmelstobart (Cohort 2), or anlotinib (Cohort 3) every 3 weeks. Primary endpoint was objective response rate (ORR) assessed by independent review committee (IRC) per RECIST v1.1. Here, the results of Cohort 1 expansion stage were reported. As of May 9, 2024, 85 of the 107 non-MSI-H/pMMR EC patients enrolled in Cohort 1 constituted the expansion stage population for primary efficacy analysis. The IRC-assessed ORR was 34.1% (95% CI, 24.2-45.2), with a median duration of response of 15.2 months (95% CI, 6.9-not evaluable). Median progression-free and overall survival were 8.8 months (95% CI, 5.8-15.2) and 21.8 months (95% CI, 19.5-29.1), respectively. Grade ≥ 3 treatment-related adverse events occurred in 69.2% of patients, most commonly hypertension (21.2%) and palmar-plantar erythrodysesthesia syndrome (9.4%). Overall, benmelstobart plus anlotinib showed promising anti-tumor activity and an acceptable safety profile in advanced non-MSI-H/pMMR EC, supporting further evaluation of this combination in randomized Phase III studies. Trial Registration: ClinicalTrials.gov, NCT04574284.
中文摘要:晚期子宫内膜癌患者在既往系统治疗失败后预后差、治疗选择有限。这项多队列II期研究(ETER200)纳入转移性或复发性子宫内膜癌且至少接受过一种化疗方案的患者。根据MSI/MMR状态,患者每3周接受benmelstobart联合安罗替尼(队列1)、benmelstobart(队列2)或安罗替尼(队列3)。主要终点为独立评审委员会(IRC)按RECIST v1.1评估的客观缓解率(ORR)。此处报告队列1扩展阶段结果。截至2024年5月9日,队列1入组的107例非MSI-H/pMMR子宫内膜癌患者中85例构成扩展阶段人群用于主要疗效分析。IRC评估的ORR为34.1%(95% CI,24.2-45.2),中位缓解持续时间15.2个月(95% CI,6.9-不可评估)。中位无进展生存期和总生存期分别为8.8个月(95% CI,5.8-15.2)和21.8个月(95% CI,19.5-29.1)。≥3级治疗相关不良事件发生率69.2%,最常见为高血压(21.2%)和掌跖红斑感觉异常综合征(9.4%)。benmelstobart联合安罗替尼在晚期非MSI-H/pMMR子宫内膜癌中显示出有前景的抗肿瘤活性和可接受的安全性,支持该联合方案在随机III期研究中进一步评估。试验注册:ClinicalTrials.gov,NCT04574284。
22脂肪肝 (1篇)
临床研究 (1篇)
Metabolic dysfunction-associated fatty liver disease, conventionally known as nonalcoholic fatty liver disease (NAFLD), affects over a quarter of the global population and lacks approved pharmacological treatments. We investigated whether elevated blood pressure (BP) is a modifiable risk factor for NAFLD and whether antihypertensive drugs could be repurposed for prevention. We conducted whole-genome Mendelian randomization using genetic data from over 1 million individuals of European ancestry to assess systolic BP as a risk factor for NAFLD. Drug-target Mendelian randomization was used to investigate the class-specific effects of antihypertensive agents, including renin-angiotensin system inhibitors, β-blockers, calcium channel blockers, and diuretics. NAFLD was defined by persistently elevated alanine aminotransferase levels after excluding alternative liver diseases and alcohol use disorders. Genetic estimates were compared with individual-participant meta-analyses of randomized controlled trials (n=358 636) and summary data from 104 antihypertensive drug trials (≈500 000 participants), using coronary heart disease as a positive control. A genetically proxied 5-mm Hg reduction in systolic BP was associated with an 8% lower risk of NAFLD (odds ratio, 0.92 [95% CI, 0.90-0.94]). Renin-angiotensin system inhibition was associated with a 27% lower risk (odds ratio, 0.73 [95% CI, 0.62-0.85]), whereas other drug classes showed no substantial associations. For coronary heart disease, effects were directionally consistent across classes in genetic and trial analyses. Genetically lower systolic BP is associated with reduced NAFLD risk, with renin-angiotensin system inhibition showing the most favorable association. These findings support BP lowering, particularly renin-angiotensin system inhibition, as a potential preventive strategy warranting dedicated randomized trials.
中文摘要:代谢功能障碍相关脂肪性肝病,传统上称为非酒精性脂肪性肝病(NAFLD),影响全球超过四分之一人口,且缺乏获批的药物治疗。研究评估血压升高是否为NAFLD的可改变危险因素,以及降压药能否用于预防。利用超过100万欧洲血统个体的遗传数据开展全基因组孟德尔随机化,评估收缩压作为NAFLD危险因素的作用。采用药物靶点孟德尔随机化考察降压药的类别特异性效应,包括肾素-血管紧张素系统抑制剂、β受体阻滞剂、钙通道阻滞剂和利尿剂。NAFLD定义为在排除其他肝病和酒精使用障碍后丙氨酸氨基转移酶持续升高。遗传学估计值与随机对照试验的个体参与者荟萃分析(n=358636)以及104项降压药试验(约50万参与者)的汇总数据进行比较,并以冠心病作为阳性对照。遗传代理的收缩压降低5 mmHg与NAFLD风险降低8%相关(比值比0.92,95% CI 0.90-0.94)。肾素-血管紧张素系统抑制与风险降低27%相关(比值比0.73,95% CI 0.62-0.85),其他药物类别未见实质性关联。对冠心病而言,遗传分析和试验分析中各药物类别的效应方向一致。遗传学上较低的收缩压与NAFLD风险降低相关,肾素-血管紧张素系统抑制显示出最有利的关联。这些发现支持将降压,尤其是肾素-血管紧张素系统抑制,作为值得开展专门随机试验的潜在预防策略。
23新生儿窒息 (1篇)
基础研究 (1篇)
Metabolic and neurovascular disturbances contribute to brain injury after birth asphyxia. We previously showed that plasma feeding attenuated neuropathology after transient umbilical cord occlusion in piglets. This study explored the metabolic and molecular consequences of birth asphyxia and whether plasma feeding preserves metabolic homeostasis and brain barrier integrity. Piglets (n=89) delivered by cesarean section on gestational day 113 underwent umbilical cord occlusion (asphyxia [ASP]) or remained nonasphyxiated (control [CON]). ASP and CON piglets were randomly assigned to receive formula reconstituted with either water (vehicle-treated group) or sow plasma (plasma-treated group). Animals were euthanized at 1 hour, 24 hours, or day 4 after insult. Cerebrospinal fluid metabolites were profiled by untargeted liquid chromatography-mass spectrometry metabolomics at 24 hours. Expression of metabolite transporters and structural components of the blood-brain barrier in the caudate nucleus and the blood-cerebrospinal fluid barrier at the choroid plexus was assessed by reverse transcription quantitative polymerase chain reaction and Western blotting. The CSF/plasma Na+ ratio was assessed, and cell-specific AQP4 expression was confirmed with RNAscope. Data were analyzed using linear and linear mixed-effects models. Birth asphyxia dysregulated the CSF metabolic profile, with reductions in multiple metabolites and increases in a smaller subset, consistent with impaired amino acid and lipid metabolism. This was accompanied by reduced expression of substrate transporters, including xCT, LAT1, ASCT2, FATP1, CAV1, and MCTs. In the caudate nucleus, expression of blood-brain barrier structural proteins and ion transporters, including Na+/K+-ATPase, was reduced, whereas the choroid plexus blood-CSF barrier remained largely preserved. Plasma feeding partially restored transporter expression at both brain interfaces and increased AQP4 and ion transporter expression at the blood-brain barrier by day 4. Increased VE-cadherin (vascular endothelial cadherin) and ZO-1 (zonula occludens-1) expression and elevated CSF Na+ concentrations suggested early modulation of the integrity of the 2 brain barriers. Plasma feeding preserves metabolic homeostasis and supports brain barrier integrity after birth asphyxia, highlighting plasma-derived factors as potential therapeutic targets to reduce neurodevelopmental impairment after perinatal asphyxia.
中文摘要:代谢和神经血管紊乱参与出生窒息后脑损伤。我们此前发现,血浆喂养可减轻仔猪短暂脐带闭塞后的神经病理改变。本研究探讨出生窒息的代谢与分子后果,以及血浆喂养能否维持代谢稳态和脑屏障完整性。妊娠第113天剖宫产分娩的仔猪(n=89)接受脐带闭塞(窒息[ASP])或保持非窒息(对照[CON])。ASP和CON仔猪随机接受用水(载体治疗组)或母猪血浆(血浆治疗组)复配的配方奶。动物在损伤后1小时、24小时或第4天安乐死。24小时时用非靶向液相色谱-质谱代谢组学分析脑脊液代谢物。用逆转录定量聚合酶链反应和蛋白免疫印迹评估尾状核血脑屏障及脉络丛血-脑脊液屏障的代谢物转运体和结构成分表达。评估脑脊液/血浆Na+比值,并用RNAscope确认细胞特异性AQP4表达。数据用线性模型和线性混合效应模型分析。出生窒息使脑脊液代谢谱失调,多种代谢物降低、少数代谢物升高,符合氨基酸和脂质代谢受损。同时底物转运体表达降低,包括xCT、LAT1、ASCT2、FATP1、CAV1和MCTs。尾状核中血脑屏障结构蛋白和离子转运体(包括Na+/K+-ATPase)表达降低,而脉络丛血-脑脊液屏障基本保留。血浆喂养部分恢复两个脑界面的转运体表达,并在第4天增加血脑屏障AQP4和离子转运体表达。VE-cadherin(血管内皮钙黏蛋白)和ZO-1(闭锁小带蛋白-1)表达增加及脑脊液Na+浓度升高,提示两种脑屏障完整性在早期受到调节。血浆喂养维持出生窒息后的代谢稳态并支持脑屏障完整性,提示血浆来源因子可作为减轻围产期窒息后神经发育损害的治疗靶点。
24高尿酸血症 (1篇)
临床研究 (1篇)
To compare three calorie-restricted diets for weight loss, serum urate (SU) value, early urate dynamics, gout flares, adherence, and body composition in men with overweight or obesity and hyperuricemia. In this 12-week, open-label, active-comparator randomized trial, 102 men with overweight or obesity and hyperuricemia were assigned 1:1:1 to a carbohydrate-restricted diet (CRD), Dietary Approaches to Stop Hypertension (DASH) diet, or low-purine balanced diet (LPBD). All groups followed a calorie-restricted prescription of 20-25 kcal/kg ideal body weight. The primary end point was change in SU from baseline to week 12. Of 102 randomized participants, 85 (83.3%) completed follow-up. At week 12, mean weight loss was 8.47 kg (9.3%) with no between-group difference (P = 0.99). Adjusted SU changes were -0.89 mg/dL with the CRD, -0.79 mg/dL with the DASH diet, and -0.50 mg/dL with the LPBD, without a significant between-group difference (P = 0.48). Capillary blood urate monitoring identified a transient week 1 increase coinciding with the early peak in gout flares. Dietary adherence to DASH was higher than to the other two diets and was associated with less soft lean mass loss than the CRD. In men with overweight or obesity and hyperuricemia, three calorie-restricted dietary patterns produced substantial weight loss but did not differ significantly in 12-week SU reduction. DASH was associated with higher adherence than both the CRD and LPBD and with less soft lean mass loss than the CRD. Early urate instability and coincident gout flares highlight the need for flare-risk management during structured dietary weight loss initiation.
中文摘要:比较三种限制热量饮食对超重或肥胖合并高尿酸血症男性的减重、血清尿酸(SU)、早期尿酸动态、痛风发作、依从性及体成分的影响。这项12周、开放标签、活性对照随机试验纳入102例超重或肥胖合并高尿酸血症男性,按1:1:1分配至限制碳水化合物饮食(CRD)、终止高血压膳食方案(DASH)或低嘌呤平衡饮食(LPBD)。各组均执行20~25 kcal/kg理想体重的限热量处方。主要终点为基线至第12周SU变化。102例随机参与者中85例(83.3%)完成随访。第12周平均减重8.47 kg(9.3%),组间无差异(P=0.99)。校正后SU变化为CRD -0.89 mg/dL、DASH -0.79 mg/dL、LPBD -0.50 mg/dL,组间差异无统计学意义(P=0.48)。毛细血管血尿酸监测发现第1周出现一过性升高,与痛风发作的早期高峰重合。DASH饮食依从性高于另外两种饮食,且与CRD相比软组织瘦体重丢失更少。在超重或肥胖合并高尿酸血症男性中,三种限热量饮食模式均带来明显减重,但12周SU下降幅度无显著差异。DASH依从性高于CRD和LPBD,且较CRD软组织瘦体重丢失更少。早期尿酸不稳定及同时出现的痛风发作提示,在启动结构化饮食减重时需进行发作风险管理。
25糖尿病足截肢 (1篇)
临床研究 (1篇)
Below-knee amputation (BKA) is the most common major amputation for advanced diabetic foot disease. Understanding the associated mortality, cause of death, and postoperative risks is important for patient counseling and improving care. This national population study described mortality and causes of death following BKA in people with diabetes, identifying those at greatest risk and whether mortality has improved. It investigated perioperative complications, readmission, reoperation, and further limb amputation. An England population study of people with diabetes undergoing BKA was performed using mortality-linked Hospital Episode Statistics. The primary outcome was Kaplan-Meier analysis of all-cause mortality. Cox proportional hazards modeling identified variables associated with high mortality. Secondary outcomes included causes of death, 90-day complications, readmission, and further amputation rates. A total of 25,176 people with diabetes underwent 28,232 BKA procedures. Mortality was 23.5% at 1 year, 60.0% at 5 years, and 82.3% at 10 years, with no improvement since 2012. Female sex (hazard ratio [HR] 1.06 [95% CI 1.03-1.10]), older age (HR 1.62 [95% CI 1.56-1.69]), and increasing Charlson comorbidity index (HR 1.04 per point) were independently associated with increased mortality. Ninety-day complications included reoperation (6.24%), myocardial infarction (3.74%), and readmission (20.25%). The cumulative incidence of contralateral amputation was 6.43% (95% CI 6.14-6.73%) at 5 years. The associated mortality of BKA in people with diabetes has not improved since 2012. One-year mortality was 23.5%, increasing to 82.3% at 10 years. Older age, female sex, and greater comorbidity burden identified people at greatest risk of death.
中文摘要:膝下截肢(BKA)是晚期糖尿病足病最常见的大截肢方式。了解相关死亡率、死亡原因和术后风险,对患者咨询和改善照护很重要。这项全国人群研究描述了糖尿病患者BKA后的死亡率和死亡原因,识别风险最高的人群,并评估死亡率是否改善。研究还考察围手术期并发症、再入院、再手术和进一步截肢。研究利用与死亡数据链接的英格兰医院事件统计数据库,对接受BKA的糖尿病患者进行人群研究。主要结局为全因死亡率的Kaplan-Meier分析。Cox比例风险模型识别与高死亡率相关的变量。次要结局包括死亡原因、90天并发症、再入院和进一步截肢率。共有25,176名糖尿病患者接受28,232次BKA手术。1年死亡率为23.5%,5年为60.0%,10年为82.3%,自2012年以来未见改善。女性(风险比[HR] 1.06[95%CI 1.03-1.10])、年龄较大(HR 1.62[95%CI 1.56-1.69])和Charlson合并症指数升高(每增加1分HR 1.04)与死亡率升高独立相关。90天并发症包括再手术(6.24%)、心肌梗死(3.74%)和再入院(20.25%)。5年对侧截肢累积发生率为6.43%(95%CI 6.14-6.73%)。糖尿病患者BKA相关死亡率自2012年以来没有改善。1年死亡率为23.5%,10年升至82.3%。年龄较大、女性和合并症负担更高识别出死亡风险最高的人群。
26心肌纤维化 (1篇)
基础研究 (1篇)
Cardiac fibrosis is a central pathological hallmark of diverse cardiovascular disorders, driving myocardial stiffening, ventricular dysfunction, and the progression of heart failure. Following cardiac injury, resident quiescent fibroblasts activate into pro‑fibrotic myofibroblasts, which overproduce extracellular matrix and perpetuate maladaptive cardiac remodeling. Current clinical interventions fail to specifically target pathological cells or reverse established fibrosis, leaving a major unmet therapeutic need. Chimeric antigen receptor (CAR)-based immunotherapy, originally revolutionizing oncology, has emerged as a precision strategy to selectively recognize, eliminate, or regulate cardiac fibrotic drivers. Its application to cardiac fibrosis, primarily through targeting activated fibroblasts and fibrotic niches, shows preclinical promise in halting or reversing disease. Although most evidence remains preclinical, early clinical translation has begun for selected fibrosis-targeted immunomodulatory cell therapies. This Review synthesizes advances in CAR-based immunotherapy for cardiac fibrosis, focusing on disease pathobiology, validated and emerging target antigens, diverse cellular platforms, preclinical evidence, and the key barriers to safe and effective clinical translation.
中文摘要:心肌纤维化是多种心血管疾病的中心病理特征,它会引起心肌僵硬、心室功能障碍并推动心力衰竭进展。心脏损伤后,驻留的静息成纤维细胞活化为促纤维化肌成纤维细胞,过量产生细胞外基质,使不良心脏重构得以延续。现有临床干预无法特异性地作用于病理细胞,也难以逆转已确立的纤维化,治疗需求存在明显缺口。嵌合抗原受体(CAR)免疫治疗最初在肿瘤领域带来变革,如今已成为一种精准策略,能够选择性识别、清除或调控心脏纤维化的驱动因素。该策略用于心肌纤维化主要依靠靶向活化成纤维细胞与纤维化微环境,在临床前研究中显示出阻止或逆转疾病的潜力。多数证据仍停留在临床前阶段,针对特定纤维化的免疫调节细胞疗法已进入早期临床转化。本综述梳理CAR免疫治疗用于心肌纤维化的进展,涵盖疾病病理生物学、已验证与新兴的靶抗原、多种细胞平台、临床前证据,以及安全有效开展临床转化的关键障碍。
27子痫前期 (1篇)
临床研究 (1篇)
Preeclampsia is characterized by endothelial dysfunction and angiogenic imbalance driven, in part, by excess soluble fms-like tyrosine kinase-1 (sFLT-1). Building on previous findings demonstrating vascular modulatory effects of cardiac and quercetin glycosides from Dacryodes edulis seeds during L-NAME-induced vascular perturbation, we investigated whether pear seed glycosides (PSG) modulate sFLT-1-mediated endothelial injury in preeclampsia. Endothelial, preclinical, biophysical, pharmacodynamic, and exploratory clinical approaches were integrated to evaluate PSG activity. TGFβ-stimulated HUVECs, an L-NAME-induced rat model of preeclampsia, orthogonal binding assays (SPR/BLI and MST), ligand competition assays, and a multicenter double-blind phase 1-2a exploratory clinical trial were employed. PSG reduced endothelial migration and suppressed αSMA, TNFα, and fibronectin expression in stimulated HUVECs. In preeclamptic rats, PSG attenuated systolic and diastolic blood pressure elevation, reduced inflammatory and cardiovascular injury markers, restored VEGF and placental growth factor (PlGF), and reduced circulating sFLT-1 and the sFLT-1/PlGF ratio. Bioactivity-guided fractionation identified glycosides as the principal active fraction and improved mean birth weight from 2.7 g in untreated preeclamptic dams to 3.5 g, approaching normotensive controls (3.7 g). Orthogonal SPR/BLI and MST assays demonstrated concentration-dependent PSG-sFLT-1 interactions, while competitive ELISA and BLI assays showed inhibition of sFLT-1-mediated sequestration of VEGF and PlGF. PSG additionally restored VEGFR2/KDR, AKT, and ERK signaling in sFLT-1-exposed endothelial cells. In the exploratory clinical trial, 83 participants were randomized following screening of 125 women, with approximately 80% completing follow-up. PSG administration alongside standard care did not reveal major treatment-emergent safety concerns. These findings support further investigation of PSG as a candidate adjunctive strategy targeting angiogenic dysfunction in preeclampsia.
中文摘要:子痫前期的特征为内皮功能障碍和血管生成失衡,部分由过量的可溶性fms样酪氨酸激酶-1(sFLT-1)驱动。基于既往发现,即Dacryodes edulis种子中的强心苷和槲皮素糖苷在L-NAME诱导的血管扰动中具有血管调节作用,我们研究梨种子糖苷(PSG)是否调节子痫前期中sFLT-1介导的内皮损伤。整合内皮、临床前、生物物理、药效学和探索性临床方法评价PSG活性。采用TGFβ刺激的人脐静脉内皮细胞(HUVECs)、L-NAME诱导的子痫前期大鼠模型、正交结合实验(SPR/BLI和MST)、配体竞争实验以及多中心双盲1-2a期探索性临床试验。PSG减少刺激后HUVECs的内皮迁移,并抑制αSMA、TNFα和纤连蛋白表达。在子痫前期大鼠中,PSG减轻收缩压和舒张压升高,降低炎症和心血管损伤标志物,恢复VEGF和胎盘生长因子(PlGF),并降低循环sFLT-1及sFLT-1/PlGF比值。生物活性导向的分馏确定糖苷为主要活性组分,并将平均出生体重从未治疗子痫前期母鼠的2.7 g提高至3.5 g,接近血压正常对照(3.7 g)。正交SPR/BLI和MST实验显示PSG与sFLT-1呈浓度依赖性相互作用,竞争性ELISA和BLI实验显示其抑制sFLT-1介导的VEGF和PlGF隔离。PSG还恢复暴露于sFLT-1的内皮细胞中VEGFR2/KDR、AKT和ERK信号。在探索性临床试验中,筛查125名女性后随机分配83名参与者,约80%完成随访。在标准治疗基础上给予PSG未发现重大治疗中出现的安全性担忧。这些发现支持进一步研究PSG作为靶向子痫前期血管生成功能障碍的候选辅助策略。
28肿瘤心脏病学 (1篇)
临床研究 (1篇)
Patients with prostate cancer have a high burden of cardiovascular risk factors, often suboptimally controlled, and adverse cardiovascular outcomes. To determine whether the routine referral of patients with prostate cancer to a cardiovascular specialist to implement a systematic risk factor strategy is more likely to reduce adverse cardiovascular outcomes and improve risk factor control than usual care. This randomized clinical trial included patients with prostate cancer from 55 sites in 8 countries between 2015 and 2025. Eligible patients were diagnosed with prostate cancer during the past 12 months; had received treatment with androgen deprivation therapy (ADT) for the first time within the past 6 months; or planned to start ADT in the next month. Patients taking a statin with a systolic blood pressure of 130 mm Hg or lower were ineligible. Data were analyzed from May 25 to August 7, 2026. Patients were allocated in a 1:1 ratio to receive usual care alone or usual care plus routine referral to an internist or cardiologist. The specialists provided a systematic intervention, including a target of systolic blood pressure of 130 mm Hg or lower and a statin medication, irrespective of the patient's cholesterol levels (even if not usual or guideline-driven practice); encourage smoking cessation; and provide guidance on diet and exercise. Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, suboptimal cholesterol (total cholesterol, >155 mg/dL [to convert to mmol/L, multiply by 0.0259]) and suboptimal blood pressure (systolic blood pressure, >130 mm Hg) as evaluated by the win ratio. The analysis included 2487 patients with prostate cancer (mean [SD] age, 68 [8] years). During median (IQR) follow-up of 5.8 (2.7-8.2) years, the win ratio in favor of the intervention was 1.60 (95% CI, 1.42-1.81), mostly attributable to lower cholesterol in the intervention group (mean difference, 12 mg/dL; 95% CI, 9-15 mg/dL) as a consequence of greater protocol-mandated statin use. Mean (SD) close-out systolic blood pressure values were 131.1 (16.9) mm Hg in the intervention group and 132.9 (18.3) mm Hg in the control group. There was no difference in time to cardiovascular death, myocardial infarction, stroke, or heart failure between groups (subdistribution hazard ratio, 1.08; 95% CI, 0.79-1.49). In this randomized clinical trial, routine referral of patients with prostate cancer to a cardiovascular specialist lead to improved outcomes, specifically through better cholesterol control. However, it is uncertain whether this reduced clinical cardiovascular events. ClinicalTrials.gov Identifier: NCT03127631.
中文摘要:前列腺癌患者的心血管危险因素负担高,常控制不佳,心血管不良结局较多。旨在确定将前列腺癌患者常规转诊至心血管专科医生、以实施系统性危险因素策略,是否比常规诊疗更可能减少心血管不良结局并改善危险因素控制。这项随机临床试验于2015年至2025年纳入来自8个国家55个中心的前列腺癌患者。符合条件者为过去12个月内诊断前列腺癌,或过去6个月内首次接受雄激素剥夺治疗(ADT),或计划在下个月内开始ADT;正在服用他汀且收缩压≤130 mm Hg者不符合条件。数据分析时间为2026年5月25日至8月7日。患者按1:1比例分配至单纯常规诊疗或常规诊疗加常规转诊至内科或心脏科医生。专科医生提供系统性干预,包括收缩压目标≤130 mm Hg,以及不论胆固醇水平如何均使用他汀(即使不符合常规或指南驱动的实践);鼓励戒烟;并提供饮食与运动指导。主要结局为心血管死亡、心肌梗死、卒中、心力衰竭、胆固醇不达标(总胆固醇>155 mg/dL)与血压不达标(收缩压>130 mm Hg)的分层复合终点,采用胜率比评价。分析纳入2487例前列腺癌患者(平均[SD]年龄68[8]岁)。在中位(IQR)5.8(2.7-8.2)年随访期间,支持干预的胜率比为1.60(95% CI 1.42-1.81),主要归因于干预组胆固醇较低(平均差12 mg/dL;95% CI 9-15 mg/dL),这是方案规定他汀使用更多的结果。结束时平均(SD)收缩压干预组为131.1(16.9)mm Hg,对照组为132.9(18.3)mm Hg。两组至心血管死亡、心肌梗死、卒中或心力衰竭的时间无差异(亚分布风险比1.08;95% CI 0.79-1.49)。在这项随机临床试验中,前列腺癌患者常规转诊至心血管专科医生改善了结局,具体通过更好的胆固醇控制实现;但是否减少临床心血管事件尚不确定。ClinicalTrials.gov注册号:NCT03127631。
29脑卒中 (1篇)
临床研究 (1篇)
As scientific evidence on blood pressure reduction in patients with chronic stroke accumulates year by year, target blood pressure levels recommended in guidelines, both in Japan and internationally, have tended to become lower. In addition, with respect to antihypertensive strategies, the Japanese Society of Hypertension Guidelines for the Management of Elevated Blood Pressure and Hypertension 2025 (JSH2025) assign a higher level of recommendation to the angiotensin receptor-neprilysin inhibitor and mineralocorticoid receptor antagonist, in addition to the conventional first-line major drugs. In patients with resistant hypertension, renal denervation can be clinically used in Japan from 2026. However, the effect of stroke prevention in these newer drugs or renal denervation remains unclear and should be further elucidated. Recommendations for blood pressure management in acute-phase stroke, particularly ischemic stroke without receiving reperfusion therapy, remain unsettled, despite the fact that the validity of relatively strict blood pressure targets has been examined in multiple clinical trials to date. Target blood pressure for stroke patients and stepwise approach to blood pressure-lowering treatment.
中文摘要:随着慢性卒中患者降压证据逐年积累,日本及国际指南推荐的目标血压水平呈下降趋势。在降压策略方面,日本高血压学会2025年《高血压与高血压管理指南》(JSH2025)除传统一线主要药物外,对血管紧张素受体-脑啡肽酶抑制剂和盐皮质激素受体拮抗剂给予更高推荐级别。难治性高血压患者可在日本自2026年起临床使用肾去神经术。这些较新药物或肾去神经术的卒中预防效果仍不明确,需进一步阐明。急性期卒中的血压管理推荐,尤其未接受再灌注治疗的缺血性卒中,仍未确定,尽管迄今多项临床试验已检验相对严格血压目标的有效性。卒中患者的目标血压及阶梯式降压治疗方法。
30肿瘤心脏病 (1篇)
基础研究 (1篇)
Considerable progress in oncology has substantially reduced cancer-related mortality, as reflected by the growing number of cancer survivors. In this context, the management of adverse events associated with cancer treatments has become even more important. Small-molecule VEGFR inhibitors are associated with clinically relevant cardiovascular and hepatic adverse events, including arrhythmias, heart failure, liver enzyme elevations, and hepatic failure. This review integrates the clinical profiles, organ-specific mechanisms, and shared biological pathways underlying VEGFR inhibitor-associated cardiotoxicity and hepatotoxicity. Clinical evidence primarily supports parallel cardiovascular and hepatic toxicities, whereas experimental studies identify convergent mechanisms involving endothelial injury, oxidative stress, mitochondrial dysfunction, inflammation, autophagy dysregulation, apoptosis, and metabolic disturbance. Direct evidence of cross-organ propagation was not identified in the reviewed literature, and the proposed cardio-hepatic relationship should therefore be considered a testable framework rather than an established mechanism. Particular attention is given to ageing-related susceptibility, including reduced cardiovascular and hepatic reserve, frailty, multimorbidity, and polypharmacy, which may modify treatment tolerance and monitoring needs. We also critically evaluate candidate preventive and therapeutic strategies and identify the evidence required for their clinical translation. By separating established clinical observations from mechanistic hypotheses, this review provides an evidence-graded framework for interpreting VEGFR inhibitor-associated toxicity, refining risk-adapted surveillance, directing future studies of cardio-hepatic interactions and guiding the development and validation of targeted mitigation strategies aimed at safer cancer treatment.
中文摘要:肿瘤学进展显著降低了癌症相关死亡率,癌症生存者数量不断增加也反映了这一点。在此背景下,管理抗癌治疗相关不良事件变得更加重要。小分子VEGFR抑制剂与具有临床意义的心血管和肝脏不良事件相关,包括心律失常、心力衰竭、肝酶升高和肝衰竭。本综述整合VEGFR抑制剂相关心脏毒性和肝毒性的临床特征、器官特异性机制及共享生物学通路。临床证据主要支持心血管毒性与肝毒性并行发生,实验研究则发现二者存在汇聚机制,涉及内皮损伤、氧化应激、线粒体功能障碍、炎症、自噬失调、凋亡和代谢紊乱。所综述文献中未发现跨器官传播的直接证据,因此所提出的心-肝关系应被视为可检验的框架,而非已确立的机制。特别关注衰老相关易感性,包括心血管和肝脏储备下降、衰弱、多病共存和多重用药,这些因素可能改变治疗耐受性和监测需求。我们也批判性评估候选预防和治疗策略,并明确其临床转化所需的证据。通过将已确立的临床观察与机制假说区分开来,本综述提供了一个证据分级框架,用于解读VEGFR抑制剂相关毒性、改进风险适配的监测、指导未来心-肝相互作用研究,并引导旨在实现更安全癌症治疗的靶向缓解策略的开发与验证。
31心脏外科/CABG (1篇)
临床研究 (1篇)
Cardiac surgery with cardiopulmonary bypass (CPB) frequently results in haemostatic disturbances and perioperative bleeding. The Quantra® QPlus system measures platelet contribution to clot stiffness (PCS), a viscoelastic parameter reflecting platelet clot strength obtained under low-shear conditions. Evidence regarding its ability to detect CPB-induced platelet disorders (CPD) remains limited. We conducted a single-centre prospective diagnostic accuracy study in patients undergoing elective cardiac surgery with CPB. The primary objective was to determine whether PCS could predict CPD. The composite primary endpoint was CPD, defined as postoperative thrombocytopenia (<100×109 L-1) or platelet dysfunction (prolonged prolonged collagen (COL)/adenosine diphosphate (ADP) closure time >100 s) on the PFA-200® in the absence of acquired von Willebrand syndrome. One hundred patients were enrolled (median age 62 yr, 69% male). Procedures included coronary artery bypass grafting (49%), valve surgery (23%), and combined procedures, with a median CPB duration of 122 min. CPD occurred in 53 patients: 11 had thrombocytopenia and 52 exhibited prolonged COL/ADP closure time. PCS predicted CPD with modest discrimination (ROC-AUC 0.61, 95% confidence interval [CI] 0.50-0.72, P=0.048), with a threshold of 14.7 hPa providing 81% sensitivity and 43% specificity. PCS strongly predicted post CPB-thrombocytopenia (ROC-AUC 0.89, 95% CI 0.82-0.97, P<0.001) but was not predictive of platelet dysfunction (ROC-AUC 0.59, 95% CI 0.48-0.71, P=0.105). Platelet contribution to clot stiffness poorly predicted cardiopulmonary bypass-induced platelet disorders after elective cardiac surgery. Although it reliably identified post-cardiopulmonary bypass thrombocytopenia and might serve as a point-of-care surrogate for platelet count, it does not detect cardiopulmonary bypass-induced platelet dysfunction.
中文摘要:体外循环(CPB)心脏手术常导致止血功能紊乱和围术期出血。Quantra® QPlus系统测量血小板对血凝块硬度的贡献(PCS),该黏弹性参数反映低剪切条件下血小板参与形成的血凝块强度。关于其识别CPB所致血小板功能障碍(CPD)的能力,现有证据仍有限。我们在接受择期CPB心脏手术的患者中开展了一项单中心前瞻性诊断准确性研究。主要目标是确定PCS能否预测CPD。复合主要终点为CPD,定义为术后血小板减少(<100×10^9 L^-1)或PFA-200®上胶原(COL)/二磷酸腺苷(ADP)闭合时间延长>100 s,且无获得性von Willebrand综合征。共纳入100例患者(中位年龄62岁,男性69%)。手术包括冠状动脉旁路移植术(49%)、瓣膜手术(23%)及联合手术,中位CPB时间122 min。53例发生CPD:11例血小板减少,52例COL/ADP闭合时间延长。PCS预测CPD的区分能力中等(ROC-AUC 0.61,95%置信区间[CI] 0.50-0.72,P=0.048),阈值14.7 hPa时灵敏度81%、特异度43%。PCS对CPB后血小板减少有较强预测能力(ROC-AUC 0.89,95% CI 0.82-0.97,P<0.001),但不能预测血小板功能障碍(ROC-AUC 0.59,95% CI 0.48-0.71,P=0.105)。血小板对血凝块硬度的贡献对择期心脏手术后CPB所致血小板功能障碍的预测能力较差。该指标虽能可靠识别CPB后血小板减少,或可作为血小板计数的床旁替代指标,却不能检出CPB所致血小板功能障碍。
32糖尿病并发症 (1篇)
临床研究 (1篇)
Recent awareness that metabolic dysfunction-associated steatotic liver disease (MASLD) is a common liver condition in individuals with type 2 diabetes and carries a significant risk of cirrhosis and extrahepatic disease has called for an examination of its relationship with diabetes-related complications. MASLD, especially at-risk steatohepatitis (metabolic dysfunction-associated steatohepatitis [MASH]) with significant fibrosis ≥F2, shares many metabolic abnormalities with type 2 diabetes, including insulin resistance, gluco- and lipotoxicity, chronic subclinical inflammation and mitochondrial impairment. In addition, many cross-sectional and longitudinal observational studies suggest an association between MASLD and micro- and macrovascular complications of type 1 and type 2 diabetes. However, a causal pathogenic relationship has been difficult to confirm given the overlap of cardiometabolic risk factors (CMRFs) in MASLD and type 2 diabetes. Complicating matters further, most of the available evidence has significant limitations. These include shortcomings in participant selection, heterogeneity in study design, use of diagnostic tools with low sensitivity for liver disease and diabetes-related complications, inadequate control for alcohol consumption or CMRFs, and lack of repeat measurements during longitudinal studies. Nevertheless, current evidence suggests that MASLD is a 'risk enhancer' for both micro- and macrovascular disease in diabetes, rather than an independent risk factor. Here, we review the underlying mechanistic pathways and clinical evidence that appear to link both conditions and identify knowledge gaps in need of future research. Until more robust evidence emerges, we hope that a greater awareness about the link between MASLD and diabetes-related micro- and macrovascular complications will prompt clinicians to educate their patients and peers on the potentially heightened health risks of MASLD and encourage clinicians to take a more proactive approach to risk stratification and intervention.
中文摘要:近期认识到,代谢功能障碍相关脂肪性肝病(MASLD)在2型糖尿病患者中常见,并带来肝硬化和肝外疾病的显著风险,因此需要审视其与糖尿病相关并发症的关系。MASLD,尤其是伴有显著纤维化≥F2的高危脂肪性肝炎(代谢功能障碍相关脂肪性肝炎,MASH),与2型糖尿病共享多种代谢异常,包括胰岛素抵抗、糖毒性和脂毒性、慢性亚临床炎症及线粒体损伤。多项横断面和纵向观察性研究提示,MASLD与1型和2型糖尿病的微血管及大血管并发症存在关联。然而,由于MASLD与2型糖尿病中心血管代谢危险因素(CMRFs)重叠,因果关系难以确认。现有证据大多存在明显局限,包括受试者选择缺陷、研究设计异质性、所用诊断工具对肝病和糖尿病相关并发症敏感性低、对饮酒或CMRFs控制不足,以及纵向研究缺乏重复测量。尽管如此,当前证据提示MASLD是糖尿病微血管和大血管疾病的「风险增强因素」,而非独立危险因素。这里回顾了似乎将两种疾病联系起来的机制通路和临床证据,并指出需要未来研究填补的知识空白。在更有力证据出现之前,提高对MASLD与糖尿病相关微血管和大血管并发症关联的认识,有望促使临床医生向患者和同行说明MASLD可能带来的更高健康风险,并采取更主动的风险分层和干预策略。
33心律失常(非房颤) (1篇)
基础研究 (1篇)
The Nav1.5 channel, a major isoform of voltage-gated sodium ion channel, is mainly found in ventricular cardiomyocytes, playing a key role in generating essential cardiac action potentials for normal heart rhythms. Mutations in Nav1.5 have been associated with severe heart conditions such as long QT syndrome, Brugada syndrome, cardiac conduction disorders, atrial fibrillation, and dilated cardiomyopathy. Recent research has linked Nav1.5 to cardiac fibrosis and proposed its role in non-cardiac illnesses, including specific neurological disorders and cancers, subjects that will be reviewed in this paper. On the other hand, sodium-glucose cotransporter 2 inhibitors (SGLT2i), initially designed to manage diabetes by facilitating glucose excretion through urine, have demonstrated unexpected and encouraging cardioprotective benefits in clinical trials. This review compares the important SGLT2 inhibitors empagliflozin, dapagliflozin, and canagliflozin in terms of their interactions with Nav1.5 and their therapeutic effects on the heart. We also investigate new medications and compounds being developed to regulate Nav1.5 function, providing a preview of potential future treatments. Past attempts to develop late INa inhibitors and difficulties in transitioning from the research phase to clinical trials have raised doubts about the optimal design of such trials. In addition, we cover the applications of molecular dynamics simulations in understanding the mechanism of action of these drugs within the Nav1.5 channel computationally. We hope that this review identifies new opportunities to generate more effective inhibitors using novel methods and advanced multiscale molecular modelling techniques.
中文摘要:Nav1.5通道是电压门控钠离子通道的主要亚型,主要存在于心室心肌细胞,在产生维持正常心律所需的心脏动作电位中起关键作用。Nav1.5突变与长QT综合征、Brugada综合征、心脏传导障碍、心房颤动和扩张型心肌病等严重心脏疾病相关。近期研究将Nav1.5与心脏纤维化联系起来,并提出其在非心脏疾病中的作用,包括特定神经系统疾病和癌症,这些内容将在本综述中讨论。另一方面,钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)最初设计用于通过促进尿糖排泄来管理糖尿病,在临床试验中显示出意外且令人鼓舞的心脏保护获益。本综述比较重要SGLT2抑制剂恩格列净、达格列净和卡格列净与Nav1.5的相互作用及其对心脏的治疗效应。我们还考察正在开发用于调节Nav1.5功能的新药物和化合物,展望未来可能的治疗。过去开发晚期INa抑制剂的尝试以及从研究阶段向临床试验转化的困难,使人们对这类试验的最佳设计产生疑问。我们还涵盖分子动力学模拟在计算层面理解这些药物在Nav1.5通道内作用机制的应用。希望本综述能识别利用新方法和先进多尺度分子建模技术产生更有效抑制剂的新机会。
34门脉高压 (1篇)
临床研究 (1篇)
The non-invasive Baveno VII criteria for clinically significant portal hypertension (CSPH), based on liver stiffness measurement (LSM) and platelet count (PLT), yield indeterminate ("gray-zone") results in approximately 40-50% of patients, and their performance varies across etiologies and elastography techniques. Spleen stiffness measurement (SSM) has been proposed to improve the accuracy of the Baveno-VII CSPH criteria. We developed and validated the ELM score, a machine learning-based model integrating pan-elastographic LSM and SSM with clinical variables to improve accuracy for CSPH diagnosis, while minimizing indeterminate classifications. We analyzed 1,435 patients with compensated advanced chronic liver disease who underwent paired hepatic venous pressure gradient measurements, LSM, SSM, and clinical assessment. LSM and SSM were obtained using vibration-controlled transient elastography, two-dimensional shear-wave elastography, or point shear-wave elastography. Models were trained (n = 943) and internally validated (n = 150) using harmonized elastography measurements and clinical variables. External validation was performed in 342 patients from seven centers. Cut-offs were selected to maximize rule-out and rule-in performance and compared with the Baveno VII criteria, Baveno-SSM criteria, and, in the vibration-controlled transient elastography subgroup, the ANTICIPATE and NICER scores. A random forest-based model achieved the highest performance in the external validation cohort (AUC = 0.91; Brier score = 0.13). Cut-offs of ≤0.45 (rule-out) and ≥0.60 (rule-in) yielded a negative predictive value of 0.91 (95% CI 0.84-0.95) and a positive predictive value of 0.96 (95% CI 0.92-0.98). The ELM score reduced the gray zone to 12.3%, compared with 47.9% for the Baveno VII criteria (p <0.001), 38.6% for the Baveno-SSM dual cut-off criteria (p <0.001), and 19.6% for the Baveno-SSM single cut-off criteria (p <0.05). In the vibration-controlled transient elastography external validation subgroup (n = 275), the ELM score achieved rule-in performance comparable to that of the ANTICIPATE and NICER scores while reducing the gray zone to 12.0%, compared with 38.2% and 26.5%, respectively. The ELM score outperformed the current Baveno VII criteria and substantially reduced the gray zone across elastography modalities, supporting broader and safer non-invasive identification of patients with CSPH who may benefit from non-selective beta-blocker therapy. Clinically significant portal hypertension is central to prognosis in compensated advanced chronic liver disease, yet current non-invasive strategies classify 40-50% of patients as indeterminate. This study introduces a pan-elastography machine-learning model that integrates liver and spleen stiffness with clinical variables to address this limitation. The results are important for hepatologists and healthcare systems because the ELM score reduced the diagnostic gray zone to ∼12% in external validation, compared with 47.9% for Baveno VII, while maintaining high rule-out and rule-in accuracy (NPV up to 0.91 and PPV up to 0.96). In practice, these findings could support earlier non-invasive identification of patients eligible for non-selective β-blocker therapy, more targeted use of HVPG in indeterminate cases, and harmonized risk stratification across elastography modalities, while recognizing that prospective validation and regulatory approval are required before routine clinical implementation.
中文摘要:基于肝脏硬度测量(LSM)和血小板计数(PLT)的Baveno VII无创标准用于临床显著门静脉高压(CSPH),约40-50%患者得到不确定的「灰区」结果,且其表现随病因和弹性成像技术而变化。脾硬度测量(SSM)被提出用于提高Baveno VII CSPH标准的准确性。我们开发并验证了ELM评分,这是一种基于机器学习的模型,整合泛弹性成像LSM和SSM与临床变量,以提高CSPH诊断准确性并尽量减少不确定分类。我们分析了1435例代偿期进展性慢性肝病患者,这些患者接受了配对的肝静脉压力梯度测量、LSM、SSM和临床评估。LSM和SSM通过振动控制瞬时弹性成像、二维剪切波弹性成像或点剪切波弹性成像获得。模型使用统一化的弹性成像测量和临床变量进行训练(n=943)和内部验证(n=150)。在来自七个中心的342例患者中进行了外部验证。选择截断值以最大化排除和确认效能,并与Baveno VII标准、Baveno-SSM标准比较,在振动控制瞬时弹性成像亚组中还与ANTICIPATE和NICER评分比较。随机森林模型在外部验证队列中表现最佳(AUC=0.91;Brier评分=0.13)。≤0.45(排除)和≥0.60(确认)的截断值产生阴性预测值0.91(95%CI 0.84-0.95)和阳性预测值0.96(95%CI 0.92-0.98)。ELM评分将灰区降至12.3%,而Baveno VII标准为47.9%(p<0.001),Baveno-SSM双截断标准为38.6%(p<0.001),Baveno-SSM单截断标准为19.6%(p<0.05)。在振动控制瞬时弹性成像外部验证亚组(n=275)中,ELM评分的确认效能与ANTICIPATE和NICER评分相当,同时将灰区降至12.0%,二者分别为38.2%和26.5%。ELM评分优于当前Baveno VII标准,并在不同弹性成像方式中大幅减少灰区,支持更广泛、更安全地无创识别可能受益于非选择性β受体阻滞剂治疗的CSPH患者。临床显著门静脉高压是代偿期进展性慢性肝病预后的核心,但当前无创策略将40-50%患者归为不确定。本研究引入一种泛弹性成像机器学习模型,整合肝脏和脾脏硬度与临床变量以解决这一局限。结果对肝病医生和医疗系统重要,因为ELM评分在外部验证中将诊断灰区降至约12%,而Baveno VII为47.9%,同时保持较高的排除和确认准确性(NPV最高0.91,PPV最高0.96)。在实践中,这些发现可支持更早无创识别适合非选择性β受体阻滞剂治疗的患者、在不确定病例中更有针对性地使用HVPG,以及在不同弹性成像方式间实现统一的风险分层,同时需认识到在常规临床实施前仍需前瞻性验证和监管批准。
35系统性硬化症 (1篇)
临床研究 (1篇)
Autologous stem cell transplantation (ASCT) for Refractory juvenile-onset systemic sclerosis (JSSc).
Juvenile-onset systemic sclerosis (JSSc) is a rare autoimmune disease characterised by vasculopathy and multiorgan fibrosis, leading to significant morbidity and early mortality. Autologous stem cell transplantation (ASCT) is an established therapy for severe adult systemic sclerosis, but data in JSSc are limited. We reported outcomes of 8 consecutive patients with treatment-refractory JSSc who received ASCT at a single centre. Patients with moderate-to-severe JSSc refractory to ≥ 2 disease-modifying antirheumatic drugs underwent CD34+-selected ASCT using institutional review board- and US Food and Drug Administration-approved protocols (ClinicalTrials.gov: NCT03630211). Conditioning included alemtuzumab, rituximab, antithymocyte globulin, total body irradiation, and thiotepa. Clinical outcomes were assessed at baseline and every 6 months up to 48 months post-ASCT. All patients engrafted successfully (median neutrophil and platelet engraftment: 13 and 22 days, respectively). There were no treatment-related deaths or organ toxicities. Event-free survival (no death, cardiopulmonary failure, or renal crisis) was 100% at a median follow-up of 30 months. Skin scores (modified Rodnan skin score) improved by a median of 93%, and 6-minute walk distance improved by 13%. All patients discontinued immunosuppression for ≥18 months post-ASCT; 1 patient later required reinitiation for disease flare. Pulmonary function stabilised; both patients with pulmonary hypertension showed normalised pulmonary pressures. Gastrointestinal symptoms, including oesophageal motility and reflux, improved in most patients. Musculoskeletal function (Childhood Health Assessment Questionnaire and Childhood Myositis Assessment Scale), vascular symptoms, and quality of life (Scleroderma Health Assessment Questionnaire and performance scores) improved across the cohort. ASCT was safe and well-tolerated in patients with refractory JSSc and resulted in durable, multisystem improvement. These findings support earlier consideration of ASCT for patients with JSSc with progressive, treatment-resistant disease.
中文摘要:儿童起病系统性硬化症(JSSc)是一种罕见自身免疫病,以血管病变和多器官纤维化为特征,可造成显著疾病负担和早期死亡。自体造血干细胞移植(ASCT)是成人重型系统性硬化症的成熟治疗,但JSSc中的数据有限。我们报告了单中心连续8例接受ASCT的治疗难治性JSSc患者的结局。对至少2种改善病情抗风湿药无效的中重度JSSc患者,按机构审查委员会和美国食品药品监督管理局批准的方案(ClinicalTrials.gov:NCT03630211)接受CD34+筛选的ASCT。预处理包括阿仑单抗、利妥昔单抗、抗胸腺细胞球蛋白、全身照射和塞替派。在基线和ASCT后每6个月评估临床结局,直至48个月。所有患者均成功植入,中性粒细胞和血小板植入中位时间分别为13天和22天。无治疗相关死亡或器官毒性。中位随访30个月时,无事件生存(无死亡、心肺衰竭或肾危象)为100%。皮肤评分(改良Rodnan皮肤评分)中位改善93%,6分钟步行距离改善13%。所有患者在ASCT后停用免疫抑制至少18个月;1例后来因疾病复发需要重新开始免疫抑制。肺功能稳定;2例肺动脉高压患者的肺动脉压力均恢复正常。包括食管动力和反流在内的胃肠道症状在多数患者中改善。队列中肌肉骨骼功能(儿童健康评估问卷和儿童肌炎评估量表)、血管症状和生活质量(硬皮病健康评估问卷和表现评分)均有改善。ASCT在难治性JSSc患者中安全且耐受良好,并带来持久的多系统改善。这些结果支持对进行性、治疗抵抗的JSSc患者更早考虑ASCT。
36心律失常/电生理 (1篇)
基础研究 (1篇)
Glaucoma is one of the leading causes of irreversible blindness, and lowering intraocular pressure alone is insufficient to rescue lost retinal ganglion cells (RGCs) or restore visual function. In this study, we intravitreally injected a liquid chitosan gel loaded with nerve growth factor (NGF), previously developed by our group, into the vitreous body of rats with ocular hypertension-induced glaucoma. Using a combination of techniques--including multiplex immunofluorescence staining, TUNEL staining, CTB tracing, Western blotting, visual electrophysiology, and behavioral assessments--we demonstrated that, compared with the lesion control (LC) group, the NGF-chitosan hydrogel significantly enhanced RGC survival following glaucomatous injury (by approximately 27%), preserved dendritic architecture and long-distance axonal projections, and promoted recovery of visual function. Mechanistically, treatment with the NGF-chitosan hydrogel upregulated the expression of NGF and its high-affinity receptor, tropomyosin receptor kinase A (TrkA), in the retina. In addition, it suppressed retinal glial activation and enhanced mammalian target of rapamycin (mTOR) signaling, collectively contributing to RGC protection and repair. Notably, we further observed activation of Nestin+ neural stem cells in the ciliary body region, along with their differentiation into BrdU+/Brn3a+ neuron-like cells; the precise mechanisms underlying this phenomenon warrant further investigation. In conclusion, intravitreal delivery of NGF-chitosan hydrogel provides novel mechanistic insights and represents a promising therapeutic strategy for the treatment of glaucoma.
中文摘要:青光眼是不可逆失明的主要原因之一,单纯降低眼压不足以挽救已丧失的视网膜神经节细胞(RGC)或恢复视功能。本研究将本课题组此前开发的负载神经生长因子(NGF)的液态壳聚糖凝胶注射到眼压升高诱导的青光眼大鼠玻璃体腔。综合使用多重免疫荧光染色、TUNEL染色、CTB示踪、Western blotting、视觉电生理和行为学评估等技术,显示与损伤对照(LC)组相比,NGF-壳聚糖水凝胶显著提高青光眼损伤后的RGC存活率(约27%),保留树突结构和长距离轴突投射,并促进视功能恢复。机制上,NGF-壳聚糖水凝胶上调视网膜中NGF及其高亲和力受体原肌球蛋白受体激酶A(TrkA)的表达。同时,它抑制视网膜胶质细胞活化并增强哺乳动物雷帕霉素靶蛋白(mTOR)信号,共同促进RGC保护和修复。进一步观察到睫状体区域Nestin+神经干细胞活化,并分化为BrdU+/Brn3a+神经元样细胞;该现象的具体机制尚需进一步研究。NGF-壳聚糖水凝胶玻璃体腔递送提供了新的机制认识,并可能成为青光眼治疗的有前景策略。
37神经调控 (1篇)
基础研究 (1篇)
Neuromodulation approaches can target specific brain functional circuits to treat various brain disorders, and resting-state functional magnetic resonance imaging is increasingly being used to map functional circuits in individual patients for target localization. However, this strategy faces three major hurdles for clinical translation: time-intensive resting-state functional magnetic resonance imaging processing, insufficient robustness for clinical use and a lack of automated targeting solutions. Here we cover the use of a generic, rapid, robust and automated platform for personalized functional circuit-guided target planning across different neuromodulation techniques, termed Unified Platform for Neuromodulation with Individualized Target Estimation (UNITE). UNITE is computationally efficiency and robust and uses DeepPrep, a recently developed end-to-end preprocessing pipeline that achieves a tenfold speedup and improved robustness compared with state-of-the-art clinical pipeline. Using DeepPrep's preprocessed data, UNITE maps functional circuits and localizes personalized targets through automated targeting algorithms. Currently, UNITE offers three built-in transcranial magnetic stimulation-targeting algorithms for post-stroke functional rehabilitation and one focused ultrasound stimulation-targeting algorithm for Parkinson's disease. Notably, it is designed to be adapted for other brain disorders and neuromodulation applications. To ensure quality and usability, UNITE generates a data quality control report and a visual verification report of the identified targets, with target coordinates exported in multiple formats for compatibility with different neuronavigation systems. Overall, this platform enables personalized neuromodulation target localization within 30 min on a local graphics processing unit-equipped workstation. A basic level of computer science proficiency, along with neuroimaging experience, is sufficient for its use.
中文摘要:神经调控方法可靶向特定脑功能环路以治疗多种脑部疾病,静息态功能磁共振成像越来越多地用于在个体患者中绘制功能环路以定位靶点。这一策略在临床转化中面临三大障碍:静息态功能磁共振成像处理耗时、临床使用稳健性不足以及缺乏自动化靶点规划方案。我们介绍一个通用、快速、稳健且自动化的平台,用于跨不同神经调控技术的个性化功能环路引导靶点规划,称为 Unified Platform for Neuromodulation with Individualized Target Estimation(UNITE)。UNITE 计算高效且稳健,使用 DeepPrep,这是一种近期开发的端到端预处理流程,与当前最先进的临床流程相比实现十倍加速并提高稳健性。利用 DeepPrep 的预处理数据,UNITE 通过自动化靶点算法映射功能环路并定位个性化靶点。目前,UNITE 为卒中后功能康复提供三种内置经颅磁刺激靶点算法,为帕金森病提供一种聚焦超声刺激靶点算法。该平台设计为可适配其他脑部疾病和神经调控应用。为确保质量和可用性,UNITE 生成数据质量控制报告和所识别靶点的可视化验证报告,靶点坐标以多种格式导出,以兼容不同的神经导航系统。该平台可在配备图形处理单元的本地工作站上于30分钟内完成个性化神经调控靶点定位,具备基础计算机科学能力和神经影像经验即可使用。
38外周血管病 (1篇)
基础研究 (1篇)
Given the scarcity of autologous graft donors, a substantial and pressing demand exists for small-diameter (<6 mm) vascular grafts (SDVGs) as viable alternatives in bypass and reconstructive surgeries for the treatment of cardiovascular diseases, including coronary artery disease and peripheral artery disease. However, the challenges of compliance mismatch, inadequate endothelialization, and insufficient anticoagulation of SDVGs generally lead to side effects like thrombosis, inflammation and intimal hyperplasia. To address these issues, this study proposes a biomimetic bilayer SDVG with heparin modification fabricated through dry-jet wet spinning. This comprises a reinforced outer layer for sufficient mechanical strength and a flexible inner layer for high compliance, effectively mimicking the mechanical properties of natural vessels. The one-step in-situ heparin coating strategy represents a significant simplification for fabrication, ensuring uniform heparin distribution to prevent platelet aggregation and thrombus formation, and enhancing endothelial cell (EC) adhesion, spreading, and proliferation. The in vivo evaluation of rabbit carotid artery demonstrates that the vascular graft achieves excellent long-term patency without apparent obstruction or thrombosis. Five months post-implantation, compositions similar to native blood vessels are formed, and immunofluorescence staining shows positive expression for ECs and smooth muscle cells and the persistent infiltration of M2-polarized macrophages on the inner surface. The proposed fabrication strategy provides a novel solution for vascular replacement and has potential applications in vascular bypass and reconstruction.
中文摘要:自体移植供体稀缺,小直径(<6 mm)血管移植物(SDVGs)作为旁路和重建手术中的可行替代物,用于治疗包括冠状动脉疾病和外周动脉疾病在内的心血管疾病,存在大量且迫切的需求。然而,SDVGs的顺应性不匹配、内皮化不足和抗凝不足通常导致血栓形成、炎症和内膜增生等副作用。为解决这些问题,本研究提出一种通过干喷湿纺制备的、经肝素修饰的仿生双层SDVG。该移植物包括用于提供足够机械强度的增强外层和用于实现高顺应性的柔性内层,有效模拟天然血管的力学性能。一步原位肝素涂层策略显著简化了制备过程,确保肝素均匀分布,以防止血小板聚集和血栓形成,并增强内皮细胞(EC)的黏附、铺展和增殖。兔颈动脉体内评价表明,该血管移植物获得优异的长期通畅性,无明显阻塞或血栓形成。植入5个月后,形成与天然血管相似的组成,免疫荧光染色显示内皮细胞和平滑肌细胞阳性表达,以及M2极化巨噬细胞在内表面的持续浸润。所提出的制备策略为血管置换提供新方案,并在血管旁路和重建中具有潜在应用。
39心肌病 (1篇)
临床研究 (1篇)
Hypertrophic cardiomyopathy (HCM) exhibits great prognostic heterogeneity, necessitating the identification of high-risk patients for timely treatment. This study aimed to find novel prognostic biomarkers directly from diseased cardiac tissue to improve risk stratification of HCM. We utilized a myocardial transcriptome discovery cohort (n = 246; median follow-up 6.8 years) alongside two independent plasma validation cohorts (Beijing, n = 1,238; follow-up 2.5 years; Xi'an, n = 402; follow-up 4.8 years). The primary and secondary endpoints were cardiovascular death and sudden cardiac death (SCD), respectively. In the discovery cohort, myocardial expression of CECR1 (cat eye syndrome chromosome region, candidate 1, also known as ADA2, Adenosine Deaminase 2) demonstrated the strongest association with cardiovascular death (P = 9.6 × 10-5). Plasma CECR1 levels correlated modestly but significantly with myocardial expression. In the Beijing validation cohort, decreased plasma CECR1 predicted increased risks of cardiovascular death (adjusted hazard ratio (HR) 3.731, P < 0.001) and SCD (adjusted HR 7.398, P < 0.001), with areas under the curves (AUCs) of 0.720 and 0.798, respectively. These findings were replicated in the Xi'an validation cohort. Integrating plasma CECR1 into the HCM Risk-SCD model significantly enhanced its predictive performance, increasing the AUC from 0.723 to 0.845 (P = 0.031) in the Beijing validation cohort and consistently improving it from 0.600 to 0.781 (P = 0.018) in the Xi'an validation cohort. In conclusion, CECR1 represents a novel prognostic biomarker of HCM. Measurement of CECR1 may improve risk stratification by facilitating the identification of individuals at higher risk of cardiovascular mortality. CECR1 assessment may provide additional information for SCD risk evaluation and support clinical decision-making regarding implantable cardioverter-defibrillator therapy.
中文摘要:肥厚型心肌病(HCM)的预后异质性很大,需要识别高危患者以便及时治疗。本研究试图直接从病变心肌组织中寻找新的预后生物标志物,以改善HCM的风险分层。研究使用一个心肌转录组发现队列(n=246,中位随访6.8年)以及两个独立的血浆验证队列(北京,n=1,238,随访2.5年;西安,n=402,随访4.8年)。主要终点为心血管死亡,次要终点为心脏性猝死(SCD)。在发现队列中,CECR1(猫眼综合征染色体候选区域1,又称ADA2,腺苷脱氨酶2)的心肌表达与心血管死亡的关联最强(P=9.6×10-5)。血浆CECR1水平与心肌表达呈中度但显著的关联。在北京验证队列中,血浆CECR1降低预示心血管死亡风险升高(校正风险比HR 3.731,P<0.001)和SCD风险升高(校正HR 7.398,P<0.001),曲线下面积(AUC)分别为0.720和0.798。这些结果在西安验证队列中得到重复。将血浆CECR1纳入HCM Risk-SCD模型后,其预测性能明显提升,北京验证队列AUC由0.723升至0.845(P=0.031),西安验证队列由0.600升至0.781(P=0.018)。结论认为,CECR1是HCM新的预后生物标志物。检测CECR1有助于识别心血管死亡风险较高的人群,从而改善风险分层,并可为SCD风险评估提供补充信息,支持植入型心律转复除颤器治疗的临床决策。